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ABSTRACT: 
Human Stem Cells for Modeling Amyotrophic Lateral Sclerosis  
Disease Mechanisms and Modifiers 
 
Derek H. Oakley 
 
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease of the 
motor system. Although ALS has been extensively studied in post-mortem patient 
samples and animal models, there are currently no very effective treatments and there 
is no cure. One reason for the lack of treatment options in ALS may stem from the 
inaccessibility of living human motor neurons for use in disease research and 
subsequent therapeutic target validation. Recent developments in the field of stem cell 
biology can potentially provide access to living human motor neurons from individual 
ALS patients. It is now possible to derive induced pluripotent stem cells (iPS cells) 
from the somatic tissues of ALS patients and then to differentiate these iPS cells into 
motor neurons with the precise genetic makeup of the donor patient (iPS-MNs).  
Before iPS-MNs can be put to productive use, however, the iPS system as a whole 
must be validated as a reliable source of motor neurons with characteristics that 
closely resemble their endogenous or hES-derived counterparts. This thesis will first 
address a series of issues relating to the validation of iPS cells as a reliable source of 
motor neurons a then move on to expression profiling studies aimed at identifying a 
transcriptional signature of ALS in iPS-MNs.  
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I will first describe a collaborative study aimed at determining whether or not 
iPS cells are as useful as ES cells for the production of motor neurons. By comparing 
motor neuron differentiation efficiency across a panel of 6 ES lines and 16 iPS lines, 
we demonstrated that iPS cells are equally capable of producing electrophysiologically 
active motor neurons as ES cells. Moreover, both ALS and control iPS lines produce 
motor neurons with equal efficiency, suggesting that iPS cells will be useful in the 
production of ALS iPS-MNs for disease research. In addition, our results identify 
some of the variables that contribute to differentiation efficiency, including donor 
identity and individual iPS/ES line identity.  
The following section will serve to provide a deeper molecular and 
electrophysiological understanding of human stem cell-derived motor neurons. I first 
generated expression profiles from purified hES-MNs to identify potential motor 
neuron-specific surface markers as well as maturational changes occurring in motor 
neurons in vitro. Using calcium imaging techniques, I then demonstrated that iPS-MNs 
behave functionally similarly to ES-MNs and described culture-wide rhythmic 
depolarizations that are likely influencing multiple properties of iPS-MNs. 
After characterizing the iPS-MN culture system, I made a first attempt at 
defining the transcriptional phenotypes of ALS in iPS-MNs. This work relied on the 
use of a motor neuron-specific lentiviral reporter that I developed to isolate and 
transcriptionally profile iPS-MNs from two control iPS lines and four ALS iPS lines. I 
show evidence of significant transcriptional differences between motor neurons 
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isolated from ALS lines and those from control patients. These differences may in the 
future help to define ALS-specific phenotypes. Lastly, I conducted a meta-analysis 
comparing transcriptional changes in ALS iPS-MNs to those in existing models of 
ALS and identified some common stress-related features of ALS in iPS-MNs. 
In order to form new hypotheses about what sorts of individual patient-specific 
phenotypes may be present in iPS-MNs, I will then utilize published expression 
profiles from post-mortem ALS patient motor neurons to identify a previously-
overlooked class of genes that exhibit expression levels highly correlated with 
individual age at ALS onset. This group of 43 onset-correlated genes contains many 
members with known or hypothesized relationships to neurodegenerative disease. I 
discuss how onset-correlated genes may function as disease-modifiers or biomarkers 
and design experiments to investigate these possibilities. 
Taken together, the work in this thesis will lay the foundations for developing a 
human iPS-based model of ALS and point toward numerous avenues of future 
investigation.   
! ! ! ! !!
"!!








































































! ! ! ! !!
A!!



































































































I consider myself very fortunate to have labored for the past 4.5 years on this 
body of work and would like to recognize some of the people who provided material 
support along the way. 
I am particularly grateful to my mentors Christopher Henderson and Hynek 
Wichterle for providing me with scientific training and opportunity of the highest 
quality. I have found working with them to be challenging, rewarding, and a constant 
impetus towards scientific growth. My work and ways of approaching scientific 
inquiry have benefited greatly from their input and influence. 
The parts of this thesis dealing with basic characterization of iPS differentiation 
potential and electrophysiology were performed in close and productive collaboration 
with a team of scientists from both Columbia University and Harvard University. 
From this team, I would like to specifically recognize Mackenzie Amoroso, Gist 
Croft, Gabriella Boulting, Evangelos Kiskinis, Damian Williams, Amy MacDermott 
and Kevin Eggan.  
Many other members of the Columbia University community have also directly 
assisted in the production of this research. Throughout my time in the Project ALS 
laboratory, I have been the recipient of excellent technical assistance from Alejandro 
Garcia Diaz and Annie Hon, as well as logistical help from Mariela Flambury, Monika 
! ! ! ! !!
A"""!!
Jakowski, and Erica Stine. Numerous members of the Wichterle and Henderson labs 
have also contributed to my training and the development of protocols and reagents 
used in this research. I would like particularly to thank Esteban Mazzoni and Kevin 
Kanning for their guidance and assistance during the earlier parts of my work on this 
project.  
The Project A.L.S. organization deserves recognition for major financial, 
logistical, and moral support of this research. Nearly all of the work in this thesis was 
conducted in the Jenifer Estess Laboratory for Stem Cell Research: a laboratory 
funded largely through donations to the Project A.L.S. charity. Valerie Estess and 
Meredith Hulbert deserve special recognition for working tirelessly to facilitate 
collaboration and the open exchange of ideas between many of the laboratories in this 
field of research.  
I would like to thank the Columbia University Medical Scientist Training 
Program as well as Patrice Spitalnik, Ron Liem, and Michael Shelanski for their 
support over the last 6.5 years of my training. I would also like to acknowledge the 
National Institute on Aging for F30 NRSA funding supporting my work dealing with 
onset-modifiers in ALS.  
Finally, I would like to express my gratitude to my committee members: Serge 
Przedborski, Tom Maniatis, Gil Di Paolo, and Robert Brown for their guidance and 
collaboration throughout the course of this work, both on matters directly related to 
! ! ! ! !!
"M!!
my thesis and other scientific endeavors. I would also like to thank them for taking 
the time to read my thesis. 
  















This work is dedicated to Dennis, Teresa, Lara, Alaina, & Sheena. Without your 









Chapter 1: General Introduction !
Opening remark: 
The work in this thesis involves ideas and approaches developed in multiple branches of 
the biological sciences. These include the study of clinical medicine, neurodegeneration, and 
developmental biology. As an introduction to these topics and their relationship to my work, this 
chapter will be broken into sections roughly mirroring these three fields. I will begin with a 
description of amyotrophic lateral sclerosis (ALS), the disease this work is broadly focused on 
understanding. Then, I will discuss how models of ALS have improved our knowledge of its 
pathogenesis and point out where some gaps in this understanding lie. Following this, I will 
explain how the principles of developmental biology may be used to create a new patient-
specific model of ALS in the form of induced pluripotent stem cells (iPS cells). Finally, I will 
describe some ways in which patient-specific iPS cells can be used to model neurodegenerative 
disease and some basic questions about iPS cells that are still unanswered. This will lead into the 
data chapters, which are focused on validating the iPS system as a reliable substrate to model 
ALS and on using iPS cells as a tool to better understand ALS pathogenesis. 
 
I. Amyotrophic Lateral Sclerosis: a disease of the motor system 
Amyotrophic lateral sclerosis (ALS) is a uniformly fatal age-associated 
neurodegenerative disorder that destroys both upper and lower motor neurons. The incidence of 
ALS is approximately one in two thousand, making it the most common adult motor neuron 
disease (Bruijn et al. 2004). Although somewhat variable in its onset, ALS most often presents in 
the fifth to sixth decade of life as distal muscle weakness, cramping, and fasciculation. Following 
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onset, ALS progresses relentlessly and leads to respiratory failure in an average of three to five 
years. 
Clinical characteristics of ALS: 
“Classical” or “Charcot” ALS was first described by Jean-Martin Charcot as a 
progressive spastic then flaccid paralysis presenting in the upper limbs as weakness and 
fasciculation, subsequently progressing to bulbar regions, and eventually leading to respiratory 
failure and death approximately 3 years after onset.  The disease was subsequently named by 
Charcot to reflect the muscle wasting and spinal cord pathology found in patients. Charcot noted 
the characteristic loss of lower motor neurons in the anterior horn of the spinal cord as well as 
degeneration of the upper motor neuron axon tracts:  
“… the spinal lesion is constituted by a combination, so to speak, of the obligatory 
alteration of the anterior grey substance, with symmetrical and primary sclerosis of the 
lateral white columns.” (Charcot 1881, p.180-181).  
Charcot went so far as to correctly hypothesize that initial muscle spasticity and subsequent 
flaccid paralysis with muscle wasting were due to degeneration of neurons in the upper and 
lower divisions of the motor system respectively (Charcot 1881, p. 203). More recently, ALS has 
received the eponym of “Lou Gehrig’s Disease” for the Columbia University alumnus and New 
York Yankee baseball player who contracted the disease in 1939.  
The initial descriptions of classical ALS are still quite adequate to describe many 
patients. However, we now understand ALS symptomatology in much greater detail. Initial 
symptoms may present in many different muscle groups following degeneration of motor 
neurons in the corresponding motor pools. The most common locations of primary symptom 
onset are: limb onset (classical ALS) (70%), bulbar onset (20%), and trunk/respiratory onset 
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(5%) (Kiernan et al. 2011). At presentation, patients may exhibit signs of upper motor neuron 
degeneration, lower motor neuron degeneration, or both. Initial symptoms of ALS include: 
weakness (60% of patients), bulbar symptoms (20%), muscle atrophy (10%), and fasciculations 
(3%) (O'apos et al. 2006). Once symptoms begin, ALS progresses inexorably towards paralysis 
and death from respiratory failure. Although eye movement and sphincter control are relatively 
spared in ALS, a significant fraction of ventilated patients eventually progress to a “totally 
locked-in state” losing all voluntary control of movement (Hayashi and Oppenheimer 2003). 
Following onset in a particular motor pool, degeneration often progresses in a contiguous 
manner, with motor pools closest to the location of onset generally affected before those farther 
away (Ravits and La Spada 2009). This is believed to be true for both upper and lower motor 
neuron degeneration, sometimes producing a complex distributions of symptoms (Ravits and La 
Spada 2009). Thus, proximity of symptom onset to critical respiratory motor pools influences 
prognosis: median survival in bulbar-onset forms of ALS is 2.2 years, compared to 3.0 years for 
limb-onset cases (Figure 1.1) (Gubbay et al. 1985). Median survival across all ALS patients is 
3.4 years from symptom onset (Gubbay et al. 1985).  
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Figure 1.1 (Gubbay et al. 1985) 
 
 
Figure 1.1: Survival of amyotrophic lateral sclerosis (ALS) patients as compared to the 
expected survival.  
(survival in the general Israeli population of the same age and sex as the ALS patients)  
Figure depicts reduced survival in bulbar onset cases of ALS (squares) compared to non-bulbar 







Table 7. Associated symptoms and diseases in all ALS cases 
 o. of patients 
Symptoms Dementia 20 
Loss of sphincter control 15 
Decreased deep sensation (mostly vibration) 9 
Cranial motor nerve lesions 14 
Emotional lability 6 
Diseases Diabetes 23 
Malignancy histologically proven 9 
highly suspected 3 
Cervical spondylosis 92 
Thyroid dysfunction 4 
Trauma 11 
Table 8. Associated malignancy in ALS cases 
Site and type 
of malignancy 
 o. with malignant tumour 
Definite or Possible Discard a Total 
probable 
Bronchogenic - -  - -  2 2 
Stomach 1 - -  - -  1 
Breast - -  1 1 2 
Mediastinal mass 1 1 1 3 
Oesophagus - -  2 1 3 
Colon 1 - -  1 2 
Pancreas - -  1 1 2 
Uterus 1 - -  1 2 
Bladder - -  1 - -  1 
Prostate - -  1 1 2 
Leukaemia - -  - -  2 2 
Melanoma of iris 1 - -  - -  1 
Total 5 7 11 23 






Malignant tumour (Tu) diagnosed before ALS 12 27.1 
Malignant Tu and ALS diagnosed simultaneously 2 0 
Malignant Tu diagnosed after ALS 9 47.4 
a Refers to 11 patients with atypical ALS who were not included in 
the clinical analysis 
study, as well as f rom the  p re sen t  clinical analysis. As  this 
could exclude some real  A L S  cases, we inc luded these  
pa t ien t s  in Tab le  8 as a separa te  group.  T he  tumours  were  not  
conf ined  to any  specific site or  histological  group (Table  8). In 
12 pa t ien ts ,  ma l ignan t  t u m o u r  was d iagnosed  before  the  onse t  
of A L S  (4 m o n t h s  to 5.8 years;  m e a n  27.1 months ) .  In 9 
pa t ien ts ,  symptoms  of  A L S  a p p e a r e d  before  the  diagnosis of 
ma l ignan t  t u m o u r  (4 m o n t h s  to 10 years;  m e a n  47.4 months ) .  
In  2 pa t i en t s  signs of  b o t h  a p p e a r e d  s imul taneously .  
In  2 cases t he re  was a n o t h e r  m e m b e r  of the  family with 
ALS.  B o t h  of  t h e m  had  long-s tanding  disease.  A n o t h e r  
pa t i en t  had  an unver i f ied  familial  h is tory  of M  D  but  with  
shor t  du ra t i on  of the  disease.  
10C 
oG 
70 ony weakness 
butbar signs 
6 0  neither weakness 
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Fig.I. Survival of amyotropbic lateral sclerosis (ALS) patients as 
compared to the expected survival (survival in the general Israeli 
population of the same age and sex as the ALS patients) 
Table 9. Prognosis of ALS patients by first sign 
First sign  o. Median survival (years) Mean age 
crude corrected a at onset 
(years) 
Bulbar 70 2.2 2.2 59.81 
Weakness b 195 3.3 3.8 55.92 
Upper limbs only 99 3.4 
Lower limbs only 60 3.2 
Combined 36 3.0 
Others 52 3.8 4.1 54.64 
Total 318 3.0 3.4 56.56 
a When taking out the expected mortality in the general population of 
Israel of the same age and sex as the corresponding patients 
b Six patients with weakness and bulbar signs at onset were excluded 
from this group 
The  med ian  survival t ime in our  group of ALS  pa t ien ts  was 
3.0 years. This  survival t ime was shor te r  in pa t ien ts  with  onse t  
of  the i r  disease with bu lbar  signs (2.2 years)  t han  wi th  muscu- 
lar weakness  only (3.3 years)  or  o the r  symptoms  (3.8 years)  
(Fig. 1, Tab le  9). 
D i s c u s s i o n  
Despi te  the  difficulties due to the  re t rospect ive  charac te r  of 
the  analysis,  here  was a un ique  oppor tun i ty  to examine  such a 
large a m o u n t  of mater ia l  ( indeed a comple te  popu la t ion  
within one  country)  compris ing the  sal ient  fea tures  of the  gen- 
eral  p re sen ta t ion  of AL S  pat ients .  The  clinical p re sen ta t ion  
could be  compared  to the  publ i shed  studies of  pa t ien ts  refer-  
red  to big, wel l -known clinics or  hospi ta ls  [2, 13], pr iva te  files 
of one  au thor  [12], or  pa t ien ts '  vo lun ta ry  repor t  to a registry 
[18]. Ou r  series includes all the  pa t ien ts  d iagnosed  in Israel ,  
f rom the  mos t  mal ignan t  cases wi th  dea th  within 1 year  to the  
mild ben ign  cases. Re f inemen t s  in observa t ion ,  such as proxi- 
mal  or distal  l imb invo lvement ,  could be  made ,  and  the  out-  
come of the  disease in different  groups could be  s tudied.  Most  
of the  clinical in format ion  has been  ob ta ined  f rom one  or  two 
( somet imes  more)  clinical assessments  dur ing the  course  of 
the  disease.  Clearly,  a physical observa t ion ,  such as muscle 




Other subtypes of ALS demonstrate variable clinical progression and survival. Flail arm, 
or bi-brachial ALS, preferentially affects lower motor neurons innervating the upper limbs, 
giving a characteristic “flail arm” appearance to patients: marked wasting of the upper limb and 
scapular muscles, and relative preservation of the nearby trapezius muscles (Aguirre et al. 1998; 
Hu et al. 1998; Kiernan et al. 2011). Survival in these patients is better than in other forms of 
ALS (Wijesekera et al. 2009). Classical ALS can also occur in the setting of frontal-temporal 
dementia (ALS-FTD) (~3-15% of cases), suggesting that at least some cases of the disease lose 
motor neuron specificity and cause degeneration in other cortical neuron populations (Murphy et 
al. 2007).  
ALS diagnosis and management: 
Despite progress in our understanding of the symptomology and disease mechanisms 
underlying ALS, there are still no diagnostic tests or biomarkers to establish a definitive 
diagnosis (Kiernan et al. 2011). Instead, clinicians rely on diagnostic algorithms, the progressive 
nature of symptoms, and family history. The most commonly used diagnostic criteria for ALS, 
the El Escorial criteria, require that symptoms of both upper and lower motor neuron 
degeneration be present in multiple muscle groups as well as documented or observed spread of 
symptoms from one body region to another (Brooks et al. 2000).  Complementary diagnostic 
methods include electromyography to document fasciculation potentials, muscle biopsy to assess 
fiber type grouping and fiber group atrophy caused by denervation, MRI to assess degenerative 
changes in the spinal cord and cortex, and transcranial magnetic stimulation to assess potential 
upper motor neuron involvement (Hardiman et al. 2011). 
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Although multiple proteomic studies have been conducted on cerebral spinal fluid (CSF) 
and blood from patients with ALS, there are currently no biomarkers in clinical use either to 
detect the presence of disease or to monitor to its progression (Turner et al. 2009). However, 
current work in this direction is promising and may eventually yield clinically useful results by 
evaluating constellations of CSF protein changes that together indicate disease (Turner et al. 
2009).  In particular, a recent study reported an CSF test based on the ratio of phosphorylated 
neurofilament heavy chain to complement C3 with 84% sensitivity and 95% specificity for ALS 
(Ganesalingam et al. 2011). Validated ALS biomarkers could be very useful in advising patients 
and monitoring response to experimental therapies. 
Clinical management of ALS consists largely of supportive care. Patients are taught 
strategies to compensate for decreased strength, provided with devices to assist in breathing, 
mobility, and feeding, and managed symptomatically for the secondary sequelae of ALS. The 
single FDA-approved treatment for ALS, riluzole, can extend survival for several months and is 
thought to operate, in part, by reducing glutamate-mediated neurotransmission, thus diminishing 
excitotoxic damage to motor neurons (see below). As ALS progresses, patients may choose to be 
placed on a ventilator or to receive palliative care during the final stages of disease.  
II. Etiology of ALS 
ALS can be broken down into two groups: familial (~10% of cases) and sporadic (90%). 
In familial cases, the disease follows a clear monogenic and usually dominant inheritance pattern 
(Cudkowicz et al. 1997). Penetrance is high but not necessarily complete because the age-related 
nature of ALS allows some cases to be masked by premature death due to other factors. Sporadic 
ALS, on the other hand, is thought to arise from the interaction of multiple environmental and 
genetic factors, many of which are still unknown. Below I will briefly cover some of the known 
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genetic causes of familial ALS (fALS) and sporadic ALS (sALS) as well as environmental risk 
factors believed to interact with genetic predisposition. 
Genetic causes of familial ALS: 
Currently, approximately 22 genes and loci haven been well established as Mendelian 
causes of familial ALS (See Table 1.1) (Wroe et al. 2008; Hardiman et al. 2011; Lill et al. 2011; 
Swarup and Julien 2011). Although these genes are involved in diverse cellular functions, four 
main areas - disruptions in protein folding and degradation, the oxidative stress response, RNA 
processing, and axonal transport - seem to be overrepresented as causes of fALS. Thus, it is 
likely that motor neurons are selectively vulnerable to perturbations in these systems. 
Furthermore, the diversity of genetic insults resulting in ALS suggests that there are multiple 
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.1: Genes and loci !
 
The most well studied genetic causes of ALS are dominant mutations in Cu,Zn 
superoxide dismutase 1 (SOD1). Linkage of an area on chromosome 21q with fALS led to the 
discovery that 10-20% of all fALS cases are caused by mutations SOD1, a ubiquitously 
expressed enzyme that catalyzes the degradation of superoxide radicals to hydrogen peroxide and 
oxygen (Rosen et al. 1993). Currently, 157 different SOD1 mutations have been implicated in 
ALS (Wroe 2011). All are dominant except SOD1 D90A, which is recessive in Scandinavian 
populations but has been observed in heterozygous forms in several isolated ALS patients 
(Andersen et al. 1995; Robberecht et al. 1996). ALS-causing mutations have no consistent 
effects on SOD1 dismutase activity or other predicted protein functions and the effects of 
individual mutations on these properties do not predict disease severity (Turner and Talbot 2008; 
Wroe 2009).  
However, all SOD1 mutations do not seem to be of equal pathogenicity. Within a 
population, patients with a particular SOD1 mutation tend to exhibit a characteristic age of onset 
and rate of decline (Cudkowicz et al. 1997). The SOD1 A4V mutation, which is the most 
prevalent in North America, is associated with a rapid disease course (Broom et al. 2008). The 
SOD1 G37R mutation, conversely, is associated with an early onset and longer duration 
(Cudkowicz et al. 1997). For every SOD1 mutation, however, there is significant variability in 
age of onset and rate of progression, indicating that genetic or environmental factors other than 
SOD1 also contribute to the development of fALS. 
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Figure 1.2: Kaplan-Meier plots of survival probability for each significant covariate of 
survival. 
 All familial amyotrophic lateral sclerosis (FALS) patients were divided into six groups: A4K 
G37R, G41D, G93C, all remaining SOD1 patients, and all non-SOD1 patients. The presence of 
mutations A4V was associated with shorter survival; the G37R, G41D, and G93C SODl 
mutations were associated with longer survival. The risk ratios for A4K G93C, G37R, and G41D 
and the corresponding 95% confidence limits, respectively, were 3.02 (2.30, 3.98), 0.28 (0.11, 
0.69), 0.16 (0.06 0.41), and 0.14 (0.05, 0.38). 
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Fig 6. Kaplan-Meier plot o f  survival probabiliq from time of 
disease onset for all familial amyotrophic lateral sclerosis 
(FALS) patients divided into non-SOD1 and SODl groups. 
The median disease duration inas 2.0 years in the SODl 
group and 2.5 years in the non-SOD1 group. There was a 
sign$cant difference in survival between non-SOD1 and 
SODl patients only at early survival times, with a lower 
probability o f  survival in the SODl group (Wilcoxon test, p 
= 0.0007). Each point may represent multiple subject events. 
The graph was truncated at 10 years f o r  better visual clarity 
at shorter time points. 
in patients with one of the following three muta- 
tions-G37R, G41D, and G93C. Figure 7 plots the 
probability of survival for each significant covariate of 
disease duration. The following variables were not sig- 
nificant covariates of survival: age at onset, maternal 
inheritance, paternal inheritance, site of disease onset, 
gender, absence of mutation in SOD1, or any of the 
remaining SODl mutations. Comparison of the sur- 
vival probability between the non-SOD1 group and 
the SODl group after removal of patients with the 
mutations associated with shortest survival (A4V), and 
longest survival (G37R, G41D, and G93C) revealed 
that in general, FALS patients with SODl mutations 
had similar survival probability to FALS patients with- 
out mutations in SODl (see Fig 7). 
Discussion 
Over the last decade we have accumulated epidemio- 
logical data on an extensive group of FALS pedigrees. 
More recently we examined the status of the SODl 
gene in affected members from these families. Because 
there has been no comprehensive description of the 
clinical phenotype of individuals bearing SOD 1 muta- 
tions, we analyzed our family database to study both 
the influence of SODl gene mutations on FALS and 
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Fig 7 .  Kaplan-Meier plots o f  survival probability for each sig- 
ni$cant covariate of survival. All familial amyotrophic lateral 
sclerosis (FALS) patients were divided into six groups: A4K 
G37R, G41D, G%C, all remaining SOD1 patients, and all 
non-SOD1 patients. The presence of mutations A4V was asso- 
ciated with shorter survival; the G37R, G41D, and G93C 
SODl mutati s were associated with longe  urvival. The 
risk ratiosfor A4K G93C, G37R, and G41D and the corre- 
sponding 95% conjidence limits, respectively, were 3.02 
(2.30, 3.98), 0.28 (0.11, 0.69), 0.16 (0.06 0.41), and 
0.14 (0.05, 0.38). 
of these two broad issues, several points have been dis- 
cerned. 
First, mutations in SOD1 are highly specific to pa- 
tients with FALS. These mutations were not detected 
in 200 normal individuals, in nearly 100 patients with 
sporadic or familial parkinsonism, or in patients with 
other neurological diseases. 
Second, the mutations are found only in 23.4% of 
ALS families. Thus, there must be at least one addi- 
tional gene defect responsible for FALS. At our center 
and elsewhere, collaborative studies are under way to 
identify these other genes. We and colleagues detected 
genetic linkage of a juvenile-onset form of recessively 
inherited ALS to a locus on chromosome 2q33. How- 
ever, no specific gene defect has yet been identified 
in that region [30] nor has this locus been linked to 
any pedigrees with adult-onset, dominantly inherited 
FALS. It was recently demonstrated that even in the 
absence of a specific, disease-causing gene defect, it may 
be instructive to identify genes whose polymorphisms 
may confer heightened risk for specific diseases. Thus, 
the E4 allele of the protein apolipoprotein E is associ- 
ated with earlier onset of Alzheimer’s disease [3 11. We 
reported previously that this allele is not overrepre- 
sented in early-onset or more rapidly progressive forms 
of ALS [32]; moreover, in our FALS patients, it was 
not associated with any particular pattern of disease 
onset. However, the allele reportedly is overrepresented 
in sporadic ALS with bulbar onset [33].  
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Other notable causes of fALS include genetic alterations in the genes TDP-43, FUS, 
C9ORF72, PON1-3, and UBQLN2 (See Table 1 for a more complete list). TDP-43 and FUS are 
involved in RNA splicing and transport and represent 4-7% and 4% of fALS cases respectively 
(Kwiatkowski et al. 2009; Ticozzi et al. 2009; Swarup and Julien 2011; Ticozzi et al. 2011). 
Mutations in both of these genes are associated with ALS with frontal-temporal dementia (ALS-
FTD).  Increased hexanucleotide (GGGGCC)n repeats in C9ORF72 are a very recently described 
genetic abnormality also associated with ALS-FTD. Repeat expansions in C9ORF72 account for 
~24% of fALS cases in one study and up to 46% in one Finnish population, making it by far the 
most common cause of fALS in some patient groups (van Es et al. 2009; Dejesus-Hernandez et 
al. 2011; Renton et al. 2011).  Repeat expansions in C9ORF72 are also likely to influence RNA 
metabolism, although likely in a different manner than TDP-43 and FUS (Renton et al. 2011). 
The paraoxonases (PON1, PON2, PON3), which are enzymes involved in handling lipid 
peroxidation and detoxifying certain classes of environmental toxins, have also recently been 
implicated in a small number of familial ALS cases (Draganov and La Du 2004; Ticozzi et al. 
2010). This class of genes is particularly interesting because of links to sporadic ALS, 
environmental exposures, and other motor neuron disorders (see below). Finally, UBQLN2, a 
regulator of protein degradation, has been described as a cause of juvenile X-linked dominant 
ALS and ALS-FTD (Deng et al. 2011). UBQLN2 is the first ALS-causing mutation directly 
linking the disease to a malfunction in protein degradation, a pathological correlate of disease 
common in all forms of ALS. In addition to fALS, many of the above genes have also been 
identified as de novo mutations in sporadic cases of ALS (see Table 1.1).  
Genetic risk factors for sporadic ALS: 
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Risk for sporadic ALS also depends upon genetic factors, although in a more complex 
fashion than familial ALS. Twin studies give heritability rates between 0.35 and 0.85, 
demonstrating that there is a strong genetic component to sALS (Graham et al. 1997). Although 
multiple candidate-based studies have shown statically significant associations of various alleles 
with increased sALS frequency, these results have been extremely difficult to replicate in 
independent data sets (Shaw and Al-Chalabi 2006). However, several notable potential sALS 
risk genes are DPP6, ATXN2, PON1-3, and UNC13A (Cronin et al. 2009; van Es et al. 2009; 
Elden et al. 2010; Ticozzi et al. 2010).  
In an effort to obtain more robust results, several large genome wide association (GWAS) 
studies have been conducted to assess single nucleotide polymorphism (SNP) associations with 
sALS (Dunckley et al. 2007; Chio et al. 2009; Cronin et al. 2009; van Es et al. 2009).  These 
studies have identified relatively weak SNP associations with disease that confer on the order of 
1.3 fold increase in ALS risk and often do not replicate in GWAS studies performed in different 
populations (Dunckley et al. 2007; van Es et al. 2009). The relatively small single-gene risks 
uncovered by GWAS studies suggest that sALS is a heterogeneous disease caused by variable 
constellations of multiple mutations.  
Another explanation for the low reproducibility of many SNP and candidate-based 
studies may be that some cases of sALS may be caused by de novo nucleotide repeat expansions 
in ALS-susceptible genes (Renton et al. 2011). The recent identification of repeat expansions in 
C9ORF72 as a major cause of sporadic ALS suggests that at least some of these patients had 
undergone anticipation at the C9ORF72 locus, increasing the number of hexanucleotide repeats 
to pathogenic levels (Renton et al. 2011). A similar story is also emerging for intermediate length 
repeat expansions in the spinocerebellar ataxia gene ataxin2 (ATXN2) (Van Damme et al. 2011). 
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The overall proportion of sALS cases caused by C9ORF72 repeat expansions or similar changes 
in other genes is unkonwn, but these cases would be more difficult to detect using GWAS 
techniques. 
Even sALS risk genes that have not replicated in GWAS remain interesting targets for 
research because risk for sALS may have population-specific components. As an example, SNP 
alterations in the paraoxonase gene cluster have shown significant sALS associations in six case-
control studies but not in a large meta-analysis including GWAS data (Wills et al. 2009). Wills et 
al. (2009) suggest that pre-existing population differences (stratification) between case and 
control groups could have been responsible for earlier PON associations with ALS and that 
removal of outliers in the GWAS data lessened this bias in their analysis. However, follow-up 
studies utilizing direct sequencing of the entire PON locus have identified non-synonymous 
mutations in all three PON genes that have significant associations with both sporadic and 
familial ALS (Ticozzi et al. 2010).  Moreover, interaction of environment and genotype has not 
been evaluated in most gene-association studies, leaving out a potentially important modifier of 
sALS risk, especially in the case of PON mutations.  Another example would be DPP6 
polymorphisms that are associated with sALS in U.S., Dutch, Swedish, Belgian, and Irish 
patients, but not ALS patients of Polish or Italian descent (Cronin et al. 2009; Fogh et al. 2011) 
(Fogh et al. 2011). DPP6 has also been implicated in risk for progressive muscular atrophy, an 
isolated lower motor neuron disease closely related to ALS (van Es et al. 2009). These data 
suggest that risk alleles for sALS may be population-specific as well as environmentally 
influenced, further complicating results from large GWAS studies.   
Environmental risk factors for sporadic ALS: 
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In fact, there does appear to be an environmental component to sALS risk. An increased 
risk for sALS has been associated with exposure to formaldehyde, smoking, and work as a 
laboratory technician, computer programmer, or machine assembler (Weisskopf et al. 2005; 
Weisskopf et al. 2009). Tobacco smoking and formaldehyde exposure both increase the risk for 
sALS in a dose-dependent manner. Consumption of the neurotoxic amino acid !-methyl-amino-
L-alanine has also been linked to an ALS-like disorder with Parkinsonian symptoms (Kiernan et 
al. 2011). Finally, there is a higher incidence of sALS in agricultural workers and gulf war 
veterans, and both groups are at increased risk for exposure to organophosphate chemicals (Chio 
et al. 2005; Govoni et al. 2005; Miranda et al. 2008). 
Organophosphate pesticides (OPs) are a particularly interesting environmental risk factor 
because these chemicals are a potential link between the environmental and genetic components 
of ALS risk. Organophosphates (OPs) are small molecule inhibitors of acetylcholinesterase 
which were originally developed as pesticides in the 1940s and have seen wide use in 
agriculture. Certain highly toxic OPs, such as Sarin, Soman, and Vx have also been used as nerve 
agents in chemical warfare. Sub-lethal exposures to some OPs cause a peripheral sensory and 
motor neuropathy via inhibition of neuropathy target esterase (NTE), a gene that when mutated 
cases motor neuron disease (see below) (Abou-Donia and Lapadula 1990).  Interestingly, OPs 
are degraded by the aforementioned PON1 in the bloodstream, providing a link to genetic causes 
of ALS.  
Circumstantial evidence suggests that OP exposure is not likely to act alone in increasing 
sALS risk, but may require the setting of a particular genetic background or PON mutation. 
Cigarette smoking and exposure to formaldehyde, both environmental risk factors for sALS, 
strongly inhibit serum paraoxonase activity (Valentina Gallo 2009; Weisskopf et al. 2009). 
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However, in a study of 140 ALS patients and controls, serum PON activity was not decreased on 
average in ALS, suggesting that functional deficits in the PON enzymatic pathways do not 
contribute to a large proportion of sALS cases (Wills et al. 2008). Furthermore, a 15-year 
prospective study of over one million individuals saw no increase in sALS risk following 
exposure to herbicides or pesticides, but did not specifically evaluate OPs (Weisskopf et al. 
2009).  
Connection with other diseases of the motor system: 
RNA metabolism, mitochondrial regulation, OP-related damage, and other ALS-related 
pathways represent vulnerabilities in motor neurons that play causal roles in more than one 
disease. Below, I will very briefly describe a few of these overlapping disorders. In Chapters 4 
and 5, I will identify several ALS-related gene expression changes in iPS-MNs and in post 
mortem patient spinal cords involving genes closely related to several of these diseases (namely 
SMA, SCA2, and CT2A). 
SMA: Spinal muscular atrophy (SMA), a juvenile-onset disorder causing degeneration of 
lower motor neurons, is caused by a reduction in levels of the SMN protein, which is necessary 
for RNA splicing.  
CMT2A: Another juvenile disorder of sensory and motor neurons, Charcot-Marie-Tooth 
disease (CMT2A), is caused by mutations in mitofusin2 (MFN2), a gene involved in 
mitochondrial fusion. Recently, a form of CMT2A with ALS-like features has been described 
(Marchesi et al. 2011).  
HSP: Hereditary spastic paraplegia (HSP) is a heritable disorder characterized by 
progressive lower limb spasticity and gait disturbance (Strong and Gordon 2005). Although 
multiple genes have been linked to the development of HSP, a subgroup of HSP cases is caused 
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by mutations in neuropathy target esterase (NTE), a key neuronal target of OPs (Rainier et al. 
2008).  
SCA2: Finally, spino-cerebellar ataxia type 2 (SCA2), a multisystem neurodegenerative 
disorder, is likely to share some pathogenic mechanisms with ALS (Elden et al. 2010). PolyQ 
repeat expansions within the ataxin-2 gene numbering greater than 34 cause SCA2, however, 
repeats numbering between 27 and 33 have been shown to increase the risk for ALS (Elden et al. 
2010). It is believed that this increased risk for ALS is mediated through an interaction of the 
ATXN2 gene with TDP-43. 
III. Disease modifiers in ALS 
Dissociation of ALS onset and progression:  
Clinical variability in fALS cases suggests a dissociation of disease onset and subsequent 
rate of progression. Functional reserve is thought to prevent the appearance of ALS symptoms 
until as many as 50% of the motor units innervating the symptomatic muscle group have 
degenerated (see Figure 1.4) (Tomlinson and Irving 1977; Aggarwal and Nicholson 2002). At 
this level of degeneration, the margin of safety for neuromuscular transmission is overcome. One 
can imagine at least two means of disease progression by which this may occur: 1) motor 
neurons begin to degenerate long before symptom onset and do so at a steady rate until 
overcoming a critical threshold for disease presentation, or 2) motor neurons are present in 
normal numbers until very shortly before disease onset and begin rapid degeneration just prior to 
the onset of symptoms (Figure 1.3) (Aggarwal and Nicholson 2001). Taking into consideration 
the long pre-symptomatic phase of ALS, which lasts most of life, coupled with the rapid 
progression to paralysis following onset, it seems likely that motor neuron death in ALS must at 
least greatly accelerate as the disease becomes symptomatic or begin relatively near the time of 
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symptom onset. By following pre-symptomatic fALS patients, several with known SOD1 
mutations, Aggarwal & Nicholson have shown that motor unit number appears normal until 
several months before symptom onset and then rapidly declines (Figure 1.4) (Aggarwal and 
Nicholson 2001; Aggarwal and Nicholson 2002). Furthermore motor unit loss is specific to 
symptomatic muscles and can be monitored as symptoms progress. These results demonstrate 
that ALS is a biphasic disease with an asymptomatic prodromal component and a (largely) 
symptomatic progressive component. In fact, time to symptom onset and duration of disease 
(rate of progression) vary greatly in the patient population (Gubbay et al. 1985). Theoretical 
dissociation of onset and progression permits the search for independent modifiers of each 
component of ALS. 
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Figure 1.3: (Aggarwal and Nicholson 2001), with modification. 
 
Figure 1.3: Diagram of possible patterns of loss of motor neurons in a person. 
 This figure conveys potential patterns for motor neuron loss in ALS patients. Given that 
symptoms begin at an significant percentage of motor unit loss (estimated at 70% in this figure), 
depicted are two possible patterns of approaching this point. First, gradual loss may occur 
throughout life, eventually leading to symptoms. Second, sudden deterioration may occur after 
































Figure 1.4 (Aggarwal and Nicholson 2002) 
 
 
Figure 1.4: Rapid loss of motor units just prior to clinical ALS onset.  
Progressive results of case 1 showing the change in (A) abductor pollicis brevis (APB) and (B) 
extensor digitorum brevis (EDB) motor unit number estimates (MUNE) over time in relation to 
handgrip strength and power. APB and EDB MUNE are reduced before the onset of weakness. 




In our previous study,7 there was no detectable difference in
the number of motor units in 19 SOD1 mutation carriers as a
group compared with their 34 SOD1 negative family controls
(APB p > 0.46 and EDB p > 0.95) or with 23 population con-
trols (APB p > 0.70 and EDB p > 0.50). The 12 patients with
symptomatic ALS had fewer motor units than all other groups
(p < 0.001; table 1). Test-retest correlation was high, with
Pearson correlation coefficients of 0.93 for APB MUNE and
0.78 for EDB MUNE.
There was no significant loss of motor units in 17 of the 19
SOD1 mutation carriers and the 32 population controls over
the three years of the study. The average difference between
MUNE results on separate occasions for the same person was
±5%. In two SOD1 mutation carriers, there was a detectable
reduction of 51% in one and 37% in the other before the onset
of clinical symptoms.
Case 1
A 48 year old woman with a strong history of familial ALS
(Val148Gly) was asymptomatic at the time of recruitment,
with a normal neurological examination. She had no evidence
of wasting, fasciculations, or weakness. Initial nerve conduc-
tion studies were normal, as was concentric needle and quan-
titative EMG of the upper and lower limb muscles. Her left
EDB MUNE dropped from 130 to 100 (23% reduction) within
six months (fig 1). At the time, she had no detectable
weakness. Over the next six months, her left EDB MUNE
dropped further to 64 (total reduction of 51%), when she had
wasting and weakness of the anterior compartment muscles
Table 1 Abductor pollicis brevis and extensor digitorum brevis and mean motor unit
number estimates (MUNE)
Abductor pollicis brevis Extensor digitorum brevis
No MUNE (range) No MUNE (range)
Population controls 23 148 (115–254) 12 138 (119–169)
SOD1 negative family controls 34 138 (106–198) 32 134 (107–180)
SOD1 mutation carriers 19 144 (109–199) 14 136 (111–187)
Patients with sporadic ALS 12 45 (5–84) 9 70 (8–82)
SOD1, Cu, Zn superoxide dismutase 1.
Figure 1 Progressive results of case 1 showing the change in (A) abductor pollicis brevis (APB) and (B) extensor digitorum brevis (EDB) motor
unit number estimates (MUNE) over time in relation to handgrip strength and power. APB and EDB MUNE are reduced before the onset of
weakn ss. L, left; MRC, Medical Research C uncil; R, right.
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Onset modifiers in ALS:  
The large clinical variability in ALS suggests the presence of disease modifiers in the 
patient population in addition to disease causing alleles. Although, these modifiers seem to 
influence both the onset and progression of ALS, only onset modifiers will be addressed here.  
As well as being a risk factor, sex is a well-established modifier of ALS onset. The 3:2 
predominance of ALS in men is partially due to a higher incidence of early-onset ALS in males 
(Manjaly et al. 2010). It has been hypothesized that this may be a result of hormonal differences 
because the difference in ALS risk between men and women is less severe following menopause 
(Manjaly et al. 2010).  
It is thought that other genetic factors modify ALS age of onset as well. In fact, statistical 
modeling of age at onset across multiple SOD1 fALS pedigrees indicates that familial factors 
account for ~42% of the variance in age at onset in fALS (Fogh et al. 2007). However, within a 
single fALS family, onset can vary widely. For instance, ALS families with the SOD1 L144F 
mutation have shown ages of onset ranging from 18yo to 72yo within the same pedigree (Figure 
1.5) (Mase et al. 2001; Ferrera et al. 2003). This suggests a large contribution of environmental 
and/or genetic onset modifying factors. Similar onset-variability is seen in other 
neurodegenerative diseases such as Alzheimer’s and Parkinson’s and in some cases these two 
diseases are thought to share common onset-modifying pathways (Li et al. 2002). It is yet 
unknown whether or not any disease modifying pathways in ALS overlap with those in other 
neurodegenerative disorders.  
  





Figure 1.5 from: (Mase et al. 2001; Ferrera et al. 2003) 
 
Figure 1.5: Age of onset in two SOD1 L144F families. 
Figure depicts high degree of variability within related individuals with the same SOD1 
mutation. 
  












Several specific sALS onset-modifying genes have been described. Homozygosity for a 
50bp deletion in the promoter of the SOD1 gene, which lowers SOD1 expression appreciably, 
delays non-SOD1 sALS onset by an average of 6 years, although this change is population 
specific (Broom et al. 2008). In one study, an SNP in thioredoxin reductase 1 (TXNRD1) was 
associated with an 8-year earlier onset, specifically in male sALS patients (Mitchell et al. 2009). 
Additionally, a CNTF null mutation has been associated with a decreased age at onset by 
approximately 10 years in two small populations of sALS patients, but failed to show this 
association in a larger follow-up study, mirroring the complications with underpowered studies 
and potential population-specific effects observed in sALS risk factor studies (Giess et al. 1998; 
Giess et al. 2002; Al-Chalabi et al. 2003). In support of this idea, an sALS SNP association study 
that specifically addressed age at onset failed to find any SNPs associated with this variable 
(Landers et al. 2009).  
Thus, methods complementary to SNP studies may aid in the identification of new onset-
modifying pathways. Similarly to sALS risk genes, onset-modifying factors may be poly-genic, 
population-specific, or epigenetically regulated. Alternatively, specific repeat expansions could 
influence age of onset. In order to identify any such factors, it may be fruitful to use methods 
such as whole genome sequencing or to look downstream of genetic alterations by evaluating 
epigenetic states or gene expression in cells involved in the pathogenesis of ALS. In Chapter 5 of 
this thesis, I will use gene expression data from sALS patient motor neurons in precisely this 
manner. This work will define a set of candidate onset-modifying genes that show onset-
correlated expression patterns in sALS patient motor neurons. 
IV. Mechanisms of Disease 
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ALS appears to be a disease of multiple dysfunctions converging to initiate the selective 
degeneration and death of motor neurons. Proposed pathogenic mechanisms for motor neuron 
death in ALS include: oxidative stress, protein misfolding and aggregation, compromised protein 
degradation, excitotoxicity, mitochondrial dysfunction, disrupted axonal transport, disruption in 
RNA processing and trafficking, decreased trophic factor signaling, activation of death receptors, 
and direct toxicity from neighboring cell types (Boillée et al. 2006; Harraz et al. 2008; Rothstein 
2009). Despite extensive study of these processes, the precise pathways leading to motor neuron 
death in ALS remain obscure. Below, I will review some of the proposed mechanisms in ALS by 
discussing our knowledge of patient samples and animal models.  
Spinal cord pathology in ALS: 
Similarly to other age-related diseases of the nervous system, protein accumulations and 
inflammation are observed in post mortem spinal cord samples from ALS patients.  On gross 
inspection, the ALS spinal cord exhibits sclerotic changes in the anterior horn and myelin pallor 
in the corticospinal tracts. Histological analysis of the spinal cord reveals a large reduction in 
motor neurons and reactive gliosis throughout. Macrophages, microglia, and lymphocytes invade 
the grey and white matter in the ALS cord and are thought to participate in an inflammatory 
reaction during disease progression. Motor neurons of the oculomotor, abducens, trochlear, and 
Onuf’s nuclei are relatively spared in ALS, but still undergo some degree of degeneration 
(Hayashi and Oppenheimer 2003). At endstage, axonal spheroids, neurofilament accumulations 
and inclusion bodies are present in remaining motor neurons in both sALS and fALS. 
Ubiquitinated skein-like and Lewy body-like inclusions are seen in motor neurons and are a 
common feature in all forms of ALS (Gordon et al. 2003). In fALS, these inclusion bodies 
contain aggregates of disease-causing proteins, which are often made conformationally unstable 
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by their respective mutations.  Non-ubiquitinated Bunina bodies also commonly occur in motor 
neurons and stain positive for transferrin and cystatin-c (Gordon et al. 2003; Okamoto 2008). 
Finally, increased markers of autophagy have also been observed in motor neurons from sALS 
patients, often in close approximation with inclusion bodies (Sasaki 2011). In general, it remains 
unknown to what extent the histological hallmarks of ALS are causative or simply a result of 
ongoing disease processes.  
Most ALS cases share a remarkably similar composition of protein aggregates, despite 
some notable differences that depend on the underlying cause of disease. In sALS, and fALS 
caused by mutations in TDP-43, FUS, OPTN, and UBQLN2, inclusion bodies often stain for 
TDP-43, FUS, OPTN, and UBQLN2, as well as Ubiquitin and p62 (Maruyama et al. 2010; Fecto 
and Siddique 2011). In SOD1-mediated forms of fALS however, ubiquitinated inclusion bodies 
stain positive for p62, OPTN, UBQLN2, and SOD1, but not TDP-43 or FUS (Fecto and Siddique 
2011). A subset of SOD1 fALS and non-SOD1 sALS cases also stain positive for misfolded 
forms of SOD1 in motor neurons, suggesting that SOD1 may play a wide role in ALS 
pathogenesis (Bosco et al. 2010). Taken together, these results demonstrate common pathways of 
degeneration in both in fALS and sALS despite some heterogeneity in neuropathological 
markers.  
Models of SOD1 familial ALS:  
By far the most studied models of fALS are rodents overexpressing one of the many 
ALS-causing SOD1 mutations (Gurney et al. 1994; Wong et al. 1995; Bruijn et al. 1997). 
Transgenic mice overexpressing mutant SOD1 develop an ALS-like disorder with predominantly 
lower motor neuron symptoms and die of respiratory failure. Mouse spinal cord pathology 
exhibits death of motor neurons, SOD1-positive ubiquitinated inclusion bodies in surviving 
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motor neurons, and severe astrocytosis, but no Bunina bodies. Onset and duration of disease in 
SOD1 transgenic mice are highly dependent upon the particular mutation and SOD1 transgene 
copy number, with a higher dosage of mutant SOD1 leading to an earlier presentation of disease 
(Turner and Talbot 2008).  As in humans, there is no correlation between SOD1 activity level 
and disease severity. However, the relative clinical severities of different SOD1 mutations do not 
follow the same trend in mice as in ALS patients for reasons that likely include transgene copy 
number and species-specific factors (Turner and Talbot 2008).  
In SOD1 animal models, as in ALS patients, each motor neuron subtype is not equally 
affected by mutations in SOD1. Oculomotor and Onuf’s nuclei are relatively spared, mirroring 
the subtype sparing seen in human patients (Kaplan et al., in preparation). Even within 
vulnerable motor neuron pools, fast fatigable (FF) motor neurons degenerate before fast-fatigue 
resistant (FR) and slow (S) ones (Saxena et al. 2009). 
Involvement of multiple cell types in ALS pathogenesis: 
Work on SOD1 transgenic mice provides convincing evidence that ALS is a disease 
involving interactions between multiple cell types. In transgenic mice ubiquitously expressing 
mutant SOD1, Cre-mediated removal of SOD1 selectively from motor neurons delays disease 
onset, while SOD1 removal in astrocytes or microglia slows disease progression (Boillee et al. 
2006; Yamanaka et al. 2008). Recently, a proliferating population of NG2+ oligodendrocyte 
precursors has been described in the anterior horn the SOD1 mouse spinal cord (Kang et al. 
2010). Preliminary data suggests that removal of SOD1 from these cells also increases survival 
(J. Rothstein & D. Bergles, unpublished).  Interestingly, removal of a dismutase-active mutant 
SOD1 from Schwann cells speeds disease progression, indicating that increased oxidative stress 
may generally hasten motor neuron dysfunction (Lobsiger et al. 2009).  
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Thus, it seems at first sight that cell-intrinsic properties of motor neurons affect age at 
disease onset while surrounding cells in the spinal cord control the rate of disease progression. 
However, this idea is complicated by the use of Cre drivers for microglia and astrocytes that can 
become more efficient upon initiation of the inflammatory component of ALS, raising the 
possibility that complete excision of transgene does not occur until after disease initiation. Thus, 
while it is certain that multiple cell types play a role in ALS models, it is still somewhat unclear 
where and to what extent each cell type acts during the initiation and progression of disease.  
Glial cells, which become activated early in the disease, appear to be key regulators of 
ALS. It has been known for some time that astrocytes down-regulate their expression of the 
glutamate transporter GLT1 during the course of ALS in both humans and rodent models 
(Boillée et al. 2006). This leads to increased glutamate concentration locally in the anterior horn 
and is believed to enhance excitotoxic death of motor neurons. Furthermore, mutant SOD1 
causes astrocytes to release less lactate into the extracellular space, depriving motor neurons of 
an important energy source (Ferraiuolo et al. 2011).   
Astrocytes are also thought to play a more direct role in killing motor neurons through 
the secretion of toxic factors. Mouse primary astrocytes expressing mutant SOD1 secrete protein 
factors that are selectively toxic to both mouse and human embryonic stem cell-derived motor 
neurons (ES-MNs) (Di Giorgio et al. 2007; Nagai et al. 2007; Marchetto et al. 2008). The toxic 
factor (or factors) secreted by astrocytes causes death of motor neurons, but not other neuronal 
cell types, and appears to do so through a Bax-dependent pathway (Nagai et al. 2007). Some 
work suggests that astrocyte toxicity is mediated via prostaglandin signaling, but there is not a 
consensus in the field on this matter (Di Giorgio et al. 2008). Astrocytes derived from ALS 
patients also display toxic properties, thus strengthening results from animal models. Recent 
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work has shown that human primary astrocytes amplified from neural precursors from sALS and 
SOD1 fALS patients secrete factors that are toxic to ESMNs (Haidet-Phillips et al. 2011). Quite 
surprisingly, this toxicity is reported to be dependent upon SOD1 expression both in SOD1 fALS 
cases and one non-SOD1 sALS case, suggesting a common pathway involving SOD1 for 
astrocyte toxicity. Finally, mutant SOD1, acting through NAPH oxidase, may also increase 
reactive oxygen species (ROS) production by microglia, thus providing a second source of non-
cell autonomous damage to motor neurons (Harraz 2008). 
Motor neurons in fALS models: 
Motor neurons in SOD1 models exhibit a multitude of potentially deleterious phenotypes, 
both cell-autonomous and non-cell-autonomous in nature. These include defects in survival and 
morphological characteristics, protein aggregates, increased ER stress and protein misfolding, 
defective endosomal trafficking, increased neuroinflammation, physiologic and mitochondrial 
abnormalities, and finally, sensitivity to noxious external stimuli. Below, I will discuss some of 
these processes in order to define possible phenotypes that might be observed in an iPS-based 
model of ALS. 
Motor neuron growth and survival is generally compromised in mutant SOD1 motor 
neurons. Mouse embryonic stem cell derived motor neurons (ES-MNs) expressing SOD1 G37R 
have shorter axons and smaller cell bodies than wildtype ES-MNs at 14 days post differentiation 
(14DIV) (Nagai et al. 2007). By 28DIV, SOD1 G93A mouse ES-MNs, show survival deficits 
and increased caspase-3 activation (Di Giorgio et al. 2007). Additionally, mouse SOD1 G93A 
motor neurons produced by direct conversion from fibroblasts (iMNs, see below) also exhibit 
survival deficits, further suggesting cell-autonomous deficits in ALS MNs (Son et al. 2011). 
Finally, overexpression of disease-causing SOD1 variants in human embryonic stem cell derived 
! ! ! !!
!
:L!
motor neurons (ES-MNs) leads to decreased motor neuron survival and reduced axon outgrowth, 
suggesting that work in rodent cells generalizes to human ES-MNs (Karumbayaram et al. 2009).  
Protein aggregation and the unfolded protein response in ALS motor neurons: 
Protein aggregation within motor neurons is present only in some in vitro SOD1 ALS 
models although it is a common feature across in vivo rodent models. Ubiquitinated inclusion 
bodies have been observed by 28DIV in SOD1 G93A mouse ES-MNs, however they were not 
reported in SOD1 G37R primary motor neurons at 14 DIV. (Di Giorgio et al. 2007; Nagai et al. 
2007). This apparent difference may be due to time in culture. No published studies have 
addressed ubiquitin- or SOD1-containing aggregates in human in vitro models of ALS.  
Misfolded proteins and ER stress can be thought of as an early and common feature of 
ALS, playing a causative role in motor neuron degeneration. Together, ER stress and the UPR 
are thought to be a two-stage response to aberrantly folded proteins including mutant SOD1. In 
the setting of increased basal levels of ER stress caused by aberrantly folded mutant SOD1, 
mouse motor neurons undergo a stereotyped degenerative process, progressing first through a 
stage of sharply increased ER stress associated with ubiquitinated protein aggregation, followed 
40+ days later by recruitment of the unfolded protein response (UPR), down-regulation of genes 
in the ubiquitin proteasome system (UPS), and finally leading to muscle denervation (Saxena et 
al. 2009). FF and FR motor neurons both degenerate through this sequence, although 
asynchronously with FF motor neurons undergoing deleterious changes before FR groups 
(Figure 1.6 for overview) (Kanning et al. 2010).  
Because alterations in the UPR and UPS are early changes in the SOD1 mouse model, 
they are ideal candidates for evaluation in human induced pluripotent stem cell-derived motor 
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neurons (iPS-MNs). Thus, they will be assessed in iPS-MNs along with other markers of cell 
stress in Chapter 4. 
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Figure1.6: (Kanning et al. 2010) 
 
 
Figure 1.6: Time course of neurodegeneration in the SOD1G93A mouse model of ALS.  
The diagram provides an overview of the complex ballet of cellular and molecular mechanisms 
that lead over six months to the death of this severe model of ALS. It is based on detailed data in 
Supplemental Table 2 (follow the Supplemental Material link from the Annual Reviews home 
page at http://www.annualreviews.org). Many changes occur before muscle strength is reduced 
by half, including initial alterations in electrophysiology and behavior followed by ubiquitination 
and ER stress in susceptible FF motor neurons leading to axonal dieback and microgliosis and 
astrogliosis in the spinal cord. These are accompanied by subcellular changes such as Golgi 
fragmentation and mitochondrial swelling. During the following months, these changes become 
exacerbated and generalized to other motor units, leading to extensive motor neuron loss and 
muscle paralysis. Indicated stages (scale in days) represent those in the G93A high-expressor 
line. Some parameters have not been studied at earlier stages, so the indicated dates represent the 
latest possible onset. The overall layout progresses from systemic and behavioral changes on the 
left toward molecular and cellular changes in motor units on the right. 
 




Autophagy in ALS motor neurons: 
Autophagy, a process by which the cell degrades cytoplasmic protein aggregates and 
organelles in the lysosome, is another component of defense against misfolded and aggregated 
proteins that may play a role in ALS. Autophagy is thought to play a beneficial role in multiple 
neurodegenerative disorders by degrading protein aggregates that have been deposited in the 
cytoplasm (Ravikumar et al. 2010). In what may be a compensatory action, autophagic activity 
appears to be increased in sALS patient spinal cord and in the SOD1 G93A mouse model of ALS 
(Morimoto et al. 2007; Li et al. 2008; Sasaki 2011). Furthermore, mutations in p62, a key 
regulator of autophagy, are believed to cause some cases of fALS (see table 1.1) (Fecto et al. 
2011). Mutations in Alsin (ALS2), which cause juvenile-onset ALS, are also hypothesized to 
disrupt autophagy by decreasing the maturation and clearance of autophagosomes (Hadano et al. 
2010). Concordantly, loss of ALS2 in SOD1 H46R mice exacerbates their mild ALS symptoms 
and causes accumulation of autophagosomes in motor neuron cell bodies (Hadano et al. 2010).  
If autophagy is functioning to remove deleterious misfolded proteins in ALS, augmenting 
the process should be helpful in the disease. However, compounds that modify autophagy do not 
appear to be helpful in SOD1 mouse models or in ALS patients. Despite an initial report 
demonstrating that lithium carbonate, an autophagy-inducer, lead to increased survival in SOD1 
G93A mice and human sALS patients, two follow-up drug trials on both SOD1 mouse models 
and sALS patients showed no benefit from lithium carbonate (Fornai et al. 2008; Gill et al. 2009; 
Pizzasegola et al. 2009; Aggarwal et al. 2010; Miller et al. 2011). One study unfortunately 
documented an increased rate of decline for ALS patients in the lithium-treated group compared 
to controls (Miller et al. 2011). Another autophagy inducer, rapamycin, has also shown 
deleterious effects in the SOD1 G93A mouse model (Zhang et al. 2011). Although this would 
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appear to indicate that recruitment of autophagy is somehow deleterious in ALS, both drugs have 
significant off-target effects and genetic manipulation of autophagy has not yet been assessed in 
SOD1 models, leaving room for debate about the precise role of autophagy in ALS.  
Excitotoxicity in ALS motor neurons: 
Excitotoxic stress is a common feature in multiple neurodegenerative diseases and is 
thought to be a major contributor to motor neuron death in ALS. In addition to increased levels 
of glutamate secondary to downregulation of GLT1 on astrocytes, the physiologic properties of 
human ALS motor neurons are altered in ways that increase the likelihood of excitotoxicity 
(Boillée et al. 2006). First, ALS patients demonstrate cortical hyperexcitability early during the 
course of disease (Vucic et al. 2011). This may lead to over-stimulation of lower motor neurons. 
Secondly, lower motor neurons are particularly vulnerable to excitotoxic stimuli because they 
express high levels of natively calcium-permeable AMPA receptors, and low levels of the 
AMPA receptor subunit GluR2, which blocks calcium entry during channel opening (Kawahara 
et al. 2003). In ALS patients, the calcium permeability of AMPA channels is further increased 
due to decreased editing of existing GluR2 subunit mRNA, which prevents GluR2 from blocking 
calcium entry (Kawahara et al. 2004). This could be a self-reinforcing process because high 
intracellular calcium levels inactivate adenosine deaminase, the enzyme responsible for Glur2 
editing (Mahajan et al. 2011). 
Mitochondria in ALS motor neurons: 
As the primary site of calcium buffering in motor neurons, mitochondria are critically 
important for regulating neurotransmission and excitotoxicity. However, on a mutant SOD1 
background, the calcium buffering capacity of mitochondria is compromised both in cell 
autonomous and non-autonomous manners (Damiano et al. 2006; Bilsland 2008). Following a 
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kainate-stimulated calcium influx through AMPA channels, SOD1 G93A mouse primary motor 
neurons exhibit delayed recovery to basal calcium levels as compared to wild type SOD1 
overexpressing cells (Guatteo et al. 2007). Furthermore, co-culture of wild type or SOD1 G93A 
mouse primary motor neurons with SOD1 G93A astrocytes causes decreased mitochondrial 
membrane potential and an overall increase in mitochondrial calcium content (Bilsland 2008). 
Thus, mitochondrial abnormalities in mutant SOD1-expressing motor neurons likely contribute 
to increased cytoplasmic calcium levels and subsequent excitotoxicity.  
Other ALS-dependent changes that have been reported in mitochondria include altered 
morphology and energetics, impaired transport, and increased ROS production (Kawamata and 
Manfredi 2010; Schon and Przedborski 2011). Mitochondrial transport defects themselves have 
the potential to play a causative role in ALS pathogenesis by preventing the renewal or removal 
of damaged mitochondria by mitochondrial fusion or mitophagy respectively (Schon and 
Przedborski 2011).  
Mutant SOD1 directly associates with the outer mitochondrial membrane and is present 
at increasing levels within vacuolar aggregates inside mitochondria as ALS progresses, 
suggesting direct action of SOD1 on mitochondria (Ferraiuolo et al. 2011). In support of this 
idea, expression of mitochondrially-targeted SOD1 G93A or G85R in NSC34 motor neuron-like 
cells leads to decreased cell survival following exposure to oxidative stress, reduced size of 
mitochondria in neurites, and defects in mitochondrial transport (Magrane et al. 2009).  
Defects in mitochondrial transport have been reported in multiple SOD1 ALS models, 
although not always in consistent directions of movement. Motor neurons from transgenic SOD1 
G93A mice exhibit defects in retrograde, but not anterograde movement (Magrane et al. 2012). 
However, primary rodent cortical neurons transiently transfected with G93A SOD1 have 
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demonstrated a defect specifically in anterograde movement (De Vos et al. 2007). Oxidized 
forms of SOD1 as well as misfolded SOD1 purified directly from some sporadic ALS patients 
also appears to inhibit anterograde, but not retrograde mitochondrial fast axonal transport in an in 
vitro squid axoplasm model (Bosco et al. 2010). This finding is particularly interesting because it 
suggests a link between mitochondrial dysfunction in sALS and fALS. Although reasons for the 
discrepancies in the directionality of mitochondrial transport abnormalities are unclear, it is 
certain that mitochondria are adversely affected in ALS.   
Sensitivity to stress in ALS motor neurons: 
Motor neurons expressing mutant SOD1 are also selectively sensitive to specific noxious 
external stimuli. Mutant SOD1 mouse primary motor neurons show selective sensitivity to 
detaNONOate, a nitric oxide donor, and a sensitized Fas-mediated cell death pathway, but 
normal responses to excitotoxic stimuli and neurotrophic factor withdrawal (Raoul et al. 2002; 
Raoul et al. 2002; Raoul et al. 2006). Motor neuron-like cells expressing mutant G93A SOD1 
also show an increased sensitivity to oxidative stress despite full dismutase activity in the G93A 
mutation (Menzies et al. 2002). Increased sensitivity to oxidative stress has also been described 
in cultured fibroblasts and myoblasts from ALS patients (Aguirre et al. 1998; Bradley et al. 
2009). Human ES or iPS-derived motor neurons have not been characterized under any of the 
above stressors.  
Gene expression changes in mouse and human ALS motor neurons: 
Whole-genome expression profiling can be a useful tool for deducing underlying disease 
mechanisms in ALS. Expression profiles provide an unbiased readout that can be mined not only 
for single genes aberrantly expressed in disease, but for pathways or groups of genes that are 
either coordinately dysregulated or report quantitative variables. While a fair number of profiling 
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studies have been conducted in ALS patients and various model systems, there is no published 
up-to-date meta-analysis of the gene expression changes caused by ALS. This will be attempted 
for ALS motor neurons in Chapter 4 as a means to contextualize results generated with the new 
iPS model of ALS. Below, several of the more consistent profiling findings will be discussed in 
order to give a gestalt of the available data. 
The population of cells used in profiling experiments is critically important for 
interpretation of results. Even under normal circumstances, and especially in late-stage ALS, 
motor neurons are far outnumbered by other cell types in the spinal cord. Thus, profiling 
experiments conducted on whole spinal cord or ventral horn isolations are best suited to answer 
questions about cell population shifts and major changes that are not overwhelmed by the noise 
of multiple transcriptional signatures arising in different cell types. Studies performed on isolated 
cell types have increased sensitivity for changes specific to the cell type of interest, but must be 
interpreted with the knowledge that non-cell autonomous changes may also play an important 
role in any observed gene expression changes.  
In isolated motor neurons, mutant SOD1 perturbs global gene expression patterns. 
Expression profiles of mutant SOD1-expressing mouse motor neurons or motor neuron-like cell 
lines show little increase in prototypic cell death genes, but show an up-regulation of cell cycle 
genes, decreased levels of antioxidant response genes, and dysregulation of motor proteins, often 
in the setting of general transcriptional repression (Kirby et al. 2005; Perrin et al. 2005; 
Ferraiuolo et al. 2007). In multiple mouse models of ALS, vimentin levels are upregulated before 
disease onset and continue to increase throughout progression (Perrin 2006). However, vimentin 
does not seem to be upregulated in motor neurons from sALS patients (Jiang 2005). Down-
regulation of the motor protein dynactin, and up-regulation of cyclins seem to be common to 
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motor neurons both from deceased ALS patients and mouse models of the disease (Jiang 2005; 
Ferraiuolo et al. 2007; Jiang et al. 2007). Gene expression differences between mouse models 
and patient samples could be due to species variability, differences in SOD1 expression level, 
cellular environments, organism age, or different degrees of tissue preservation.  
Inflammatory changes in the spinal cord are one of the hallmarks of ALS. Accordingly, 
evidence of neuroinflammation is present in gene expression data from ALS motor neurons. The 
activated astrocytes, microglia, and monocytes present in the ventral horn are all known to 
secrete pro-inflammatory factors. Some of these factors, such as MCT-1 and IL8, are increased 
in CSF early on in the course of ALS (Kuhle et al. 2009). Components of the complement 
system, notably C1q, are upregulated in motor neurons from SOD1 mice and in human sALS 
patients (Ferraiuolo et al. 2007; Lobsiger et al. 2007; Sta et al. 2011). Along with its involvement 
in the innate immune response, C1q has recently been described as a critical component in the 
process of synaptic elimination, targeting synapses for destruction by the classical complement 
system (Stevens et al. 2007). In the SOD1 G93A mouse model, increased C1q is localized to the 
NMJ prior to symptom onset, suggesting that the complement system plays a direct role in 
denervation of the motor endplate (Heurich et al. 2011). 
Profiling studies performed on patient spinal cords have shown a multitude of ALS-
dependent expression changes, but have given relatively little mechanistic insight into disease-
initiating events. Even in studies performed on isolated motor neurons, profiling of post-mortem 
tissue can only provide a snapshot at the end-stage of disease, often following years of 
inflammatory and hypoxic damage. Therefore, it is extremely difficult with patient samples to 
separate cause and effect. An approach that has been fruitful for rodent ALS models has been to 
examine motor neuron expression in a pre-symptomatic state.  By monitoring expression before 
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disease onset and throughout progression, one can hope to find the earliest cascades of events 
that will eventually lead to motor neuron death. Although this approach is impractical and 
unethical with human spinal cords, the technology now exists to derive patient-specific motor 
neurons in abundance from induced pluripotent stem cells. Work in this thesis will generate 
expression profiles in isolated patient-specific motor neurons as a first attempt to look at pre-
symptomatic expression profiles in human ALS. 
Need for a humanized model of ALS: 
 The preceding sections have summarized mechanistic knowledge about ALS that was 
generated using multiple model systems. Although there is significant overlap in the ALS 
phenotypes observed in many model systems, they are not always in agreement. Therefore, it has 
been difficult to identify the best therapeutic targets for translation to ALS clinical trials. Below, 
I will review the rationale for developing a humanized model of ALS for the discovery of disease 
mechanisms and validation of therapeutic strategies.  
Despite extensive mechanistic knowledge about ALS, and over 30 Phase II and III 
clinical trials, there is only one marginally effective therapy for the disease (Hardiman et al. 
2011). Riluzole, the only FDA approved treatment for ALS, extends median survival by 2-3 
months and is quite expensive (Miller et al. 2007). Riluzole is an anti-excitotoxic compound that 
is believed to act by decreasing the presynaptic release of glutamate on to motor neurons as well 
as persistent inward current in motor neurons themselves, thus decreasing overall excitation 
(Wang et al. 2004; Schuster et al. 2011). Other work suggests that riluzole may also be involved 
in increasing the production of neurotrophic factors in astrocytes, suggesting more than one 
potential mechanism of action (Peluffo et al. 1997; Mizuta et al. 2001).  The high failure rate of 
drug trials in ALS is likely due to multiple factors including: initiation of treatment late in the 
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course of disease, lack of biomarkers for diagnosis and treatment monitoring, heterogeneous 
patient populations, unknown etiology in many sALS patients, and pre-clinical development 
largely in non-human model systems (Gordon and Meininger 2011). Above all, it reflects the 
lack of validated therapeutic targets, molecular events whose inhibition can delay onset or slow 
progression. 
Patient-specific iPS-derived motor neurons (iPS-MNs) potentially provide a humanized 
model of ALS that may help to address some of the above concerns. By virtue of replicating the 
exact genetic makeup of the donor patient, ALS iPS-MNs express endogenous levels of disease-
causing genes and capture individual heterogeneity within disease. Thus, they may be better 
substrates for the identification or validation of therapeutic targets. It may also be possible to 
model individualized correlates of disease severity or sensitivity to particular environmental 
factors using iPS-MNs (i.e organophosphate chemicals in the setting of PON mutations). 
Furthermore, iPS-MNs may be considered to be at pre-symptomatic disease stages and have not 
been subject to the environment of a diseased spinal cord. Thus, they may be useful tools for the 
discovery of early causal events in ALS or biomarkers that are present before clinical symptoms. 
These applications could be very useful both for identifying new therapeutic targets and 
identifying patients for early initiation of treatment. 
 Although patient specific iPS-MNs are a promising new model system for the study of 
ALS, the iPS technology is in its infancy. There are still many basic questions that need to be 
answered regarding the reliability of iPS cells as a whole before moving on to modeling disease 
using these cells. In order to place such concerns about iPS cells in context, it will be necessary 
to review the nature of iPS cells and how they were discovered. Below, I review the knowledge 
that lead to the development of human iPS cells as well as the ability to derive motor neurons 
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from them. I will begin by describing the in vitro and in vivo pathways from pluripotent stem cell 
to motor neuron. I will then cover the development of iPS technology to reprogram terminally 
differentiated cells into pluripotent stem cells. 
V. From embryonic stem cells to neurons  
In this section, I will describe the basic characteristics of embryonic stem cells as well as 
general strategies for differentiation of ESCs to neural tissues. Throughout, I will reference in 
vivo data to support the hypothesis that ESC differentiation follows endogenous developmental 
pathways. Because ESC differentiation is a stepwise process, it will be useful to first describe 
general neural differentiation before addressing motor neuron differentiation specifically. In the 
following section, I will describe application of these general principles for the specific 
production of ES-MNs. 
Characteristics of embryonic stem cells: 
 In general, the term “stem cell” refers to any cell that has both the capacity to self-renew 
and to divide asymmetrically, producing a stem cell and two or more types of daughter cells that 
are restricted to different cell fates. Stem cells reside in nearly every tissue in the body and, in the 
adult, are responsible for tissue repair and homeostasis. In the case of adult stem cells, each stem 
cell can only produce a restricted subset of derivatives, which are appropriate to the tissue in 
which it resides. Embryonic stem cells, unlike adult stem cells, are capable of giving rise to any 
cell in the body. In fact, this is their role in development: to begin as a homogenous mass of cells 
with equal potential, and through a series of progressively restrictive cell fate decisions, to 
produce an entire organism.  
 Mammalian embryonic stem cells are thought to arise typically from the inner cell mass 
(ICM) during embryogenesis. Following fertilization, the zygote symmetrically divides and then 
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compacts to produce the morula, which continues to divide and cavitates to become a hollow 
blastocyst (Yamanaka et al. 2006). Following blastocyst formation, an outer shell of cells is 
designated the trophectoderm (TE) and will give rise to extra-embryonic cells including the 
placenta. A compact group of cells adhering to the inner wall of the TE is designated the inner 
cell mass, and will eventually differentiate into all embryonic tissues. After formation of the 
ICM, an embryo can be disaggregated and cells of the ICM can be expanded indefinitely in 
culture under the appropriate conditions (Evans and Kaufman 1981). These cells are designated 
embryonic stem cells (ESCs) and in mouse systems canonically depend upon leukemia inhibitory 
factor (LIF) and bone morphogenetic protein-4 (Bmp-4) to maintain viability and cell fate in 
culture (Stadtfeld and Hochedlinger 2010).  
 In culture, ESCs retain the ability to produce all cell types of the body: a property dubbed 
“pluripotency”. Three tests are used as a formal demonstration of pluripotency in rodent ESC 
lines. In order of increasing stringency they are: teratoma formation, germline transmission, and 
tetraploid complementation. Following implantation of pluripotent ESCs into immune-
compromised mice, formation of a teratoma demonstrates that the ESCs are capable of producing 
the major tissue classes in the body. Teratomas are embryonic tumors that contain derivatives of 
all three germ layers: the ectoderm, mesoderm, and endoderm. Ectodermal derivatives include 
stratified squamous epithelium and neural tissue. Mesodermal derivatives include bone, 
cartilage, and muscle. Endodermal derivatives include pseudo-stratified gut epithelium and 
hepatocytes. If ESCs are implanted into the ICM of a developing embryo from an identical or 
similar species, they will integrate into the host and contribute to the fully developed organism. 
The resultant animal is said to be chimeric. Chimeric contribution to germ cells, from which ES 
cell-derived offspring can be generated, is known as germline chimerism. Finally, tetraploid 
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complementation is considered the gold standard demonstration of pluripotency for rodent ESC 
lines. In this process, tetraploid embryos are first created from a fertilized egg by inducing cell 
fusion at the two-cell stage, thus doubling the chromosomal number (Yang et al. 2007). Cell 
division progresses until the blastocyst stage, when ESCs are implanted into the 4n embryo and 
development is allowed to proceed. In this case, the implanted ESCs must give rise to every cell 
in the newly developed organism, because tetraploid cells can only contribute to the extra-
embryonic tissues. Thus, viable offspring from a tetraploid/ES chimeric embryo are convincing 
evidence that implanted ESCs are fully pluripotent. 
Human ESC-specific considerations for maintenance and assessment of pluripotency:   
Although human ESCs (hESCs) can be cultured and differentiated in much the same way 
as mouse ESCs, there are significant differences in culture requirements and evaluation of 
pluripotency that are worth mentioning. Unlike mouse ESCs, hESCs require fibroblast growth 
factor 2 (FGF-2) and activin A to maintain pluripotency in place of LIF (Thomson et al. 1998). 
In addition, pluripotency must be assessed differently. Although teratoma formation is the 
minimum pluripotency standard met by mouse ESC lines, it has been considered the gold 
standard in hESC lines because ethical and technological constraints prevent the production of 
most chimeras and all tetraploid embryos. Teratoma formation, in conjunction with 
immunostaining for ESC-specific cell surface molecules is typically considered sufficient 
evidence to demonstrate hESC fate in culture (Thomson et al. 1998). Because these are rather 
qualitative tests of pluripotency, it has been difficult to systematically stratify hESC lines with 
respect to suitability for making different differentiated derivatives. Work in Chapter 2 will 
utilize directed differentiation to motor neurons as a more stringent assay of pluripotency for 
both hESCs and hiPSCs.  
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Embryonic stem cell differentiation: 
The pluripotency of ESCs can be utilized in vitro to produce particular cell types of 
interest through directed differentiation. ES cells are maintained in a pluripotent state by virtue 
of specific culture conditions, normally including LIF/Fgf-2 and a medium containing serum. 
Upon withdrawal of LIF/Fgf-2, ESCs begin inexorably down differentiation pathways that may 
be controlled with the appropriate input. By exposing ESCs to the morphogens that influence 
these cell fate decisions in vivo, the process can be recapitulated in vitro. Major decision points 
during the course of differentiation include: germ layer specification, rostral-caudal patterning, 
dorsal-ventral patterning, and refinement of a restricted cell fate. Below, I will cover each of 
these fate choices for ESCs and discuss ways to bias differentiation towards specific neural 
subtypes. 
Neural fate specification in ESCs: 
Neural specification occurs early during embryogenesis. Under what is known as the 
“neural default model”, ICM cells will become neuroepithelial in the absence of instructive cues 
to do otherwise.  BMP-inhibiting proteins such as Noggin are secreted by neural-organizing 
centers of the embryo and block ectodermal differentiation to other germ layers, thus promoting 
the “default” neural cell fate (Lamb et al. 1993; Levine and Brivanlou 2007).  
During gastrulation, precursors of both the endoderm and mesoderm pass through the 
primitive streak while those of the ectoderm do not. BMP4, Wnt, and activin/Nodal signaling in 
the primitive streak all contribute to the specification of mesoderm and endoderm at the expense 
of ectoderm (Murry and Keller 2008). Following specification of the primitive streak, BMP4 and 
Wnt signaling favor specification of mesodermal derivatives such as hematopoietic and cardiac 
cells, where as activin signaling favors derivatives of the endoderm such as liver and pancreas 
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(Figure 1.7) (Murry and Keller 2008). After basic germ layers are specified, further patterning is 
necessary to produce terminally differentiated cell types.  
  
! ! ! !!
!
II!
Figure 1.7 (Murry and Keller 2008) 
 !
Figure 1.7: ESC Differentiation in Culture.  
This model depicts the regulation of primitive streak formation, primary germ layer induction, 
and tissue specification from differentiated mouse ESCs. The first step in the differentiation 
pathway is the development of a population resembling the epiblast of the mouse embryo. When 
induced with Wnt, activin, BMP4, or serum, these cells will generate a primitive streak (PS)- like 
population (indicated by the row of cells outlined in blue). If these pathways are not activated, 
the epiblast population will differentiate into the ectoderm lineage. Ectoderm differentiation is 
blocked by BMP, Wnt, and activin signaling. Following PS induction, the posterior PS cells 
(yellow) are specified to Flk-1+ mesoderm, whereas the anterior streak cells (dark orange) are 
fated to generate Foxa2+ definitive endoderm. These fates are not firmly established at this stage, 
as activin can induce endoderm from the posterior PS population (indicated by the brown 
stippled arrow below the PS). The pathways that specify Flk-1 mesoderm to the hematopoietic 
lineage and Foxa2+ definitive endoderm to either the hepatocyte or pancreatic lineages are 
shown. 
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Once neural tissue is specified as such, it takes on characteristics of the anterior neuraxis, 
and requires instructive cues to acquire more caudal fates. Retinoic acid is one notable 
posteriorizing cue for neural tissue (Durston et al. 1989). Neurally-specified tissue goes on to 
produce neurons, astrocytes, and oligodendrocytes in the fully developed organism. ESCs exhibit 
a default anterior neural fate in a manner similar to early ectodermal derivatives (Lee et al. 
2007). Thus, both low-density culture in minimal media and exposure to Noggin result in 
neurally specified derivatives from mouse ESCs (Tropepe et al. 2001; Smukler et al. 2006). 
Under minimally instructive conditions, mESCs will spontaneously form neurepithelia of 
hypothalamic origin, the most rostral and dorsal element of the neuraxis (Wataya et al. 2008). In 
mouse ESCs, neuralization is increased by Fgf8 signaling and inhibited by Wnt signaling 
(Gaspard and Vanderhaeghen 2010). Interestingly, BMP, Fgf8, activin/nodal, and Wnt signaling 
pathways all partially converge downstream at the level of Smad1/5/8 and Smad4 (Pera et al. 
2003; Fuentealba et al. 2007; Eivers et al. 2009). Accordingly, Smad1 knockout mES lines 
exhibit a higher efficiency of neural conversion (Tropepe et al. 2001). Chemical dual SMAD 
inhibition through combined use of recombinant Noggin, and the activin inhibitor SB431542 has 
also recently been reported to greatly increase the efficiency of neural conversion in human 
embryonic stem cells (Chambers et al. 2009). Such a combined approach will be utilized below 
in order to increase the efficiency of motor neuron generation from iPS cells.  
Directed differentiation of ESCs to specific neural subtypes: 
Utilizing the knowledge that ESCs follow endogenous developmental programs, many 
specific and useful neural sub-types can be produced from ES-derived neural stem cells by 
applying the appropriate patterning cues. Following the formation of anterior neural precursors, 
neural tissue is patterned by morphogen gradients within the developing embryo in order to 
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provide functionally diverse classes of neurons (Figure 1.8A) (Gaspard and Vanderhaeghen 
2010).  By exposing neuralized ESCs to these same cues at developmentally appropriate 
timepoints, ES differentiation can be driven towards a specific class of neurons. Thus, production 
of a desired neural subtype can be thought of as moving the differentiating neural progenitors to 
a specific location in a coordinate grid with rostrocaudal and dorsoventral axes determined by 
morphogen concentrations (Figure 1.8B) (Gaspard and Vanderhaeghen 2010).  
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Figure1.8: (Gaspard and Vanderhaeghen 2010). 
 
Figure 1.8: Neural induction and regional patterning in ES cell neurogenesis.  
(a) Schematic representation of the mechanisms of neural induction and early patterning of the 
neural plate/tube. Neural induction is regulated by the coordinated actions of BMP, Wnt and 
FGF/IGF signaling pathways. The neural plate, initially of anterior identity, is then subsequently 
patterned by extrinsic morphogens along the rostro-caudal and the dorso-ventral axes into 
discrete domains. (b) ES cell neural induction and ES-derived neural progenitor specification 
follow the same cues as in vivo to give rise to well-defined neuronal populations. 
  
while forebrain structures retain their identity by escap-
ing the action of some of these signals, through soluble
morphogen antagonists secreted by surrounding rostral
structures (Figure 1a). ES cell-based models have now
provided ample confirmation for this model (Figure 1b).
In most differentiation paradigms, neural progenitors
derived from ES cells initially express markers of rostral
neural identity [21!,22,23] that can be converted to more
caudal fates, including spinal cord, midbrain and hind-
brain, by retinoic acid or FGFs [12,23–30,31!]. Moreover,
adding soluble inhibitors of Wnt signals during early ES-
derived neural induction enhances the proportion of
forebrain progenitors [29,32]. Similarly it was found that
when ES cells are cultured at low density in a medium
devoid of serum or any morphogen, but allowing cell
survival by insulin, they efficiently differentiate in fore-
brain-like progenitors, mainly of telencephalic identity,
including cortical progenitors [33!]. Moreover, using a
differentiation medium completely devoid of any mor-
phogen and without insulin, ES cells were found to
efficiently convert to neural cells displaying anterior
identity, corresponding to the rostral most part of the
neural plate [34!]. These cells then further adopt a
pattern of neuronal differentiation that corresponds to
anterior hypothalamic structures, which correspond to the
derivatives of the most anterior and medial plate in vivo
[35].
Similarly, the general mechanisms of dorso-ventral neural
patterning are thought to be conserved throughout the
neural tube, where different concentrations of morpho-
gens induce specific expression of transcription factors in
successive discrete domains, which confer to distinct
subpopulations of progenitors the competence to gener-
ate types of neurons and glial cells in a region-specific
manner [36,37]. Dorso-ventral patterning is similarly
38 Development
Figure 1
Neural induction and regional patterning in ES cell neurogenesis. (a) Schematic representation of the mechanisms of neural induction and early
patterning of the neural plate/tube. Neural induction is regulated by the coordinated actions of BMP, Wnt and FGF/IGF signalling pathways. The neural
plate, initially of anterior identity, is then subsequently patterned by extrinsic m rphogens along the rostro-caudal and the dorso-ventral axes into
discrete domains. (b) ES cell neural induction and ES-derived neural progenitor specification follow the same cues as in vivo to give rise to well-defined
neuronal populations.
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Because ESCs default into an anterior neural fate, the first step in many differentiation 
protocols is either to specify more caudal fates if desired or to block signals that would drive 
neural progenitors away from an anterior fate. The patterning cues used to accomplish this are 
the same utilized during development (Figure 1.8B). Morphogen free or DKK1+LeftyA 
conditions are used to preserve anterior forebrain identity (Gaspard and Vanderhaeghen 2010). 
Increasing Fgf application can predispose towards midbrain through spinal cord identity 
respectively (Ye et al. 1998). Retinoic Acid application confers hindbrain/cervical spinal cord 
identity (Durston et al. 1989).  
Second, dorsoventral patterning agents are applied to bias differentiation towards specific 
neural sub-classes at a given rostrocaudal level.  Forebrain progenitors can be patterned into 
dorsal cortical pyramidal neurons by application of Wnt3a and blockade of sonic hedgehog 
(SHH) signaling, or into ventral forebrain neurons by application of SHH itself. Midbrain 
progenitors can be patterned into dopaminergic neurons and other ventral neurons by application 
of SHH. Hindbrain/spinal cord progenitors can be patterned into dorsal spinal cord interneurons 
via application of Bmp2 and Wnt3a or into motor neurons by application of SHH (Figure 1.8B).  
Generally, differentiation protocols do not yield pure cultures of the intended neural type. 
Rather, they bias differentiation toward this cell type and produce a mixture of cells with similar 
developmental origins. Precision of differentiation control, in conjunction with the characteristics 
of the particular cell line used, dictate the purity of the end product. Thus, there is often a need to 
purify differentiated derivatives from ES cells. In chapter 3, I will cover efforts to purify human 
iPS and ES motor neurons from mixed culture following differentiation. 
Human ESC-specific considerations for cell culture and differentiation: 
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Several general considerations are necessary when translating techniques and results 
between hESC and mESC systems. First of all, the timing of development/differentiation in an 
ESC line is determined by species-specific factors. While neurons made from mouse ES cells 
become post-mitotic approximately 7-10 days following the start of differentiation, human ES-
derived neurons take 21-32+ days to produce depending upon the differentiation protocol used. In 
each case, the timing of development in ES cells seems to mirror that seen in developing 
embryos (Zhang 2006). Second, species-specific differences may exist in the developmental 
pathways leading to a particular cell type and need to be understood in order to monitor 
differentiation progress. In the case of developing neuroepithelia, Pax6 is expressed earlier than 
Sox1 in mouse cells, but after Sox1 in human cells (Li et al. 2005). Third, many of the tools 
developed for use in mouse ES cells are not yet transferable to their human counterparts. For 
example, feeder-free culture systems have only recently been implemented for hESCs and are 
still much more complicated compared to those in use for mESCs. Furthermore, hESCs are quite 
recalcitrant to genetic modification. Since the first experiments with hESCs, only a handful of 
stable reporter lines have been derived and knock-in strategies have only become possible within 
the past few years (Hockemeyer et al. 2009; Placantonakis et al. 2009). Fourth, hESCs are 
particularly adept at silencing exogenous DNA once it has been introduced (Xia et al. 2007).  
This is believed to play a role in the difficulty of genetic modification in hESCs. Finally, hES 
differentiations are less efficient at producing the desired cell types than mES differentiations. 
This is likely caused by amplification of unintended ES derivatives over the longer time-course 
in hES differentiations.  Thus, technological barriers can be a major hindrance to work on 
hESCs.  
VI. Motor neuron differentiation 
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The major factors that control patterning in the spinal cord have been well studied, as 
have many of the factors that contribute to the development of different spinal motor neuron 
classes. Consequently, motor neurons were the first neural subtype to be successfully derived 
from ESCs (Renoncourt et al. 1998; Wichterle et al. 2002). Below, I will describe in more detail 
the basic procedures used to derive motor neurons form ESCs along with developmental 
rationale. I will begin by describing the patterning and differentiation of motor neurons in vivo 
and then move on to how these processes can be recapitulated in vitro. 
Embryonic spinal cord anatomy: 
 In the ventral horn of the spinal cord, motor neurons are anatomically separated into 
subgroups that reflect both function and developmental origin. First, motor neurons are divided 
into “columns” that run for multiple spinal segments and reflect broad categories of post-
synaptic targets outside the spinal cord. Second, motor neurons are divided into more localized 
“pools”, which reflect specific post-synaptic targets such as a particular muscle group.  
The four major motor columns are: the lateral motor column (LMC), the medial motor 
column (MMC), the hypaxial motor column (HMC), and the preganglionic motor column (PGC) 
(Dasen and Jessell 2009). The LMC innervates the limb musculature and has LMC-medial and 
LMC-lateral divisions that innervate flexor and extensor compartments respectively. The MMC 
innervates the dorsal axial musculature (muscles of the back). The HMC innervates intercostal 
and abdominal musculature. Finally, the PGC innervates sympathetic ganglia in the thorax. 
Particular motor columns are present in the spinal cord only at the rostral-caudal levels that align 
with their post-synaptic targets. Thus, the LMC is only present at limb levels while the MMC is 
present throughout the spinal cord (Dasen and Jessell 2009). Interestingly, motor neurons of the 
LMC are preferentially damaged in ALS, so identifying and studying LMC-MNs in patient-
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derived cultures may prove fruitful. Molecular markers of the LMC and MMC will be discussed 
along with approaches to generate these cells in vitro. 
Superimposed on top of the existing column architecture are motor pool divisions. Motor 
pools are functional groups that innervate the same muscle. The precise nature of these pools is 
beyond the scope of this introduction, but it is worth reminding the reader that as well as column-
specific disease preference in ALS, certain motor pools are also differentially disturbed. Motor 
neurons innervating the extraocular muscles and of Onuf’s nucleus are relatively spared in ALS. 
Motor neurons in the phrenic pool, on the other hand, are not differentially susceptible to ALS, 
but their degeneration precipitates diaphragmatic failure and death. 
The rostral-caudal identity of embryonic motor neurons can be read out via the Hox code, 
a striated expression pattern of homeobox transcription factors belonging to the Hox family. The 
13 Hox genes are present in four paralogous clusters in the genome (A-D) and are used in 
multiple tissues to confer sequential rostral-caudal identities during development. Hox genes are 
expressed along the rostral-caudal axis in the same order that they are arranged in the genome: 
low numbers rostrally and high numbers caudally. Beginning with cervical levels, spinal motor 
neurons express Hox5, Hox6, Hox8, Hox9 and Hox10 genes (Figure1.9B) (Dasen and Jessell 
2009).  
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Figure 1.9: (Dasen and Jessell 2009) 
 
Figure 1.9: Patterning along the dorsoventral and rostrocaudal axes of the neural tube.  
(A) Motor neurons and ventral interneurons are generated along the dorsoventral (d-v) axis in 
response to the graded activities of sonic hedgehog (Shh) which induces the patterned expression 
of transcription factors in progenitor cells. Class I factors are induced by Shh while Class II 
transcription factors are repressed. Selective cross- repressive interactions between Class I and 
Class II transcription factor sharpen the boundaries between progenitor domains (Briscoe et al., 
2000). Retinoic acid (RA) from the paraxial mesoderm and fibroblast growth factor (FGF) 
signaling also influence the pattern of transcription factors in neural tube progenitors (not 
shown). (B) Along the rostrocaudal axis graded FGF signaling induces the expression of 
chromosomally linked Hox genes in the neural tube. Hox genes located at one end of the cluster 
are expressed more rostrally (r) while genes at the opposite end are expressed caudally (c) in 
response to higher levels of FGF. At more rostral levels Hox genes are regulated by graded RA 


































Figure 6.1 Patterning along the dorsoventral and rostrocaudal axes of the neural tube.
(A) Motor neurons and ventral interneurons are generated along the dorsoventral (d-v)
axis in response to the graded activities of sonic hedgehog (Shh) which induces the
patterned xpression of tra scription factors in prog nitor cells. Cl ss I factors are
induced by Shh while Class II transcription factors are repressed. Selective cross-
repressive interactions between Class I and Class II transcription factor sharpen the
boundaries between progenitor domains (Briscoe et al., 2000). Retinoic acid (RA)
from the paraxial mesod rm and fibroblast growth fa tor (FGF) signaling also influence
the pattern of transcription factors in neural tube progenitors (not shown). (B) Along
the rostrocaudal axis graded FGF signaling induces the expression of chromosomally
linked Hox genes in the neural tube. Hox genes located at one end of the cluster are
expressed more rostrally (r) while genes at the opposite end are expressed caudally (c)
in response to higher levels of FGF. At more rostral levels Hox genes are regulated by
graded RA signaling while at more caudal levels Hox genes are regulated by graded
Gdf11.
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Hox gene expression is critical for refining LMC and PGC subtype identity and thus 
directing the proper connectivity of motor pools in the LMC and PGC. Removal of a necessary 
Hox co-factor, Foxp1, causes reversion of LMC identity to that of its evolutionary precursor, the 
HMC, resulting in extreme functional disturbance of the mammalian motor system (Dasen et al. 
2008; Rousso et al. 2008). Monitoring spinal segmental location using the Hox-code becomes 
especially important when working with ES-derived motor neurons because rostral-caudal 
patterning cues can bias differentiations away from or towards different motor columns and 
pools.  
Specification of motor neurons in vivo: 
Specification of motor neuron identity during embryogenesis begins with caudal 
patterning of naive anterior neurectoderm. Early Wnt signaling plays a role in caudalizing 
presumptive spinal cord and rendering it responsive to later patterning factors (Nordstrom et al. 
2006). Following Wnt exposure, retinoic acid, produced by the paraxial mesoderm, specifies 
caudal hindbrain and rostral-cervical levels of the spinal cord. Graded Fgf and Gdf-11 specify 
more caudal regions, with Gdf-11 being the most caudal morphogen (Liu et al. 2001).  
Following rostral-caudal specification, spinal progenitors receive dorsal-ventral 
patterning information from a gradient of Sonic Hedgehog (SHH) secreted ventrally by cells of 
the floor plate and underlying notochord (Figure 1.9A). Graded SHH signaling establishes five 
dorsal-ventral progenitor domains through the cross-repressive interactions of SHH-responsive 
homeodomain proteins (Jessell 2000). The second most ventral domain, the pMN domain, gives 
rise first to motor neurons, then oligodendrocytes. The identity of Pax6/Ngn1/Ngn2 expressing 
progenitors of the pMN domain is solidified by expression of the bHLH protein Olig2 and the 
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homeodomain proteins Nkx6.1 and Nkx6.2 (Alaynick et al. 2011). Expression of these proteins 
is repressed in adjacent dorsal and ventral progenitor domains by Irx3 and Nkx2.2 respectively 
(Chen et al. 2011). 
Once specified, Olig2-positive motor neuron progenitors progress through a stereotyped 
series of transcriptional states that consolidate motor neuron identity. Exit from the cell cycle is 
accompanied by transient MNR2 upregulation and sustained Isl1 expression that allows 
transcription of HB9, Isl2 and Lhx3 (Pfaff et al. 1996). Subsequently, newly born motor neurons 
begin to acquire column and pool identity. Non-canonical Wnt4/5 signaling from the ventral 
spinal cord confers MMC identity to a subset of cells by stabilizing Lhx3 expression (Jessell 
2000; Agalliu et al. 2009). Those cells not exposed to sufficient levels of Wnt4/5 downregulate 
Lhx3 and may respond to the rostral-caudal Fgf gradient by inducing Hox gene expression and 
subsequently acquiring a hox-dependent LMC or PGC fate. Motor neurons that respond to 
neither the Wnt4/5 nor the Fgf gradient become HMC cells (Agalliu et al. 2009) (Figure 1.10).  
  
! ! ! !!
!
<<!
Figure 1.10: (Agalliu et al. 2009) 
 
Figure 1.10: Model for the relative contributions of Wnt4/5 and FGF/Hox signaling in the 
diversification of motor neuron columnar identities.  
Shh-induced motor neuron progenitors (gray) are exposed to competing signals. Graded Wnt4/5 
signals along the DV axis (orange arrow) promote the maintenance of Lhx3 and acquisition of an 
MMC fate (red). FGF signaling along the AP axis induces differential Hox expression (blue line) 
so specifying LMC (green) and PGC (brown) fates at limb and thoracic levels, respectively. 
Some motor neurons at thoracic levels evade Wnt4/5 and FGF-Hox activity and progress to an 





the ventral neural epithelium (Jessell, 2000; Chamberlain et al.,
2008; Dessaud et al., 2008). In contrast, the range of activity of
many secreted Wnts is more limited (Mikels and Nusse, 2006;
Hausmann et al., 2007), supporting the idea that the spatial
profile of Wnt4/5 activity is established primarily through the
graded ventral expression of Wnt transcripts. A second differ-
ence in the logic of Shh and Wnt4/5 signaling may be the
concentration dependence of their activities. Shh functions as
a gradient morphogen—specifying distinct ventral cell fates at
different concentration thresholds (Jessell, 2000; Dessaud
et al., 2008)—whereas the specification of MMC fate could
simply require exposure to a critical threshold level of Wnt4/5
signaling. In this view, the graded expression of Wnt4/5 tran-
scripts may merely serve as an effective strategy for ensuring
that an appropriate fraction of cells within the pMN domain are
exposed to a threshold level of Wnt4/5 activity.
The slope and spread of the Wnt4/5 activity gradient within
the ventral spinal cord appears to be steeper and shorter than
that of the Shh gradient. We infer this from the observation that
all motor neurons generated in ectopic ventral positions acquire
MMC character whereas few if any of the ectopic motor neurons
generated dorsal to the normal pMN domain do so. The dorsal
limit of Wnt4/5 signaling activity may be constrained by the
high level of Sfrp expression evident within the p0, p1, and p2
progenitor domains (Kawano and Kypta, 2003; Lei et al., 2006).
In this view, the secretion of Sfrp proteins may block the actions
of secreted Wnt4/5 proteins that manage to reach these more
dorsal domains of the ventral neural tube. The inverted dorso-
ventral profiles ofWnt4/5 and Sfrp expression are therefore likely
to contribute to the restricted range of Wnt4/5 signaling evident
within the ventral spinal cord.
How does the Wnt4/5 activity gradient determine the position
of generation of motor neuron columnar subtypes within the
pMNdomain?WereWnt4/5 protein activity to extend throughout
the pMN domain, the probability of generation of neurons of the
MMC and segmental motor columns would presumably change
smoothly as a function of the dorsoventral position of progenitor
cells within the domain. Alternatively, the limit of Wnt4/5
signaling activity could be located within the pMN domain,
such that only the most ventrally positioned pMN domain
progenitors would have the opportunity to generate MMC
neurons. Independent of the linear or step landscape of Wnt4/5
signaling, our findings imply that the diversification of neurons
within a single ventral progenitor domain depends on a dorso-
ventral difference in the intensity or quality of inductive signals
(Figure 7A). This position-dependent plan for motor neuron
diversification differs conceptually from the mosaic, position-
independent mode of Notch signaling that directs to the diversi-
fication of certain ventral interneuron subtypes (Peng et al.,
2007). Plausibly, the combination of both strategies within
a single ventral progenitor domain could further enhance the
diversity of neuronal subtypes.
Figure 7. Wnt4/5 Signaling and the Specifi-
cation of MMC Identity
(A) Fractional representation of MMC neurons in
various experimental conditions, with quantifica-
tion derived from our thoracic-level data. Wnt4,
Wnt5a, and Wnt5b are distributed in a ventralhigh
to dorsallow gradient in the ventral spinal cord
(red triangle). Model shows a scenario in which
cells located in more ventral regions of the pMN
domain have a higher probability of acquiring
MMC identity (red cells), whereas cells located at
more dorsal regions of the pMN domain are
more likely to acquire segmental column fates
(S-MC, blue cells). This model is supported by
the finding that in Nkx2.2!/! mice all motor
neurons generated from the p3 domain acquire
MMC identity, whereas in SmoW535L chick
embryos, neurons generated at positions dorsal
to the pMN domain acquire segmental columnar
fates. Misexpression of Wnt4, Wnt5a, or Wnt5b
increases the fractional allocation of MMC
neurons, whereas their proportion is reduced in
mice that have five mutated Wnt4, Wnt5a, or
Wnt5b alleles.
(B) Model for the relative contributions of Wnt4/5
and FGF/Hox signaling in the diversification of
motor neuron columnar identities. Shh-induced
motor neuron progenitors (gray) are exposed to
competing signals. Graded Wnt4/5 signals along
the DV axis (orange arrow) promote the mainte-
nance of Lhx3 and acquisition of an MMC fate
(red). FGF signaling along the AP axis induces
differential Hox expression (blue line) so specifying LMC (green) and PGC (brown) fates at limb and thoracic levels, respectively. Somemotor neurons at thoracic
levels evade Wnt4/5 and FGF-Hox activity and progress to an HMC fate (purple). For details, see text and Dasen et al. (2008).
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Enumerating a simplified subset of molecular markers for motor neuron subtype identity 
will prove useful in assessing particular sub-classes of motor neurons produced in ES and iPS 
differentiations. MMC MNs express Isl1/2, HB9, Lmo4 and Lhx3. HMC MNs express HB9 and 
ISL1. PGC MNs express HB9, Isl1/2, Foxp1 and HFN-6. LMC-medial MNs express, ISL1/2 and 
Foxp1 and low levels of HB9. LMC-lateral MNs express HB9, Isl1/2, Lhx1, and Foxp1 (Rousso 
et al. 2008; Alaynick et al. 2011). 
Refinement of motor neuron identity: 
Motor neuron identity is not entirely conferred by morphogen gradients in the spinal 
cord. Both spontaneous electrical activity and target-derived trophic factors play a role in the 
refinement of motor neuron identity and axon pathfinding. Although manipulation of these 
factors is not a key component of motor neuron differentiation protocols, they are likely to have 
some influence on ESMN identity and behavior in culture. 
Electrophysiological activity in newly born motor neurons influences axon guidance 
choices. Early in development, at a time when glycine and GABA are still excitatory 
neurotransmitters, motor neurons experience spontaneous, rhythmic depolarizations that 
propagate across the spinal cord as calcium waves (Hanson et al. 2008). Pharmacologically 
decreasing the occurrence of these rhythmic episodes causes dorsal-ventral pathfinding errors in 
LMCl and LMCm motor neurons by decreasing expression of Lhx1 and subsequent 
downregulation of guidance molecules such as EphA4, EphB1 and PSA-NCAM (Hanson and 
Landmesser 2004; Kastanenka and Landmesser 2010). Increasing the frequency of bursting 
episodes causes anterior-posterior fasciculation errors leading to mis-innervation of target 
muscles (Hanson and Landmesser 2006). Because calcium influx regulates a large number of 
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genes and second messenger systems, these activity-dependent changes are likely only a fraction 
of those occurring in motor neurons following perturbation of electrical activity. 
Target-derived factors also play a role in the maturation of newly formed motor pools. In 
many cases, the precise roles that specific factors play are poorly defined. However, in one 
particularly well-established example, GDNF, secreted from post-synaptic muscle targets 
induces expression of the ETS transcription factor Pea3 in motor neurons of the LMC (Haase et 
al. 2002). Pea3, in turn, induces maturational changes in cell body position and synaptic 
connectivity, as well as dendritic and axonal arborization (Livet et al. 2002; Vrieseling and Arber 
2006). Thus, components of cell culture systems, both cellular and soluble, are likely to influence 
even the final steps of motor neuron ESMN maturation. Because of this, all differentiations and 
cell culture media used in this work contain a common cocktail of neurotropic factors (with 
minor exceptions). 
Specification of motor neurons in vitro from embryonic stem cells: 
Procedures to derive motor neurons from mouse and human embryonic stem cells 
recapitulate the major developmental pathways of motor neuron specification. Sequential 
application of retinoic acid (RA) and SHH to neuralized mouse ES cells results in cultures that 
are approximately 40% HB9+ motor neurons at 7 days in vitro (DIV) (RA/HH protocol) 
(Wichterle et al. 2002). These mES-MNs express other canonical motor neuron markers such as 
Islet1/2 and components of the acetylcholine synthesis pathway such as VAChT and CHAT. 
When transplanted into the developing chick spinal cord, mES-MNs settle in the ventral horn 
and exit primarily through the ventral root, projecting to both axial and limb musculature 
(Wichterle et al. 2002). Due to the presence of relatively high levels of RA during differentiation, 
mES-MNs derived under the RA/HH protocol assume a primarily cervical MMC identity. Most 
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motor neurons are Lhx3-positive and express either Hoxc6 or Hoxa5 (Wichterle et al. 2002; 
Peljto et al. 2010). Finally, survival of mE-SMNs in culture is dependent upon neurotrophic 
factor signaling in a manner similar to embryonic primary motor neurons. Taken together, these 
data demonstrate that mES RA/HH motor neurons exhibit properties strikingly similar to cervical 
motor neurons in the mouse. Furthermore, RA/HH mESMNs show electrophysiological 
properties consistent with embryonic motor neuron identity. This includes spontaneous action 
potential firing and excitatory responses to the neurotransmitters glutamate, GABA, and glycine 
(Miles et al. 2004). After 5 days in culture, RA/HH MNs show synaptic connectivity with other 
motor neurons as well as muscle cells grown in co-culture (Miles et al. 2004). 
ES-derived motor neurons have also been successfully differentiated from human ES 
cells using a derivative of the RA/HH protocol. Sequential exposure of un-patterned, neuralized 
hESCs to RA and HH is used as in mouse protocols, but over a period of approximately 32 days 
as opposed to 7 (Figure 1.11) (Li et al. 2005). Still, motor neurons produced from hESCs are 
remarkably similar to those derived from mESCs. hES-MNs express the expected markers of 
motor neuron identity such as HB9, Islet 1/2, and ChAT, and are capable of firing action 
potentials, as well as projecting axons out of chick spinal cord to muscle following 
transplantation (Li et al. 2005; Lee et al. 2007; Li et al. 2008). Unexpectedly, many hES-MNs 
generated under these protocols express the brachial-thoracic marker Hoxc8 (Li et al. 2005). One 
potential explanation of this rostral to caudal shift in hESC cultures is that Fgf-2 is used as a 
neuralizing agent before the addition of RA and may bias MNs towards more caudal fates even 
in the presence of RA (Li et al. 2005).  
Emerging protocols demonstrate that ESMNs can also be prospectively patterned along 
the rostral-caudal axis to produce different classes of limb-innervating motor neurons. As 
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mentioned above, the majority of mES-MNs generated under standard RA protocols are of 
cervical identity. Under the appropriate morphogen free conditions however, mES cells 
spontaneously differentiate into motor neurons of mostly brachial and thoracic identity as 
evidenced by increased expression of Hoxc8 and Hoxc9 and decreased expression of Hoxa5 in 
HB9+ cells as compared to standard RA protocols (Peljto et al. 2010). Caudal motor neuron fates 
in these cultures are dependent upon endogenous SHH, FGF, and Wnt signaling and can be 
blocked by antagonists to these pathways. Furthermore, the addition of exogenous FGF-8 or 
GDF-11 to low RA motor neuron differentiations induces significant expression of the caudal 
Hox genes Hoxc9 and Hoxd10 in motor neurons respectively, demonstrating that mES-MNs can 
be patterned into specific rostrocaudal sub-types (Peljto et al. 2010). Unpublished work in hES-
MNs suggests that they are also caudalized in response to FGF signaling in the presence of Wnts 
(Gist Croft, in preparation).  
Enhanced neuralization via dual SMAD inhibition has also been successfully applied to 
hES and iPS motor neuron differentiation (Chambers et al. 2009; Boulting et al. 2011). This 
protocol, which will be further discussed in Chapter 2, is of higher efficiency than protocols that 
do not force neuralization early during differentiation. Furthermore, motor neurons can be 
derived in a shorter time period (21 days as opposed to 30) (Figure 1.11). 
Since limb-innervating LMC motor neurons are preferentially affected in ALS, a protocol 
to generate these motor neuron subtypes specifically could be very useful. Fortunately, a 
differentiation protocol that produces FOXP1+ LMC motor neurons at the expense of Lhx3+ 
MMC motor neurons has recently been developed in our lab (Amoroso et. al, submitted). This 
particular protocol uses early and enhanced neuralization by dual SMAD inhibition along with 
both purmorphamine (PUR) and smoothened agonist (SAG) in place of SHH (SAG/PUR 
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protocol) (Figure 1.11). Of motor neurons in SAG/PUR cultures, ~70% are FOXP1+ compared to 
~30% in traditional SHH protocols without dual SMAD inhibition. Thus, the SAG/PUR protocol 
is an effective way to enrich for ALS-susceptible LMC motor neurons in culture. This method of 
deriving motor neurons will be used for the ALS profiling experiments in Chapter 4. 
  







Figure 1.11: Human stem cell differentiation to motor neurons.  
hESCs/iPSCs are differentiated to motor neurons through exposure to Fibroblast Growth Factor-
2 (FGF2), Retinoic acid, and Sonic Hedgehog (or smoothened agonist (SAG)± purmorphamine 
(Pur)) at developmentally appropriate time-points. The neurotrophic factors brain derived 
neurotrophic factor (BDNF), glial derived neurotrophic factor (GDNF), and ciliary neurotrophic 
factor (CNTF) are added to increase motor neuron survival and maturation following 
differentiation. In the accelerated protocol (Blue), Activin and BMP inhibition speed and 
increase the efficiency of neuralization during differentiation. This results in higher yields of 
motor neurons and a shorter differentiation time scale (21 Days as opposed to 29-32). Notably, 
inclusion of SAG+PUR in the accelerated protocol leads to an increased percentage of Foxp1 












































Practical considerations for human ESC differentiation and the study of hES-MNs: 
Scalability is a particularly useful feature of ES-derived motor neuron differentiation 
protocols. The average adult human has approximately 50,000 motor neurons in the spinal cord 
(Tomlinson and Irving 1977). Thus, even if primary cultures from post-mortem spinal cords were 
technically feasible, the low number of cells would be a limiting factor for many avenues of 
research. Fortunately, ES-derived motor neurons can be produced in much greater quantity.  An 
average differentiation can yield up to 40 million cells, of which 20-35% are motor neurons. 
Thus, one 21-day hESC differentiation can yield 160 to 280 human-equivalents of motor 
neurons. 
 Although motor neuron yield can be scaled to suit nearly any experimental design, low 
motor neuron purity in culture can be a confounding variable. Abundance of motor neurons in 
human ES-derived cultures ranges from 10% to 40% of total cells when using current versions of 
motor neuron differentiation protocols. Thus, purification of ESMNs is a critical step towards 
isolating populations of cells for study. Unfortunately, the p75 receptor, which is used to 
efficiently isolate motor neurons from primary rodent cultures, is not motor neuron-specific in 
hE-SMN cultures (see Chapter 3). Additionally, since human ES cells are quite recalcitrant to 
genetic modification, expression of a sortable surface marker under the control of a motor 
neuron-specific promoter has proven difficult.  
 Nevertheless, motor neuron reporter strategies have been useful in circumventing some of 
the obstacles posed by low motor neuron yield. Although difficult to derive, two published hES-
MN reporter lines exist, both expressing GFP from the motor neuron-specific HB9 promoter (Di 
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Giorgio et al. 2008; Placantonakis et al. 2009). One of these lines will be used in Chapter 3 as a 
tool to molecularly characterize hES-MNs (Di Giorgio et al. 2008). 
 Another approach, utilizing a shortened version of the HB9 promoter, has also been 
implemented to label hES-MNs in culture. Studies of the HB9 promoter indicate that a great deal 
of its motor neuron-specific activity is contained in a 3.5kb segment that is 5.5kb upstream of the 
transcriptional start site (Lee et al. 2004; Nakano et al. 2005). Pairing this 3.5kb segment with 
generic minimal promoters has proven a useful strategy for labeling hES-MNs in vitro by either 
plasmid transfection or lentiviral transduction (Singh Roy et al. 2005; Marchetto et al. 2008). 
The development of an hES motor neuron purification strategy that is easily transferable 
between genetically unmodified cell lines is a practical necessity for studying motor neurons 
derived from a large number of iPS lines. In Chapters 3 and 4, two strategies will be explored in 
hopes of purifying non-transgenic iPS-MNs. First, an attempt will be made to identify novel 
motor neuron-specific surface molecules in hES-MNs. Second, a lentiviral strategy will be used 
to introduce a motor neuron reporter construct into differentiating hES-MNs.  
Application of ES-MNs to the study of ALS: 
Both genetic manipulation of hESCs and transient transfection of hES-MNs could be 
used to introduce ALS causing genes into these cells and study their downstream effects. 
Recently developed zinc finger nuclease approaches will likely allow the directed mutagenesis of 
ALS-causing genes and produce a productive avenue of inquiry (Urnov et al. 2010). Transient 
transfection of hES-derived motor neurons with fALS- causing genes can also be achieved using 
current technology, albeit with poor control of transgene expression level (Karumbayaram et al. 
2009). However, both of these approaches forfeit access to patient-specific genetic background, 
which has a known modifying effect in ALS, and to all sporadic forms of the disease.  
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Thus, an ideal embryonic stem cell-based system for studying ALS would consist of 
hESCs with a genetic makeup identical to a patient with a known clinical phenotype and fALS 
mutation: a cloned hESC line. Although current technology cannot produce such an ESC line, 
research in the somatic cell nuclear transfer and ESC field has provided an alternative approach 
for the production of patient-specific pluripotent stem cell lines (iPS lines). In the next section, I 
will describe the experiments that lead to the discovery of iPS cells and how this discovery 
changes the current model of cell fate. Then, I will address the application of iPS cells to ALS. 
VII. Nuclear reprogramming: Somatic cell nuclear transfer and induced pluripotency 
In order to understand the mechanisms of induced pluripotency, it will be helpful to 
describe the experiments and ideas that lead to its discovery. These experiments began with the 
demonstration that terminally differentiated cells can be reprogrammed to a totipotent state using 
a technique known as somatic cell nuclear transfer (SCNT). Research into the mechanisms at 
play in SCNT eventually lead to the discovery that a small number of “reprogramming” genes 
could be used to convert terminally differentiated cells into pluripotent ones. Below, I provide a 
summary of these experiments: 
Somatic cell nuclear transfer (SCNT): 
SCNT is a procedure in which the nucleus of an egg or oocyte is replaced by one from a 
more differentiated somatic cell. Cytoplasmic components of the oocyte/egg are then capable of 
reprogramming the somatic nucleus to a totipotent state. This cloned embryo can then undergo 
normal embryological development and give rise to a fertile organism (Gurdon and Uehlinger 
1966). SCNT cloning procedures have been implemented in multiple mammalian species, but in 
human cells (Wilmut et al. 1997; Gurdon and Byrne 2003).  
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There has been a long-standing debate about whether the donor nuclei producing 
successful SCNT embryos might be, in fact, derived from rare stem cells residing in otherwise 
terminally differentiated tissues. Definitive proof that terminally differentiated post-mitotic cells 
can be reprogrammed exists in the form of successful SCNT on B-cells, T-cells, and olfactory 
neurons in mice; all classes of cells that undergo well defined genetic rearrangements during the 
final stages of differentiation, thus labeling all progeny in SCNT embryos (Hochedlinger and 
Jaenisch 2002; Eggan et al. 2004). These experiments, among others, established three key 
features of nuclear reprogramming. 1) Reprogramming can be performed on terminally 
differentiated post-mitotic cells. 2) Reprogramming is a rapid process that occurs largely before 
cell division. 3) Reprogramming does not require transcription. It is dependent only on the 
protein and mRNA constituents of the oocyte nucleus. 
Human somatic cell nuclear transfer: 
Despite success with many mammalian species, human SCNT has remained elusive. 
Following nuclear transfer into enucleated oocytes or zygotes, human oocytes undergo 
developmental arrest at the 6-10 cell stage for incompletely understood reasons (Egli et al. 2011; 
Noggle et al. 2011). This barrier is likely technical because relatively few groups have had 
access to large numbers of human oocytes (Egli et al. 2011). In support of this idea, a human 
pluripotent cell line has recently been produced via fusion of a haploid human oocyte with a 
donor somatic nucleus (Noggle et al. 2011). This cell line passes the gold standard teratoma 
assay for pluripotency in hESCs. Furthermore, Noggle et al. show that nuclear components of the 
oocyte, but not oocyte transcription, are necessary to successfully reprogram human somatic 
nuclei, and that reprogramming occurs rapidly following nuclear transfer (Noggle et al. 2011). 
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Although this technique produces triploid cell lines that would complicate therapeutic and 
research applications, it does demonstrate the technical possibility of successful human SCNT. 
Induced pluripotency as an alternative to SCNT: 
In light of the difficulties in producing human SCNT ES lines, observations in ES cells 
have pointed to an alternative method for reprogramming somatic nuclei to an ES-like state. 
Fusion of mouse or human ES cells with fibroblasts creates a hybrid 4n cell line with pluripotent 
characteristics (Tada et al. 2001; Cowan et al. 2005). These hybrid human cells demonstrate 
teratoma formation, re-activation of ES cell-specific genes, and modification of DNA 
methylation to a more ES-like state (Cowan et al. 2005). Such properties suggest that the actively 
transcribed components of ESCs are capable of at least partially reprogramming somatic nuclei. 
Furthermore, they lead to the hypothesis that the particular genes responsible for inducing 
pluripotency are known master-regulators of stem cell identity. 
Mouse induced pluripotent stem cells (miPSCs): 
Shinya Yamanaka directly tested this hypothesis by retrovirally expressing a group of 24 
such master-regulators in mouse fibroblasts and monitoring these cells for re-activation of known 
ES cell markers. Remarkably, multiple ES-like colonies appeared approximately 16 days after 
transduction (Takahashi and Yamanaka 2006). A simple subtractive analysis performed on the 
initial group of 24 genes yielded a set of 4 key factors for induced pluripotency: Oct-3/4, Sox-2, 
Klf-4, and c-Myc (Takahashi and Yamanaka 2006). Pluripotent cell lines derived by this method 
are dubbed induced pluripotent stem cells (iPS cells). iPS cells, although derived from 
fibroblasts, express protein markers and DNA methylation patterns characteristic of ES cells. 
Furthermore, the first iPS cells passed both the teratoma and chimera tests of pluripotency and 
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could be differentiated in vitro into derivatives of all three germ layers (Takahashi and 
Yamanaka 2006).  
Very importantly, iPS cells largely silence the integrated viral transcripts of 
reprogramming genes once they have entered a pluripotent state. The cellular machinery behind 
this silencing is believed to be the same used to prevent the re-activation of endogenous 
retroviruses in ES cells (Hotta and Ellis 2008). Because reprogramming factors are silenced in 
iPS cells, differentiated derivatives do not normally express high levels of potentially oncogenic 
pluripotency genes. However, the degree of retroviral silencing can vary from line to line, likely 
due to viral integration effects. There is currently an open question as to precisely how much 
reprogramming transgene expression is acceptable for lines used in research. Work in Chapter 2 
will demonstrate that many terminally differentiated derivatives can be produced even in lines 
that continue to express significant levels of reprogramming factors. 
The initial four-factor cocktail is not the only method that can be used to produce iPS 
cells. Expression of an alternative group of four factors Oct-3/4, Sox2, Nanog, and Lin28 in 
fibroblasts also allows the derivation of pluripotent iPS colonies (Yu et al. 2007). Additionally, 
concerns about the tumorigenicity of reprogramming factors, primarily that of c-Myc and 
secondarily of Klf-4, lead to attempts at removing these factors form the reprogramming 
cocktail. iPS cells can be generated with acceptable efficacy in the absence of c-Myc and in the 
absence of both c-Myc and Klf-4 in the presence of the histone deacetylase inhibitor valproic 
acid (Huangfu et al. 2008). Thus, the minimal complement of reprogramming factors appears to 
be only Oct-3/4 and Sox-2 under appropriate conditions. In support of this idea, iPS cells have 
been derived using Oct-3/4 alone by reprogramming a neural stem cell population that 
endogenously expresses Sox-2 (Eminli et al. 2008). These results demonstrate that the ES-like 
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pluripotent state of iPS cells can be achieved by multiple means. Furthermore, the existence of 
multiple pathways to pluripotency suggests that the reprogramming process simply “jump-starts” 
a dormant pluripotent state.  
An early concern about the utility of iPS technology was that retroviral integrations from 
reprogramming would disrupt proto-oncogenes, leading to tumor formation in animals or 
patients somehow transplanted with iPS derivatives. However, reprogramming methods can now 
produce iPS cells entirely free of genetic modifications by expressing reprogramming factors by 
transient transfection, episomally from adenoviral vectors, removable transposons, or membrane 
permeable preparations of reprogramming proteins (Okita et al. 2008; Stadtfeld et al. 2008; Kaji 
et al. 2009; Kim et al. 2009). Although these methods sacrifice efficiency to avoid transgene 
insertions, they point a potential way towards therapeutic applications for differentiated 
derivatives of iPS cells. 
Further work on mouse iPS cells has demonstrated that they pass all standard assays of 
pluripotency used for ES cells, albeit at a somewhat lower efficiency. Although teratoma 
formation and chimeric contribution to all three germ layers was demonstrated in the initial 
description of iPS cells, production of healthy germline chimeras as well as tetraploid 
complementation require a more careful selection of reprogrammed cell lines (Okita et al. 2007; 
Boland et al. 2009). Importantly, not every iPS line can pass all the standard tests of 
pluripotency, suggesting some heterogeneity within the iPS group (Boland et al. 2009). 
However, the successful production of tetraploid iPS embryos strongly suggests that iPS cells are 
bona fide pluripotent stem cells and not partially reprogrammed intermediates.  
Human induced pluripotent stem cells (hiPSCs): 
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Human cells can also be reprogrammed to pluripotent iPS cells (hiPSCs). 
Reprogramming of dermal fibroblasts has been reported with the both the Yamanaka and 
Thompson 4-factor cocktails, Oct-3/4, KLF-2 and Sox-2 without c-MYC, as well as Oct-3/4 and 
Sox-2 alone in the presence of valproic acid (Takahashi et al. 2007; Yu et al. 2007; Huangfu et 
al. 2008; Park et al. 2008). Reprogramming of human dermal fibroblasts occurs over a slightly 
longer time period than in mouse, likely due to slower cell division rates in hES cells and 
fibroblasts. Quite strikingly, the culture conditions necessary for the derivation of hiPS cells 
mirror those necessary for the culture of hES cells, not mouse iPS cells. Thus, although similar 
transcription factors are involved in the establishment of pluripotency in mice and humans, the 
environmental requirements to maintain that pluripotency are species-specific (Park et al. 2008). 
Furthermore, hiPS cells pass the gold standard teratoma assay for human pluripotency and 
undergo directed differentiation in a manner similar to hES cells (Takahashi et al. 2007). 
However, because the teratoma test is relatively crude, a more comprehensive method is needed 
to reliably verify that hiPS lines will be useful for their intended applications. To this end, results 
in Chapter 2 will use quantitative measures of motor neuron differentiation efficiency to address 
differences in pluripotency in a panel of hES and hiPS lines. 
Mechanisms of reprogramming by induced pluripotency: 
Although human and mouse iPS cells can be produced from many classes of donor cells, 
the efficiency of reprogramming varies by donor cell type, and is thought to be a function of 
differentiation state. Similarly to SCNT, the efficiency of iPS reprogramming goes down with 
increasing differentiation stage of the cell type being reprogrammed (Gurdon and Melton 2008; 
Park et al. 2008; Eminli et al. 2009). In less differentiated cell types, not only does the efficiency 
of 4-factor reprogramming increase, but expression of reprogramming factors is required for 
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shorter periods of time (Eminli et al. 2009). Increasing the basal rate of cell division in 
differentiated cells also greatly increases both the kinetics and efficiency of 4-factor 
reprogramming, suggesting that cell division itself is an important factor in erasing the epigenetic 
marks left by differentiation (Hanna et al. 2009; Utikal et al. 2009). This can be contrasted with 
SCNT in which reprogramming is very rapid and requires neither cell division nor transcription.   
Due to both the slow rate of reprogramming and its seeming dependence upon multiple 
cell divisions, a stepwise, stochastic model of reprogramming has been proposed (Hanna et al. 
2009; Yamanaka 2009). According to this model, reprogramming occurs in multiple, stochastic 
steps following cell division when DNA-associated proteins are more loosely associated with 
their target sequences, thus allowing reprogramming factors greater access to drive expression of 
pluripotency genes. Therefore, it has been proposed that more primitive cells require a smaller 
number of transitions to reach the iPS cell state (Stadtfeld and Hochedlinger 2010). 
A revised model of cell fate: 
The success of induced pluripotency has led to a re-working of the current model of cell 
fate specification. Previously, the fate of a terminally differentiated cell was considered to be 
discrete and final. In the cases where reprogramming was possible, it relied on undefined oocyte 
factors and produced a reprogrammed cell in its most primitive, undifferentiated state. 
Conversion of a somatic cell to an iPS cell via induced pluripotency showed that one cell type 
could be converted to another without first going through the intermediate stage of the zygote. 
Such direct conversion has now also been observed between other, non-pluripotent cell types. In 
each instance, the known master regulators of cell fate specification for a target cell type were 
overexpressed in an unrelated tissue and caused direct conversion to the target cell fate. Notable 
examples of this phenomenon include the conversion of exocrine pancreas into beta-islet cells 
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and fibroblasts into blood progenitors, cardiomyocytes, forebrain neurons, and motor neurons 
(Zhou et al. 2008; Ieda et al. 2010; Szabo et al. 2010; Qiang et al. 2011; Son et al. 2011). The 
discovery that key transcription factors can direct multiple sorts of fate re-specification, even in 
adult somatic cells, demonstrates that the barriers between different cell fates are not as absolute 
as once thought. In fact, it is now thought that many cells must continually express key fate-
regulating genes to maintain a stable set of characteristics (Gurdon and Melton 2008). These 
results suggest that it may be useful to conceptualize cell fate as a “potential energy” landscape 
of metastable states (cell fates) that can be navigated at will using the appropriate master-
regulators of transcription (Figure 1.12). 
  






Figure 1.12: “Potential energy” landscape of differentiation.  
In a revised model of cell fate, terminally differentiated derivatives are seen as occupying low 
locations on a potential energy landscape. Adding potential energy to the system 
(reprogramming) drives cells into a higher potential energy stage (iPS/ES cells) from which they 






















Applications of iPS cells: 
iPS cells have generated enormous excitement due to their potential applications in 
disease modeling and regenerative therapy. Directed differentiation of iPS cells provides the first 
patient-specific access to living preparations of many tissue types. By capturing patient-specific 
genetic background, iPS cells will enable modeling of poorly understood complex genetic 
disorders, creation of humanized disease models that may be used to study disease modifiers and 
other correlations with clinical data, and immunologically matched tissue for eventual cell-
replacement therapy. 
These advantages of patient-derived iPS cells are particularly promising for ALS 
research. Using established techniques, iPS cells derived from ALS patients can be differentiated 
into motor neurons (ALS iPS-MNs) (Dimos et al. 2008). ALS iPS-MNs provide the first access 
to pre-symptomatic ALS motor neurons. These cells express endogenous levels of ALS causing 
genes in the context of an individual-specific genetic background. Such iPS-MNs will not only 
be quite useful for modeling fALS of known genetic causes, but also will provide the first 
glimpse of living motor neurons in sporadic forms of the disease. 
In the work presented in Chapter 4, I will take a first step towards defining the 
phenotypes of ALS in iPS-MNs. Using transcriptional profiling, I will identify expression 
patterns in iPS-MNs that co-vary with disease state. Furthermore, I will compare these 
expression patterns to our expectations about ALS and show that iPS-MNs do appear to exhibit 
some previously described phenotypes of disease.  
Concerns about iPS cells: 
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Before it is possible to assess phenotypes of ALS in iPS-MNs, it is necessary to more 
robustly establish the iPS system as a reliable alternative to the gold standard of human ES cells. 
Although iPS cells resemble ES cells in many ways, serious concerns about iPSCs and their 
differentiated derivatives have been raised. These concerns pertain to retention of epigenetic 
marks during reprogramming, transcriptional differences between iPSCs and ESCs, potential 
deleterious effects of sustained transgene expression, accumulation of somatic mutations, and 
reduced efficiency of directed differentiation. They will be discussed in more detail below. 
Several studies have indicated that many iPS lines are incompletely reprogrammed and 
retain a “memory” of the cell type of origin. During iPSC derivation, nascent iPS lines pass 
through a partially reprogrammed state before becoming fully pluripotent. Some iPS lines may 
become trapped in this state and never attain true pluripotency (Mikkelsen et al. 2008). Those 
lines that do become fully pluripotent can retain epigenetic marks of the tissue of origin and 
exhibit reduced differentiation efficiency towards other cell lineages, especially at early passages 
(Kim et al. 2010). Furthermore, parentally imprinted genes may never be properly re-
programmed during iPSC derivation (Stadtfeld et al. 2010). However, with continued passaging, 
the transcriptional state of both human and mouse iPS cells begins to converge upon that of ES 
cells, although there are still some iPS-specific differences in expression (Chin et al. 2009). It has 
been suggested that expression of retrovirally integrated reprogramming genes is responsible for 
some of the differences in global gene expression between iPSCs and ESCs. In support of this 
idea, the overall transcriptional similarity between hES cells and hiPS cells significantly 
increases following LoxP-mediated excision of reprogramming factors (Soldner et al. 2009).  
Finally, and perhaps most importantly for ALS modeling, it has been suggested that iPS 
cells may show a specific deficit in forming neural tissues and motor neurons. Hu et al. 
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differentiated a set of 12 iPS lines and 5 hES lines to neural epithelia and observed that 11 of 12 
iPS lines formed Pax6 positive neural progenitors at reduced efficiency compared to ES lines 
(Hu et al. 2010). Furthermore, a subset of iPS lines also showed a diminished capacity to form 
HB9+ motor neurons as compared to a single hES line. However, these same iPS lines formed 
Olig2+ motor neuron progenitors more efficiently than the hES line. The reason for this 
discrepancy is unclear, but the results suggest that iPS cells may be a difficult substrate from 
which to make neurons. If this is the case, then modeling ALS with iPS cells may prove difficult.  
One potential confounding variable in these experiments, however, is that the hES line used in 
the production of motor neurons (H9) has a particularly high neurogenic potential (Osafune et al. 
2008; Bock et al. 2011). Furthermore, it has recently been shown that longer times in culture 
seem to increase the efficiency of neuralization in iPS cells, suggesting that the reduced 
efficiencies observed by Hu et al. may be a transient effect (Koehler et al. 2011).  
Work in Chapter 2 will address some of these potential problems with iPS cells. First, the 
issue of variable neural potency will be investigated by comparing the differentiation potential of 
a panel of hiPS and hES lines. Our results will suggest that hiPS cells produce neurons as 
efficiently as hES cells, in contrast to the results of Hu et al. (2010) (Boulting et al. 2011). 
Furthermore, work I will only briefly touch on in Chapter 2 has compared ES and iPS cells with 
respect to their global transcriptional and epigenetic profiles (Bock et al. 2011). This work 
demonstrates that, although there can be real differences between the two cell types, hES and 
hiPS cells are overlapping populations, with outliers in both groups.  
VIII. Disease modeling with hiPS cells 
 Despite the above concerns, the past several years have seen the development of a 
number of hiPS-based neurodegenerative disease models. The basic “disease in a dish” paradigm 
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of these models involves producing iPS cells from various groups of patients, differentiating 
these cells into disease-relevant cell types, and assessing the differentiated derivatives for 
differential gene expression, survival, protein localization/aggregation, sensitivity to exogenous 
stressors, and physiologic activity. Disease-related phenotypes have been observed in iPS-
derived neurons from patients with schizophrenia, Huntington’s disease, Parkinson’s disease, 
familial dysautonomia, Rett syndrome, spinal muscular atrophy, and fALS caused by mutations 
in VAPB (Ebert et al. 2009; Lee et al. 2009; Marchetto et al. 2010; Brennand et al. 2011; Mitne-
Neto et al. 2011; Nguyen et al. 2011). In each of these iPS models, full characterization of 
disease-specific phenotypes and mechanisms is nascent, but very promising. It is worth 
discussing a few of the phenotypes observed in existing iPS models of neurodegeneration as 
examples of what may be found during the search for an ALS phenotype in iPS-MNs. 
Phenotypes of neurodegeneration in iPS-derived neurons: 
Familial dysautonomia: iPS cells from patients with familial dysautonomia exhibit a 
reduced capacity to differentiate into derivatives of the neural crest; a characteristic that matches 
well with the early autonomic nervous system defects seen in patients (Lee et al. 2009). 
However, it is unknown whether or not this defect is specific to the neural crest, or also occurs 
during iPS differentiation into other derivatives of the neurectoderm.  
Rett syndrome: iPS cells derived from female patients with Rett syndrome, another 
neurodevelopmental disorder, can be efficiently differentiated to neurons. However, Rett iPS-
neurons exhibit decreased synaptic connectivity, spine density, and soma size, as well as reduced 
spontaneous action potential firing in culture (Marchetto et al. 2010). These deficits are 
consistent across multiple Rett-iPS cell lines, and can be rescued by repletion of mutant protein 
or treatment with Igf-1.  
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Schizophrenia: iPS-neurons derived from adult-onset schizophrenic (SCZD) patients also 
display decreased synaptic connectivity, spine density, and soma size in culture, but show no 
apparent differences in spontaneous action potential firing (Brennand et al. 2011). Expression 
profiling reveals a large number of differences between SCZD neurons and controls, some of 
which have been observed in previous work performed on post-mortem patient samples. 
Treatment with Loxapine, but not other antipsychotic drugs, was able to reverse some putative 
SCZD-iPS disease phenotypes, including select expression changes.  
Parkinson’s disease: Sensitivity to environmental stressors has also been observed in 
disease-specific iPS-neurons. Dopaminergic neurons derived from a single PD patient were more 
sensitive to 6-OHDA induced cell death than those derived from a control iPS or hES line 
(Nguyen et al. 2011). Although mixed cultures of dopaminergic neurons derived from a PD 
patient were also more sensitive to the oxidative stressor hydrogen peroxide, the tyrosine 
hydroxylase-positive dopaminergic neurons themselves were not.   
Spinal muscular atrophy (SMA): Several disease-related phenotypes have been described 
in iPS-derived motor neurons, although their precise relation to motor neuron degeneration is 
still uncertain. In a single iPS line, SMA iPS-derived motor neurons exhibit a dearth of nuclear 
SMN aggregates, a pathological hallmark of the disease (Ebert et al. 2009). This effect can be 
partially rescued by treatment with drugs known to increase SMN in other tissues. Furthermore, 
SMA iPS-MNs are less abundant in culture than control iPS-MNs following 6 weeks of 
differentiation, despite being present at similar levels two weeks prior to this time-point (Ebert et 
al. 2009). This result can be interpreted either as decreased SMA iPS-MN survival or a shift in 
late-stage differentiation potential away from motor neurons in the SMA iPS line, but not the 
control iPS line.  
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Amyotrophic lateral sclerosis (ALS): ALS iPS-MNS derived from VAPB fALS cases 
display a decrease in VAPB levels, potentially due to mutant protein instability (Mitne-Neto et 
al. 2011). This is particularly informative because most ALS8 cell models rely on overexpression 
of mutant VAPB and thus may engage cellular responses not seen in disease. VAPB iPS-MNs do 
not seem to show frank cell death in culture or accumulation of ubiquitinated aggregates (Mitne-
Neto et al. 2011). No disease phenotypes in an SOD1 ALS iPS line have yet been reported. 
The currently known phenotypes of neurodegeneration in iPS-neurons point to the great 
potential of iPS cells to model human disease, but also demonstrate some of the pitfalls when 
working with a poorly defined system. It is very encouraging that phenotypes of both juvenile 
and adult neurodegenerative diseases have been observed. Furthermore, responsiveness to drug 
treatment and sensitivity to environmental toxins suggests that iPS-neurons will be useful for 
screening new compounds and elucidating the role of environmental stressors in causing disease. 
However, many studies do not make comparisons between a large number of control and disease 
lines and tend to utilize better-established cell lines as controls, leading to a potential bias of 
disease-specific findings towards phenotypes that are driven by line-to-line variations. 
Additionally, most transcriptional profiling and survival analysis of disease-specific iPS-neurons 
has been performed on mixed populations of mostly neural cells. Thus, results may be 
confounded by production of different neuronal subtypes with variable efficiency or factors 
acting on neurons in a paracrine manner. Finally, genetic background differences between 
disease and control lines have the potential to give false positive disease-associations. 
The next steps in modeling neurodegenerative disorders with iPS-derived neurons should 
overcome these obstacles. Several ways to do this include increasing the number of cell lines 
used for analyses, focusing only on the cell types of interest, and isolating cell autonomous from 
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non-cell autonomous effects as much as possible. In addition, isogenic controls should be 
constructed where possible by either knocking out or knocking down disease-causing genes.  
Work in Chapter 4 will partially address these concerns by evaluating phenotypes of ALS in 
enriched populations of motor neurons and doing so across multiple ALS and control lines.  
IX. Questions addressed in the following chapters: 
 In the following chapters, I will address a series of the concerns I have raised in this 
introduction. The general layout of the thesis is first to establish the iPS-MN system more 
robustly and then to move towards using it as a tool to understand ALS-related expression 
changes in iPS motor neurons. To do this, I will first describe motor neuron differentiation 
potential in a panel of iPS and ES lines. Then, I will more carefully describe the normal 
properties of hES and iPS-MNs using expression profiling and electrophysiological 
measurements with calcium sensitive dyes. Following this, I will develop a technique to enrich 
iPS-MNs from differentiated cultures and apply this technique to generate expression profiles of 
ALS and control iPS-MNs. As a part of a general effort to understand patient-specific aspects of 
ALS, I will also identify expression patterns in post mortem ALS-patient motor neurons that 
correlate with age of ALS onset. These genes will serve as future candidates for patient-specific 
phenotypes in iPS-MNs. The major questions addressed in each chapter are as follows: 
• Chapter 2:  
o Are iPS cells a reliable system in which to study motor neurons? 
o Can iPS cells generate motor neurons with comparable efficiency to ES cells? 
o What are the factors that influence iPS-MN differentiation efficiency? 
o Do ALS iPS lines produce motor neurons as efficiently as control iPS lines? 
• Chapter 3: 
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o What are the basal properties of hES motor neurons? 
o Do ES/iPS-MNs express endogenous surface markers that can be used to isolate these 
cells in culture? 
o What are the electrophysiological properties of iPS-MNs? Are they similar to hES-
MNs? 
o Do iPS-MNs display synaptic connectivity in culture? If so, to what degree? 
• Chapter 4:  
o Can iPS-MNs be isolated in culture using motor neuron-specific lentiviral reporters? 
o Do ALS iPS-MNs display distinct expression profiles compared to control iPS-MNs? 
o Do ALS iPS-MNs show increased markers of cell stress? 
o How do ALS iPS-MN expression profiles compare to previously published profiles of 
ALS? 
• Chapter 5:  
o Can expression profiles from post mortem sALS patient motor neurons be used to 
investigate correlates of ALS onset? 
o Do onset-correlated genes from sALS patients generalize to iPS-MNs from fALS 
patients? 
o What are the effects of overexpressing onset-correlated genes in iPS-MNs? 
• Chapter 6:  
o What are the most promising candidate genes from this work? 
o What experiments would be appropriate for future directions? 
o Does this work suggest any new therapeutic strategies for ALS? 
  
! ! ! !!
!
L.!
Chapter 2: Validation of iPS technology for the study of motor neurons. 
Introduction: 
Before the iPS system can be applied to modeling diseases of the nervous system, it must 
be validated as a reliable source of disease-relevant cell-types. For this to be the case, iPS cells 
must behave reproducibly in culture and not show systematic deficits in the production of 
differentiated neural subtypes. Furthermore, any line-to-line variation in differentiation 
efficiency and quality of resulting neurons should not be so large as to overwhelm potential 
disease phenotypes.  
The most clearly articulated of the concerns relating to the general reliability of iPS cells 
is that the reprogramming process may be incomplete or aberrant, leaving a signature of original 
cell type of origin. Multiple studies have reported that DNA methylation patterns in iPSCs 
resemble an intermediate between the donor tissue and embryonic stem cells (ESCs), suggesting 
that iPSCs may, in fact, not be completely reprogrammed (Mikkelsen et al. 2008; Kim et al. 
2010; Kim et al. 2011). Despite this, it appears that mouse ES and iPS cells do not differ greatly 
in global transcriptional profile, except possibly at parentally imprinted loci (Stadtfeld et al. 
2010). Although a signature of reprogramming in and of itself does not necessarily limit the 
utility of iPS cells, it could pose a problem if it caused reduced efficiency of differentiation or 
aberrant differentiated cells.  
In fact, several studies suggest that iPS cells may display systematic defects in 
differentiation that may be cell-type specific.  iPS lines which retain a partial DNA methylation 
pattern of their original donor tissue seem more efficient at forming this tissue type than others 
during directed differentiation (Kim et al. 2010; Polo et al. 2010). In addition, cells with 
aberrantly silenced imprinted loci exhibit generally compromised pluripotency in a chimera 
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assay (Stadtfeld et al. 2010). Perhaps most relevant to this study is a report that iPS cells have a 
generally reduced potential for neural differentiation and specific deficits in forming motor 
neurons when compared to hES cells (Hu et al. 2010).  
Finally, because most existing iPS studies have used a small number of iPS lines (<4), it 
is unclear to what extent line-to-line or donor-to-donor variability might affect the differentiation 
potential of iPS cells or the characteristics of their differentiated derivatives (Taura et al. 2009; 
Armstrong et al. 2010; Ghosh et al. 2010; Grigoriadis et al. 2010; Tokumoto et al. 2010; Xi et al. 
2010).  
If iPS cells were a generally poor source of neurons or other disease-relevant cell types, 
then they would have greatly reduced potential for patient-specific research and therapeutics. 
Because we were concerned with these issues, we joined forces with Dr. Kevin Eggan’s lab 
(Harvard University) to perform an extensive phenotypic characterization of human iPS cells as 
they compare to human ES cells before initiating disease-modeling research. To accomplish this, 
we generated a panel of iPS lines from fibroblasts donated by ALS patients and healthy controls. 
We then performed a broad characterization of their pluripotency and differentiation capacity, 
comparing results from independent experiments in two different laboratories. Along with 4 
others, I was a co-first author on this work, which was published in Nature Biotechnology in 
March 2011 (see author contribution section) (Boulting et al. 2011).  
In this study, we evaluated pluripotency and efficiency of directed differentiation to 
motor neurons in a “test set” of 5 hES lines and 16 hiPS lines (Boulting et al. 2011). Aside from 
comparing ES and iPS lines, the test-set was designed to assess variability in iPS lines conferred 
by individual donor identity, iPS clone, 3 vs 4-factor reprogramming, age, sex, and ALS 
genotype. 
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A companion study addressed variability in iPS differentiation efficiency using a 
genome-wide profiling strategy. This work, published in the March 2011 edition of Cell, was a 
collaboration with Alex Meissner’s lab at Harvard in which I was a middle author (Bock et al. 
2011). By measuring the expression of a series of lineage markers during morphogen-free 
random differentiation, the Meissner group was able to compute a “scorecard” of lineage 
differentiation potential for a panel of iPS lines. Our iPS-MN differentiation efficiency data was 
then used as one means of validating this scorecard. These results will be shown at the end of 
this chapter.  
Author Contributions from Boulting et al. (2010): 
 All experiments described in this chapter were designed and performed in collaboration 
with the other authors as listed below. I was most heavily involved in the culture of dermal 
fibroblasts for the generation of iPS lines, differentiation of motor neurons from the test set of 
iPS lines, analysis of flow cytometric data for pluripotency markers, and assessment of 
physiologic activity in motor neurons using calcium imaging. The calcium imaging segments 
from this paper will be presented in Chapter 3 along with other unpublished results.  
“G.F.C., M.W.A. and D.H.O. derived and maintained human fibroblasts. C.T.R. and 
J.T.D. reprogrammed all iPSC lines. G.L.B. and E.K. expanded all iPSC lines. G.L.B. and E.K. 
led and contributed equally to all other experiments and analyses in the Eggan laboratory. 
G.F.C., M.W.A. and D.H.O. led and contributed equally to all other experiments and analyses in 
the Project ALS laboratory. D.J.K. did flow cytometry analysis.” [D.H.O performed statistical 
analysis of flow cytometry data.]” A.B.M., D.J.W. and D.H.O. designed and carried out Ca2+ 
imaging. B.J.W., G.L.B. and C.J.W. did intracellular recordings. M.Y. assisted with teratomas. 
L.D. assisted with quantitative analysis. S.M. assisted with stem cell culture. G.L.B., E.K., K.E., 
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G.F.C., M.W.A., D.H.O., C.E.H. and H.W. conceived the experiments and wrote the 
manuscript.”(Boulting et al. 2011) 
Results: 
A test set of human iPSC lines: 
 We first established a “test set” of 16 human iPS lines to be used throughout the study. 14 
of the lines were newly derived and 2 were previously published (Dimos et al. 2008) (Table 2.1). 
Lines in the test set were chosen to represent potential sources of variation in differentiation 
efficiency. All lines were derived through retroviral transduction of dermal fibroblasts (see 
Methods). Newly derived lines were reprogrammed using three factors (OCT4, KLF4, SOX2) 
and previously published lines were derived using 4 factor reprogramming including c-MYC. 
Including both reprogramming methodologies in our test set allowed us to evaluate the effect of 
c-MYC on pluripotency. Lines in the test set were derived from seven donors, both male and 
female, with ages ranging from 82 to 29 years old. We included multiple iPS lines from 5 donors 
in order to assess the roles of individual genetic background and unique reprogramming events 
on iPS cell characteristics. Finally, we included lines both from healthy control donors (n=10 
lines, 5 donors) and from ALS patients carrying mutations in SOD1 (n=6 lines, 2 donors). To 
evaluate the characteristics of hiPS cells as compared to hES cells, we also included six hESC 
lines in the test set (Table 2.1). 
In order to begin our analysis, we first sought to establish pluripotency in all iPS lines 
using the current gold-standard measurements for hESCs. All iPSC lines formed adherent 
colonies with morphology and cell cycle profiles similar to hESCs (Figure 2.1 A-B). 
Furthermore, all iPS colonies stained positively for the pluripotency markers alkaline 
phosphatase (AP), OCT3/4, NANOG, SSEA3, TRA-1-60, and TRA-1-81 in the expected 
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subcellular distributions (Figure 2.1A and as shown in Boulting et al. (2011)). In order to assess 
the pluripotent potential of the iPS lines in the test set, we first performed a 16-day morphogen-
free “random” differentiation assay and verified that each iPS line could produce derivatives of 
all three germ layers (Figure 2.1C, See Methods). Neuron-specific tubulin (TUJ1) was used to 
mark neurons, smooth muscle actin ("SMA) to mark mesodermal derivatives, and "–fetoprotein 
(AFP) to mark endoderm. Finally, we assessed the pluripotency of 14 iPS lines using the 
teratoma assay: the most stringent test of pluripotency normally performed on hESC lines. 
Following injection into immune-compromised mice, 14 of 14 iPS lines successfully formed 
teratomas that contained tissue derivatives of all three germ layers (Figure 2.1D, See Methods). 
Thus, all iPS lines tested satisfy the current gold-standard criteria for pluripotency in hESCs. See 
Figure 2.1E for a summary of which experiments were performed on each iPS line in this study. 
13 of 16 iPS lines generate motor neurons using standard differentiation protocols: 
 To more rigorously evaluate the pluripotency of individual iPS lines, we determined the 
efficiency with which each line could be differentiated to motor neurons. These experiments 
used a standard motor neuron differentiation protocol with a chemical agonist of the hedgehog 
pathway in place of SHH (see Methods). We evaluated motor neuron production in each line by 
assessing the presence of cells with neural morphology that also stained positive for the neural 
marker TUJ1 and the motor neuron marker Islet1/2 (Figure 2.2A,B,D, see Methods). We 
determined that all of the hES lines in the test set produced motor neurons as assessed by these 
measures (5/5 lines, Figure 2.2C,G). However, only 13 of 16 iPS lines formed motor neurons 
upon directed differentiation (Figure 2.2C,G, See Supplemental Table 2.2 for N and values). 
 Because Islet1/2 expression is not unique to motor neurons in the spinal cord, we verified 
that the Islet1/2-positive cells measured above also expressed other markers of motor neuron cell 
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fate. We first stained differentiated cultures for the motor neuron marker HB9 and verified that 
the iPS lines producing the highest percentage of Islet1/2 also produced the highest percentage of 
HB9 (Figure 2.2D,F,G). Then, we verified in a reduced set of lines that Islet1/2 cells expressed 
ChAT, an enzyme involved in acetylcholine synthesis (Figure 2.2E). Finally, we established 
expression of the neural marker NCAM by flow cytometric analysis and used qPCR to verify 
expression of the motor neuron markers HB9, ChAT and CHT1 by qPCR (data shown in 
Boulting et al. 2010). Therefore, the cells produced in our differentiations seem to be bona fide 
iPS-MNs and are not largely composed of other Islet1/2-expressing neural subtypes.  
 In order to determine the generalizability of our results and the stability of line-dependent 
differentiation potential, a subset of iPS and hES lines was independently differentiated to motor 
neurons in two geographically distinct laboratories: the Project A.L.S. Laboratory at Columbia 
University and the Eggan Laboratory at Harvard University. We found a remarkable 
concordance in differentiation efficiency for individual lines across the two laboratories (Figure 
2.2C). In fact, there was no difference in the overall differentiation efficiency for each of the 
lines analyzed between the two laboratories (ANOVA F=1.132, p=0.301, Supplemental Table 
2.1). This strongly suggests that iPS lines exhibit stable propensities towards differentiation and 
will retain these characteristics upon transfer between different laboratories.  
iPS-MNs are physiologically active: 
To determine if iPS-MNs display functional properties that are similar to hES-MNs, we 
compared the electrophysiological properties of motor neurons from 4 iPS lines and 2 hES lines. 
We first used calcium sensitive dyes to evaluate both spontaneous activity and responses evoked 
by Kainate and KCL. These experiments were conducted on a subset of 4 iPS lines and 1hES 
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line. The data describing them will be included in Chapter 3 along with a more complete 
description of calcium activity and connectivity in iPS-MNs. 
Intracellular recordings were also performed on a group of 2 iPS lines and 1 hES line 
(18a, 27b, Hues3 HB9::GFP). These recordings demonstrated the consistent presence of voltage 
gated sodium and potassium currents as well as evoked action potentials in motor neurons 
generated from each cell line (data shown in Boulting et al. 2010). Importantly, rapid inward 
currents were TTX-sensitive, indicating that they require voltage-gated sodium channels. Along 
with the calcium imaging data, these two approaches showed no gross differences in 
electrophysiological properties between ES-MNs and iPS-MNs. 
Factors influencing motor neuron differentiation efficiency: 
 Having established reliable measures of motor neuron differentiation capacity for each 
iPS and ES line, we were then in a position to ask which variables represented in the test set 
seemed to influence that capacity.  
We first addressed one of the major questions of this work: do iPS cells produce motor 
neurons as efficiently as ES cells? We found that there was no difference in the efficiency of 
motor neuron production between ES (n=5) and iPS lines (n=13). ES lines produced 11.2 ± 1.6% 
Islet1/2 positive cells on average, whereas iPS cells produced 10 ±  0.8% (p=0.439,  ±  SEM) 
(Figure 2.3A, Supplemental Table 2.1). iPS lines that failed to make motor neurons entirely were 
excluded from this and subsequent analyses. They will be addressed in a separate section below. 
Because it has been reported that different hESC lines display characteristic efficiencies 
of differentiation to neurons, we hypothesized that the same would be true for iPS cells (Osafune 
et al. 2008). Therefore, we evaluated the effect of individual cell line on the efficiency of 
differentiation. We found that cell line identity indeed made a significant contribution to the 
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percentage of Islet1/2+ motor neurons formed in culture (ANOVA F=3.35, p=0.001, d.f.=18, 
Figure 2.2G, Supplemental Table 2.2). Furthermore, post-hoc line-by-line comparisons were 
significant for 18c vs. 11a (p=0.017) and 18c vs 11c (p=0.039) (Supplemental Table 2.2). 
We next analyzed sources of variation within the group of iPS lines. Despite the variable 
production of motor neurons between different iPS lines, there were no significant contributions 
to differentiation efficiency from either disease status (ALS vs. control) or reprogramming 
method (3 vs. 4 factor) (Figure 2.3B, Supplemental Table 2.1). Furthermore, although six lines 
developed karyotypic abnormalities during culture (29d, 27b, 29e, 11a, 11b, 15b), these lines did 
not produce motor neurons with a different efficiency than karyotypically normal lines (p=0.932, 
Supplemental Table 2.1, Supplemental Table 2.7). Finally, donor age at time of fibroblast 
donation did not correlate with percent Islet1/2+ neurons produced during differentiation 
(R2=0.0084). 
However, two factors did influence motor neuron differentiation efficiency in cell lines of 
the test set: donor sex and individual donor identity. We found that male ES/iPS cell lines 
produced significantly fewer motor neurons than female lines (p=0.048, Supplemental Table 
2.3). Donor identity also displayed a significant effect on differentiation potential both amongst 
all iPS and ES differentiations as well as in iPS differentiations alone (ANOVA F=11.8, 
p=0.006, d.f.=6, Figure 2.3C, Supplemental Table 2.4). However, no post-hoc pairwise 
comparisons for the donor analysis reached significance (Supplemental Table 2.4). Overall, this 
is consistent with the line-by-line differentiation efficiency data showing that iPS line 18c 
produced significantly more motor neurons than either 11a or 11c (Figure 2.2G). To strengthen 
these results, we used southern blot analysis to confirm that the different iPS lines from donors 
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18, 11, and 29 were, in fact, derived from independent reprogramming events (data shown in 
Boulting et al. 2010). 
One property of iPS lines that has the potential to limit their intended uses is persistent 
low-level expression of reprogramming factors, which may cause untoward effects. Although 
most of our iPS lines were not produced using the potentially oncogenic factor c-MYC, changes 
downstream of other reprogramming factors still remain a concern. To address this, we measured 
residual viral reprogramming factor expression both in iPS cells and in differentiated neural 
cultures using quantitative real time (qRT)-PCR (Data shown in Boulting et al. 2010). We noted 
residual expression of viral KLF4 in 8 of 16 iPS lines (11b, 11c, 15b, 18b, 18c, 27b, 27e, and 
29e) and residual viral expression of OCT4 in 3 of 16 iPS lines (15b, 18c, 27b). However, we 
found no correlation between the cumulative level of transgene expression and Islet1/2+ 
differentiation efficiency (R2=0.1687). Surprisingly, we were able to identify Oct4 and Islet1/2 
co-positive motor neurons in differentiations of the iPS line 15b (data shown in Boulting et al. 
2010). Such a finding suggests that some level of persistent Oct4 expression can be tolerated 
even as iPS cells become terminally differentiated. Taken together, these results suggest that 
low-level persistent transgene expression does not alter the differentiation capacity of iPS lines. 
Lines with compromised differentiation capacity can be rescued by enhanced neuralization: 
Three of the 16 iPS lines reproducibly failed to make motor neurons. Two of these three 
lines, 27e and 29e, formed embryoid bodies (EBs) normally during early differentiation, but then 
consistently became cystic and disintegrated during culture (data shown in Boulting et al (2011)). 
Cells that did survive were not Tuj1+ neurons. The other line, 11b, appeared to differentiate 
normally, but formed far fewer Tuj1+ cells than all other iPS cell lines (8 ± 0.2%SEM) 
(Supplemental Table 2.5).  
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We hypothesized that these deficits may be due to either a stage-dependent blockade in 
differentiation, or a strong bias towards producing cells belonging to other germ layers. Flow 
cytometric (FC) analysis of pluripotency marker expression supports this idea for the iPS line 
27e. Using FC, we assessed the surface expression of the pluripotency markers SSEA3 and 
TRA-1-60 for a panel of 13 undifferentiated iPS lines and 2 hES lines (Figure 2.4A-C). The 
percentage of SSEA3 and TRA-1-60 positive cells was very high for all lines and not 
significantly different between lines in the panel. However, iPS line 27b displayed significantly 
higher median fluorescence intensity for Tra-1-60 staining when compared to all other lines 
(p<0.007 for each post-hoc comparison) (Figure 2.4D, Supplemental Table 2.6). Visualization of 
FC plots confirmed more intense and homogenous expression of Tra-1-60 in 27e as compared to 
representative hES and iPS lines (Figure 2.4E). These results suggest that the iPS line 27e may 
be in some way “locked in” to an undifferentiated state. 29e and 11b did not display this 
phenotype.  
 We then asked if the blockade in neural differentiation we observed in these three iPS 
lines could be overcome using stronger neural induction signals during the early stages of 
differentiation. To do this, we added a dual SMAD inhibition period to the first 9 days of our 
differentiation protocol by applying small molecule inhibitors of bone morphogenic protein and 
transforming growth factor !-1 activin receptor-like kinase (see Methods) (Chambers et al. 2009; 
Zhou et al. 2010). A similar approach had recently been reported to greatly increase neuralization 
efficiency in human ES and iPS cells and, through an unclear mechanism, to shorten 
differentiation time (Chambers et al. 2009). Using this accelerated protocol, we found that all 
three “defective” lines now gave rise to high numbers of TuJ1+ neurons as well as Islet1/2+ and 
HB9+ motor neurons following 21 days of differentiation (Figure 2.5A-C). In fact, the percentage 
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of these three markers in the defective lines was indistinguishable from two sub-clones of the 
Hues3 hES line differentiated using the same protocol (Figure 2.5 A-C). Thus, increased 
neuralization seems to rescue lines that are otherwise incapable of producing substantial numbers 
of motor neurons. 
Motor neuron differentiation efficiency reflects propensity to neural differentiation in iPS-MNs: 
In this study, we have shown that human iPS lines display characteristic and stable 
propensities towards motor neuron differentiation and have identified several factors that 
influence this efficiency in a group-wise fashion. However, we have not addressed the drivers 
behind line-by-line variation in differentiation efficiency. Data from the companion study, Bock 
et al. (2011), provide a window into this problem. Bock et al (2011) developed a quantitative 
differentiation assay based on measuring the expression of 500 pre-selected lineage marker genes 
to form a scorecard of differentiation potential (Bock et al. 2011). By measuring these genes in 
EBs subjected to a 16-day morphogen-free “random” differentiation, they were able to produce a 
snapshot of lineage differentiation propensity at this timepoint. Application of this technique to 
14 of the iPS lines used above produced illuminating results. The individual propensity of an iPS 
line to differentiate towards neural or ectodermal lineages correlates extremely well with the 
line-specific motor neuron differentiation efficiency (R2=0.87, Figure 2.6). Thus, it appears that 
neural lineage commitment is the key factor driving iPS-MN differentiation efficiency in our 
study. 
Discussion: 
In this study, we derived and characterized a panel of iPS lines in order to assess the 
utility of the iPS system as a research tool for neuroscience. We first assembled a test set of 16 
iPS and 6 hES lines that represents many of the potential sources of variation that might affect 
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iPS cells. These include reprogramming method, age, sex, disease status, and individual donor 
identity. Importantly, the entire set of iPS lines was validated by the gold-standard tests of 
pluripotency currently applied to hES lines.  We then assessed pluripotency in a more stringent 
manner by measuring the efficiency of directed differentiation to motor neurons. The 
concordance of results obtained independently from the two laboratories demonstrate that, 
although there is variation amongst iPS lines, they are likely to serve as reliable substrates 
through which to study nervous system development and disease.  
One major outcome of this study is the finding that iPS cells produce motor neurons with 
similar efficiency to ES cells. However, the only previous study to address this issue came to the 
opposite conclusion (Hu et al. 2010). Because Hu et al. (2010) only compared the motor neuron 
differentiation efficiency of 5 iPS lines to a single hES line (H9), it is difficult to say if the iPS 
lines they evaluated would make fewer motor neurons than hES cells on average, or if a larger 
group of iPS lines would change their results. In fact, the H9 hES line displays a high neural 
lineage propensity in the Bock et al. (2011) scorecard. This is predicted to correlate with high 
motor neuron differentiation efficiency for the H9 line and may have biased interpretation of the 
iPS-MN differentiation data. Another conclusion of the Hu et al (2010) study, that iPS cells are 
less efficient at neuralization, was not specifically addressed by our work. However, since neural 
lineage propensity explained much of the difference in motor neuron differentiation efficiency 
between iPS lines in our study, and there was no overall difference in the percentage of motor 
neurons made by hES and iPS cells, it seems likely that iPS lines in the test set were undergoing 
neural induction at similar efficiencies to hES cells. However, since the iPS lines in the two 
studies were not derived and cultured identically we cannot say for certain why they came to 
different findings. 
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Although iPS cells were not systemically different from hES cells in our assays, we did 
observe factors that influenced motor neuron differentiation capacity. These included the donor 
identity, donor sex, and individual iPS line. The effect of donor identity on motor neuron yield 
suggests that donor genetic background has an influence on differentiation potential. This is 
encouraging both because it shows that iPS cells are capturing patient-specific features and that 
the influence of these features is not so large as to overwhelm potential disease modeling assays. 
To my knowledge, this is the first demonstration of donor-specific effects in iPS cells. We also 
observed significant line-by-line differences in differentiation potential, including some lines that 
failed to produce motor neurons entirely. This result was unexpected given that each of the iPS 
lines in the test set passed stringent pluripotency assays. However, there is some precedence for 
marked line-by-line variability in stringent tests of iPS cell pluripotency. Work demonstrating 
the competency of iPS cells to produce tetraploid embryos showed that efficiency of embryo 
derivation varies in a line-specific manner (Boland et al. 2009; Zhao et al. 2009).  
Also notable, was that persistent reprogramming transgene expression and karyotypic 
abnormalities did not influence differentiation efficiency. Within reasonable limits, karyotype 
does not seem to influence differentiation potential in hESCs, neural or otherwise, which is in 
agreement with our data (Osafune et al. 2008).  Although the effect of persistent reprogramming 
gene expression on differentiation efficiency has not been extensively studied, it had been 
reported that cre-mediated excision of reprogramming factors improves differentiation efficiency 
(Sommer et al. 2010). Although an absence of obviously deleterious phenotypes stemming from 
abnormal karyotype or transgene expression may simplify working with iPS lines that display 
these features, they should certainly be used with caution. 
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One criticism that could be raised about the iPS-MN differentiations in this chapter is that 
they are of relatively low efficiency compared to some published studies from other groups 
working with hES cells, which can report up to 40% HB9+ cells (Li et al. 2005; Li et al. 2008). 
However, our standard differentiation above was slightly different than these studies in that it 
utilized a chemical agonist of the hedgehog pathway in place of SHH protein. Additionally, we 
did not utilize a neural-rosette picking strategy and thus miss a potential opportunity to enrich the 
motor neuron progenitor pool. We find this preferable for its simplicity and, in this case, as a 
truer measure of line-specific differentiation capacity.  
On concerning thing we did observe in this study was Oct-4 protein expression in 
differentiated neurons from the line 15b (see Boulting et al. 2010). Although Oct-4 mRNA 
expression has been reported in electrophysiologically normal cardiomyocytes, the effects of 
protein expression have not been studied in electrically active cells (Zhang et al. 2009). Because 
many iPS lines express low levels of reprogramming genes, it may be impossible to entirely 
avoid persistent transgene expression in differentiated derivatives without switching to a non-
integrating reprogramming approach (Yu et al. 2009). Therefore, it would be prudent to evaluate 
the expression of reprogramming factor target genes as well as the physiological properties of 
iPS-MNs from such lines before using them for disease modeling purposes. 
Because the ultimate purpose of this set of iPS lines is to model ALS, we also assessed 
ALS vs. control motor neuron differentiation efficiency. We did not observe an ALS-dependent 
loss of motor neurons during the course of our assay. ALS is an age-associated 
neurodegenerative disease and thus we may not expect to see death of motor neurons directly 
following their formation in culture. Whether or not ALS iPS-MNs display other phenotypes of 
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ALS was not addressed in this study, but will be partially evaluated in the subsequent chapters of 
this thesis. 
Finally, the motor neuron differentiation efficiencies we observed for individual iPS lines 
were, in large part, explainable by the line-specific efficiency of morphogen-free neural 
induction (Bock et al. 2011). The Bock et al. (2010) study also identified the three iPS lines that 
failed to produce motor neurons as having the lowest neural differentiation propensities. This 
result fits well with our data showing rescue of these three recalcitrant lines in the setting of 
enhanced neuralization. However, there is still an open question as to what mechanisms underlie 
variability of neural specification in iPS cells and how they may interact with other determinants 
of differentiation ability. In the future, it may be possible to use enhanced neuralization 
procedures to normalize neural fate specification between lines and subsequently isolate other 
factors that influence motor neuron differentiation potential. 
Although we identified three lines that failed to form motor neurons, none of these lines 
displayed consistent features in the iPS-state that suggested they would be incapable of 
differentiating properly. Between the Boulting et al. and Bock et al. studies, each of these lines 
(27e, 29e, 11b) was subjected to phenotypic pluripotency tests as well as expression and 
epigenetic profiling. However, prior to being differentiated, none of the lines was a clear outliner 
on any of these measures. The line 11b did show a high number of aberrantly expressed lineage 
marker genes in the work done by Bock et al., but 27e did not (29e was not characterized for this 
experiment) (Bock et al. 2011). That 27e shows a high median staining intensity for the 
pluripotency marker Tra-1-60 can be retrospectively correlated with reduced differentiation 
capacity. However, this measure did not correlate with reduced efficiency for the other two 
poorly differentiating lines (see Figure 2.3). Thus, we are left with no prospective test to identify 
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aberrant lines prior to differentiation. If this is generally the case, then a differentiation assay of 
some sort (scorecard or directed) may be the best way to assess the true utility of an iPS line for 
deriving a particular cell type of interest. In the general discussion, I will cover the relative 
merits of scorecard and directed differentiation assays for selecting individual iPS lines for 
research purposes. 
In conclusion, we have produced a panel of iPS lines that should have broad utility to the 
research community. We expect that this extensively characterized set of iPS lines will prove 
useful for understanding the differences between ES and iPS cells, understanding variability 
within iPS cells as a group, and isolating the factors that influence iPS differentiation to neurons 
as well as other germ layers. Finally, the iPS lines in our test set seem suitable for developing a 









(Legends are reproduced from Boulting et al. 2011) 
 
Table 2.1: Test set of iPS and hES lines. 
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Figure 2.1: Characterization of pluripotency in the test set of iPSC lines. 
(A) iPSC colonies were morphologically identical to ESC colonies and expressed the 
pluripotency markers NANOG and TRA-1-60, unlike the patient fibroblasts from which they 
were derived. FB, fibroblasts. Scale bars, 200 µm.  
 
(B) iPSC lines showed cell cycle profiles similar to those of ESCs and different from their 
parental fibroblasts. The percentage of cells at different stages of the cell cycle was determined 
by propidium iodide staining and flow cytometry. The percentage of cells in S, G2 and M phase 
was determined for each cell line and then averaged for each category. ***P < 0.001, mean ± s.d.  
 
(C,D) Like ESCs, iPSC lines generated cell types of all three embryonic germ layers (endoderm, 
AFP; mesoderm, "-SMA; ectoderm, TUJ1) in vitro, as embryoid bodies (C, EBs; scale bars, 100 
µm), and when injected into mouse kidney capsules and allowed to form teratomas in vivo (D; 
scale bars, 50 µm). Representative images of H&E-stained sections are shown for lines 11b and 
27e. Glands and goblet cells (endoderm), cartilage and muscle (mesoderm), pigmented neural 
epithelium and neural rosettes (ectoderm) are shown in the top and bottom panels, respectively, 
for both lines.  
 
(E) Summary chart depicting assays by which iPSC lines in the test set were characterized. 
Pluripotency assays for 29A and B were previously published (Dimos et al. 2008). 
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Figure 2.2: Directed differentiation of iPSCs to motor neurons. 
(A) Protocol for directed differentiation of human stem cell lines into motor neurons. Cells were 
differentiated as embryoid bodies from day 0–29 in media formulations containing morphogens, 
including retinoic acid (RA), a small molecule agonist of the sonic hedgehog pathway (HAg) and 
neurotrophic factors BDNF, GDNF and CNTF. Embryoid bodies were dissociated and single 
cells plated for adherent culture on day 29. On day 32 cultures were analyzed. NIM, neural 
induction medium.  
 
(B) Representative immunostaining results for iPSC (18c) and ESC (HuES-6) cultures show 
many ISL+ TUJ1+ motor neurons (scale bars, 50 µm).  
 
(C) The percentage of all nuclei that were ISL+ was quantified from differentiations performed 
independently in the Eggan and PALS laboratories. Data sets from lines differentiated in both 
laboratories are compared here, are highly similar and have reproducible, characteristic percent 
ISL+ efficiencies. 29e and 27e did not differentiate efficiently in either laboratory. Hu-13, HuES- 
13; Hu-3, HuES-3.  
 
(D) Efficiency of motor neuron differentiation was also measured by an alternative marker of 
motor neuron identity, HB9 (scale bars, 50 µm).  
 
(E) Many ISL+ motor neurons were also ChAT+, indicating proper maturation toward a 
cholinergic transmitter phenotype (scale bar, 50 µm).  
 
(F) The percentages of HB9+ nuclei were compared for a subset of iPSC lines and HuES-13. 
Although comparisons again suggest donor- or line-specific differences, iPSC lines were overall 
equally capable of generating HB9+ motor neurons as HuES-13 (mean ± s.d.).  
 
(G) Percent ISL+ data from both laboratories were pooled for each iPSC and ESC line, and 
comparisons between lines showed generally similar performance, with significant differences 
between iPSC line 18c and iPSC lines 11a and 11c (P < 0.05). Hu, HuES. 




Figure 2.3: iPSCs show similar differentiation capacity compared to hESCs. 
(A) iPSC lines from hESC and hiPSCs differentiated to motor neurons with similar efficiencies 
 
(B) iPSC lines from hESC and hiPSCs differentiated to motor neurons with similar efficiencies 
 


































































































































































































Figure 2.4: Analysis of pluripotency markers in sub-optimal iPSC lines. 
Quantification of cell surface markers associated with pluripotency by FC. No significant 
differences were observed between lines when comparing the percentage of (A) SSEA3+, (B) 
TRA-1-60+ or (C) double positive cells in iPSC and ESC cultures by FC analysis. In contrast, 
line 27e showed atypical TRA-1-60 staining, which was more uniform and significantly higher 
intensity than other ESC and iPSC lines (D-E). Experiments were performed at least in 
biological triplicate. 
  






Figure 2.5: Suboptimal iPSC lines can be rescued using SMAD inhibition. 
(A-C) Quantification of immunostaining in differentiated cultures derived from the three 
previously problematic iPSC lines (11b, 27e, 29e) and ESC controls; percentage of TUJ1+ cells 



































Figure 2.6: (Bock et al. 2011) 
!!
Figure 2.6 (From Bock et al (2011)): The Lineage Scorecard Predicts Cell-Line-Specific 
Differences in the Efficiency of Motor Neuron Differentiation. 
Correlation between the lineage scorecard estimates for the neural lineage and three germ layers 
versus the cell-line-specific efficiency of directed differentiation into motor neurons (rp, 
Pearson’s correlation coefficient; rs, Spearman’s correlation coefficient). Motor neuron 
efficiencies were measured by the percentage of ISL1-positive cells at the end point of a 32 day 
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Supplementary Table 1: % ISL+ ANOVA by lab, ES vs. iPS, 3 vs. 4 factor, ALS vs. Ctrl. 
 Day 32 differentiations were stained,  imaged, and quantitated for mean % ISL+ cells ( of 
DAPI+ cells) per image field per line, and  then mean %ISL+ was compared for n different lines  
per grouping variable.  Mean ± SEM is shown for each variable setting.  No ANOVAs indicated 
a significant effect of the tested variable. 
% ISL+ cells (One Way ANOVA) 
Eggan v PALS 
n= # of 
lines experiments mean  ±  SEM F-value p-value 
Eggan 10 30 11.6  ± 1.1 
1.132 0.301 PALS 10 42 10.1  ± 0.8 
ES v. iPS 
n= # of 
lines experiments mean  ± SEM   
ES 5 13 11.2  ± 1.6 
0.629 0.439 iPS 13 59 10.0  ± 0.8 
3 v. 4 factor  
n= # of 
lines experiments mean  ± SEM F-value p-value 
3 factor 11 45 9.7  ± 0.9 
0.49 0.622 
4 factor 2 14 11.2  ± 0.9 
0 - hES 5 13 11.2  ± 1.6 
ALS v. control 
n= # of 
lines experiments mean  ± SEM F-value p-value 
ALS 4 26 10.6  ± 0.5 
0.413 0.669 
control 9 33 9.7  ± 1.1 




n= # of 
lines experiments mean  ± SEM F-value p-value 
normal 9 41 10.0  ± 1.0 0.007 0.932 abnormal 4 18 9.9  ± 1.4 
 
Supplementary Table 2: % ISL+ ANOVA by line.  
Day 32 differentiations were stained,  imaged, and quantitated for mean % ISL+ cells ( of 
DAPI+ cells) per image field per experiment,  and then mean % ISL+ was compared for n 
different experiments per line.  Mean  ± SEM is shown for each line. All significant post hoc 
pairwise comparisons are shown. 
% ISL+ cells (One Way ANOVA) 
line N 
mean  ±  
SEM F-value p-value 
  11a  * 5 6.2  ± 0.7 
3.355 0.001 
    11c   + 4 6.3  ± 1.7 
15b 1 13.3  ± na 
17a 1 8.3  ± na 
! ! ! !!
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17b 2 7.2  ± 0.2 
18a 6 10.7  ± 1.2 
18b 7 12.4  ± 1.4 
      18c  * + 6 15.3  ± 1.8 
20b 1 7.6  ± na 
27b 7 9.9  ± 1.8 
29A 10 12.1  ± 0.9 
29B 4 10.3  ± 2.1 
29d 5 10.0  ± 2.2 
HUES13 5 9.3  ± 1.4 
HUES3 4 8.7  ± 1.0 
HUES3-GFP 1 12.2  ± na 
HUES6 2 17.2  ± 2.9 
HUES9 1 8.8  ± na 
Holm Sidak pairwise Difference of means t value p-value 
*  11a vs. 18c 9.03 4.176 0.017 
+  11c vs. 18c 9.008 3.908 0.039 
 
 
Supplementary Table 3: % ISL+ ANOVA by donor sex.  
Mean %ISL+ of all cells (DAPI+ nuclei) cells per image field were compared for n different 
lines per donor sex.  Mean ± SEM is shown for each donor.  The ANOVA indicated a significant 
effect donor sex effect, with female lines being more able to produce ISL+ cells on average. 
 
Holm Sidak pairwise Difference of means t value p-value 





Male v. Female n= # of lines experiments mean  ± SEM F-value p-value 
Male 6 13 8.4  ±  0.9 4.595 0.048 
Female 12 57 11.3  ± 0.8 
! ! ! !!
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Supplementary Table 4: % ISL+ ANOVA by donor.  
Mean %ISL+ of all cells (DAPI+ nuclei) cells per image field  were compared for n different 
lines  per donor.  Mean ± SEM is shown for each donor.  The ANOVA indicated a significant 
effect donor identity; however no post hoc pairwise comparisons were significant. 
% ISL+ cells (One Way ANOVA) 
donor iPS/ES 
n= # of 
lines experiments 
mean  ±  
SEM F-value p-value 
11 iPS 2 9 6.2  ± 0.01 
11.816 0.006 
15 iPS 1 1 13.3  ±  na 
17 iPS 2 3 7.7  ± 0.6 
18 iPS 3 19 12.8  ± 1.3 
20 iPS 1 1 7.6 ±  na 
27 iPS 1 7 9.8  ±  na 
29 iPS 3 19 10.8  ± 0.6 









HUES3 ES 2 5 10.5  ± 1.8 
HUES6 ES 1 2 17.2  ±  na 
HUES9 ES 1 1 8.8  ±  na 
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Supplementary Table 5: % TUJ1+ cells.  ANOVA by line.  
Day 32 differentiations were stained,  imaged, and quantitated for mean TUJ1+ cells ( of DAPI+ 
cells) per image field , and  then Mean % Tuj1+ per image field per line  were compared for n 
different experiments per line.  Mean  ± SEM is shown for each line.  All significant post hoc 
pairwise comparisons are shown. 
% TUJ1+ cells (One Way ANOVA) 
line N 
mean  ±  
SEM F-value p-value 
11a 3 32.9  ± 1.2 
2.934 0.012 
   11b * 3 8.1  ± 0.2 
11c 4 30.4  ± 4.6 
   18a * 5 56.6  ± 8.3 
18b 7 38.5  ± 3.6 
18c 6 33.9  ± 6.2 
27b 7 39.7  ± 4.3 
29A 10 35.1  ± 5.7 
29B 4 35.5  ± 8.0 
29d 5 24.8  ± 3.4 
HUES13 5 33.3  ± 3.1 
HUES3 4 27.0  ± 1.8 
Holm Sidak pairwise Difference of means t value p-value 
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Supplementary Table 6: TRA1-60 MFI ANOVA by line (following page).  
Day 0 undifferentiated ES cells were stained for pluriptoency marker TRA1-60.  TRA1-60 
Median Fluorescence staining intensity (MFI) was calculated, and mean MFI  was compared 
from n experiments per line.  Mean ± SEM is shown for each line.  The ANOVA showed 
significant effect of line identity and post hoc pairwise comparisons identified line 27e as 
significantly different from each other line.  No other pairwise comparisons were significant. 
  
! ! ! !!
!
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TRA1-60 Median Fluorescence Intensity (One Way ANOVA) 
line n mean  ±  SEM F-value p-value 
11a 2 489.5  ± 34.5 
3.355 0.001 
11b 3 1165.7  ± 558.5 
11c 3 846.0  ± 299.7 
18a 4 895.3  ± 345.6 
18b 3 403.7  ± 74.2 
18c 2 1689.5  ± 876.5 
27b 3 1549.3  ± 209.8 
    27e  * 3 5090.7  ± 606.0 
29a 2 2386.0  ± 735.0 
29b 3 1172.0  ± 79.7 
29d 3 1304.0  ± 302.5 
29e 3 864.0  ± 95.2 
H3 3 541.0  ± 163.9 
H13 2 2419.5  ± 116.5 
Holm Sidak pairwise Difference of means t value p-value 
27e vs. 18b 4687 9.171 <0.001 
27e vs. H3 4549.667 8.903 <0.001 
27e vs. 18a 4195.417 8.776 <0.001 
27e vs. 11c 4244.667 8.306 <0.001 
27e vs. 29e 4226.667 8.271 <0.001 
27e vs. 11a 4601.167 8.053 <0.001 
27e vs. 11b 3925 7.68 <0.001 
27e vs. 29b 3918.667 7.668 <0.001 
27e vs. 29d 3786.667 7.41 <0.001 
27e vs. 27b 3541.333 6.93 <0.001 
27e vs. 18c 3401.167 5.953 <0.001 
27e vs. 29a 2704.667 4.734 0.006 
27e vs. H13 2671.167 4.675 0.007 
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Supplementary Table 7: Karyotype analysis of iPSC lines.  
The reports of karyotypic analysis for a number of iPSC lines are summarized including the 
percentage of normal cells as well as abnormalities detected. Passage number (p) and lab that 
cells were grown is indicated for each report. Bold fonts indicate normal lines. We have 






























(From Boulting et al. 2011) 
Cells and cell culture. All cell cultures were maintained at 37 °C, 5% CO2. Human fibroblasts 
were cultured in KO-DMEM (Invitrogen), supplemented with 20% Earl’s salts 199 (Gibco) and 
10% hyclone (Gibco), 1# GlutaMax, penicillin/strep- tomycin (Invitrogen) and 100 µM 2-
mercaptoethanol (Gibco). HuES and iPSCs were maintained on gelatinized tissue culture plastic 
on a monolayer of irradiated CF-1 mouse embryonic fibroblasts (MEFs) (GlobalStem), in hES 
media23, with substitution of plasmanate (Talechris) by an additional 10% knockout serum 
replacement (Invitrogen) in PALS laboratory only supplemented with 20 ng/ml of bFGF. Media 
was changed every 24 h and lines were passaged by trypsiniza- tion (0.5% trypsin EDTA, 
Invitrogen) or dispase (Gibco, 1 mg/ml in hES media for 30 min at 37 °C). 
Derivation of human fibroblasts and iPSC generation. Human fibroblasts were generated from 3 
mm forearm dermal biopsies after informed consent was obtained, as reported previously2. The 
murine leukemia retroviral vector pMXs containing the human cDNAs for KLF4, SOX2 and 
OCT4 (ref. 2) were modified to produce higher titer virus by including the Woodchuck Post-
transcriptional Responsive Element (WPRE) of FUGW (Addgene plasmid 14883) downstream 
of the cDNA. Vesicular stomatitis virus (VSV)-g pseudotyped viruses were packaged and 
concentrated by the Harvard Gene Therapy Initiative at Harvard Medical School. To produce 
iPSCs, 30,000 human fibroblasts were transduced at an multiplicity of infection of 10–15 with 
viruses containing all three genes in hES medium with 8 µg/ml polybrene (Sigma-Aldrich). Cells 
were incubated with virus for 24 h before medium was changed to standard fibroblast medium 
for 48 h. Cells were subsequently cultured in standard hES medium and iPSC colo- nies were 
manually picked based on morphology within 2–4 weeks. 




Southern blot analysis. Genomic DNA was extracted from day 21 or day 29 motor neuron 
differentiation samples for each line using QiaAMP DNA Mini kit (Qiagen) according to 
manufacturer’s protocols, including RNase digestion. 8 µg gDNA was restricted with BglII 
overnight according to standard protocols and 6.5 µg run on a 0.8% agarose gel. Neutral 
Southern capillary transfer was performed overnight, using Amersham Ny+ membrane. OCT4 
and SOX2 probes were gen- erated by PCR amplification from OCT4 and SOX2 cDNA 
plasmids2 using the following primers (OCT4 primer forward: 
GAGAAGGAGAAGCTGGAGCA, reverse: GTGAAGTGAGGGCTCCCATA, 620 bp product; 
SOX2, primer forward: AGAACCCCAAGATGCACAAC, reverse: 
TGGAGTGGGAGGAAGAGGTA, 600 bp product) and Roche PCR DIG Probe Synthesis Kit 
following manufac- turer’s instructions. DNA was bound to membrane by UV, then probe was 
hybrid- ized overnight (45 °C for OCT4, 55 °C SOX2) using DIG Easy Hyb, followed by 
immunolabeling with anti-digoxigenin–alkaline phosphatase Fab fragments and detection with 
CPD-Star chemiluminescent substrate (Roche, following manufacturer’s protocols). After 
hybridization with OCT4 probe, the blot was stripped in 0.4 M NaOH, 0.1% SDS for 40 min at 
65 °C, then washed twice in 2# SSC (Fisher) at 25 °C for 15 min, and reprobed with SOX2 
specific probe. Blots were imaged on a KODAK Image Station 4000MM Pro. 
Flow cytometry for TRA-1-60, SSEA3 and NCAM. Trypsinized suspensions of ~1 M single cells, 
at day 0 or day 29 of differentiation, were fixed in 4% PFA for 30 min at 4 °C. After washing in 
PBS, cell suspensions were incubated with the fol- lowing antibodies obtained from BD 
Biosciences: SSEA3 PE (1:100, 560237), Tra- 1-60 AlexaFluor647 (1:100, 560219) or the neural 
differentiation marker NCAM (CD56 V450 BD biosciences 1:100, 560361) for 30 min protected 
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from light at 4 °C. Stained cells were washed once with PBS and analyzed immediately there- 
after on a 5 laser ARIA-IIu ROU Cell Sorter configured with a 100 mm ceramic nozzle and 
operating at 20 p.s.i. SSEA3+Tra-1-60+ populations were analyzed first by forward and side-
scatter properties (FSC, SSC) then analysis gates were set using a combination of fluorescence 
minus one (FMO) and isotype controls. 
Cell cycle analysis. Fibroblasts, ESCs and iPSCs were trypsinized to single cells, fixed overnight 
in cold 70% ethanol, treated with RNaseA (Qiagen) and stained with propidium iodide (PI; 50 
µg/ml, Invitrogen) in 0.1% BSA for at least 30 min. Cells were analyzed using the BD 
Biosystem LSRII FACS analyzer by doublet dis- crimination, giving rise to a histogram of PI 
signal with clear 2n and 4n peaks. 
Spontaneous in vitro three-germ layer differentiation. Whole stem cell colonies were isolated by 
dispase treatment and plated in suspension in low-cluster 6-well plates (Corning) in hES media 
without bFGF and plasmanate. Cells aggregated to form embryoid bodies within 24 h. Media 
was replaced every 48 h, and on day 16 embryoid bodies were trypsin and/or mechanically 
dissociated and plated on gelatin-coated tissue culture plastic for another 2–7 d of adherent 
culture before fixation and staining. 
Teratoma assay. IPSC lines were trypsinized to single cells, washed and resus- pended in a 
minimal volume of CMF-PBS (Cellgro), supplemented with 10% FCS (Invitrogen). At least 1 # 
106 cells were injected into the left kidneys of 5- to 6-week-old, severe combined 
immunodeficient hairless outbred (SHO) mice (3–5 mice/cell line). Xenograft tissue masses 
formed within 62–131 d, which were extracted, fixed, paraffin-embedded, sectioned and H&E 
stained. Cells repre- senting all three germ layers were identified after careful examination under 
the microscope. Further staining images and individual cell line details available upon request. 




qRT-PCR. Total RNA was isolated using Trizol LS (Invitrogen), 1 µg was treated with DNase 
(Invitrogen) and was subsequently used to synthesize cDNA with iScript (Bio-Rad). qRT-PCR 
was then performed using SYBR green (Bio-Rad) and the iCycler system (Bio-Rad). 
Quantitative levels for all genes were nor- malized to endogenous GAPDH. For pluripotency 
genes, levels were expressed relative to the levels in human ES line HuES-3, for motor neuron 
genes, levels are expressed relative to human ES line HuES-3 hb9-GFP. Standard curves were 
run to ensure equal efficiency of all primers, and RNA from 293 cells transfected with the 
plasmids encoding the transgenes was used as a positive control for viral transgene detection. 
Primer sequences are available upon request. 
Immunocytochemistry. Pluripotency marker, three-germ layer and OCT3/4– ISL1 stains were 
applied after fixation overnight in 4% paraformaldehyde at 4 °C, as previously described2. 
Neuronal cultures were fixed in 4% PFA for 15–30 min at 4 °C, permeabilized and quenched 
with 0.1–0.2% Triton-X in PBS (wash buf- fer) and 100 mM glycine (Sigma) for 20 min. Cells 
were blocked in wash with 10% donkey serum for 30 min and then incubated in primary 
antibody over- night, secondary antibodies for 1 h. Primary antibodies used in this study are 
SSEA-3 (1:2, Developmental Studies Hybridoma Bank (DSHB)), SSEA-4 (1:2, DSHB), TRA1-
60 (1:500, Chemicon), TRA1-81 (1:500, Chemicon), NANOG (1:500, R&D), OCT3/4 (1:500, 
Santa Cruz), AFP (1:500, DAKO), "-SMA (1:500, Sigma), ISL (1:200, DSHB, 40.2D6 or 
39.4D5, both of which detect Islet1 and Islet2 in the identical pattern in vivo in mouse and chick, 
Susan Morton, personal communication), HB9 (1:100, DSHB), ChAT (1:100, Chemicon), TUJ1 
(1:1,000, Sigma), Ki67 (1:400, Abcam), and Pax6 (1:50, DSHB). Alkaline phosphatase activity 
was detected in live cultures using the alkaline phosphatase substrate kit (Vector) according to 
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the manufacturer’s instructions. Secondary antibod- ies used in the Eggan laboratory were 
AlexaFluor 488, 555, 594 and 647 conju- gated (1:300, Invitrogen) and images were acquired on 
the Opera High-Content Screening System (PerkinElmer) for ISL and HB9 quantifications, and 
otherwise using an Olympus 1X51 epi-fluorescence microscope, or an LSM 510 META confocal 
microscope (Zeiss). Secondary antibodies used in the PALS laboratory were DyLight 488, 549, 
647 conjugated (1:1,000, Jackson ImmunoResearch) and images (9, 10# fields/sample) were 
acquired on a fully automated Zeiss Observer Z1 epi-fluorescence microscope. 
Motor neuron differentiation. Pluripotent stem cell colonies were treated with dispase (1 mg/ml) 
to separate colonies from feeder cells, then with 10 µM ROCK inhibitor Y-27632 (Sigma) for 1 
h in suspension, then followed by trypsinization to single cells, and seeded in low-adherence 
dishes at 0.2–0.4 million cells/ml in hES medium with 20 ng/ml of bFGF and 10 µM Y-27632 
for the first 3 d. At day 4 embryoid bodies were switched to a neural induction medium 
(DMEM/F12 with l-glutamine, NEAA, penicillin/streptomycin, heparin (2 µg/ml), N2 
supplement (Invitrogen) and bFGF (20 ng/ml). At day 10, retinoic acid (RA) (0.1 µM, Sigma), 
ascorbic acid (0.4 µg/ml, Sigma), db-cAMP (1 µM, Sigma) and 0.1 µM HAg were added. At day 
17 the concentration of HAg was increased to 1 µM. At day 25 the base medium was changed to 
Neurobasal (Invitrogen), with all previous factors and with the addition of 10 ng/ml each of 
BDNF, GDNF and CNTF (R&D). At day 29 embryoid bodies were dissociated with 0.05% 
trypsin (Invitrogen), and plated onto poly-d-lysine laminin-coated chamber slides (BD 
Biosciences) at 0.2– 0.5 million cells/well. Plated neuron cultures were cultured in the same 
medium with the addition of B27 (Invitrogen), 25 µM !-mercaptoethanol (Millipore) and 25 µM 
glutamic acid (Sigma), and fixed 3 d later. 
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Neuralizing motor neuron differentiation. IPSCs and ESCs were differenti- ated as described 
above, but with the following modifications: differentiations were started from dispased colonies 
triturated to become ~50-cell aggregates of iPSCs, and from days 1–9 were cultured in the 
presence of SB431542 (10 µM, Sigma-Aldrich) and LDN193189 (0.2 µM, Stemgent) to 
neuralize the cultures. From day 5 onward, BDNF (10 ng/ml, R&D), ascorbic acid (0.4 µg/ml, 
Sigma) and RA (Sigma) were added. From day 7 onward, Smoothened agonist 1.3 (SAG) 
(Calbiochem) was added at 0.5 µM to replace HAg. Aggregates were dissociated, plated and 
assayed as described above on day 21. 
Quantitative image analysis. Quantitative image analysis of differentiated neuronal cultures, for 
DAPI, TUJ1, ISLET and HB9, was done using the multi- wavelength cell scoring module in 
MetaMorph (Molecular Devices) software by the PALS laboratory, or Opera/Acapella software 
(PerkinElmer) by the Eggan laboratory. In brief, intensity thresholds were set, blinded to sample 
identity, to selectively identify as positive cells, which displayed unambiguous signal inten- sity 
above local background. These parameters were used on all samples, and only minimally 
adjusted for different staining batches as necessary. Script and Parameter files available upon 
request. Eggan: a minimum of 20,000–160,000 cells per sample were analyzed from 60–180 20# 
fields per sample. PALS: a minimum of 4,000 cells per sample were analyzed from nine 10# 
fields per sample. 
Total cell number analysis. As different image field sizes were used in different laboratories, 
total cells/field were normalized as follows. For all cell lines differen- tiated in parallel in both 
laboratories, the mean value for each line was averaged with the mean value of the other lines in 
this set. These values then generated a ratio (mean cells/field in PALS laboratory/mean 
cells/field in Eggan laboratory), which was then used to normalize the values from the Eggan 
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laboratory to those from the PALS laboratory. 
Voltage-clamp and current-clamp recordings. Differentiated d44 embryoid bodies were 
dissociated, plated at 8,000 cells/cm2 on lysine/laminin-coated cov- erslips, and allowed to 
mature for 6 d. Whole-cell voltage-clamp or current-clamp recordings were made using a 
Multiclamp 700B (Molecular Devices) at 21–23 °C. Data were digitized with a Digidata 1440A 
A/D interface, and recorded and ana- lyzed using pCLAMP 10 software (Molecular Devices). 
Data were sampled at 20 kHz and low-pass filtered at 2 kHz. Patch pipettes were pulled from 
borosilicate glass capillaries on a Sutter Instruments P-97 puller and had resistances of 2–4 M$. 
The pipette capacitance was reduced by wrapping the shank with Parafilm and compensated for 
using the amplifier circuitry. Series resistance was typi- cally 5–10 M$, always <15 M$, and 
compensated by at least 80%. Linear leak- age currents were digitally subtracted using a P/4 
protocol. Leak currents were typically <100 pA, but occasionally leak currents up to 500 pA 
were tolerated to accurately document the percentage of cells with voltage-activated sodium cur- 
rents. Voltages were elicited from a holding potential of –90 mV to test potentials ranging from –
90 mV to 20 mV in 10 mV increments. The intracellular solution was a potassium-based solution 
and contained (mM) KCl, 135; MgCl2, 2; HEPES, 10 (pH 7.4 with KOH). The extracellular was 
sodium-based and contained NaCl, 135; KCl, 5; CaCl2, 2; MgCl2, 1; glucose, 10; HEPES, 10, 
pH 7.4 with NaOH). Tetrodotoxin was purchased from Tocris Bioscience. 
Statistical analyses. All quantitative data were analyzed using SigmaPlot. Sample groups were 
subject to One Way ANOVA, with Holm-Sidak post hoc pairwise comparisons, or, if equal 
variance tests failed, by Kruskal-Wallis ANOVA on ranks, with Dunn’s post hoc pairwise 
comparisons. Alpha was set at 0.05 for all ANOVAs, ANOVAs on ranks and post hoc tests. 
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Chapter 3: Molecular and functional characterization of ES and iPS-MNs. 
 
Introduction: 
 Work in Chapter 2 established protocols to reliably and efficiently derive ES and iPS-
MNs from undifferentiated cells and explored the inherent differentiation potential of several ES 
and iPS lines. This work showed that ES and iPS cells produced motor neurons with similar 
efficiency, contrary to prevailing ideas about the differentiation capacity of iPS cells (Hu et al. 
2010; Boulting et al. 2011; Kim and Studer 2011). At the time-points analyzed, we also observed 
no difference in the motor neuron differentiation capacity of iPS lines derived from ALS patients 
as compared to those derived from healthy controls. This similarity suggests that ALS-dependent 
phenotypes in iPS-MNs are likely to be more subtle than a general reduction of motor neuron 
viability observable in short term experiments. Therefore, identification of an ALS-dependent 
phenotype in iPS-MNs will require either a more detailed analysis of newly born neurons, or 
longer-term in-vitro experiments, possibly in the presence of stressful conditions designed to 
magnify small viability differences. For work in this direction to proceed, it will be helpful to 
first understand both the transcriptional and physiological processes occurring in non-ALS 
cultures of ES/iPS-MNs.  Thus, in this Chapter, I will endeavor to set baseline values for global 
gene expression and electrophysiological activity in healthy ES/iPS-MNs. I will also define some 
potential confounding variables in ES/iPS-MN cultures deriving from asynchronous birth of 
motor neurons in culture and activity-dependent processes.  
The transcriptional profile of hES-MNs is not well characterized. Although one group 
does report a short list of the top-enriched genes in hES-MNs derived from an hESC motor 
neuron reporter line, this data is used chiefly as a means of validating reporter specificity and is 
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not publically available (Placantonakis et al. 2009; Placantonakis et al. 2009). Additionally, 
because motor neurons from only one hESC line have been profiled, we know little about 
potential line or differentiation protocol-dependent differences in gene expression or what role 
reporter specificity might play in hESC-MN expression profiles. Finally, although the 
maturational changes in rodent motor neurons are well studied (see General Intro), we do not 
know to what extent these same changes are occurring in hES-MNs. In order to address these 
issues, I will perform molecular profiling of reporter-expressing hES-MNs. These experiments 
will be carried out at two timepoints in order to generate a candidate lists both of motor neuron-
enriched genes as well as temporally regulated ones. 
 Aside from addressing the above questions, an improved knowledge of the hES-MN 
transcriptional profile also has the potential of providing useful tools for the isolation of hES-
MNs from mixed cultures. The percent yield of ES/iPS-MNs following differentiation is 
relatively low (10-30%), complicating analysis of motor neuron-intrinsic characteristics in bulk 
cultures. From a purely practical perspective, if motor neurons could be enriched from culture 
using a surface epitope via FACS or immuno-magnetic sorting, it would be of great use to the 
field. Unfortunately, the epitope often used to immuno-isolate rodent primary motor neurons, 
p75NTR, is expressed on a majority of cells in hESC cultures, which are rich in neural crest 
derivatives, rendering it unusable as a MACS tag (data not shown) (Camu and Henderson 1992). 
Because hESC lines are relatively recalcitrant to genetic modification, discovery of an 
endogenous motor neuron-specific cell surface molecule would be preferable to a transgenic one, 
particularly for prospectively isolating motor neurons from large numbers of hESC and iPS lines. 
Therefore, I will focus part of my work here on using hES-MN transcriptional profiles to identify 
a surface marker that is enriched on hES-MNs.  
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Because ALS is believed to have a large excitotoxic component, it will also be important 
to study the electrophysiological properties of iPS-MNs derived from ALS patients. However, 
this is another area where the basic characterization of human iPS-MNs is lacking. In fact, only 
one study has addressed the physiological properties of iPS-MNs and then demonstrated only 
that iPS-MNs from two iPS lines were capable of firing repetitive action potentials using current 
clamp recording (Karumbayaram et al. 2009). Thus, it is currently unknown whether iPS-MNs as 
a group behave physiologically like their hES counterparts or if they are spontaneously active in 
culture. Furthermore, we do not know if there will be line-by-line differences in spontaneous 
activity level, synaptic connectivity, or response to depolarizing cues. To address these issues, I 
used calcium imaging techniques to characterize spontaneous and evoked physiologic activity in 
a panel of cultured ES and iPS-MNs. Much of the calcium imaging work in this chapter was 
performed in direct collaboration with Damian Williams, a postdoctoral fellow in Dr Amy 
MacDermott’s lab (Columbia University), and sections from figures 3.5 and 3.6 were published 
in Boulting et al. 2011 (Boulting et al. 2011). We describe spontaneous and evoked calcium 
transients in identified iPS motor neurons in culture and show their dependence upon active 
propagation via voltage gated sodium channels. Importantly, we do not find gross differences in 
calcium handling between iPS-MNs derived from ALS patients and controls. Finally, I will 
provide evidence that iPS-MNs form functional neural networks in culture and that these 
networks undergo sustained and highly regular depolarizations reminiscent of calcium waves in 
the developing nervous system.  
Relationships between different profiling and physiology experiments in the thesis: 
The profiling experiments presented here are interrelated with other chapters of this 
thesis.  A brief outline will help keep these different approaches from becoming confused. 
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Notably, different methods of motor neuron enrichment and different motor neuron 
differentiation protocols were used for these experiments as both were evolving protocols 
throughout the course of my work. 
In this Chapter (Chapter 3), I will describe microarray profiling of purified hES-MNs 
from a normal hES line. Motor neurons in these experiments will be FACS purified using a 
transgenic hES line that expresses GFP from the motor neuron-specific HB9 promoter. These 
experiments will be used to identify potential motor neuron-specific surface markers and to 
evaluate maturational changes occurring in hES-MNs following differentiation. A 32-day 
“standard” differentiation protocol will be used for hES-MNs in these experiments. The 32-day 
protocol utilizes 0.1 %M retinoic acid and 200 ng/mL recombinant SHH-C as morphogens  (see 
Figure 1.11 and Methods). 
In Chapter 4, I will perform expression profiling of iPS-MNs derived from a panel of iPS 
lines from ALS patients and control donors. The purpose of these profiling experiments will be 
to identify ALS-specific expression changes in iPS-MNs. In this approach, iPS-MNs will be 
enriched using a lentivirus that drives RFP from a shortened version of the HB9 promoter. The 
lentivirus will be validated as motor neuron specific in the first part of Chapter 4 (Figure 4.1). A 
22 day “accelerated” differentiation protocol will be used for iPS-MNs in these experiments. The 
22-day protocol utilizes dual SMAD inhibition for neuralization and 1 %M retinoic acid, 1uM 
smoothened agonist (SAG) and 1uM purmorphamine (PUR) as morphogens  (see Figure 1.11 
and Methods). 
In Chapter 5, I will use published microarrays from post mortem ALS patient motor 
neurons to identify expression patterns that correlate with patient age at onset. As part of the 
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validation of this list of genes, I will use expression values from the microarrays performed in 
Chapter 4 on ALS iPS-MNs.  
Finally, in the calcium imaging section of this chapter (Figure 3.7) I will make use of the 
HB9::RFP lentivirus developed in Chapter 4 to prospectively label iPS-MNs prior to assessing 
electrophysiological activity. For details of the sHB9::RFP virus construction and validation, 
please see figure 4.1. A 22 day “accelerated” differentiation protocol will be used for iPS-MNs 
in these experiments. The 22-day protocol utilizes dual SMAD inhibition for neuralization and 1 
%M retinoic acid, 1uM smoothened agonist (SAG) and 1uM purmorphamine (PUR) as 
morphogens  (see Figure 1.11 and Methods). 
Results: 
hES-MN microarray profiling: 
A significant hurdle to fully characterizing hES-MNs is the difficulty of isolating motor 
neurons from differentiated cultures. To circumvent this problem, I first utilized a transgenic 
hESC line that stably expresses enhanced green fluorescent protein (GFP) under the motor 
neuron-specific mouse HB9 promoter (Hues3 HB9::GFP, gift from K. Eggan) (Di Giorgio et al. 
2008). The Hues3 HB9::GFP hESC line can be used to prospectively isolate motor neurons by 
FACS sorting (see Figure 3.1D,G).  
In order to ensure a generalizable expression profile from hES-MNs, as well as to 
identify potential developmentally-regulated genes, I performed whole genome expression 
profiling on FACS isolated HB9::GFP hES-MNs at two time points: immediately following a 
32-day differentiation protocol and after 20 days of post-differentiation maturation (day 52), by 
which point hES-MNs exhibit a more mature pattern of electrophysiological activity (Figure 3.1, 
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physiology data not shown)(Tawazaka et al. submitted). Two separate passages of the Hues3 
HB9::GFP hESC line were differentiated to motor neurons in a 32-day protocol utilizing 0.1 %M 
retinoic acid and 200 ng/mL recombinant SHH-C (see Methods). Following differentiation, 
many cells in culture expressed the HB9::GFP reporter and the motor neuron marker Islet1/2 
(Figure 3.1 B-C, D-E). During FACS isolation, both GFP-positive and -negative fractions were 
collected in order to determine genes enriched in motor neurons as compared to other cells in 
culture (Figure 3.1D,G). Following FACS isolation, RNA was prepared using Trizol ls according 
to the manufacturer’s instructions, purified using Invitroven RNeasy columns, and assessed to be 
of high quality using an Agilent bioanalyzer with RNA pico6000 chips (RIN>8)(see Methods 
and Figure 3.1A-J). After RNA was validated to be of high quality, amplified cDNA was 
prepared using Nugen technology (see Methods). A quality control qPCR analysis of cDNA 
prepared from each sample showed a ~32-fold enrichment of HB9 expression in GFP-positive 
fractions as compared to GFP-negative fractions. Following cDNA preparation and validation, I 
then performed microarray analysis on both GFP-positive and GFP-negative samples using 
Affymetrix Human Genome 133 Plus 2.0 arrays (n=2, see Methods).  
Microarray data revealed distinct expression profiles for day-32 and day-52 hES-MNs as 
well as non-motor neuron cells. Hierarchical clustering of arrays using centered correlation and 
average linkage revealed that GFP-positive and GFP-negative cells cluster into two distinct 
groups (Figure 3.2A). Furthermore, samples from the same developmental time-point cluster 
together within these groups indicating a reproducible change in motor neurons between day-32 
and day-53 (Figure 3.2A). This demonstrates that cell type and maturational age are the major 
determinants of transcriptional profile in this assay.  
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At both time points, genes known to be important for motor neuron identity and function 
were enriched in HB9::GFP positive cells as compared to GFP negative cells. An un-paired class 
comparison analysis for GFP+ vs GFP- cells (p<0.001) at both time points demonstrated that 
GFP-positive cells are >25-fold enriched for HB9 and >10-fold enriched for Islet2, both markers 
of motor neuron fate (Figure 3.2B). General markers of cholinergic neurotransmitter phenotype 
such as Cht1 (Slc5A7) and VAcht were also enriched in HB9::GFP cells (>20-fold and >15-fold 
respectively) (Figure 3.2B). These results demonstrate successful enrichment of hES-motor 
neurons in GFP-positive fractions (see Supplemental figures 3.2.2 and 3.2.3 for complete tables 
of enriched genes). 
Comparison of gene expression between motor neurons profiled at day-32 and at day-52 
allowed the assessment of maturational changes in these cells (Figure 3.2C). Most strikingly, I 
observed large increases in the expression levels of multiple Hox proteins, including HoxC6 (69-
fold), HoxA7 (12-fold), HoxD8 (7.6-fold), HoxB9 (30-fold), HoxD9 (13-fold), and HoxD10 
(4.1-fold) suggesting the consolidation of motor neuron cell fates (Figure 3.2C). (See 
Supplemental figure 3.2.4 for complete tables of enriched genes and gene ontology (GO) 
analysis.) 
Since one of our interests is to evaluate the electrophysiological properties of hES/iPS-
derived motor neurons and since the ion channel complement of hES-MNs is not well described, 
I also specifically evaluated the expression of ion channels in day-32 hES-MNs. I assessed this 
by subsetting the list of motor neuron enriched genes to only those with the term “channel” in the 
gene ontology description. This analysis demonstrated that a wide variety of ion channels are 
expressed in hES-MNs including multiple types of NMDA, AMPA, kainate, and GABA 
receptors (Supplemental Figure 3.2.1). Notably, hES-MNs express high levels of the ionotropic 
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glutamate receptor GRIN2A (NR2A), a marker of embryonic motor neurons in rodents (Fukaya 
et al. 2005). Additionally, expression of the hyperpolarization activated cyclic nucleotide-gated 
potassium channels HCN1 and HCN4 suggest ongoing pacemaking activity in hES-MNs.  
Because one objective of the microarray profiling in this chapter was to identify motor 
neuron-enriched cell surface antigens, I manually selected candidate surface proteins from the 
lists of motor neuron-enriched genes generated above (Figure 3.3H). These proteins, many of 
which have been described on motor neurons in other species, may serve as new motor neuron-
specific markers that can be assessed on living cells and used as antigens for FACS or MACS 
enrichment of non-transgenic motor neurons. The top three candidates Ret, Tmeff2, and GYPB, 
are discussed below.  
The Ret and Tmeff2 receptors were enriched 14-fold and 20-fold in Day-32 HB9::GFP+ 
hES-MNs, respectively (Figure 3.3). Live extracellular immunostaining of motor neurons 
demonstrated that Tmeff2 was expressed on a subset of HB9::GFP+ motor neurons at 5 days post 
dissociation (Figure 3.3D-F, see methods). Live extracellular immunostaining for the Ret 
receptor  demonstrates that this protein is enriched in hES-MNs (Figure 3.3A-C). However, Ret 
is also expressed on other cells with neural morphology in culture and thus is not motor neuron 
specific (Figure 3.3 A-C).  
Because Tmeff2 appeared to be expressed specifically on a subset of HB9::GFP+ cells, I 
attempted to immunomagnetically enrich iPS-MNs using a Tmeff2 antibody (see Methods). A 
MACS sort for Tmeff2 on iPS-MNs following 7 days of post-dissociation adherent maturation 
produced a 5.3-fold enrichment in Islet1/2 positive motor neurons in the Tmeff2 bound fraction 
compared to the unsorted culture (5.3 ± 3.4 fold; mean ± STDEV, n=2, p=0.022). Unfortunately, 
yield in the Tmeff2 bound fraction was very low in these experiments (average 11.5±7.6% of 
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total Islet+ cells sorted ± STDEV, n=2). Thus, Tmeff2 is a promising MACS tag for motor 
neuron enrichment, but sorting conditions will require optimization. MACS sorting has not yet 
been attempted for the Ret receptor. 
Because validated antibodies for FACS sorting are often available for CD markers, I 
decided to investigate the expression of an unexpected family of blood group CD markers that 
appears to be highly enriched in hES-MNs. Glycophorins A, B and E (GYPA, GYPB, GYPE) 
are among the top motor neuron-enriched genes identified by microarray at day 32 showing 18-, 
43-, and 31-fold enrichment in motor neurons respectively (Fig 3.3G-H). These proteins, which 
are highly glycosylated in-vivo, are expressed on erythrocyte cell membranes and determine the 
MNS blood group subtype (CD235a-e) (Reid 2009). Because glycophorin expression has not 
been described on motor neurons previously, I first decided to validate GYP A, B and E 
expression in both hES-MNs and iPS-MNs. Quantitiative PCR analysis of cDNA from the 
HB9::GFP MNs used in the above microarrays and from iPS-MNs FACS isolated using a motor 
neuron-specific lentivirus (see Chapter 4), confirmed reproducibly enriched GYPA, B, and E 
expression in MNs compared to the negative samples (Figure 3.3.G and see Chapter 4). The next 
step in validating the glycophorins as motor neuron-enriched proteins will be immunostaining 
and western blot, which have not yet proven successful (see Discussion). 
ES-MNs and iPS-MNs are spontaneously active in culture, respond to appropriate depolarizing 
cues, and form functional neural networks in-vitro: 
 In order both to demonstrate that iPS-MNs are functionally similar to gold-standard hES-
MNs and to begin to set baseline values for studying the functional consequences of ALS in iPS-
MNs, we assessed the physiologic properties of ES and iPS-MNs using calcium sensitive dyes 
(Boulting et al. 2011). Both spontaneous and evoked activity was assessed in motor neurons 
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derived from a panel of iPS lines and one hES line (Figure 3.4A-B). Following a 21-day 
accelerated differentiation protocol (1uM RA, 0.5uM SAG, see Chapter 2) ES- and iPS-MNs 
were plated and allowed to mature for 12-14 days prior to calcium imaging (Fig 3.4A). 
Immediately before calcium imaging, neuronal cultures were loaded with Fluo-4 and FuraRed 
AM dyes or Fluo-4 alone (See methods).  A summary of all calcium imaging experiments is 
presented in Figure 3.4B. 
 We first monitored spontaneous calcium transients in the absence of exogenous 
stimulation and determined the dependence of this activity on active propagation through 
voltage-gated sodium channels (Fig 3.5; see Methods). Multiple spontaneously active Islet1/2 
positive motor neurons were observed in every iPS line studied (11a, 18a, 18c, 27b, hES-Rues1, 
n=3 each) (Figures 3.5, 3.6). Although some Islet1/2 positive iPS-MNs were continuously active 
over the course of measurement (150 seconds), others did not show spontaneous calcium 
activity, indicating functional heterogeneity in the iPS-MN population (Fig 3.5E). Cell-wide 
calcium transients (Fig 3.5A-C) were completely abrogated in the presence of 500 nM 
tetrodotoxin (TTX), indicating their dependence upon active propagation (Fig 5.5F). However, 
localized calcium transients were still visible in some neurites during TTX administration (data 
not shown). Following removal of TTX from solution and a 40-minute washout period, 
spontaneous calcium transients resumed in iPS-MNs (Fig 3.5F). 
   To assess the response of iPMNs to depolarizing cues, we exposed cultures of 
spontaneously active cells to brief bath-applications of kainate and KCl. During application of 
kainate, which activates ionotropic glutamate receptors, or KCl to open voltage-gated calcium 
channels, iPS-MNs exhibited a sustained increase in intracellular calcium levels (Fig 3.6A-F). 
Induced calcium transients occurred in both Islet1/2-positive and -negative cells (Fig 3.6G-H). 
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Upon exposure to kainate, increased intracellular calcium levels were observed in the cell bodies 
and processes of 78% of cells with neuronal morphology (n=132 cells). Immunostaining 
confirmed that many of the cells responsive to kainate and KCL were Isl1/2 positive motor 
neurons (Fig 3.6.1). Kainate and KCL responsive cells were observed in every cell line tested 
(Fig 3.6I-J and Fig3.4B). 
Previous studies have not addressed the degree of synaptic connectivity between iPS-
MNs in culture. In a separate set of experiments from those above, I attempted to address 
synaptic connectivity in reporter-labeled iPS-MNs. I produced iPS-MNs from the 18c (control) 
and 29A (ALS) lines using a 22-day differentiation protocol (1uM RA, 1uM SAG, 1uM PUR). 
These iPS-MNs were then labeled with a motor neuron-specific lentivirus (see below, Fig 4.1) 
and were cultured for 21 days post differentiation (see methods). Following the labeling and 
maturation period, I imaged spontaneous and kainate evoked calcium activity in labeled motor 
neurons. Unexpectedly, spontaneous and rhythmic culture-wide activity was observed in 2 of 2 
biological replicates of 18c iPS-MNs cultures and 0 of 1 biological replicates of 29A iPS-MN 
cultures (Figure 3.7, See Supplemental figure 3.7.1 for a summary of replicates for these 
experiments). In 18c cultures, highly correlated activity with a frequency of approximately 0.2hz 
was present in nearly all cells with neural morphology across the field imaged, including labeled 
motor neurons (Fig 3.7A-B).  A 3-minute kainate application caused sustained depolarization of 
labeled motor neurons and abrogated the culture-wide coordinated activity. However, rhythmic, 
spontaneous activity returned following kainate washout and a 5-minute rest period (Figure 
3.7E-G).  
Finally, I also evaluated calcium handling differences between the soma and end of the 
distal-most neurite in the labeled motor neurons undergoing spontaneous activity in Figure 3.7. 
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Calcium transients were of much shorter duration in neurites than in cell bodies and not all 
transients propagated from the soma to the distal-most neurite (measure, Fig 3.7.2). 
Discussion: 
 In this Chapter, I have established some of the basic characteristics of ES-MNs and iPS-
MNs in culture. I first produced genome-wide expression profiles of purified hES-MNs that 
describe the hES-MN transcriptome at two timepoints. The data suggest that hES-MNs, as 
expected, share many characteristics with their mouse counterparts. In addition, they provide a 
first glimpse of the maturational changes occurring in post-mitotic motor neurons and may serve 
as a basis for the identification of new motor neuron-specific markers to be used in human motor 
neuron purification strategies. In the second half of the chapter, I extended my analysis of the 
basic properties of ES and iPS-derived motor neurons to more functional aspects. Using calcium-
sensitive dyes, I assessed spontaneous and evoked electrophysiological activity in 5 iPS lines and 
1 hES line. Finally, using a lentiviral motor neuron reporter, I established that iPS-MNs form 
functional networks capable of generating sustained, rhythmic activity patterns.  
Molecular characterization of hES-MNs: 
 The hES-MN microarray data in this chapter demonstrates a broad similarity between 
hES-MNs and motor neurons derived from mouse ES cells. My data is of general interest 
because it provides an otherwise unavailable cataloging of the hES-MN transcriptional profile. 
Furthermore, knowledge about the ion channel and receptor complement of hES-MNs should aid 
in future assessment of their electrophysiological properties. 
The day-32 hES-MN expression data set generated in this chapter is very similar to that 
generated by Placantonakis et al (2009), which was performed on the same array platform at a 
similar timepoint. In fact, along with Isl2, HB9, and SLC5A7 (choline transporter CHT1), their 
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study also identifies Ret and Tmeff2 as among the most enriched motor neuron genes. 
Interestingly, both my array data and this data set identify Rap1a among the most upregulated 
genes in motor neurons (2 probesets, see Appendix 3.1) (Placantonakis et al. 2009).  Rap1a, a 
modulator of NMDA receptor trafficking, has not been described in mouse or human motor 
neurons aside from these two studies and does not appear motor neuron-specific in the Allen 
Brain Atlas (Zhu et al. 2002; Placantonakis et al. 2009).  Additionally, a similar array study 
conducted in our laboratory using Illumina arrays shows decreased expression of Rap1a in 
HB9::GFP hES-MNs compared to GFP-negative cells, suggesting that this finding is of uncertain 
significance (Amoroso et al. Unpublished).  
Profiling of motor neurons at early developmental timepoints provides a starting point for 
an array of functional and molecular studies. However, many important functional changes in 
motor neurons are maturation-dependent. Therefore, I evaluated maturational changes in hES-
MN cultures over a period of 20 days.  Give the heterogeneity of hESC cultures, it was 
encouraging that hierarchal clustering of microarrays showed that early and late samples of 
motor neurons and non-motor neurons clustered together, suggesting common, widespread 
maturational changes between the two profiling replicates (See Figure 3.2). I also observed a 
strong upregulation of HOX genes in motor neurons between day-32 and day-52, which is 
suggestive of cell fate consolidation.  
By examining a couple of the genes that are changed between day-32 and day-52, we can 
arrive at a provisional developmental staging for an “average” hES-MN at these two timepoints. 
NR2A (Grin2a, NMDAe1), an NMDA receptor subunit, is enriched in GFP-positive hES-MNs at 
both day-32 (27-fold) and day-52 (14-fold) (See Figure 3.2B). However, NR2A expression is not 
significantly different between day-32 and day-52 GFP-positive motor neurons. In the 
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developing mouse, NR2A is only expressed by motor neurons up to an age of P14, when it is 
replaced by the NR3B subunit of the NMDA receptor (Fukaya et al. 2005). Thus, the constant 
NR2A expression profile, if consistent between rodents and humans, places an upper bound on 
the age of HB9::GFP-positive motor neurons at the equivalent of rodent post-natal day 14. A 
lower bound, at least in the case of day-52 motor neurons, can be arrived at by evaluating 
expression of c-Met, the receptor for the neurotrophic hepatocyte growth factor (HGF). Between 
day-32 and day-52, the c-Met receptor is 11-fold downregulated in GFP-positive cells (See 
Figure 3.2B-C). In Rat spinal cord, c-Met is highly expressed until after the period of 
neurotrophic factor-dependent cell death (~P0), and is then rapidly downregulated (Yamamoto et 
al. 1997). Thus, day-52 hES-MNs seem to exhibit a developmental stage between rodent P0 and 
P14. day-32 hES-MNs would be somewhat younger than this. This result suggests that day-52 
aged motor neurons would exhibit less dependence on trophic factor support than their younger 
counterparts: a testable hypothesis.   
In the case of both NR2A/3B and c-Met, using these two genes to produce an accurate 
developmental staging is based on temporal consistency between rodent and human motor 
neuron development. Since we know that not all aspects of neural fate specification during ES 
differentiation occur in an identical order between mice and humans, it would be useful to verify 
both the NR2A/3B switch and c-Met expression in human spinal cord samples (Li et al. 2005). 
Furthermore, it is important to keep in mind that the expression changes seen on 
microarray are population-level effects, and that the population of cells profiled is not 
homogenous. In fact, proliferation and neurogenesis occurs throughout the culture period and it 
is certain that not all GFP+ cells profiled at day-52 are 20 days old. Thus, some of the expression 
changes observed between the two timepoints are likely to be a result of shifts in the population 
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of cells being born and some of the maturational changes that do seem to be occurring are likely 
diluted by newly-born neurons. Therefore, repeating these experiments with a brief application 
of antimitotics during the early phase of adherent maturation would be a logical next step. (I 
have observed 20+ day survival of motor neurons in such cultures, although there is a significant 
amount of cell death.).  
The initial intent of the profiling experiments in this chapter was to produce a listing of 
motor neuron-enriched cell surface molecules to be used as a basis for developing a MACS or 
FACS-based hES/hiPS-MN purification strategy for lines without a GFP reporter. Fortunately, 
multiple hES-MN-enriched surface molecules were identified in the array study (See Figure 3.3). 
Of these, TMEFF2 and GYPB seem most worth pursuing with future work.   
TMEFF2 (transmembrane protein with EGF-like and follistatin-like domains 2) is a 
neuronally-enriched transmembrane protein believed to have neurotrophic properties (Horie et 
al. 2000; Kanemoto et al. 2001). A specific enrichment of TMEFF2 has been shown in mouse 
cranial motor nuclei (Kanemoto et al. 2001). My data indicate that TMEFF2 expression is 
present in a sub-set of HB9::GFP-positive motor neurons (see Figure 3.3D-F). This is somewhat 
in contrast with in situ hybridization data from the Allen Brain Atlas, which indicate that Tmeff2 
is expressed in a range of spinal neurons including motor neurons.   It would therefore be 
interesting to confirm expression of TMEFF2 on sections of fetal human spinal cord that are 
available to us (M. Amoroso and G.F. Croft, Unpublished).  
Pilot MACS sorts using an antibody to TMEFF2 proved successful at enriching cultures 
for GFP-positive motor neurons from the Hues3 HB9::GFP hES cell line. However, motor 
neuron yield was very low in these experiments. Preliminary data (not shown) indicates that the 
TMEFF2 antigen is trypsin-sensitive, potentially explaining low yields in MACS sorting. Time 
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did not permit further analysis, but it would seem worthwhile to investigate alternative enzymatic 
and non-enzymatic methods of preparing single cell suspensions for MACS sorting with the 
TMEFF2 epitope.  
GYPB is a gene not previously described in human or mouse motor neurons, but among 
the most enriched genes in my array data. Members of the Glycophorin (GYP) family are 
typically expressed on erythrocyte cell membranes and determine the MNS blood group subtype 
(CD235) (Reid 2009). Notably, GYPB was 44-fold enriched in GFP-positive cells at day-32 and 
only 8-fold enriched at day-52, suggesting that it may be developmentally regulated.  GYPB was 
not reported as a motor neuron-enriched gene by Placantonakis et al (2009) who used the same 
Affymetrix array platform and appears to give weak signal, if any, in the Allen brain atlas. 
However, an independent hES-MN profiling strategy in our lab conducted using Illumina arrays 
also confirms the Glycophorins as among the top upregulated genes in GFP-positive motor 
neurons from the Hues3 HB9::GFP line (Amoroso et al., Unpublished). Glycophorin expression 
has also been confirmed by qPCR experiments in both hES-MNs and iPS-MNS (see Figure 
3.3C). Finally, expression profiling in Chapter 4 will demonstrate that GYPB is highly enriched 
in motor neurons from every iPS line profiled. Thus, I believe there is convincing evidence for 
glycophorin mRNA expression in hES- and iPS-motor neurons from our laboratory.  
However, glycophorin protein levels will need to be assessed before moving forward 
with these genes. Unfortunately, I have not successfully stained GYPB in motor neurons in either 
live or fixed cells. However, positive control assays need to be performed to determine if our 
antibody is working properly. A recent CD-marker screen performed on neural derivatives from 
hESCs also failed to find CD235a staining, but did not look specifically at motor neurons (Yuan 
et al. 2011). Thus, it is still somewhat unclear if GYP protein expression is occurring 
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downstream of its transcription in motor neurons. In order to answer this question, Western 
blotting should be attempted using antibodies that have been verified for this purpose. The New 
York Blood Center has a series of Western-verified antibodies that could be used (commercially 
available antibodies are typically verified only for FACS).  
Finally, although I focused my efforts here on identifying a surface marker for motor 
neuron enrichment, other strategies are possible. One study did report centrifugation gradient-
based enrichment of hES-MNs (Wada et al. 2009).  However, I was unable to replicate their 
results (data not shown). This study utilized an adherent maturation stage following 
differentiation in contrast to our differentiation protocols. Future work could include an adherent 
maturation step and re-assess the viability of gradient enrichment for hES-MNs. 
Electrophysiological characterization of iPS-MNs and hES-MNs: 
In Chapter 2, I described a comparison of differentiation potential between hES and iPS 
cells as well as experiments aimed at understanding line-by-line variability in this property. As a 
part of this study, we also initiated a comparison of electrophysiological properties between ES 
and iPS-MNs and between different iPS-lines (Boulting et al. 2011). In this chapter, I report a 
more complete version of the results than was published previously.   
We found that every iPS line tested displayed functional properties similar to the ES line 
included in the comparison and consistent with our expectations of motor neurons. All lines 
exhibited spontaneously active Islet+ motor neurons that responded to the depolarizing cues 
kainate and KCL. Furthermore, spontaneous activity was completely and reversibly abrogated by 
TTX, indicating that action potentials underlie the observed calcium transients. By using an 
imaging strategy instead of single cell recording, we were more easily able to obtain population-
level data and determined that both Islet+ and Islet- cells were spontaneously active and 
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responded to exogenous stimulation our assay. This is expected given that the measures we used 
are not designed to prove the identities of motor neurons, but to demonstrate that pre-identified 
motor neurons behave as expected. Thus, we conclude that iPS-MNs show electrophysiological 
properties consistent with motor neuron identity. A broader characterization of neurotransmitter 
response may be helpful to refine this analysis. However, marker expression is likely a preferable 
way to confirm the particulars of motor neuron identity as I am aware of no completely motor 
neuron-specific electrophysiological properties observable in vitro. 
Although these calcium imaging experiments were not designed to demonstrate any ALS 
vs. control differences, it seemed as if the ALS line 27b was displaying reduced calcium handing 
ability compared to the control iPS lines (See Supplemental figure 3.6.1). However, given that 
the number of cells assessed from 27b was small and general health of the culture did not seem 
ideal, we could not draw a firm conclusion from this data. Further work will be necessary to 
determine if 27b, in fact, responds differentially to kainate application and to what extent culture 
conditions influence this response. Our collaborators in the MacDermott lab have begun these 
experiments and are focusing on recovery from kainate induced calcium entry as a metric of 
calcium buffering capacity in iPS-MNs (see below). 
Future work should also focus on general ALS vs. control differences in calcium 
handling using multiple ALS and control iPS lines. Increased duration of calcium transients 
following the application of kainate has been reported as an ALS-specific phenotype in primary 
rodent motor neurons (Guatteo et al. 2007). This would seem a reasonable place to begin work 
aimed at finding electrophysiological correlates of ALS in iPS-MNs. With this in mind, I have 
instituted a lentiviral labeling strategy for motor neurons that works well with Fluo-4 calcium 
imaging as well as single cell recording (Damian Williams, unpublished data) (See Figure 3.7, 
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Supplemental figure 3.7.1, Figure 4.1). Prospective identification of motor neurons using this 
method is considerably easier than post-electrophysiology staining.  
Using virally labeled iPS-MNs, I was also able to easily visualize calcium transients in 
the axon and soma of individual motor neurons. This technique may have utility in studying 
compartment-specific calcium handling in ALS iPS-MNs. It would be particularly interesting to 
use for visualization of calcium handling in the distal axons of SOD1 mutant iPS-MNs given a 
recent report of decreased mitochondrial density at this location (Magrane et al. 2012). If calcium 
handling is selectively reduced in distal axons, it could suggest a potential mechanism for the 
axon retraction that precedes motor neuron death in ALS. 
Furthermore, this work is the first to report rhythmic, culture-wide spontaneous activity 
in hiPS-derived neurons. Previous studies that have evaluated hES or hiPS-derived neurons in a 
similar manner have either observed only sporadic culture-wide activity or connectivity that was 
more limited in scope and rhythmicity (Heikkila et al. 2009; Karumbayaram et al. 2009; 
Brennand et al. 2011). Here, I describe highly correlated activity that is present in many, if not 
all, neurons in culture, including virally labeled motor neurons. This activity was stable over the 
time-course measured (~2min) and could be abrogated by brief depolarization of cells with 
kainate. Recovery of spontaneous, rhythmic firing 15 minutes after kainate application indicates 
that it is a robust feature of the network. Furthermore, the decrease in frequency observed 
following recovery suggests that the driving force behind culture-wide calcium waves is 
somewhat malleable. Although the mechanisms behind calcium oscillations in iPS-MNs are 
unclear, the presence of the hyperpolarization activated channels HCN1 and HCN4 in iPS-MNs 
suggests a possible pacemaking activity (Harris-Warrick 2002; Bender and Baram 2008). 
Alternatively, persistent inward sodium current could be driving activity in iPS-MNs (Harris-
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Warrick 2002). Future work should look towards modulating pacemaker and other channels to 
determine which factors are responsible for the initiation and propagation of calcium waves in 
iPS-MNs. Additionally, increased temporal resolution during calcium imaging should help 
define the directionality and speed of calcium wave spread. 
Aside from being an unexpected and interesting phenomenon, rhythmic electrical activity 
in culture has the potential to affect the characteristics of iPS-MNs and could become a 
confounding variable in disease modeling studies. Frequency of bursting episodes in the 
developing spinal cord is known to affect the refinement of motor neuron identity in the LMC 
(Hanson and Landmesser 2004; Kastanenka and Landmesser 2010). Thus, it seems likely that 
iPS-MN identities or electrophysiological properties will be changed by different levels of 
synaptic connectivity and firing in culture. If this is the case, then downstream studies could 
inadvertently measure secondary effects of these differences. I did not systematically evaluate 
line-by-line variation in rhythmic activity in this study. However, the results of Chapter 2 suggest 
that there are likely to be differences in the cellular components of iPS-MN cultures and it is 
conceivable that these could affect aspects of spontaneous activity. In particular, variable factors 
such as culture density, neural percentage, mixed maturational stages of neurons, or line-
dependent bias towards specific neural sub-types could alter the factors driving rhythmic 
activity. Thus, it would be useful to adopt a co-culture approach at some stage in the validation 
of any ALS vs. control differences discovered in iPS-MNs. By culturing ALS and control lines 
in the same dish (appropriately labeled with different fluorophores), synaptic coupling between 
cells belonging to the two lines should at least partially normalize the spontaneous activity 
between them. In this case, electrical activity would then need to be experimentally isolated from 
soluble and contact-mediated factors in culture. 
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I did notice an absence of rhythmic activity in iPS-MNs derived from line 29A, but 
cannot ascribe this to any line intrinsic properties (Supplemental figure 3.7.1). The cultures from 
29A that were subjected to calcium imaging in this chapter were not of optimal quality and often 
had a lower cell density than those from 18c (data not shown). These factors likely influence the 
probability of calcium transient propagation. Future work should expand this analysis and 
attempt to correct for these factors.  
Overall, this chapter provides a basic phenotypic characterization of iPS and ES-MNs. It 
sets expectations for ES- and iPS-MN expression patterns and provides a description of 
electrophysiological properties in iPS-MNs. Importantly, it demonstrates that iPS-MNs are 
behaving physiologically in a manner that is not distinguishable from ES-MNs and does not vary 
greatly from line to line. Finally, it describes connectivity properties in iPS-MNs that bear further 
investigation. The dataset presented here should prove useful as a starting point for future 
research into the physiologic and developmental characteristics of ES and iPS-MNs. 
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Figure 3.1: hESMN microarray sample preparation. 
 (A) Schematic of hESMN microarray profiling experiments. HB9::GFP+ and negative cells are 
FACS isolated at two time points in order to identify motor neuron-specific genes and temporally 
regulated genes. (B-C, E-F) Representative images of HB9::GFP ESMN cultures used for 
profiling at differentiation day 35 (top) and day 54 (bottom) stained for GFP (B,E) and Islet1/2 
(C,F). Scale bar =100µM (D,G) Representative FACS plots acquired during isolation of day 32 
(D) and day 52 (G) GFP+ ESMNs. Green data points represent cells called “GFP+”. Blue area in 
(G) indicates a representative GFP negative population FACS isolated for profiling. (H,I) 
Bioanalyzer traces for all GFP+ and GFP- samples profiled show high quality RNA. Samples as 
indicated. (F) qPCR valdation of HB9 enrichment in GFP+ population vs. GFP negative 
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Figure 3.2: hESMN microarray results. 
(A) Clustering of arrays shows that motor neurons and non-motor neurons cluster into distinct 
groups which are further segregated by culture age. (B) Select genes enriched in motor neurons 
(asterisms indicate potentially sortable surface proteins, complete table in appendix). (C) Select 
temporally regulated genes which are enriched in motor neurons either at day-32 (left) or day-52 
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Figure 3.3: Potential hESMN surface markers. 
(A-F) Immunostaining for potential motor neuron-enriched surface markers identified by 
microarray in day32+3 HB9::GFP ESMNs. (A,D) GFP staining identifies motor neurons. Live 
non-permeablized staining for Ret (B) and Tmeff2 (E) show motor neuron enrichment. (C,F) 
merged images of A, B and D, E respectively. (G) qPCR data showing enrichment of 
Glycophorins A (GYPA), B (GYPB), and E (GYPE) in GFP+ cells compared to GFP negative 
cells in both day 32 and day 52 ESMNs as well as in day-32 iPSMNs enriched using a motor 
neuron specific lentivirus (See Figure 4.1). (H) Table of selected motor neuron-enriched surface 












Figure 3.4: Calcium imaging experimental design. 
(A) Schematic of differentiation procedure and experimental aims used for calcium imaging 
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Figure 3.5: iPSMNs are spontaneously active in culture. 
(A-D) Images of iPS and ES-derived neurons filled with Fura Red AM and Fluo-4 AM calcium 
indicators. Scale bar =100µM. (A-C) Spontaneous electrical activity in cultured iPSC- and ESC 
derived neurons visualized by a ‘subtracted image’ that shows the difference in pixel intensities 
between two images acquired 1.7 s apart in the Fluo-4 channel. Higher gray values represent 
increased pixel intensity over time. (D) Islet & staining and pseudocolored Fluo-4 fluorescence 
of 18c iPSC-neurons depicted in panels A and E showing multiple Islet+ motor neurons. (E) 
Spontaneous activity of Islet+ cells in panel D measured by changes in the ratio of Fluo-4 to Fura 









Figure 3.6: iPSMNs depolarize in response to Kainate and KCL. 
(A) Image of iPSC 11a–derived neurons filled with Fura Red AM and Fluo-4 AM dyes. The 
Fura Red channel is shown. The field illustrated is that imaged in B–G. Activity of labeled cells 
is represented in G and H. Scale bar =100 µm. (B) ISL immunostaining of 11a field in A-F 
showing ISL+ neurons (arrow) and ISL– neurons (star). (C-F) Identically exposed pseudocolored 
averages of ten Fluo-4 AM images taken during the control period before addition of kainic acid 
(KA) (C), after treatment with 100 µM KA (D), after washing following KA administration (E) 
and after treatment with 50 µM KCl (F). Warmer colors represent increased fluorescence 
intensity. (G) Plot of Fluo-4/Fura Red intensity ratio in the somata of the two cells indicated by 
the triangle and arrow in A-B; only the triangle-marked cell shows spontaneous activity. (H) 
Fluo-4/Fura Red intensity ratio of cells in A-B during sequential administration of KA and KCl 
indicated by bars below graph. (I) Examples of Fluo-4/Fura Red ratios from cell bodies of single 
spontaneously active cells in cultures of ESC RUES1–derived neurons, and iPSC 11a–, 18a–, 
18c– and 27b–derived neurons as well as one example of a nonresponsive (NR), nonactive cell in 
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Figure 3.7: Coordinated, rhythmic firing in labeled iPSMNs. 
(A) Live image of D22+14 sHB9::RFP labeled motor neurons (red) in a culture loaded with 
Fluo-4 calcium indicator (green). Scale bar =100 µm. (B) Coordinated calcium activity in the 18c 
culture depicted in panel A. Cross-correlation of temporal changes in pixel intensities as 
compared to a central cell (triangle) is represented graphically in Cyan for each pixel in the 
image. Overlap of areas of high cross-correlation with sHB9::RFP labeled motor neurons (red) 
demonstrates long-distance integration of motor neurons into a common circuit. (C) sHB9::RFP 
labeling in a different 18c culture from A. (D) overlap of sHB9::RFP label with Fluo-4 labeled 
cells in culture. (E-G) Coordinated activity before (E), during (F), and after a 3 minute kainate 
application (G) in day-22+14 18c iPMNs (labeled 1-3 in panel C).  Breaks in X-axis correspond 
to 5-minute rest periods between epochs.  
  





Supplemental figure 3.2.1.Top 30 ion channels in Hues3 HB9::GFP+ motor neurons. 
List of top 30 ion channels upregulated in GFP+ hESMNs compared to GFP negative samples. 
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Supplemental Figure 3.6.1: 
Preliminary KA and KCL data for 
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Supplemental Figure 3.7.1: Axon vs. soma calcium handling in labeled iPSMNs and Spon. 
Ca2+ wave replicates. 
(A) Top traces represent Fluo-4 signal during spontaneous calcium transients in sHB9::RFP 
labeled iPSMNS. Bottom traces represent the same events in axons from the same cells.  
 
(B) Replicates in which calcium waves were observed. Biological replicates are denoted by 
passage numbers. 1-3 coverslips were analyzed per passage, with up to three fields per coverslip. 
“Waves?” column denotes the presence (+) or absence (-) of spontaneous calcium waves for each 
field analyzed per coverslip. Fields are listed in temporal order of imaging from left to right and 
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 Motor neuron differentiation: As described above. Hues3 HB9::GFP experiments used 
the “standard” differentiation protocol (0.1µM RA, 200ng/mL SHH-C). Calcium imaging in 
figures 3.5-3.6 used the optimal differentiation protocol #1 from Boulting et al. 2011. Calcium 
imaging experiments with sHB9::RFP and connectivity measurements used Optimal 
differentiation protocol #2. 
FACS isolation, cDNA preparation, and Microarray of HB9::GFP hES-MNs: At the 
stated time points, 50,000 reporter-expressing motor neurons and an equal number of reporter-
negative cells were isolated by FACS sorting into 750uL Trizol-LS for mRNA collection. High 
purity FACS settings were used on a BD FACS Aria with a 100 %M nozzle size and 20 PSI 
sheath pressure to minimize damage to sorted cells. Post-sort purity was >95%. RNA was 
extracted from Trizol into aqueous supernatant using the manufacturer’s protocol and further 
purified with Qiagen RNEasy columns. RNA was then verified to be of high quality using an 
Agilent Bioanalyzer and RNA Pico 6000 chips (RIN>8.0). RNA was reverse transcribed, 
amplified, fragmented and biotinylated using NuGen Ovation-FL technology (RNA amp V2 and 
Ovation-FL kits). In the Columbia University Genomics core facility, Labeled cDNA was 
hybridized to Affymetrix Human Genome 133 Plus 2.0 arrays, Arrays were imaged to produce 
.CEL files. .CEL files were compiled using Affymetrix expression console. Analyses were 
performed using BRB-ArrayTools developed by Dr. Richard Simon and BRB-ArrayTools 
Development Team. (BRB array tools is an excel-based graphical user interface for the 
Bioconductor suite of functions in R.)  All groups of arrays used for analysis were normalized 
using robust multi-array averaging (RMA), which included quantile normalization. RMA was 
carried out either by Affymetrix expression console software or BRB Array tools. Global 
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clustering analysis and class-comparisons were performed in BRB array tools using all probes on 
each array unless otherwise stated.  
Functional annotation clustering with D.A.V.I.D.:  Functional annotation clustering was 
performed with DAVID using only gene ontology terms and the list of genes upregulated >2fold 
in day-52 hES-MNs comared to day-32 hES-MNs (Huang da et al. 2009; Huang da et al. 2009). 
GO annotations in the most enriched functional annotation cluster from this analysis were 
reported in the text (enrichment score= 3.6). 
FACS/MACS Sorting: Cells were trypsinized as described in the differentiation section, 
then resuspended at 106 cells/mL in supplemented CMF-PBS as above. FACS Sorting was 
performed as described in the HB9::GFP microarray section. MACS sorting (Miltenyi) was 
performed according to the manufacturer’s protocol. 
qPCR: qPCR was performed on a Stratagene Mx3000p machine using Brilliant II Syber 
Green qPCR master mix (Stratagene) with ROX loading control according to the manufacturer’s 
recommendations. 1ng of amplified cDNA template was used per reaction with 3.4uM of each 
primer. Data was analyzed using MxPro QPCR software. All expression values are normalized 
to GAPDH and a ROX loading control prior to comparison. All samples are run in duplicate. See 
supplemental data section for all primer sequences.  
Immunostaining: All cultures were fixed with 4% paraformaldehyde in 1x PBS at 4ºC. 
They were then washed 3x with PBS, and blocked with 1x PBS 10%, donkey serum, 0.1% 
Triton-X100. Primary antibodies were incubated overnight at 4ºC in blocking buffer at 
appropriate concentrations. Following removal of primary antibodies, cells were washed 3x in 
PBS-T-X100 and secondary antibodies were used at 1 %g/mL for one hour at RT. Cultures were 
then washed 3x with PBS-Tx100 and once with PBS lacking triton. DAPI was used at 0.5 %g/mL 
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in PBS at RT for 15 minutes. See supplemental data section for antibodies used and 
concentrations. 
Live, extracellular immunostaining: live cells cultured on poly-ornithine/laminin coated 
coverslips were removed from incubation at 37 °C, washed twice with 4°C Neurobasal media, 
and incubated for 30 minutes on ice with primary antibody at 1:100 in cold neurobasal. Cells 
were then washed 3 times with cold neurobasal and fixed with fresh 4% PFA as above. Blocking, 
staining for other antigens, and application of secondary antibodies then proceeded as above for 
fixed immunostaining.  
Calcium imaging: iPS- cells were differentiated under the optimal differentiation protocol 
#1 using SB/LDN/SAG (as described above) and dissociated at day 21 of differentiation. 
Dissociated motor neurons were cryopreserved. When required, motor neurons were thawed and 
seeded in NDM plus neurotrophic factors on PO/LAM-coated, 15-25mm diameter coverslips at a 
density of 250-125K cells per coverslip. Seeded motor neurons were cultured 12-14 days prior to 
Ca2+ imaging. To load the Ca2+  indicators into the cells, coverslips were exposed to a solution of 
5 %M Fura Red AM and 3 %M Fluo-4 AM (Invitrogen, Carlsbad, CA) dissolved in 0.2% 
dimethyl sulfoxide/0.04% pluronic acid (Sigma-Aldrich, St. Louis, MO) in HEPES-buffered 
physiological salt solution (PSS) for 1 hour at  room temperature. The PSS contained (mM): 
NaCl 145, KCl 5, HEPES 10, CaCl2 2, MgCl2 2 and glucose 5.5, pH 7.4. The cultures were then 
washed with PSS and mounted on the stage of a C-1 inverted confocal microscope (Nikon 
Instruments, Melville, NY). Cultures were continuously superfused with PSS at a rate of 
approximately 0.5 ml/minute, using a gravity-fed system. The fluorescent Ca2+ indicators were 
excited using the 488 line of a HeNe laser and emitted light from the Fluo-4 and Fura-Red 
recorded in separate channel using 500-530 nm band-pass and 650 nm long-pass filters, 
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respectively. 256 x 256 pixel images were acquired using a 20x 0.7 NA air objective (Nikon).  
For imaging spontaneous Ca2+ transients, and TTX treatment single sets of 300 images were 
acquired at a rate of approximately 2 Hz from each coverslip. TTX was added to superfusing 
PSS at 500nM. For TTX experiments, images were acquired before addition of TTX, following 
20 minute perfusion with TTX containing PSS, and after a 40 minute TTX wash out period. For 
the kainate and KCl experiments, the superfusing PSS was replaced with PSS containing kainate 
(100 %M) or KCl (50 mM; the NaCl concentration of the PSS was reduced to maintain a constant 
osmolality and choride ion concentration). Images were acquired at a rate of 0.033 Hz. Image 
analysis was performed using ImageJ (http://rsb.info.nih.gov/ij/) and custom written macros. 
Ca2+ transients were determined from regions of interest encompassing the soma of individual 
cells, using the ratio of intensities from the Fluo-4 and Fura Red channels. 
Calcium imaging of sHB9::RFP virus labeled samples: For virally labeled samples, 
calcium imaging was performed as above, except iPS-MNs were freshly seeded from 22 day 
SB/LDN, SAG/PUR differentiations (see above, optimal differentiation protocol #2) at 1 million 
cells per well in a 12 well plate. Cultures were infected with sHB9::RFP lentivirus 48-72 hours 
post feeding and allowed to mature and express virus for 7 days (see Chapter 4 for a more 
complete viral infection protocol). Cultures of labeled motor neurons were then dissociated and 
re-plated at 500k cells/18mm coverslip and allowed to mature 14 days prior to calcium imaging. 
Virally labeled cultures were loaded with calcium dye as above, except Fura-Red AM was 
omitted in order to allow visualization of the sHB9::RFP marker. Imaging was performed on an 
inverted Zeiss epifluorescence microscope using the second neutral density filter and exposure 
times giving a 50% maximum pixel saturation at baseline (~200mS). Image acquisition rates and 
image processing were as described above (one exposure every 0.5 seconds, 250 frames for 
! ! ! !!
!
.F:!
connectivity assays). Calculation of temporal cross-correlation between pixels in figure 3.7B was 
performed using ImageJ and publically available macros.  
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Chapter 4: Identification of ALS-related changes in gene expression in iPSMNs !
Introduction: 
Having established the general reliability of iPS cells and developed an understanding of 
the molecular and physiologic processes at play in ES/iPS-MN cultures, I next turned to a 
preliminary analysis of ALS-specific phenotypes in iPS-MNs. To date, no studies have identified 
deleterious phenotypes in any iPS model of ALS. I selected genome-wide transcriptional 
profiling to accomplish this goal because it will allow both unbiased analysis of global gene 
expression as well as the post-hoc testing of specific hypotheses. The data presented in this 
chapter will show that there are ALS-specific expression changes in iPS-MNs and that some of 
these changes are consistent with phenotypes observed in patients and other models of ALS. 
The difficulty involved in genetically manipulating either hES or iPS cell lines presents a 
problem for disease modeling studies that focus on a single cell type. Currently, there are no 
published iPS lines that have been genetically modified to carry motor neuron-specific reporters, 
let alone panels of such lines derived from ALS patients and controls. However, pure populations 
of motor neurons are highly desirable for generating reliable expression profiles from ALS and 
control motor neurons. If heterogeneous populations of cells are used for such experiments, line-
specific differences in differentiation propensity could easily overwhelm disease-specific signals 
in gene expression.   
To overcome this obstacle, I have implemented a motor neuron-specific reporter strategy 
that relies on lentiviral introduction of a reporter directly into neurons and neural progenitors, 
rather than stable genetic modification of the parental iPS line. A distinct advantage of the 
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lentiviral approach is the ease with which it can be transferred between multiple ALS and control 
iPS lines.  
Using the sHB9::RFP lentivirus, I have produced gene expression profiles of motor 
neurons from a panel of 4 ALS and 2 control iPS lines, allowing a first pass at identifying ALS-
specific phenotypes in iPS-MNs. A large number of genes are differentially expressed in ALS 
iPS-MNs, including genes involved in neuronal excitability, motor neuron fate specification, and 
known ALS-related pathways. Moreover, I will show data suggesting increased levels of UPR 
and cell stress markers in ALS iPS-MNs and will compare gene dysregulation in ALS iPS-MNs 
to published expression profiles taken from many other ALS model systems.  
Results: 
sHB9::RFP lentivirus to label and isolate iPS-MNs: 
Because our iPS lines do not carry motor neuron reporters, I used a lentiviral strategy to 
label and isolate iPS-MNs in mixed differentiated cultures. The lentivirus contains a shortened 
3.6kb fragment of the motor neuron-specific HB9 promoter which drives tagRFP protein 
expression specifically in motor neurons (sHB9::RFP) (Figure 4.1A-D). The sHB9 promoter, 
which contains a minimal CMV transcriptional start site, was a generous gift of Fred Gage and 
Carol Marchetto. With assistance from members of our lab, I cloned the sHB9 promoter into an 
existing lentiviral backbone (pRRLsin) along with the tagRFP reporter protein (Figure 4.1A, see 
Methods for construction, lentiviral production, titer, and infection). As an alternative to RFP, a 
version with surface-tagged human CD2-GFP fusion protein was also produced. When iPS-MNs 
were infected with sHB9::RFP or sHB9::CD2-GFP lentivirus 2 days following differentiation 
and allowed 7-8 days to express viral transgene, Islet1/2-positive cells were enriched in the 
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labeled fraction: 66%± 6.8%SEM compared to 19%± 4.6%SEM in the total culture, giving an 
average fold-enrichment of 4.1± 1 SEM  (n=5, p=0.00037) (Figure 4.1B-C). This result is 
remarkably consistent with that previously published by Marchetto et al (2008) who reported a 
68.8% overlap with endogenous HB9 (Marchetto et al. 2008). Following RFP labeling, iPS-MNs 
can be FACS isolated using standard procedures (Figure 4.1D) (see Methods). 
Microarray profiling and clustering analysis: 
After validating the sHB9 lentiviral reporter system, I selected a panel of iPS lines from 
fALS patients and unaffected controls to be used for microarray profiling of labeled iPS-MNs. 
Two control lines were selected (11c, 18c) and 4 fALS lines were selected (27b, 39b, 25b, and 
29A) (Figure 4.2B). All lines were female, with the exception of the control line 11c. 
Additionally, all lines were reprogrammed using 3-factors with the exception of 29A, which 
contains c-Myc. Each fALS line was derived from a patient with a known mutation in SOD1 (see 
Figure 4.2). Amongst the fALS lines used for profiling, there is a wide range of age at disease 
onset, which is necessary for a subsequent analysis of onset-dependent factors in Chapter 5. The 
fALS lines 25b and 39b were derived as in Chapter 2 and have not been previously published. 
Microarray profiling was then performed on sHB9::RFP virally labeled motor neurons 
from each of the 6 iPS lines (Figure 4.2A). Three separate passages from each line were 
differentiated to iPS-MNs using a 22-day protocol (SB/LDN+SAG/PUR: see Methods and figure 
1.11). Differentiated iPS-MNs were then plated and infected with sHB9::RFP lentivirus at 48-72 
hours post-plating.  Eight or nine days after infection, sHB9::RFP labeled cells were FACS 
isolated and total RNA was extracted from RFP+ and RFP negative populations (~day 32 of 
differentiation)  (see Figure 4.2 for a complete listing of sample characteristics). Importantly, 
there was no difference in the average percentage of RFP labeled cells between the ALS and 
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control groups (1.3± 0.4% and 0.94± 0.7% respectively P=0.177). In addition, no line-by-line 
differences in the percentage of RFP-positive cells were observed (ANOVA P=0.301 F=1.388, 
d.f.=5). Following RNA preparation cDNA was synthesized from RNA using an oligo dT-based 
method and subsequently amplified, fragmented, and biotinylated for use in array hybridizations 
(see Methods). Quality control was then performed on all RNA samples to verify RNA integrity 
and on cDNA to verify the enrichment of motor neuron markers (RIN>8) (Figure 4.2C-D, 
Supplemental Figure 4.3.1). Fragmented, labeled cDNA from RFP+ fractions was then 
hybridized to Affymetrix Hu133 2.0 plus arrays. Arrays were judged to be of good quality by the 
Columbia University Genomics Core facility. Microarray data for all arrays was then normalized 
and processed as described in Chapter 3. 
In order to further validate the enrichment of motor neurons in sHB9::RFP labeled cell 
fractions, I assessed microarray expression values for several motor neuron markers. Marker 
expression was compared between all iPS-MN samples and the day-32 HB9::GFP hES-MN and 
non-MN samples profiled in Chapter 3 (Figure 4.3). Because these two profiling experiments 
were performed in an identical manner following FACS isolation of labeled cells, I was able to 
group the arrays prior to normalization and assessment of marker expression (see Methods). I 
then assessed expression of the motor neuron markers HB9, VAChT, CHT1 (SLC5A7), Isl1, 
Ret, and GYPB by selecting the probe for each gene with the highest average expression level 
and plotting the average expression of this single probe for each cell line (n=3 per line). 
Although there is variability from line to line, each sHB9::RFP sample is highly enriched for 
most motor neuron markers compared to HB9::GFP negative cells (Figure 4.3 A-F). 
Furthermore, the iPS-MN samples display similar levels of these markers when compared to 
HB9::GFP labeled hES-MNs (Figure 4.3 A-F). Together, these results indicate successful 
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enrichment of iPS-MNs. Statistical tests of line-by-line differences for these genes are contained 
in Figure 4.8 and discussed below. 
Following array hybridization, I performed a clustering analysis to assess global 
similarity between the different iPS-MN arrays. For this and all subsequent analyses, only iPS-
MN arrays were included in the array normalization group (see Methods). First, the number of 
probes used for clustering analysis was reduced by sub-setting the array data to probesets for 
each gene with highest signal intensity, though sub-setting on the most variable probesets 
produced identical results in this analysis (not shown). Then, arrays were clustered using 
centered correlation and average linkage (Figure 4.4A). Clustering revealed two important 
features of the array data. First, replicates from the same line tend to cluster together, indicating 
that line- and/or patient-specific gene expression patterns are maintained across passages and that 
replicate-to-replicate variability does not overwhelm these differences. Second, control iPS-MNs 
clustered together and away from ALS iPS-MNs, indicating that expression patterns in these two 
lines are more similar to each other than to the other lines in the analysis. Importantly, all ALS 
iPS-MNs did not cluster together. One group of ALS iPS-MNs showed higher correlation values 
compared to control iPS-MNs than to the other group of ALS iPS-MNs (see Figure 4.4A).  
ALS vs. control and line-by-line differences in gene expression: 
In order to determine which genes are changed in ALS iPS-MNs, and therefore potential 
genetic and phenotypic indicators of disease state, I performed a class-comparison analysis 
between ALS and control iPS-MNs using all probesets on the arrays. The results of this analysis 
are presented as a volcano plot in Figure 4.4B. At p=0.001, I identified 217 genes that were 
changed > 1.5 fold in ALS iPS-MNs as compared to control iPS-MNs. 88 genes were 
upregulated, whereas 129 genes were downregulated. Without the fold-change cutoff, 238 genes 
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were identified at the same p value. Genes differentially expressed in ALS iPS-MNs have 
diverse functions, including roles in neurotransmission and excitability, neural development, and 
response to cellular stressors. A list of the top upregulated and downregulated genes from this 
analysis is presented in Figure 4.5. The complete list is in Appendix 4.1. 
Gene ontology analysis of the complete ALS vs. control list without fold-change cutoff 
showed overrepresentation of genes involved in nucleosome and chromatin remodeling, cell 
division, N-linked protein glycosylation, Notch signaling, and microtubule regulation, among 
other processes (Figure 4.6A-C, see Methods).  
Pathway analysis with DAVID (Huang da et al. 2009; Huang da et al. 2009) produced 
several interesting results. Supplemental figures 4.6.1 and 4.6.2 detail genes changed in the 
Notch signaling pathway and Axon guidance pathways respectively.  
After evaluating the broad categories of genes that are differentially expressed between 
ALS and control samples, I examined the ALS vs. control gene list for candidates that might 
have a relationship to selective motor neuron vulnerability or ALS disease processes. I found that 
the genes differentially expressed between ALS and control groups suggest multiple deleterious 
phenotypes in ALS iPS-MNs. Line-by-line expression of several candidate genes is presented in 
Figure 4.7 A-F. FOXP1 (forkhead box p1), an embryonic marker of the limb innervating motor 
neuron class most susceptible in ALS, is decreased 3.0-fold in ALS iPS-MNs (p=2.83e-4). 
Notch2 is 4.9-fold increased in ALS (p=3e-7), suggesting potential defects in neuronal 
differentiation (see Discussion). AHNAK nucleoprotein and GRIK1 (glutamate receptor, 
ionotropic, kainate 1), both genes involved in neurotransmission and excitability, are 32-fold 
upregulated and 11-fold downregulated in ALS respectively  (p=1.14e-5, p=2.4e-4 respectively). 
Finally, A2BP1 (ataxin 2 binding protein 1), a binding partner of ATXN2 (a recently described 
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fALS- and sALS-causing gene), is 13-fold decreased in ALS iPS-MNs (p=3e-7). Specific 
hypotheses arising from these candidate genes will be covered in the General Discussion.  
I then performed a line-by-line comparison of differentially expressed genes in order to 
understand some of the variability within the ALS and control groups. Additionally, this type of 
analysis allows the potential identification of line-specific ALS phenotypes. Thus, class 
comparison between each grouping of two lines was performed at p<0.001. The results were then 
aggregated to form a list of 1095 unique genes differentially expressed in iPS-MNs from the 6 
iPS lines in the study (No fold-change cutoff). 53 of these genes were significant by ANOVA 
after Bonferroni correction (d.f.=5, see Appendix 4.2 for a complete gene list). Heatmaps 
(p<0.001) and volcano plots for each individual line-by-line comparison are presented in 
supplemental figures 4.4.1-4.4.6. 
One noteworthy gene identified in this fashion, but not in the initial ALS vs. control class 
comparison, is DPP6 (dipeptidyl-peptidase 6). DPP6 is a voltage sensitive subunit of Kv4.2 
potassium channels that has previously been implicated as a sALS risk gene. DPP6 was 13-fold 
downregulated in ALS iPS-MNs as compared to controls (p=0.025). This p value did not reach 
the more stringent significance criteria used above for the ALS vs. control comparisons due to 
unusually low DPP6 expression levels in iPS-MNs from the ALS line 29A (see below). With 
29A removed from the ALS vs. control comparison, DPP6 is 3.3-fold downregulated in ALS 
iPS-MNs (p=5.27e-5). Furthermore, individual line-by-line comparisons of DPP6 expression are 
significant for each ALS line compared to each control line (Figure 4.7B). One ALS line in 
particular, 29A, expresses very low to undetectable levels of DPP6, placing it in a separate class 
from control as well as other ALS lines (Figure 4.7B).  
Candidate-based analysis of gene expression: 
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Following the unbiased identification of genes dysregulated in ALS iPS-MNs, I took a 
candidate approach to quantify the expression of motor neuron column and sub-type markers as 
well as markers of cell stress: two groups of genes that might serve as indicators of disease state. 
If column or subtype markers are differentially expressed between ALS and control iPS-MNS, it 
may indicate that certain classes of motor neurons have differential viability in culture or are 
somehow produced at variable efficiencies during differentiation. If markers of cell stress are 
increased in ALS iPS-MNs, it may indicate that these cells will show deleterious phenotypes of 
disease. Furthermore, interactions between cell stress and subtype-specific vulnerability may also 
be evident.  
Expression of motor column and sub-type markers: 
Several motor neuron subtype markers do appear to be differentially expressed between 
ALS and control cells, as well as in a line-by-line fashion. I selected a short list of motor neuron, 
motor column, and subtype markers and looked for significant changes in expression of these 
genes between ALS and control cells at p<0.01 (Figure 4.8A-B). Within this list, only FOXP1 
and Islet1 were expressed differentially in all ALS iPS-MNs as compared to control iPS-MNs 
(Figure 4B). Both genes were lower in ALS iPS-MNs.  When I assessed gene expression through 
independent pair-wise comparisons between each iPS line, I found differences in the expression 
of LHX3, CHODL, ISL1, MNX1, FOXP1, HOXA5 and HOXC6 in a line-dependent manner 
(Figure 4.8C). Most notably, iPS-MNS derived from the ALS line 25b showed greatly increased 
expression of the medial motor column (MMC) marker LHX3 and downregulation of the lateral 
motor column marker (LMC) FOXP1. This data may represent either a LMC to MMC shift in 
cell viability or may be a peculiar propensity of 25b to form MMC-MNs. Furthermore, CHODL, 
a potential marker of fast fatigueable (FF) motor neurons, was decreased in 3 of the 4 ALS lines 
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studied. A shift away from FF motor neurons in culture may indicate subtype-specific survival 
deficits in ALS iPS-MNs. Other expression changes in this subset of genes are listed in Figure 
4.8C. Taken together, these data may be interpreted in two distinct but non-exclusive manners.  
First, they suggest that each iPS line may produce a unique population distribution of motor 
neuron sub-classes. Second, iPS lines may initially produce similar populations of motor 
neurons, and then exhibit line- or disease-specific reductions in cell viability for the most 
vulnerable cells.  
Expression of cell stress markers from Saxena et al (2009): 
Several markers of the unfolded protein response (UPR), inflammation, and cell stress 
were also present in ALS iPS-MNs. Saxena et al. (2009) describe a panel of such genes that are 
dysregulated in a mouse model of ALS early during disease, particularly in the most vulnerable 
motor neurons (Saxena et al. 2009). To see if this is also the case in young iPS-MNs, I selected 
the homologous human genes and assessed their expression both in ALS vs. control iPS-MNs 
and in a line-by-line manner at p<0.05 (25 total genes) (Figure 4.9A-C). I found that ALS iPS-
MNs express higher levels of the stress proteins GADD45B, HEXB, and GRN as well as higher 
levels of the inflammatory protein IFITM3 (Figure 4.9A-B). Furthermore, UBE2QL1, a 
ubiquitin ligase, was downregulated in all ALS lines compared to controls (Figure 4.9A-C).  
To assess whether or not individual ALS lines differentially express cell stress markers, I 
compared marker expression in iPS-MNS from each ALS line to the average expression value in 
the two control iPS lines combined (p<0.05). Significant variability was present amongst the 
ALS iPS-lines with respect to their expression of cell stress markers (Figure 4.9A). 25b showed 
evidence of increased cell stress in 9/25 genes, 27b in 6/25, 29A in 6/25, and 39b in 1/25. The 
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most commonly changed gene in this group, UBE2QL1, was decreased in every ALS iPS line 
compared to controls as well as in all ALS lines on average (Figure 4.9C). 
Taken together, these data suggest a generalized increase of cell stress in ALS iPS-MNs 
and may partially explain why these cultures are depleted in markers of ALS-susceptible motor 
neurons. In fact, iPS line 25b, which exhibits the strongest shift towards MMC motor neurons, 
also shows the greatest increase in markers of cell stress (Figure 4.9A). 
Meta analysis with other ALS microarray data sets: 
 One way of better understanding the above expression data is to place it in the context of 
other ALS model systems through a meta-analysis with published data sets. An added benefit to 
such an approach would be to reduce a possible bias in my data created by shifts in the 
populations of iPS-MNs profiled in ALS vs. control cultures through focusing analysis only on 
genes that have previously been reported to demonstrate aberrant expression in ALS. Therefore, 
I performed a meta-analysis of differential gene expression by comparing published reports with 
the data I generated above. I selected 11 studies from the literature that perform some sort of 
microarray profiling to identify genes potentially involved in the pathogenesis of ALS (Kirby et 
al. 2002; Jiang 2005; Kirby et al. 2005; Perrin et al. 2005; Ferraiuolo et al. 2007; Lobsiger et al. 
2007; Saxena et al. 2009; Cox et al. 2010; Rabin et al. 2010; Kirby et al. 2011; Lenzken et al. 
2011). The ALS model systems used in these studies ranged from generic neural cells 
overexpressing mutant SOD1, to laser capture micro-dissected (LCM) motor neurons from 
SOD1 expressing rodents, and motor neurons isolated by LCM from post-mortem fALS and 
sALS patients. A key feature of each study is the use of homogenous cell populations and not 
mixed cultures or large blocks of neural tissue. For each ALS vs. control comparison performed 
in the published studies, a list of differentially expressed genes was generated and then 
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intersected with the list of genes changed in ALS vs. control iPS-MNs. The results of this 
analysis are presented in figure 4.10A-B.  
 First, gene lists were built from each ALS vs. control comparison in the indicated studies. 
Each comparison studied is listed in a separate row of figure 4.10A-B. In order to standardize the 
studies as much as possible, I obtained and re-analyzed array data where available (see 
Methods). ALS vs. control comparisons were analyzed at three p values: p=0.05, 0.01, and 0.001 
(Figure 4.10A). Genes from p=0.01 were used for further analysis. Where raw microarray data 
were unavailable, published gene lists were used for intersection with ALS iPS-MN data 
(indicated by “List” in Figure 4.10A). Once a gene list had been produced, DAVID was used to 
convert gene identifiers to human official gene symbols in order to facilitate comparison with the 
iPS-MN data (Huang da et al. 2009; Huang da et al. 2009).  
 The iPS-MN microarray data set was then restricted to genes from each of the above lists 
and an ALS iPS-MN vs. control iPS-MN comparison was performed for each subset of genes at 
p<0.05. The results of these comparisons are presented both as the raw number of probesets that 
reached significance for each list and fractionally as a percentage of probesets in the analysis (i.e. 
the fraction of significant ALS vs. control probesets compared to the total number of probesets 
that mapped to the particular gene symbol list being evaluated) (Figure 4.10A). Importantly, this 
stage of analysis did not take into account the valence of expression changes. This will be done 
below for a subset of the data. 
 Overlap with published ALS studies ranged from 15.8% to 0% of total probes in each 
analysis (Average 9%± 4% STDEV) (Figure 4.10A). Expression changes in ALS iPS-MNs 
show the highest concordance with data sets from e14 rat primary motor neurons expressing 
G93A SOD1 as compared to those expressing WT SOD1 (15.8% overlap) (Lobsiger 2007). This 
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is followed by two LCM studies performed on p60 mouse motor neurons also expressing G93A 
SOD1, but compared to non-SOD1-expressing control motor neurons (11.1% and 13.2% overlap 
respectively) (Perrin 2005, Ferraiuolo 2007). Although there is some overlap with most 
microarray studies in the meta-analysis, expression changes in SOD1 ALS iPS-MNs do not seem 
to strongly resemble those in any existing model system (maximum 15.8% identity).  
Both to prioritize potential disease phenotypes in ALS iPS-MNs and to identify common 
mechanisms across the disparate ALS model systems, I then identified the genes that were most 
often changed in the various ALS vs. control comparisons as well as in the iPS-MN data. 15 
different genes are changed in the same direction in both the ALS iPS-MN data and in 2 or more 
other studies in the meta-analysis (Figure 4.10B-C). These genes are involved in diverse cellular 
processes, but are enriched in regulators of neurotransmission and excitability as well as the cell 
stress response. Common genes were distributed across many different studies, but seem to be 
over-represented in the human motor neuron LCM study performed by Rabin et al (2010) 




This chapter represents an early step towards defining patient-specific phenotypes in ALS 
iPS-MNs. In it, I perform transcriptional profiling of iPS-MNs derived from panel of ALS and 
control iPS lines.  My results indicate a unique transcriptional profile related to ALS in iPS-MNs 
that has some overlap with previously published studies. Although these results still require 
confirmation, they suggest phenotypes of disease that are testable in the iPS-MN system.  
! ! ! !!
!
.?<!
One novel feature of the work in this chapter was the use of a sHB9::RFP lentivirus to 
enrich motor neurons from culture following differentiation. An average iPS-MN differentiation 
contains approximately 20-25% Islet+ cells. Although this is sufficient for some purposes, it 
could prove problematic for expression profiling. Using the sHB9::RFP lentivirus, I was able to 
enrich cultures up to approximately 65% Islet+ motor neurons. Although still not a pure 
population, this represents a significant improvement. An enriched population of motor neurons 
gives my study access to motor neuron-specific expression patterns that could otherwise be 
overlooked when profiling mixed cultures following differentiation. Another advantage of this 
approach was that it allowed for an adherent maturation period before profiling. Because 
phenotypes of ALS may take time to develop in culture, profiling at a later stage increases the 
chances of identifying disease relevant changes in iPS-MNs. Importantly, this method does not 
discriminate between cell-autonomous and non-cell-autonomous changes in iPS-MNs. 
However, culture-to-culture variability is a significant disadvantage of the viral approach 
to isolating motor neurons. Although all cultures were plated at the same density and infected 
with sHB9::RFP virus in the same manner, there was significant variability in the expression of 
motor neuron markers within the enriched populations (See Figures 4.3, 4.3.1, and 4.8). 
Although all samples used for profiling showed enrichment for these markers compared to motor 
neuron-depleted samples, it is somewhat concerning that this enrichment occurred at different 
levels for different samples. In fact, ALS iPS-MNs as a group expressed lower levels of ISL1, 
but not other general motor neuron markers (See Figure 4.8). There are multiple explanations for 
why this could have been the case, including reduced survival of motor neurons in ALS lines, 
variable rates of motor neuron maturation, or variable perdurance and specificity of the RFP 
reporter protein. Interestingly, the levels of motor neuron marker enrichment were relatively 
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stable for the same line from replicate to replicate, indicating that, whatever the cause, it was 
reproducible. Due to the small number of virally labeled cells, I was unable to collect sufficient 
quantities to independently assess motor neuron numbers and sHB9::RFP/Islet overlap for each 
virally labeled array sample (see Figure 4.2D). Future work should scale up production of both 
virus and motor neurons in order to make this a standard practice. It is possible that much of this 
variability could be removed by using stable reporter lines in future studies, however, such lines 
may still be subject to some line-dependent differences in reporter expression. A more ideal 
solution would be to utilize endogenous motor neuron-specific surface markers in iPS-MNs in 
order to FACS purify cells for expression profiling. However, I do not yet have sufficient 
evidence of motor neuron specificity for any of the candidate surface markers discussed in 
Chapter 3.  
Thus, it is worth keeping in mind that this study is working with enriched, but not pure 
cultures of iPS-MNs. Additionally, because many of the genes differentially expressed between 
ALS and control samples are motor neuron-enriched in general (FOXP1, A2BP1, GRIK1), it is 
likely that some of the ALS vs. control differences are driven by differential viral enrichment of 
motor neurons between these two groups. Although this serves as a caveat, it should not prevent 
further work with the iPS-MN data set provided that important results are first confirmed at the 
single-cell level by immunohistochemistry before progressing to more time-consuming 
experiments.  
An encouraging finding in this study was that, despite worries about culture-to-culture 
variability, biological replicates from the same iPS line showed similar global expression 
profiles. Hierarchical clustering of all samples showed that replicates nearly always clustered 
together. This result suggests that the gene-level differences I observed are a property of the iPS 
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lines themselves and not replicate-to-replicate variability. That all replicates from the two control 
lines clustered separately suggests that they are most similar to one another, but does not 
necessarily have bearing on disease phenotypes.  
ALS vs. control differences in gene expression: 
A comparison of gene expression between ALS and control motor neuron samples 
revealed 217 genes that were differentially expressed between the two groups. This group of 
genes was slightly skewed towards transcriptional repression, with 59% of genes being 
downregulated. Notably, gene ontology results demonstrated that several biological processes 
related to ubiquitin ligase activity were overrepresented in the ALS vs. control gene list (Figure 
4.6C). Because defects in protein degradation are an important component of ALS, these results 
bear further investigation (see below). In addition, gene ontology and pathway analysis indicated 
that Notch signaling is increased in ALS iPS-MNs. The functional significance of this change is 
not known. However, Notch signaling regulates cell cycle exit in motor neuron progenitors and 
has been implicated in patterning of distinct motor neuron subtypes (Sabharwal et al. 2011). 
Thus, increased levels of Notch signaling may indicate differences in the motor neuron subtypes 
in culture. 
Multiple hypotheses about ALS pathogenesis in iPS-MNs arise from a survey of the 
individual genes that are differentially expressed between ALS and control samples. Although 
space will not permit the discussion of all gene expression changes in ALS iPS-MNs that have 
potential functional consequences, several ALS-relevant candidates will be mentioned briefly 
below and covered in more detail in the General Discussion along with other candidate gene-
based hypothesis arising from my work. Genes of specific interest include: 
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A2BP1: Ataxin2-binding partner1 (A2BP1, Rbfox1), a regulator of alternative splicing, 
was 13-fold downregulated in ALS iPS-MNs. A2BP1 is a binding partner of Ataxin-2, the 
genetic cause of spinocerebellar ataxia II and a recently described risk gene for sALS (Elden et 
al. 2010).  
DPP6: Dipeptidyl peptidase 6 (DPP6) expression was reduced in all ALS iPS-MN 
samples and nearly absent in iPS-MNs derived from the ALS line 29A (see Figure 4.7B). DPP6 
is a voltage sensitive subunit of Kv4.2 potassium channels and several studies have identified 
mutations in DPP6 as a risk factor for sALS, although this appears to be population specific 
(Cronin et al. 2009; Fogh et al. 2011).  
FOXP1: A marker of ALS-susceptible LMC motor neurons, FOXP1 is consistently 
downregulated in ALS iPS-MNs as compared to control iPS-MNs (Figure4.7-4.8). It is possible 
that this reflects the death of FOXP1+ motor neurons specifically in ALS cell lines.  
Post-hoc analysis of candidate genes: 
Throughout the subsequent comparisons, I biased the data towards more sensitivity and 
lower specificity by lowering the P-value cutoffs below what as used to derive the initial list of 
217 genes changed in ALS vs. control (P<0.001). This was done in order to generate as many 
candidate genes as possible for further analysis. Therefore, this data should be viewed with a 
higher false positive rate in mind.  
The observation that FOXP1 was decreased in iPS-MNs led me to specifically evaluate 
the expression of other motor neuron subtype and column markers both in ALS iPS-MNs as a 
group and in a line-by-line manner. Most notably, I found that iPS-MNs derived from one 
particular ALS line, 25b, show a large increase in expression of the MMC marker LHX3. This 
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line also displays the lowest levels of the LMC marker FOXP1, suggesting a shift towards more 
disease-resistant motor neurons. Whether this shift is at the level of motor neuron survival or 
generation still needs to be addressed.  
Because increased markers of cell stress and the UPR are thought to be early symptoms 
of ALS in motor neurons, I also evaluated the expression of genes involved in these processes 
(Figure 4.9) (Saxena et al. 2009). Increased levels of Hexosaminidase B and Granulin in ALS 
iPS-MNs suggest that iPS-MNs are experiencing increased levels of cell stress. Decreased levels 
of the ubiquitin ligase UBE2QL1 were also observed in every ALS iPS line and suggest a 
possible defect in the ubiquitin ligase system. However, I did not see a general decrease in the 
levels of other ubiquitin ligases, leaving these results open to other interpretations. Given the 
recent identification of another ubiquitin-related protein, UBQLN2, as an ALS causing gene 
(Deng et al. 2011), UBE2QL1 seems an interesting target for further investigation.  
Line-by-line analysis of the same cell-stress markers demonstrated that all iPS lines are 
not equally affected by changes in these pathways. The ALS iPS line 25b showed potentially 
deleterious changes in 9/25 genes tested, more than any other line. Together with the data 
showing that 25b expresses the lowest levels of FOXP1 and the highest levels of LHX3, this 
suggests that phenotypes of ALS may be most severe in this line. This is rather unexpected 
because 25b was derived from a patient with age of onset at 59yo, and not one of the early onset 
ALS cases. 
Meta Analysis: 
In order to situate ALS iPS-MNs in the larger context of ALS model systems, I 
performed a meta-analysis of my microarray data along with 11 other ALS expression studies. 
This approach will also allow me to identify potential ALS-related expression changes that are 
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not as biased by the differential motor neuron enrichment in ALS and control samples. Overall, I 
found a relatively low concordance between my results and the set of published studies. This is 
not surprising given the historically low overlap encountered when comparing ALS expression 
studies in this manner (see General Intro).   
Since multiple studies showed overlapping expression changes in the 10-15% range, I 
will not attempt to define a single best-fit study. Rather, it will be more useful to discuss the 
genes most commonly found in my data and in other expression profiles of ALS (See Figure 
4.10B-C). This approach may help to define some of the features of ALS that are the most 
generalizable to the iPS-MN system. Notably, it is potentially encouraging that the greatest 
overlap of this category of genes was between my iPS study and the most carefully-performed of 
the in vivo profiling studies, that by Rabin et al. (2010). 
 Six genes were changed in the same direction in ALS iPS-MNs and 3 or 4 other 
comparisons from the meta-analysis. Of these, GRN and HEXB were both increased in iPSMNs. 
These proteins were discussed above because they are also cell stress markers from the Saxena et 
al. study (2009). LGALS3, SPOP, and CD44 will be covered in the general discussion. 
Future Directions: 
Taken together, the results in this chapter suggest that cultures of ALS iPS-MNs are 
considerably different than those derived from healthy donors, to a degree that I did not initially 
anticipate given the early embryonic developmental stage of the neurons under study. Although 
the interpretation of this data is complicated by multiple factors, ALS iPS-MNs show gene 
expression patterns that correlate potentially well with some expected phenotypes of disease. 
Future work should confirm these findings as well as investigate the potential effects of the ALS-
candidate genes discussed above. 
! ! ! !!
!
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For each ALS-candidate gene, the first step in further research is to validate motor 
neuron-specific changes in ALS iPS-MNs. This can be accomplished via qPCR of independent 
samples or, perhaps preferably, using quantitative immunohistochemistry and Western blotting. 
A staining approach in particular would allow the use of multiple motor neuron markers and the 
evaluation of motor neuron sub-type specific changes in protein expression.  
Given the changes in cell stress genes observed in ALS iPS-MNs, particularly decreased 
levels of the ubiquitin ligase UBE2QL1, it would also be interesting to assess the presence of 
protein aggregates and mis-folded proteins in ALS iPS-MNs. Many such changes are considered 
among the pathological hallmarks of ALS and are thought to be interrelated with defects in 
protein and protein-aggregate clearance mechanisms. Immunohistochemical analysis of iPS-
MNs should assess SOD1 aggregates, mis-folded SOD1, and ubiquitinated inclusion bodies. 
Careful investigation of these markers will be considerably useful in defining phenotypes of ALS 
in the iPS-MNs system. Since we do not know how long after differentiation it may take protein 
aggregates to form in ALS iPS-MNs, it would seem best to perform such assays on iPS-MNs that 
have undergone a period of adherent maturation. In this case, the presence of antimitotics can aid 
in limiting the overgrowth of non-motor neurons in culture. 
Batch effects during array hybridization are unlikely to be responsible for the observed 
differences in gene expression between ALS and control iPS-MNs, but should be considered in 
future studies. Arrays were hybridized in two batches, with ALS and control cells in each (one 
group of 3 arrays and one group of 15 arrays, see methods). Clustering analysis demonstrated 
that line identity is a more important determinant of transcriptional profile than hybridization 
batch (Figure 4.4). Further work should ensure that ALS vs. control as well as individual line 
samples remain distributed across multiple batches if all arrays are not hybridized in one 
! ! ! !!
!
.L:!
experiment. Balanced batch sizes, when possible, should also help to minimize the likelihood of 
spurious results.  
Finally, line-by-line heterogeneity posed a challenge for the interpretation of this 
research. The number of genes differentially expressed between two iPS lines in the same group 
(ALS or control) was similar in magnitude both to the number of genes differentially expressed 
between the two groups on average and to the number differentially expressed between two iPS 
lines from different groups (see supplemental figures 4.4.1-4.4.6). In order to move forward in 
the analysis of ALS-dependent gene expression in iPS-MNs, this problem must be addressed. 
Two ways of approaching the issue are to expand the pool of lines studied, especially for control 
iPS lines, or to create isogenic rescue lines from select fALS iPS lines. The most straightforward 
approach would be to begin by adding expression profiles from more control iPS lines into the 
data set from above, using the same methods to isolate motor neurons. In future studies, it would 
also be very useful to profile an ALS iPS-line before and after mutant-specific SOD1 knockdown 
or correction of the mutant SOD1 allele via zinc finger nuclease-mediated recombination. Either 
approach has the capacity to isolate SOD1-dependent changes on a particular iPS genetic 
background. Finally, repeating this analysis on several SOD1 ALS iPS lines and more controls 
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Figure 4.1: sHB9::RFP lentivirus for enrichment of iPSMNs 
(A) Schematic for lentiviral insert containing a truncated HB9 promoter fused to a minimal CMV 
promoter transcriptional start site and drivinf tagRFP (sHB9::RFP lentivirus).  
 
(B) Expression of sHB9::RFP lentivirus in 39b SOD1 A4V iPSMNs 7 days following infection. 
Staining for tagRFP (red), Islet1/2 (Green), and HB9 (magenta). Scale bar=50µM.  
 
(C) Islet percentage of LV sHB9 labeled cells in culture 7-8 days post-infection (n=5, 3 with 
sHB9::CD2GFP virus and 2 with sHB9::RFP virus). (D) Representative FACS plot of 
sHB9::RFP labeled iPSMNs. Red cells are designated  “RFP+” for FACS sorting. Green region 
indicates representative “RFP negative” cells collected for comparison to RFP+ cells. 
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Figure 4.2: Expression profiling of ALS and control iPSMNs. 
(A) Schematic of expression profiling using sHB9::GFP lentivirus. iPSCs are differentiated to 
day 22, infected 48-72 hours post seeding, and sHB9::RFP labeled iPSMNs are FACS isolated 7-
9 days following infection. Quality control is then performed at the RNA and cDNA level prior 
to array hybridization.  
 
(B) Table of cell lines used for profiling.  
 
(C) Representative bioanalyzer traces for RNA isolated from FACS sorted sHB9::RFP iPSMNs.  
 
(D) Table of iPS-MN samples used for microarray. Table indicates the passage number of cells, 
total number of RFP+ motor neuron collected through FACS sorting, Concentration of RNA 
following purification (12uL total volume), Integrity of RNA (RIN), and age of motor neurons at 











































































































































































































































Figure 4.3: Quality control of sHB9::RFP array samples (array values).  
(A-E) Expression of indicated motor neuron markers in all samples used for array (avg ±  SEM, n=3 per iPS 
line). (A) Mnx1 (HB9), (B) Vacht, (C) Ret, (D) Isl1, (E) Slc5A7 (Cht1), (F) GypB.  Results are compared to 
reference values from HB9::GFP arrays from figure 3.1-3.2. !
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Figure 4.4: ALS vs control iPSMN microarray results.  
(A) Clustering of sHB9::RFP iPSMN array samples. control lines cluster away from ALS lines. 
Clustering was performed using Max expressed probe for each gene, centered correlation, and 
average linkage.  
 
(B) Volcano plot of expression differences between ALS and control arrays depicted in A. Blue 
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Figure 4.5: Top 26 genes upregulated and downregulated in ALS iPSMNs (p<0.001) !




Figure 4.6: Gene Ontology results: ALS vs control 
(A-C) Gene ontology analysis of gene set differentially expressed between ALS and control 
iPSMNs (p<0.001) arranged by  
 
(A) Cellular component,  
 
(B), Molecular function, and  
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Figure 4.7: Expression of select genes changed in ALS iPSMNs. 
(A-F) Bar graph of expression values for selected genes differentially expressed between ALS 
and control iPSMNS (p<0.001) (Average values for all arrays, ±  SEM).  
 
(A) FoxP1: forkhead box p1  
 
(B) DPP6: dipeptidyl-peptidase 6, DPP6 (ALS vs. control p=0.025) was identified using line-by-
line comparisons with p<0.001 (asterisms) 
 
(C) Notch2: notch 2  
 
(D) Ahnak: ahnak nucleoprotein  
 
(E) A2bp1: ataxin 2 binding protein 1  
 














A'BC=DE A'BC=DE ()FG E)EB FHG)HE ()*H ()EF ()*I 9JKI 9LM'N13&1>1O'I
PBQ'GRQ'PBQ'IRQ'PGQ'IRQ'P(Q'GRQ'PSQ'GRQ'
PHQ'GRQ'P(Q'IRQ'PSQ'IRQ'PHQ'IR
I)H*C=DS E)G(C=D( GE()FF IDF)*E BHI)EB B(D)*I BH)GH IIF)FB <JT,9 /N1.5%12&/6".
PSQ'BRQ'PSQ'GRQ'PSQ'IRQ'PSQ'(RQ'P(Q'HRQ'
PSQ'HR
B)S(C=D( B)((C=DI SBHF)II FDEG)ES FSF)S( SE*B)EE GGED)FF BD*E)*I L:9B L:9'9LM'N13&1>1O'B
PIQ'BRQ'PSQ'BRQ'PHQ'BRQ'PIQ'GRQ'PSQ'GRQ'
PHQ'GRQ'PIQ'(RQ'PIQ'SRQ'PSQ'(RQ'PHQ'(R
B)HGC=D( B)((C=DI BHS*)E BGEH)BF IDGH)DE SSD)S* HF)*I IEE)H( MUKB 3161%'.&$%1.'4.5'@4./%&40'N13&1>1O'B
PSQ'BRQ'PHQ'BRQ'PSQ'GRQ'PHQ'GRQ'P(Q'IRQ'
PSQ'IRQ'PHQ'IRQ'PSQ'(RQ'PSQ'HR
I)BDC=DI B)(BC=DG HSED)(H *EBH)GG B(*I)H( GG*I)SI ID*S)IE ISEG)SF !TKVB -1%7N&45'>1O'VB
PIQ'BRQ'P(Q'BRQ'PIQ'GRQ'P(Q'GRQ'PSQ'GRQ'
PHQ'GRQ'PIQ'HR
H)HHC=DI G)SDC=DG (FSE)GS SSGF)DE G*H*)FB IGG()EI I*GD)E (SSG)IB JTK8S N13&1>1O'8S
PIQ'BRQ'P(Q'BRQ'PIQ'GRQ'P(Q'GRQ'PSQ'GRQ'
PIQ'HRQ'P(Q'HR
























H)FIC=DI S)BBC=DG BDIDH)EH BSSEI)S( D)HH !TKVB -1%7N&45'>1O'VB

































Figure 4.8: Differences in column and motor neuron markers: ALS vs control and line-by-
line comparisons.  
(A) List of 28 genes assessed in line-by-line and ALS vs. control comparisons.  
 
(B) 2 significant genes for ALS vs. control comparison with 28 column and subclass markers.  
 
(C) 7 significant genes in a line-by-line comparison using the same gene subset. Arrows indicate 
particularly noteworthy expression changes. Far right column indicates significant comparisons 
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Figure 4.9: Overlap with UPR & UPS genes in Saxena et al. 2009. 
(A) Table of stress induced genes identified by Saxena et al. as dysregulated in FF prior to FR 
motor neurons in a mouse mode of ALS. Right half of the table shows significant changes in 
indicated genes as assessed by microarray (p<0.05). Multiple probes were reduced by selecting 
the probe with the most significant differences and secondarily the highest overall expression 
value in control iPS-MNs.  
 
(B) More detailed description of genes in table A that are changed in profiled ALS iPSMNs vs. 
control iPSMNs (p<0.05).  
 
(C) Expression of UBE2QL1 (Ubiquitin –conjugating enzyme E2Q family-like 1) in ALS 
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Figure 4.10: Meta-analysis with iPS-MN microarray data set. 
(A) Table: overall similarity between ALS iPS and other array data sets. The left side of the table depicts specific ALS microarray studies and 
comparisons made within these studies. Row groupings by shading indicate comparisons from the same publication or those that rely on 
common control arrays. (Kirby 2011, Cox 2010) ALS iPS-MN data is in the top row. The right side of the table (numerical values) gives the 
number of significant genes in the indicated ALS vs. control comparisons at different P values and the fraction of these genes that are also 
differentially expressed in the ALS iPS-MN profiling conducted in this chapter. For most studies, raw array data was re-processed identically to 
the ALS iPS arrays and the genes changed in ALS at p<0.01 (first blue column) were intersected with those changed in the ALS iPS-MNs at 
p<0.05 to give a total number of overlapping probesets (red column). In cases where raw array data was unavailable, published lists (second 
blue column) were intersected with ALS iPS genes. The far right column depicts the percentage of genes from a given study that were also 
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 Figure 4.10: Meta-analysis with iPS-MN microarray data set (Continued). 
 (B) (following page): Genes from B mapped onto studies from meta-analysis (right side of 
table). The top rows indicate the magnitude and significance of change for a given gene in 
ALS iPS-MNs. “X” marks indicate that a given gene is also changed in the same direction in 
specific studies. (C) List of genes dysregulated in ALS iPS-MNs and two or more other 
studies. Genes are changed in the same direction in each study (See B). !!
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Supplemental Figure 4.3.1: Quality control of sHB9::RFP array samples (qPCR).  
(A-C) Expression of motor neuron markers by qPCR in each sample used for array and two 
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Supplemental Figure 4.4.1: 11c sHB9::RFP+ gene expression vs. other iPS lines – Volcano 
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Supplemental Figure 4.4.2: 18c sHB9::RFP+ gene expression vs. other iPS lines – Volcano 
plots and heatmap.  
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Supplemental Figure 4.4.3: 25b sHB9::RFP+ gene expression vs. other iPS lines – Volcano 
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Supplemental Figure 4.4.4: 27b sHB9::RFP+ gene expression vs. other iPS lines – Volcano 
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Supplemental Figure 4.4.5: 29A sHB9::RFP+ gene expression vs. other iPS lines – Volcano 
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Supplemental Figure 4.4.6: 39b sHB9::RFP+ gene expression vs. other iPS lines – Volcano 
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Supplemental Figure 4.6.1: Notch signaling pathway. 
Notch signaling pathway with genes differentially expressed between ALS and control 



















Supplemental Figure4.6.2: Axon guidance pathways 
Axon guidance pathways with genes differentially expressed between ALS and control highlighted. Increased genes: Ephrin-B, 
EphB. Decreased genes: PAK, srGAP, FYN. !





iPS-MN differentiation: iPS cells were differentiated into motor neurons using a derivative of the 
21 day SAG/PUR protocol discussed in Chapter 2. iPS cells were neuralized by inhibiting 
SMAD signaling (SB 10mM, LDN 0.2 µM), caudalized with retinoic acid (RA, 1µM), and 
ventralized with smoothened agonist (SAG, 1µM) and purmorphamine (PUR, 1µM) at the time-
points described above. Differentiations were dissociated as described above at day 22 and plated 
at 1M cells per well in a PORN/LAM coated 12 well plate 48-72 hours prior to lentiviral 
infection. Culture media following dissociation was cZNDM as described above and contained 
10ng/mL GDNF, CNTF, BDNF and IGF-1. Media also contained RA, SAG, and PUR at the 
levels used during differentiation. 
 iPS-MNs used for viral infection in figure 4.1 were differentiated as above, except 
without PUR and in the presence of 0.5 µM SAG. 
Lentiviral production/concentration: All lentiviruses used in this thesis are pseudotyped with a 
VSVG envelope to allow tropism of diverse cell types. For initial demonstration of motor neuron 
specificity of the sHB9 lentiviruses, sHB9::RFP and sHB9::GFP lentiviruses were produced in-
house using the second generation pCMV-'8.91 packaging plasmid as previously described. 
Briefly, ~80% confluent HEK293 cells were transfected using lipofectamine 2000 (Invitrogen) 
with pCMV-'8.91, pCMV-VSVG, and the lentiviral construct containing the sHB9::RFP 
transgene (Figure 4.1). Media was changed 6-12 hours post transfection, and viral harvest was 
conducted every 24 hours thereafter for 2-3 days depending upon the health of the culture. 
Lentivirus was concentrated using a protocol optimized for viral particles containing large insert 
sequences (al Yacoub et al. 2007). Lentivirus was then titered to determine transducing units/uL 
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by serial dilution on ~%80 confluent cultures of NSC34 cells because these cells endogenously 
express HB9.  
  All sHB9::RFP lentivirus used for profiling experiments was produced and titered by the 
University of Massachusetts Medical School Gene Therapy Center, Vector Core. (Worchester 
MA).  
Lentiviral infection and labeling of iPS-MNs: For initial demonstration of lentiviral specificity in 
iPS-MNs, cells were differentiated using iPS-MN cultures were infected with 1 transducing unit 
per plated cell at 48 hours post plating and allowed 7-8 days to express viral transgene. This 
resulted in infection rates of ~1% of total cells. 
For all iPS-MN profiling experiments, iPS-MNs were plated at 1M cells per well in a 
PORN/LAM coated 12 well plate and infected with 5.58e^8 viral particles per well at 48-72 
hours post plating. Immediately prior to infection, wells were washed 2-3x with un-
supplemented NDM and then fed with 0.5mL cZNDM. Concentrated virus was then added into 
this 0.5mL volume O/N. The following day, 1.5mL of cZNDM was added to each infected well 
and wells were let sit until FACS sorting 7-8 days later. (This titer gave infection rates of 1-3% 
of total cells as assessed by FACS.) 
FACS isolation, cDNA preparation, and Microarray of sHB9::RFP labeled iPS-MNs: As 
described above for Hues3 HB9::GFP motor neurons, except with modifications necessary to 
adapt the protocol to adherent culture and smaller cell numbers. Following ~8 days of adherent 
maturation and viral expression, iPS-MN cultures were trypsinized for 4 minutes before 
proceeding through FACS preparation as above. Smaller cell numbers (1-3 Million total cells per 
experiment) necessitated the use of a constant FACS buffer (CTWM) volume of 500uL. Where 
possible, 50-100K cells were seeded prior to FACS sorting on PORN/LAM coated slides and 
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fixed 48-72 later to assess viral specificity. Microarrays were hybridized in two batches, one 
containing 18c-P30, 18c-P31, and 29A-P30, and the other containing the remaining 15 arrays. 
Microarray normalization groups: Each group of arrays was normalized using RMA (which 
included quantile normalization). For comparison of motor neuron marker expression (Figure 
4.3), all iPS-MN arrays were normalized together with all Hues3 HB9::GFP+ and GFP- arrays 
from Chapter 3. For all other iPS-MN array studies, the group of 18 iPS-MN arrays was 
normalized without other arrays. For arrays in the meta-analysis (Figure 4.10), all arrays of the 
same type for each published study were normalized together. Studies providing only lists of 
differentially expressed genes could not be re-normalized in this manner. Kirby 2011 and Cox 
2010 use the same group of control arrays. In these comparisons, each study was first normalized 
separately and then all ALS and control arrays were normalized in the same group (Kirby+Cox). 
Microarray comparisons: ALS vs. control and line-by-line comparisons were performed using 
BRB array tools V4.2 (see above). Replicates were not averaged prior to data analysis. P values 
used to determine significance for each comparison are listed in the text. Gene ontology analysis 
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Chapter 5: Identification of potential onset-modifying genes in sALS. !
Introduction: 
One of the most promising features of iPS cells is their potential to capture not just a 
generalized disease state, but also one that preserves patient-specific characteristics. In the case 
of ALS, such characteristics might include age at onset, site of onset, rate of progression, or a 
greater degeneration in upper or lower motor neurons. Faithfully modeling the patient-specific 
features of ALS in iPS-MNs could lead to a better understanding of the molecular underpinnings 
behind the heterogeneous presentation of ALS. Subsequently, this knowledge might be exploited 
to aid in disease management or to develop personalized treatment strategies. 
iPS-MNs are a relatively new model system and they have not yet shown any patient-
specific phenotypes related to ALS. One potential reason for this is that it is not clear exactly 
where to look for such a characteristic. The multicellular nature of ALS progression, which 
involves astrocytes and microglia, as well as motor neurons, presents a difficulty in this respect. 
Factors extrinsic to motor neurons may influence many of the characteristics that separate 
patients into different sub-classes of disease. Thus, it is challenging to conceptualize a truly 
motoneuron-intrinsic phenotype of disease that varies from patient to patient and yet could be 
measured in vitro in isolated iPS-MNs. Furthermore, for any disease characteristics with single-
gene underpinnings, animal models may be a more appropriate platform for research due to their 
superior genetic tractability and in vivo biology. Thus, the most productive and novel use of iPS-
MNs for research on patient-specific phenotypes of disease should concern disease 
characteristics that have a motoneuron-intrinsic component and either undefined or complex 
genetic underpinnings. 
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Age at ALS onset appears to one patient-specific characteristic of disease that satisfies 
the above conditions. As mentioned in the general introduction, age at ALS onset is highly 
variable, appears to be at least partially dissociable from the rate of ALS progression, and does 
not depend strictly on ALS-causing mutations in fALS cases (Aggarwal and Nicholson 2001; 
Mase et al. 2001; Aggarwal and Nicholson 2002; Ferrera et al. 2003).  Therefore, age at ALS 
onset can be modeled apart from the causative factors in ALS and we can hypothesize that it may 
have similar underpinnings in ALS cases of varied etiology. Furthermore, the partial heritability 
of age at onset, coupled with a lack of gene associations in SNP studies, suggests that onset-
modifying factors are either poly-genic, population-specific, or epigenetically regulated (Landers 
et al. 2009) (Fogh et al. 2007). Finally, work in animal models suggests that ALS onset is 
determined at least partially by motor neuron intrinsic factors (Boillee et al. 2006; Yamanaka et 
al. 2008). 
Therefore, onset-modifying factors in ALS are attractive features of the disease to 
attempt modeling with patient-specific iPS-MNs. Unfortunately, the correlates of age at ALS 
onset have never been studied in human motor neurons. Thus, work in this chapter will focus 
first on identifying patient-specific factors influencing the age of onset in sALS patients and then 
return to ALS iPS-MNs in an attempt to validate a newly described set of 43 potential onset-
modifiers. 
In order to define onset-dependent phenotypes in ALS patient motor neurons, I took 
advantage of the quantitative and continuous nature of age at ALS onset. Using age at ALS onset 
as a dependent variable, I assessed onset-correlated expression patterns both in post-mortem 
sALS motor neurons and then in ALS iPS-MNs. The advantage of this approach is that it 
evaluates factors downstream of the proposed genetic and epigenetic contributors to ALS onset.  
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Although mere co-variation of gene expression with age at onset does not necessarily 
imply a causative role, genes that display this pattern of expression may reveal mechanistic 
insight into which pathways are involved in accelerating or slowing ALS disease processes. In 
fact, many of the candidate ALS onset-modifying genes identified in this chapter are known to 
be involved in neurodegenerative disease or are closely related to genes that are. Although 
validation of potential onset modifying genes in ALS iPS-MNs proved challenging, this chapter 
initiates the study of a group of genes that may eventually lead to new avenues of therapeutically 
relevant research. 
Results: 
Identification of genes with onset-dependent expression patterns in sALS patient motor neurons: 
In order to investigate potential expression-level determinants of ALS onset, I obtained 
and re-analyzed whole-genome expression data from a published ALS microarray study (Rabin 
et al. 2010). Rabin et al. (2010) performed laser capture microdissection (LCM) to isolate lumbar 
spinal motor neurons post-mortem from 12 sALS patients and 10 controls. Purified motor 
neurons were then profiled by the authors on Affymetrix Human Exon 1.0 ST arrays in order to 
identify gene and exon level expression changes in ALS MNs. Patients in this study had mostly 
bulbar or upper limb onset ALS and were selected based on the availability of surviving motor 
neurons in the lumbar segments of the spinal cord (Figure 5.1). Selecting patients in this manner 
allowed the authors to profile a better-preserved population of motor neurons than most previous 
ALS microarray studies. Following LCM isolation of motor neurons, the remaining anterior horn 
cells were collected and also profiled. In this study, the authors identified 148 gene level 
(p(0.001) and 411 exon level (p(0.00001) expression changes present in ALS MNs. This data 
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was part of the meta-analysis in chapter Figure 4.10A-B. (see Methods for array normalization 
and subsetting). 
The ALS patients in this study are ideally suited for the investigation of onset-dependent 
expression changes. The 12 patients have ages of onset ranging from age 44 to age 78, with age 
at death ranging from 47yo to 80yo (Figure 5.1A). The median age of onset was 66.85yo. Mean 
age of onset was 66.5± 12yo. control age at death ranges from 49yo to 82yo (Figure 5.1A). 
Importantly, the demographics of the ALS patient population in Rabin et al. (2010) do not 
strongly conflate age of onset with other patient-specific phenotypes of disease (Figure 5.1).  
Age of onset does not differ significantly when comparing either bulbar vs. limb onset patients or 
male vs. female patients (Figure 5.1C-D). Furthermore, duration of disease in ALS patients is 
relatively compressed, with survival ranging from 6.5 years to 1 year after onset. Thus, ALS 
onset and death are highly correlated in this population (R2=0.98) (Figure 5.1E). Furthermore, 
disease duration does not strongly correlate with age at ALS onset (R2=0.21) (Figure 5.1F). 
In order to determine if early and late-onset patients break down into two distinct 
transcriptional profiles, I performed a clustering analysis of all 12 ALS microarrays. I first 
defined “Early Onset ALS “ as onset<60yo and “Late Onset ALS” as onset after 60 years of age. 
Although these definitions are not clinically applicable, they form a group of 5 early onset cases 
and 7 late onset cases in this analysis and are thus useful for breaking the patients into two 
distinct groups. When clustered using centered correlation and average linkage, Early Onset 
cases tend to cluster together, although the age of onset is not significantly different between the 
left and right halves of the dendrogram when it is split into two populations (Figure 5.2A-B). In 
order to better understand what may be driving broad transcriptional similarities in the ALS 
motor neuron group, I also labeled the dendrogram using gender and site of onset (Bullbar or 
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Limb). In each of these cases, I did not observe a preponderance of either subclass in a particular 
clade of the dendrogram, indicating that site of onset and gender are not the major drivers of 
difference between ALS motor neurons (Figure 5.2.1). Because no one demographic factor 
seems to control clustering of samples and because age at onset is not correlated with any 
confounding variables in the demographic data provided, the Ravits data set seems usable for 
investigating onset-correlated gene expression patterns in ALS patient motor neurons. 
Thus, having established the suitability of the starting sample of ALS motor neurons, I 
then attempted to identify transcriptional profiles in motor neurons that were correlated with 
patient age at onset. To perform this analysis, known as a quantitative trait (QT) analysis, I used 
age at onset in years as a quantitative trait for a Spearman correlation with gene-level expression 
values in the microarray data set. Using a Spearman correlation test, I identified 43 genes that 
showed onset-correlated expression patterns in ALS motor neurons at p<0.001 (see Methods) 
(Figures 5.3-5.4). The P-value cutoff used was the same used by Ravits et al. (2010) to determine 
single gene expression differences between ALS and control groups. By selecting a Spearman 
correlation, which evaluates monotonic (unidirectional) change, the QT analysis includes, but is 
not limited to genes that also have high linear correlation coefficients (a sigmoidal curve is one 
example of a monotonic trend). The Spearman correlation coefficients for identified QT genes 
had absolute values ranging from 0.92 to 0.85. Interestingly, all genes except one were 
negatively correlated with age at onset (negatively correlated genes are expressed at higher levels 
in patients with earlier onset ALS). Examples of onset-correlated expression patterns are 
presented in Figure 5.3. Importantly, no QT genes were identified by the same analysis in motor 
neurons from control donors. Furthermore, no QT genes showed onset-correlated expression 
patterns in microarray data for the surrounding anterior horn cells.   
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One potential concern with my approach was that the large number of comparisons in the 
analysis might lead to false discovery of significant QT genes. I addressed this problem in two 
ways: first by performing a permutation analysis with the age-at-onset data, and second by using 
microarray processing software to calculate a false discovery rate for each QT gene (Figure 5.5, 
Appendix 5.1). In order to perform the permutation analysis, I looped the age-at-onset data, 
shifting all values by one position, and then re-ran the Spearman correlation analysis (Figure 
5.5A). This was performed 12 times until the onset values looped back to the starting position 
(12 ALS patients in the study). Significant QT genes in this analysis should approximate the 
false positive rate of the assay. I then plotted the number of QT genes produced for each 
permutation along with a measure of how well the permuted onset values correlated with the 
actual onset values (Figure 5.5B).  The average number of false positive genes in the permutation 
analysis was 3.7± 4, suggesting that most of the 43 onset-correlated genes are not statistical 
noise. Interestingly, the number of false positive QT genes was higher in the permutations that 
were most correlated with actual onset values, further suggesting that patient age or age at onset 
is responsible for some structure in the data (Fig 5.5B). False discovery rates (FDR) ranged from 
<1e-7 to 0.137 in the QT group of genes with p<0.001 (FDR measures the probability that a 
significant gene will occur by chance at a given P value for a particular data set (Benjamini and 
Hochberg 1995)).  The FDR for each gene, as well as an onset-correlated gene list out to p<0.01 
(289 genes) is listed in Appendix 5.1. Taken together, this analysis shows that most of the QT 
genes are likely not to be false positive associations. 
Thus, I have identified an ALS-specific group of genes that display onset-correlated 
expression patterns in post-mortem patient motor neurons. Many of these genes play potential 
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roles in neurodegenerative disorders (Fig 5.4). However, before discussing the specific identity 
of genes, it will be helpful to reduce the list to a more manageable number.  
In order to prioritize the list of onset dependent genes, I assessed their expression both in 
early-onset ALS cases as compared to late onset ALS cases and in early-onset ALS as compared 
control donors (Figure 5.6). The purpose of this double analysis was to identify the QT genes 
whose expression patterns differed most both within the ALS patient population as well as 
between the ALS patients and controls. I first performed a class comparison analysis on the 
Rabin et al (2010) array data (motor neurons only) to identify genes that were differentially 
expressed between early ALS cases (<60yo) and control donors (p<0.001, 90 genes) (Figure 
5.6B-C). This analysis identified 90 genes, all of which showed higher levels in ALS cases. I 
then performed an identical analysis between early-onset ALS cases and late-onset ALS cases 
(p<0.001, 28 genes) (Figure 5.6A,C). This analysis identified 28 genes, all of which showed 
higher levels in early ALS cases. By determining the overlap of the 90-gene and 28-gene lists 
with the onset-dependent QT genes identified above, I arrived at a prioritized group of 15 genes 
from the initial 43 in the correlation analysis (Figure 5.6D). Five of these genes were present in 
the QT list and were higher in early ALS patients than controls (Figure 5.7B). Nine of the genes 
were in the QT list and higher in early ALS compared to late ALS (Figure 5.7A). And one gene 
was present in all three comparisons (NBEAL1). To this list, I then added the only gene 
positively correlated with onset (ZRS2R) to form a final prioritized group of 16 candidate genes 
for further analysis (Figure 5.7C).  
Quite strikingly, many of these 16 candidate genes have known or hypothesized roles in 
neurodegeneration (Figure 5.7C).  NAA38 (LSM8), MFN1, AIMP1, and NBEAL1 are all 
closely related to genes either involved in motor neuron degeneration or necessary for motor 
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neuron development. PGGT1B is involved in motor neuron axon outgrowth following nerve 
injury (H. Li, Unpublished). Other genes on this list, such as PLD1, SOAT1, and IFT57 are 
thought to play roles in neurodegenerative disorders such as Alzheimer’s or Huntington’s 
disease. This further strengthens the supposition that these QT genes play causative roles in 
modifying or determining ALS-patient age at onset. The disease relationships and potential 
deleterious changes downstream of candidate onset-modifying factors will be discussed in 
greater detail in the following chapter along with a proposal of experimental aims to validate 
these mechanisms in vitro. 
Identification of one gene with a disease duration-dependent expression pattern in sALS patient 
motor neurons: 
Although duration of disease was relatively homogenous among patients in this study (1 
to 6.5 years, see Figure 5.1), I also performed a quantitative trait analysis on the above LCM 
motor neuron expression data to identify any expression patterns that correlated with length of 
post-onset survival.  This QT analysis was performed identically to the one described above, 
except using disease duration as the quantitative trait variable. The analysis yielded one gene that 
exhibits expression values significantly associated with disease duration: C15orf5 (NR_026813) 
(p<1e-7, correlation coefficient = 0.923, FDR<1e-7). C15orf5 is a 1512bp uncharacterized non-
coding RNA that spans chromosome 15q23-24. Due to the singular and uncharacterized nature 
of C15orf5, I did not pursue further study of this candidate gene.  
Investigation of onset-dependent expression patterns in fALS iPS-MNs: 
Having defined, for the first time, expression patterns in human ALS motor neurons that 
correlate with patient age at onset, I then set out to address expression of these candidate genes in 
another human model system. One of the advantages of the iPS-MN model system is that ALS 
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patient motor neurons can be studied in isolation from the diseased spinal cord and have not 
accumulated a lifetime of disease-related changes secondary to the actual causative factors of 
ALS. Therefore, if onset-dependent expression of the factors identified above can also be 
observed in fALS iPS-MNs, it would suggest either that they play a causative role in determining 
ALS age at onset or that they are very early phenotypic changes in ALS. 
In order to assess onset-dependent candidate gene expression in fALS iPS-MNs, I 
selected a panel of 4 fALS iPS lines with variable age of onset: the same 4 ALS iPS lines that 
were used for microarray profiling experiments in Chapter 4. Each line carries a different 
mutation in SOD1 (Figure 5.8). Ages of ALS onset in these lines are 26, 37, 57, and 77 years 
old, forming a widely spaced population that is well suited to assessing onset-dependent factors 
(Figure 5.8).  However, because I have only used 4 iPS lines, identification of new factors in 
these lines was not feasible due to the large number of comparisons present on the arrays and 
low sample number. 
I therefore decided to monitor expression of QT candidate genes using the amplified 
cDNA generated from sHB9::RFP labeled ALS iPS-MNs in Chapter 4. I first assessed the 
expression of 15 candidate genes by qPCR. I selected candidate genes for this analysis based on 
their presence in the prioritized list as well as the successful design of qPCR primers (See 
Appendix 5.2). The 15 candidate genes, along with the motor neuron markers HB9, ISL1, and 
CHT1, were measured by qPCR in three independent biological replicates of iPS-MNs from each 
line (Figure 5.9). I normalized the expression of each gene to that in the latest onset iPS line 
(29A, onset 77yo), reasoning that consistent positive fold change in the earlier-onset iPS lines 
would suggest confirmation of the candidate gene expression patterns. However, I did not 
observe onset-dependent expression in ALS iPS-MNs for any of the candidate genes as 
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evaluated by qPCR (Figure 5.9). One potential explanation was that variability between 
biological replicates in these experiments was quite high, perhaps due to technical difficulties 
brought about by low abundance of transcript combined with limited amounts of available 
template. 
Because I was only able to assess a portion of the candidate onset-dependent genes by 
qPCR, I also evaluated the expression of all 43 onset-dependent genes from the Ravits group 
using the ALS iPS-MN microarray data collected in Chapter 4. I first reduced the microarray 
data to include only probesets corresponding to the 43 onset-dependent genes identified above 
and then ran a quantitative trait analysis in order to discover any relationship between the 
expression of these genes and age of ALS onset in the iPS donor patient. This is identical to what 
was done above to initially identify the onset-dependent genes, except with p<0.05. In this 
analysis, the expression of two candidate genes, LSM8 and PGGT1B, showed a significant 
correlation with age of ALS onset in the same direction as previously described (p=0.043 and 
p=0.045 respectively) (Figure 5.10). False discovery rates for LSM8 and PGGT1B are high, 0.46 
in each case, suggesting that these results could potentially be false positive associations. 
Although LSM8 and PGGT1B did not appear as onset-regulated in the qPCR data, smaller noise 
levels in the microarray data may increase the likelihood of finding significant associations. 
Figure 5.10 depicts side-by-side qPCR and microarray data for three QT genes and demonstrates 
the larger replicate-to-replicate error levels in the qPCR data. 
Additionally, a permutation analysis suggests that 2 significant QT genes are well within 
the expected number of false positives when assessing expression of the 43 candidate genes in 
the ALS iPS-MN data set (Figure 5.10.1). Taken together with the high false discovery rate in 
the QT analysis above, these results indicate that definitive confirmation of onset-dependent 
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gene expression in ALS iPS-MNs will need to wait until a larger panel of ALS iPS lines has been 
established. 
Even so, the expression levels of several onset-dependent candidate genes in ALS iPS-
MNs are not inconsistent with the idea that they retain onset-dependent expression in these cells. 
At least three of these cases, (LSM8, PGGT1B, and ZRS2R) depicted in figure 5.10, are worthy 
of further study in this capacity. 
  




Below, I will first discuss my general impressions of the data in this chapter. I will begin 
with the work on patient samples and then progress to the iPS-MN data. Finally, I will turn to a 
series of issues arising from the data and attempting to find its most proper interpretation. 
A group of genes with onset-dependent expression patterns: 
My analysis in this chapter provides the first demonstration of onset-correlated gene 
expression patterns in human sALS motor neurons. I define a group of 43 genes that are mostly 
expressed at higher levels in earlier-onset ALS cases and at lower levels in later onset cases. 
False discovery rates and permutation analyses suggest that this number of genes is well above 
the statistical noise of the assay. Additionally, the lack of a similar transcriptional signal in other 
cells of the anterior horn from ALS patients indicates that the QT genes are part of a motor 
neuron-specific transcriptional program. This strengthens the notion that age at onset in ALS is 
at least partially determined by motor neuron-intrinsic factors.  
Importantly, onset-dependent expression patterns were not global in nature. Although 
there was a tendency for ALS cases with earlier ages of onset to cluster together, this feature of 
disease did not cleanly separate during clustering analysis (Figure 5.2). Thus, expression changes 
identified in the correlation analysis are likely to result from gene-specific mechanisms and not 
general transcriptional changes acquired during the progression of disease (See below). 
The classes of onset-correlated genes are highly suggestive of disease-relevant roles. 
Both in the 16-gene list prioritized by other criteria and in the group of QT genes as a whole, 
there is a preponderance of genes involved in critical motor neuron functions or disease-relevant 
processes. A detailed description of gene function for many of the priority genes will be provided 
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in the following chapter along with proposed experiments to further investigate their function in 
ALS iPS-MNs. 
Taken together, the data suggests a new class of ALS onset-modifying genes that could 
be mechanistically involved in progression of the pre-symptomatic phase of ALS. In mouse 
models and likely in human patients, motor neuron death in ALS begins shortly before symptom 
onset and proceeds rapidly throughout the course of disease (Aggarwal and Nicholson 2001; 
Aggarwal and Nicholson 2002). In ALS, as in other neurodegenerative diseases, it is believed 
that accumulation of small cellular insults over a lifetime eventually tips the scales towards a cell 
death program that then propagates throughout the spinal cord. However, little is known about 
what determines the length of this pre-symptomatic phase. If the onset-dependent genes 
described above are involved in causing or modifying pre-symptomatic cellular insults, then they 
could provide a window into patient-specific determinants of ALS onset. 
Expression of onset-dependent genes in iPS-MNs: 
I also attempted to validate expression of the onset-dependent genes in iPS-MNs from 
fALS patients with varying ages of onset. Using the ALS iPS lines profiled in Chapter 4, which 
have widely spaced ages of onset, I assessed candidate gene expression by qPCR and microarray 
(Figure 5.8-5.10). Although I believe patient age at onset remains a promising disease feature to 
model in iPS-MNs, my attempts at validating QT genes in these cells suggest that most genes do 
not retain strongly onset-correlated expression patterns in iPS-MNs. 
Several potential confounding factors could have hampered the replication of onset-
dependent expression patterns in iPS-MNs. First of all, the number of ALS lines in the analysis is 
relatively small (4 lines). Thus, biological noise may be masking some expression patterns. 
Second, replicate-to-replicate differences in expression were quite significant for many of the 
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genes (See Figure 5.9). Although this may be a function of natural processes occurring in motor 
neurons, another possibility is that the assay was very sensitive to small fluctuations in the 
efficiency of motor neuron purification between different replicates. In situ hybridization and/or 
protein-level expression measurements using immunohistochemistry or reporter lines may be 
useful in restricting the analysis of candidate genes to an even more pure motor neuron 
population. Third, iPS-MNs are embryonic in phenotype and may require maturation into an 
adult developmental stage in order to show onset-dependent expression patterns. This is 
particularly evident with genes such as PLD1, which are expressed in adult human motor 
neurons, but were not expressed in the iPS-MNs (data not shown). However, the presence of an 
ALS-specific expression signature as described in Chapter 4 would tend to suggest that at least 
some disease phenotypes should be visible at this time-point.  
Interestingly, the two genes that did replicate in iPS-MNs, LSM8 and PGGT1B, both 
play potential roles in motor neuron degeneration. LSM8 is a member of the LSM family of 
proteins which form a complex involved in regulating both U6 snRNA stability and localization 
(He and Parker 2000; Spiller et al. 2007). The LSM complex of proteins is known to interact 
directly with SMN, the genetic cause of Spinal Muscular Atrophy, forming a potential link 
between LSM8 function and early-onset motor neuron disease (Friesen and Dreyfuss 2000; 
Spiller et al. 2007). Protein geranylgeranyltransferase type 1-! (PGGT1B), on the other hand, is 
involved in protein prenylation, a type of post-translational protein modification that results in 
the addition of short hydrophobic side-chains (Zhang et al. 1994; Zhang et al. 1994). 
Unpublished work in the Henderson lab suggests that PGGT1B may play a key role in regulating 
axon outgrowth following injury. Reduction of PGGT1B activity levels by treatment of cultures 
with Stains causes increased axon outgrowth on a inhibitory myelin substrates and in the setting 
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of an in vivo optic nerve crush assay (Inhibition of the HMG-CoA reductase enzyme depletes 
mevalonate, a substrate upstream of PGGT1B activity.  H. Li, Unpublished). Thus, both of these 
genes are highly promising candidates for future research into potential determinants of onset in 
sALS. 
Future studies aimed at validating onset-dependent genes in iPS-MNs should focus on 
increasing the number of iPS lines analyzed as well as utilizing ALS iPS-MNs from patients with 
sporadic ALS. By extending this analysis to a larger set of fALS iPS-MNs, we may hope to 
definitively show whether or not the onset-dependent expression patterns described above 
generalize to this class of iPS-MNs. Additionally, with a larger patient population to analyze, 
iPS-MNs could be used to discover new onset-dependent changes by microarray profiling as 
described above. Finally, using sporadic ALS iPS-MNs to perform similar analyses may be even 
more informative than using mutant SOD1 cases. It is possible that SOD1 ALS cases, by virtue 
of having a slightly different etiology than sALS cases, will not show all of the same 
determinants of age at onset and therefore will not be as useful for investigating these pathways. 
Moreover, results in sporadic ALS iPS-MNs could potentially generalize to a much larger patient 
population. 
Other remaining questions and issues: 
Many questions remain as to the role potential onset-modifiers might play in the 
development and progression of ALS. Below, I will address several of these issues in a point-by-
point manner: 
What is the role of onset-correlated genes? Causative or biomarker? 
 Presupposing that some of the above genes are validated in another model system, one 
can imagine four scenarios for the roles they may be playing in ALS. The first three scenarios 
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place onset-dependent genes in a causative role and the fourth envisions them as biomarkers of 
some other process that relates to disease: 
1. Genes with onset-dependent expression may be true onset-modifiers. They may be 
involved in defining the set-point at which a motor neuron undergoes degeneration 
and first shows deleterious symptoms of ALS. 
2. Onset-correlated genes may be downstream of disease-causing factors but still play a 
functional role in motor neuron degeneration. In this case, they could be mediators of 
deleterious disease processes recruited by other causative factors. 
3. Onset-correlated genes may, in fact, be beneficial compensatory changes that impede 
the disease process but are simply overwhelmed in symptomatic ALS. In this case, 
they may be expressed at higher levels in more aggressive cases of ALS (i.e. those 
with earlier onset). 
4. Onset-correlated genes may be biomarkers of disease, reflecting ongoing cellular 
processes, but not playing important causative roles. 
Will onset-dependent factors replicate in other sALS microarray studies? 
In order to fully validate the candidate genes in this chapter, it will be necessary to 
observe the same transcriptional changes in another population of sALS or fALS patients 
profiled in an identical manner. Unfortunately, there are currently no published microarray 
studies with suitable ALS patient demographics. In fact, where age at onset is taken in to account 
when obtaining samples for profiling, attempts are normally made to select patients that are 
similar to each other in this regard, thus reducing a potential source of noise in the analysis. 
Although this method of selecting subjects allows cleaner determination of ALS-related 
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transcriptional changes, it hampers the identification of factors that effect disease-free survival in 
patients. 
Thus, in order to confirm the findings in this chapter, it will likely be necessary to initiate 
a LCM microarray or qPCR study expressly for this purpose. Fortunately, the Columbia 
University/New York Brain Bank does seem to have appropriate fresh-frozen tissue samples. If it 
proves difficult to identify patients with intact lumbar motor neurons as was done in the Rabin 
study used above, Jean Paul Vonsattel (Head of the NY Brain Bank) has suggested using the 7th 
(facial) nucleus from ALS patients. As part of the tissue banking process, the brain is 
hemisected, with half kept as a fresh frozen sample and half as a fixed sample. Thus, in order to 
identify ALS patients with intact facial nuclei, it is simply a matter of looking at stained tissue 
from one half of the brain. LCM can then be performed on the remaining sample. 
Will onset-correlated genes generalize to fALS cases? 
One of the most striking features about this data set is the homogeneity of onset-related 
gene expression patterns in the setting of a heterogeneous sALS patient population. As discussed 
above, sALS is thought to result from many different constellations of genetic and environmental 
insults. Thus, sALS cases do not share the same etiology although they do share certain 
symptomatic and pathologic features. The fact that the QT genes were found across a population 
of sALS patients suggests that these patients may exhibit convergence of onset-dependent 
pathways. One way of making sense of this is to place onset-dependent genes downstream of 
causative factors and functioning in the general motor neuron response to disease state. 
In order to generalize potential onset-modifying candidates to fALS cases caused by 
mutations in SOD1, age of onset must be at least partially dissociable from the disease causing 
mutation. Fortunately, this does seem to be the cases in families with SOD1 mutations Mase, Ros 
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et al. 2001; Ferrera, Caponnetto et al. 2003). If onset-dependent genes do end up generalizing to 
sALS cases, but not fALS cases, it would suggest new ways in which fALS differs from sporadic 
cases. This could potentially shed light on the open question of precisely where the pathways 
downstream of ALS-causing factors converge to initiate common disease phenotypes in fALS 
and sALS patients. 
What is the relationship of onset-modifying genes to ALS risk genes?  
Because the onset of ALS is often late in life, it seems likely that changes in the 
expression of genes that accelerate onset will unmask some cases of ALS that would otherwise 
have remained pre-symptomatic due to premature death from other causes. Alternatively, onset-
dependent genes could be downstream targets (compensatory or detrimental) of disease-causing 
factors and disruptions in these pathways could modify overall risk for ALS. On the other hand, 
if these genes fit somehow into the biomarker category, we may not expect to see expression-
dependent changes in ALS risk.  
Therefore, it may be useful to categorize this group of genes as potential ALS risk factors 
and to evaluate the occurrence of sequence variants in these genes in the sALS patient population 
as compared to controls. With this in mind we have begun collaboration with Robert H. Brown 
(UMASS, Worchester) to analyze sequence variants in these genes in a large panel of ALS 
patients and controls. A secondary outcome measure in this analysis could result from stratifying 
ALS patients by age at onset and assessing differential sequence variants in early onset vs. late 
onset groups. 
Are onset-correlated genes simply the result of age-dependent transcriptional repression in 
sALS? Are they expressed at stable levels throughout life? 
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Although I have characterized QT genes as being largely stable throughout life, it is 
possible that they are dynamic in expression and are progressively downregulated or upregulated 
by the causative factors in sALS. Widespread transcriptional repression is commonly seen 
downstream of SOD1 in microarray profiling experiments. If the same is true in sALS patients, 
then increased expression of a gene in early onset (younger) patients may simply be a function of 
less time spent in the context of a slightly transcriptionally repressive environment brought about 
by disease-causing factors. 
 However, Rabin et al. (2010) report that the preponderance of genes changed in an ALS 
vs. control manner are upregulated (71 upregulated genes and 14 downregulated genes). This 
suggests that transcriptional repression is not a major feature this particular cohort of sALS 
patients.  
It is still possible that the onset-dependent genes are specifically targeted for 
downregulation during the pre-symptomatic phase of ALS. In this case, the one positively 
correlated gene (ZRS2R) could be conceptualized as a downstream target of other gene(s) that 
were downregulated in the setting of sALS. If this does turn out to be the case, then these genes 
may represent previously unknown pre-symptomatic targets of ALS-causing factors and thus 
may be useful as biomarkers for patient diagnosis or mechanistic studies. 
Will ALS onset-dependent factors generalize to other neurodegenerative disorders? 
 It is tempting to speculate on whether or not genes that regulate the set-point for the 
development of ALS would also play a role in determining susceptibility to other 
neurodegenerative diseases. Presumably if this were the case, one might find similar onset-
dependent expression signatures in the most vulnerable cell types across a variety of 
neurodegenerative disorders. Alzheimers’s and Parkinson’s disease would be particularly 
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interesting to investigate in this manner given a previous report of a common onset-modifying 
locus between the two diseases (Li et al. 2002). Despite several attempts using published studies, 
I have yet to identify onset-correlated expression patterns in the cells most affected in these 
diseases. !  
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Figure 5.1: Patient demographics in Rabin et al. 2010. 
(A,B) Demographics and clinical characteristics of (A) patients and (B) controls included in 
Rabin 2010 re-analysis.  
 
(C) Age of ALS onset is not significantly different between bulbar and onset cases in this cohort.  
 
(D) Age of ALS onset is not significantly different between male and female cases in this cohort.  
 
(E) Graph of patient age at onset vs. age at death for patients in Rabin 2010 study.  
 









Figure 5.2: Early and Late onset ALS tend to cluster together. 
(A) Clustering of ALS patient arrays in Rabin study. Early-onset cases (<60yo) have a slight 
tendency to cluster away from late-onset cases (>60yo). Clustering was performed using average 
gene-level expression data for each gene, centered correlation, and average linkage. (B) Graph of 





























Figure 5.3: Onset-correlated expression in ALS patient motor neurons. 
(A-D) 4 examples of onset correlated expression patterns in ALS motor neuron. (A) NBEAL1: 
Neurobeachin-like 1. (B) ZRSR2: U2AF1-RS2, zinc finger (CCCH type), RNA-binding motif 
and serine/arginine rich 2. (C) PLD1: Phospholipase D1. (D) CASP3: Caspase 3. R^2 values are 






































































































Figure 5.4: Quantitative trait analysis results.  
Results of quantitative trait analysis for genes that co-vary with age at onset preformed on motor 
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Figure 5.5: Permutation of demographic data reduces QT genes. 
(A) Permutation table for real onset values and first 5 permutations. (B) Results of quantitative 
trait analyses performed with permuted onset values. Squares indicate the number of genes 
correlated with permutated onset values p<0.001 (left Y axis). Asterisms indicate Pearson 
correlation of permuted onset values with actual onset values (right Y axis).  
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Figure 5.6: Prioritization of gene QT genes by expression pattern. 
(A-C) ALS and control expression levels of genes within the quantitative trait analysis that are 
expressed differentially between early onset ALS (<60yo) and late onset ALS (>60yo) (A, 
MFN1), early onset ALS and control patients (B, PLD1), and both (C, NBEAL1) (P<0.001). (D) 
Venn diagram of genes in these classes.  
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Figure 5.7: Prioritized gene lists and disease relationships.  
(A,B) Genes identified in the quantitative trait analysis and in the sub-categories shown in figure 
5.6. (A) Genes in QT and increased in early onset ALS. (B) Genes in QT and increased in early 
ALS vs. control. (C) QT results and disease relationships for a combined high-priority list of 
genes in A and B along with ZRSR2, the only QT gene positively correlated with age at onset.  
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Figure 5.9: qPCR measurement of select candidate gene expression. 
(A-R) qPCR analysis of motor neuron markers (A-C) and 15 QT genes (D-R) in iPS lines of 
varying ages at onset (x axis). Bullet-labeled genes are present in the prioritized gene list from 
fig 5.7. Values are expressed as fold change compared to 29A ±  SEM. 
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Figure 5.10: Microarray measurement of candidate gene expression. 
(A-C) QT analysis genes as expressed in the Rabin et al. data set. (A) LSM8, (B) PGGT1b. (C) 
ZRS2R.  
 
(D-F) Comparison to qPCR data from iPSMNS (also in figure 5.9). (D) LSM8. (E) PGGT1b. (F) 
ZRS2R. Values are expressed as fold change compared to 29A ±  SEM.   
 
(G-H) Microarray results of expression level of QT genes in ALS iPSMNs vs. age of ALS onset 
for (G) LSM8, (H) PGGT1b, (I) ZRS2R showing significant expression correlation with onset 
for LSM8 and PGGT1b (p<0.05), but not ZRS2R.  
 
  







Figure 5.2.1: Clusters labeled by gender and site of onset. 
(A-B) Hierarchical Clustering analysis in as in Figure 5.2A, relabeled with gender of patient (A), 











Figure 5.10.1: (Supplemental) Age of onset permutation in iPSMNs. 
(A) Number of QT genes from figure 5.4 with expression patterns correlated with age of onset in 
ALS iPSMNs at p<0.05 as a function of real vs. permuted demographic data. Squares indicate 
the number of significant QT genes for real demographic values (shift=0) and permuted ones. 
Asterisms indicate R squared of permuted onset values vs. actual onset values. The high number 













































Rabin (2010) array normalization and subsetting for re-analysis: All microarrays from ALS 
(12) and control (10) motor neurons and anterior horn cells were obtained from Gene Expression 
Omnibus (GEO), www.ncbi.nlm.nih.gov/geo, accession number GSE18920 (44 arrays in all). 
Gene level annotation and RMA-core normalization was then performed on all arrays using 
Affymetrix expression console software. The annotated and normalized data set was then 
imported into BRB array tools V4.1-4.2.  
 
Microarray analysis: All data analysis after normalization was performed in BRB array tools as 
described previously using P value and fold-change cutoffs as described in the text. For 
generation of quantitative trait gene lists (onset correlation), the data was subsetted to remove 
genes in which 20% of probes did not show greater than 1.5 fold variance over their mean. This 
removes smaller effect sizes in the QT analysis. Data from QT analyses was also subsetted to 
remove non-gene level expression values contained in individual hybridization control probes.  
For microarray validation of QT candidate genes in iPS-MNs, the data was subsetted using gene 
symbol data from the Rabin et al. QT analysis and Spearman correlation was then performed 
using the set of onset-dependnet genes. No fold-change cutoff was used to reduce the number of 
probes in the analysis. For graphical representation in Figure 5.10, the probe with the average 
highest expression value was used. 
 
qPCR analysis of candidate gene expression: qPCR was described as above using 5ng of 
ovation amplified cDNA template per reaction. All samples were normalized to GAPDH. All 
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reactions were performed in duplicate. All primers were tested for efficiency by dilution of 
template and measurement of the change in cT. Primer sequences and reaction conditions are 
listed in Appendix 5.2.  
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Chapter 6: General Discussion. 
In this discussion, I will share some ideas about moving forward with the work presented 
in the previous chapters of my thesis and some thoughts on interpretation of the data that I have 
not yet covered. The chapter will be organized roughly parallel to the thesis, beginning with 
general considerations about iPS cells and their suitability to model neurodegenerative disease 
and then moving to specific hypotheses and experiments suggested by the expression profiles of 
ALS generated in Chapters 4 and 5. Before discussing specific genes from the expression 
profiles, I will provide a table of top candidates and a brief description of the function of each 
candidate gene. Finally, I will discuss future ALS-profiling strategies that make use of cellular 
reprogramming technology.  
Selection of optimal iPS lines for neural differentiation: 
The first data chapter of my thesis dealt with validating the iPS system as a reliable 
source of motor neurons and exploring the sources of variability in differentiation potential 
between iPS lines. Having shown that iPS cells will be a useful system for the generation of 
human motor neurons, the question then arises how to select the best iPS lines for a particular 
research project. We present two basic alternatives: directed differentiation to a cell type of 
interest as in Boulting et al (2011), and performance on a scorecard assay as in Bock et al (2011).  
These two alternatives can be thought of as applying generally for any tissue type being 
produced, not only motor neurons.  
Ideally, any method of choosing between iPS lines would take into account obvious red 
flags such as abnormal karyotype or high levels of persistent reprogramming transgene 
expression.  However, our studies did not identify either of these factors as contributors to 
differentiation potential. Thus, a first step in selecting among iPS lines should be ensuring that 
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abnormalities in karyotype and levels of transgene expression are within pre-determined limits. 
Since iPS lines often acquire karyotypic abnormalities during culture and express some level of 
reprogramming factors, it is likely not possible to completely avoid both of these potential 
problems when working with large numbers of iPS lines.  
Once basic quality controls are satisfied, directed differentiation or a scorecard assay can 
be used to stratify individual lines according to their ability to produce the desired cell type(s). In 
order to use either assay, operators will first need to be comfortable with basic hES/iPS culture 
techniques as well as any protocols necessary to make a particular differentiated derivative of 
interest. The advantages of the scorecard approach are: 1. Limited operator skill required 
performing “random” differentiation. 2. Savings of time and reagent costs during differentiation 
stages (16 days in Bock as opposed to 21-32 days in Boulting). 3. Measurement of differentiation 
potential to all three germ layers. 4. Much greater scalability than directed differentiation. In 
contrast, the advantages of the directed differentiation approach are: 1. Direct measurement of 
differentiation efficiency for the particular cell type of interest. 2. No need to normalize and 
interpret data from scorecard assays or to develop cutoff values to choose between lines. 3. No 
need to buy scorecard chip reagents. 4. Utilizes only existing techniques and reagents.  
Thus, for use in a specialist lab concerned only with the production of one cell type or 
germ layer, directed differentiation to the particular cell type being studied seems the most 
straightforward and cost-effective method. However, for core facilities, groups working with 
large numbers of iPS lines, or groups deriving tissues belonging to multiple germ layers, the 
scorecard assay offers greater scalability and simultaneous information about differentiation 
efficiency to all three germ layers. 
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But how does the potential of enhanced neuralization to overcome poor iPSC 
differentiation affect this choice? If changes in the differentiation procedure can produce motor 
neurons (or other cells) from any iPS line with reasonable efficiency, then why stratify line-by-
line performance in an outdated differentiation protocol? This question is more difficult to 
answer. In practice, our laboratory has switched entirely to the enhanced differentiation 
procedures described above, but has also discontinued using the lines that failed to differentiate 
using the “standard” differentiation protocol. At first glance, these actions may seem in conflict. 
However, it would seem prudent to avoid using lines with observed defects in differentiation. 
Such lines may also show more subtle flaws in their differentiated derivatives that have not yet 
been identified. If the greatest chance of observing such general defects in differentiation is 
under minimally instructive differentiation conditions, then when introducing new lines, old 
differentiation protocols may still be of some use. 
The influence of synaptic connectivity and physiologic activity in iPS-MN cultures:  
In Chapter 3, I described spontaneous culture-wide calcium oscillations in late-stage iPS-
MN cultures. It is likely that these activity patterns are influencing motor neuron differentiation 
and could become a confounding variable in some experiments. However, we may be able to 
turn this potential confounding variable to our advantage by bringing it under control and using it 
to study activity-dependent refinement of motor neuron cell fate.   
Although many aspects of motor neuron development and biology are likely to be 
regulated by activity-dependent processes, one that has been well studied and is measurable in 
vitro is the refinement of LMC identity. Frequency of bursting episodes in the developing spinal 
cord controls the expression of ephrin receptors in motor neurons of the LMC (Hanson and 
Landmesser 2004; Kastanenka and Landmesser 2010). In turn, expression of these receptors, 
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EphA4 an EphB1 in LMCm and LMCl motor neurons respectively, controls dorsal-ventral 
pathfinding during projection to the limb bud (Luria et al. 2008; Kastanenka and Landmesser 
2010).  By abrogating spontaneous activity in chick spinal cord using picrotoxin, Kastanenka and 
Landmesser (2010) caused downregulation of the EphA4 and EphB1 molecules and subsequent 
mis-projection of LMC motor neurons. Eph expression and projection defects were rescued by 
pacing activity back to normal levels with light-activated channelrhodopsin 2. 
Although the iPS-MN system does not allow the measurement of dorsal-ventral 
pathfinding - though this may eventually be possible using grafting of iPS-MNs in ovo - 
measurement of Eph expression and response to growth cone collapse assays could be used to 
investigate the role of activity-dependent processes in the refinement of LMC identity. Work in 
our laboratory shows that both LMCm and LMCl neurons are produced in iPS-MN cultures 
(Amoroso et al. submitted). However, we have not yet investigated sub-type specific Eph 
expression or response to ephrins. Recently published work from the Wichterle laboratory 
demonstrates that growth cone collapse assays are feasible using motor neurons derived from the 
Hues 3 HB9::GFP hES line (Nedelec et al. 2012). Moreover, virally expressed channelrhodopsin 
2 can be used in hES-neurons to drive the activity of entire networks in a manner similar to that 
above in embryonic chick spinal cords (Weick et al. 2011). Thus, by combining differentiation 
protocols that produce LMCm and LMCl motor neurons with channelrhodopsin-controlled levels 
of spontaneous activity, it may be possible to influence the axon guidance choices made by these 
sub-classes of motor neurons. Responses to EphrinA and EphrinB exposure could be measured 
using growth cone collapse assays. This work could then serve as a platform to demonstrate the 
similarity of iPS/hES-MNs to their in vivo counterparts and as a system to evaluate other aspects 
of activity-dependent maturation in iPS/hES-MNs. Finally, this approach could be used to derive 
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a population of iPS/hES-MNs that better represents the types of motor neurons generated during 
normal embryological development.   
However, significant differences exist between the stem cell-derived motor neuron 
culture system and animal models that will need to be accounted for in order for this work to 
advance. First of all, the rate of spontaneous rhythmic activity is more rapid in iPS-MNs than in 
the chicken spinal cord, occurring at approximately one oscillation every five seconds in iPS-
MNs and one every 20-40 seconds in chicken spinal cord (Kastanenka and Landmesser 2010). 
Although we do not know the optimal rate of spontaneous activity for consolidation of LMC fate 
in iPS-MNs, it would seem prudent to block endogenous activity with picrotoxin and then use 
light-activated channelrhodopsin to control the rate of activity as a dependent variable.  
Additionally, the local circuits forming with iPS-MNs in culture are completely unstudied, yet 
likely include several classes of cells with different neurotransmitter profiles. In particular, V2a 
and V2b interneurons, which synapse with motor neurons and are glutamatergic and 
GABAergic/glycinergic respectively, are likely present in culture as indicated by the presence of 
Chx10, a marker of V2a neurons (Wichterle et al. 2002; Al-Mosawie et al. 2007; Lundfald et al. 
2007; Di Giorgio et al. 2008). Since both V2a and V2b interneurons derive from the same 
progenitor domain adjacent to that of motor neurons, the presence of one strongly suggests the 
other. Thus, spontaneous calcium transients will need to be monitored and controlled in multiple 
classes of iPS-neurons to ensure that iPS-MNs are experiencing the intended activity levels. 
Incidentally, the effect of activity on connectivity in iPS-MN cultures has also not been studied 
and might prove an interesting future direction for this work.  
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Top candidate genes from the previous chapters: 
 Below, I will propose experiments to investigate a series of candidate genes identified in 
the iPS-MN profiling work in Chapter 4 and in the quantitative trait (QT) analysis in Chapter 5. I 
will limit my discussion to only a few of the most interesting genes from each analysis. First, I 
will discuss candidate genes from the basic ALS vs. control iPS-MN comparison and then 
several taken from the meta-analysis of my data. Before moving on to individual genes from the 
QT analysis in Chapter 5, I will outline a general format for evaluating the function of these 
genes in ALS-related cell death. Listed in the table below are the specific genes that will be 
covered.  
 
Table 6.1: Top candidate genes.  
Complete lists of the candidate genes for each analysis can be found in the figures listed in the 
right hand column and in the appendices.  
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Candidate genes from ALS vs. control iPS-MN profiling in Chapter 4: 
Ataxin2-binding partner1 (A2BP1, Rbfox1): 
A2BP1, a regulator of alternative splicing, was 13-fold downregulated in ALS iPS-MNs. 
A2BP1 is a binding partner of Ataxin-2, the genetic cause of spinocerebellar ataxia II and a 
recently described risk gene for sALS (Elden et al. 2010). A2BP1 knockout mice develop 
increased neuronal excitability and susceptibility to seizures, suggesting a link between A2BP1 
function and excitotoxic stress (Gehman et al. 2011). Taken together, this data suggests that 
reduced A2BP1 levels could lead to a hyperexcitable phenotype in ALS iPS-MNs. Thus, one 
interesting line of research may be to modulate A2BP1 levels in iPS-MNs or hES-MNs and 
measure any changes in the susceptibility of these cells to excitotoxic stressors such as prolonged 
kainate application.  
Dipeptidyl peptidase 6 (DPP6): 
DPP6 expression was reduced in all ALS iPS-MN samples and nearly absent in iPS-MNs 
derived from the ALS line 29A (see Figure 4.7B). Several studies have identified mutations in 
DPP6 as a risk factor for sALS, although this appears to be population-specific (Cronin et al. 
2009; Fogh et al. 2011). Furthermore, reduced function of DPP6 is predicted to alter excitability 
in motor neurons, potentially leading to excitotoxic damage specifically in axons. DPP6 is a 
voltage sensitive subunit of Kv4.2 potassium channels and is an important regulator of A-type 
potassium conductance. DPP6 knockout mice display deficits specifically in the dendrites of 
CA1 hippocampal neurons that include reduced A-type current, dendritic hyperexcitability, and 
increased dendritic calcium levels (Sun et al. 2011). Thus, reduced expression of DPP6 in fALS 
iPS-MNs suggests a mechanistic link between sALS and fALS patients and is predicted to have 
functional consequences on excitability in iPS-MNs. 
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However, the functional effects of DPP6 loss in motor neurons are presently unknown, 
although both Kv4.2 and DPP6 are expressed in these cells. Interestingly, filamin, a protein 
component of the post-synaptic neuromuscular junction (NMJ), is thought to recruit Kv4.2 
channels to the correct cellular localization in CA1 pyramidal cells (Bloch and Hall 1983; 
Petrecca et al. 2000). If this is also the case at the NMJ, loss of DPP6 may preferentially affect 
the site of earliest damage in ALS. Thus, the extremely low levels of DPP6 present in iPS-MNs 
from the ALS line 29A may have functional consequences.  
Several methods could be used to investigate the role of DPP6 expression in iPS-MN 
excitability. Whole-cell recording to assess A-type potassium currents and calcium imaging to 
evaluate axonal hyperexcitability should be considered and are planned by our collaborators 
Damian Williams and Amy MacDermott. Specifically, these experiments should utilize iPS-MNs 
from 29A as well as at least one control iPS line and verify the role of DPP6 in any observed 
excitability phenotypes by knockdown and overexpression. Additionally, DPP6 expression and 
localization has not previously been evaluated in motor neurons from humans or in model 
animals. Thus, immunostaining of DPP6 localization in iPS-MNs to determine whether or not it 
is enriched in axons would be worthwhile given its ALS-associations. Finally, since DPP6 
knockout mice are available and viable, a crossing with the G93A SOD1 mouse should be 
considered irrespective of results in iPS-MNs.  
Forkhead box P1 (FOXP1):  
A marker of ALS-susceptible LMC motor neurons, FOXP1 is consistently downregulated 
in ALS iPS-MNs as compared to control iPS-MNs (Figure4.7-4.8). It is possible that this reflects 
the death of FOXP1+ motor neurons specifically in ALS cell lines. If this were the case, then it 
would suggest that the iPS-MN system is recapitulating the subtype-specificity of ALS. This 
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would be a noteworthy finding because it would establish a ready system in which to investigate 
mechanisms behind the preferential cell death seen in limb-innervating motor neurons in ALS. 
Rescuing decreased survival in FOXP1+ motor neurons could also provide a disease-relevant 
endpoint for screening of candidate therapeutic compounds. Thus, I would consider FOXP1 
among the highest priority of the candidate genes discussed here. 
However, a decreased percentage of FOXP1+ motor neurons in ALS iPS-MN cultures 
needs to be confirmed by immunostaining for FOXP1 along with pan-motor neuron markers. It 
is possible that the decreased enrichment of FOXP1 in ALS iPS-MN samples is due to a general 
death of motor neurons in culture or to an increased production of FOXP1-negative motor 
neurons. Thus, these possibilities must be ruled out to properly interpret the decreased FOXP1 
expression in ALS iPS-MNs. If FOXP1+ motor neurons do show survival deficits in iPS-MN 
cultures, it is likely that this is occurring over the course of the maturational period used to allow 
lentiviral sHB9::RFP expression, since preliminary assessment of FOXP1 levels by other 
members of the lab did not detect large differences between ALS and control lines (Amoroso et 
al., unpublished). Thus, immunostaining for FOXP1 and HB9/Islet should take place 
immediately after plating and following a 10+-day adherent maturation period. The addition of 
antimitotic agents to a subset of experiments should be used to isolate the effects of cell division 
and cell death. 
Candidate genes from Meta-analysis in Chapter 4: 
Galectin-3 (LGALS3): 
LGALS3, a recently reported candidate biomarker for ALS (Zhou et al. 2010), was 
upregulated 15-fold in ALS iPS-MNs. This secreted protein is believed to play a negative role in 
nerve regeneration, although this effect may be mediated through Schwann cells (Narciso et al. 
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2009). Additionally, a closely related protein, LGALS1 has been implicated as an important 
mediator of p75NTR-dependent neurite retraction in mouse ES-derived neurons (Plachta et al. 
2007). 
More careful measurement of LGALS3 levels in iPS-MN cultures should be performed. 
ELISA assays to measure the secreted LGALS3 levels in culture medium seem an attractive set 
of experiments given its reported role as an ALS biomarker in cerebrospinal fluid (Zhou et al. 
2010). However, LGALS3 immunostaining is also a viable approach and Zhou et al (2010) 
describe increased LGALS3 levels in spinal cord sections both from ALS patients and in the 
SOD1 G93A mouse model.  Additionally, it would be interesting to determine if increased 
LGALS3 levels could be correlated with either disease severity or limb-innervating motor 
neuron subtypes. If LGALS3 levels were increased in ALS iPS-MNs, then this would strengthen 
the notion of LGALS3 as an ALS biomarker and point towards eventual clinical application as a 
diagnostic tool.  
CD44:  
CD44, a hyaluronic acid receptor, was 20-fold upregulated in ALS iPS-MNs. Signaling 
through CD44 leads to inhibition of the plasma membrane calcium pump in sensory neurons, 
suggesting a potential link between increased CD44 levels and perturbations in neuronal calcium 
handling (Ghosh et al. 2011). Furthermore, CD44 can serve as an anchor for matrix 
metalloproteinase 9 (MMP-9) at the cell surface, thus localizing its activity (Yu and Stamenkovic 
1999). Interestingly, work in the Henderson lab suggests that MMP9 may be a mediator of early 
motor neuron degeneration in ALS mice (Artem Kaplan, Krista Spiller, unpublished data).  
Along with validating expression at the protein level in iPS-MNs, future experiments 
should consider blocking CD44 function in both in vitro and in vivo models of ALS. Application 
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of soluble CD44 is capable of blocking the interaction of MMP9 with endogenous CD44. Thus, 
this approach would be worth considering in the spinal cord of the G93A SOD1 mouse model 
either through direct application of CD44 or viral overexpression of the extracellular domain (Yu 
and Stamenkovic 1999). Notably, CD44 can also be blocked with antibodies and short 
hyaluronan oligosaccharides (SHOs). However, SHOs can act through CD44 to increase the 
expression of MMP-3 and -13 in chondrocytes, suggesting that this approach may have 
deleterious side effects in vivo (Ohno et al. 2005; Ohno et al. 2006). In vitro experiments, 
however, could utilize CD44 blocking antibodies to assess the effect of CD44 activity on iPS-
MN survival in basal and excitotoxic conditions.  
Speckle-type POZ protein (SPOP): 
SPOP is an adaptor protein involved in the ubiquitination of Daxx by Cul3 ubiquitin 
ligase (Kwon et al. 2006). SPOP was 1.7 fold downregulated in ALS iPS-MNs. Lower levels of 
SPOP and subsequently decreased ubiquitination of Daxx, an intermediate in the Fas death 
pathway, could cause increased sensitivity to Fas-mediated cell death in ALS iPS-MNs. 
Furthermore, data from the Henderson group has implicated a motor neuron-specific Fas/NO 
pathway in selective motor neuron death in mSOD1 mice (Raoul et al. 2002; Raoul et al. 2006).  
Thus, modulation of SPOP levels in the setting of ALS-related stressors could be a 
productive avenue of inquiry. First, knockdown of SPOP in iPS-MNs or rodent primary neurons 
should be conducted to determine how this affects sensitivity to stimulation of the Fas/NO 
pathway. Secondarily, viral overexpression of SPOP during Fas/NO challenge in primary 
neurons or in an mSOD1 mouse model may be useful to investigate SPOP as a potential 
therapeutic strategy that would act preferentially on the FAS/NO pathway.  
  





Investigating the roles of candidate onset-modifying genes in Chapter 5:  
In Chapter 5, I described a group of genes with onset-related expression patterns in 
human post mortem samples. I previously focused on methods to validate the onset-dependent 
expression of these genes as a class. However, many of the genes have relationships to 
neurodegeneration that make them worthy of independent study in order to clarify potential roles 
in the pathogenesis of ALS.   
Below, I will focus on the rationale and basic structure of experiments intended to 
identify these relationships where they exist. I will first discuss a general structure for 
experiments that is suitable for any number of these candidate genes. This work will rely chiefly 
on the knockdown and overexpression of candidate genes in iPS-MNs, followed by basic 
phenotypic characterization. I will also cover experiments aimed at placing onset-correlated 
candidate gene expression up or down-stream of ALS-causing mutations. Finally, I will discuss a 
series of more directed experimental manipulations on a gene-by-gene basis.  
During the part of the discussion dedicated to specific candidate genes, I will provide 
preliminary data about the functions of two genes in iPS-MNs: MFN1 and HIPPI. They will not 
address the role of the two proteins in ALS pathogenesis, but will simply show that they are 
behaving as expected in iPS-MNs. They are included here in order to be grouped with the 
broader discussion of these genes. 
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General format for investigating the role of candidate onset-modifying genes in Chapter 5:  
In the discussion of Chapter 5, I described two potential roles for genes that have onset-
correlated expression patterns: causative factors and biomarkers. These two potential roles can 
be distinguished by assessing the involvement of candidate genes in ALS-related cell death and 
evaluating changes in candidate gene expression following the addition of ALS-related stressors. 
If candidate genes play an active role in ALS-relevant cell death processes, their overexpression 
or knockdown in motor neurons during stimulation of cell death pathways should modify the 
motor neuron response. A potential way of assessing this would be to manipulate candidate gene 
expression levels while measuring the survival, morphology, and electrophysiological properties 
of stressed motor neurons (Figure 6.1A). Potential deleterious phenotypes caused by changes in 
onset-dependent genes would include decreased survival, smaller cell bodies and shorter axons, 
or protracted increases in intracellular calcium levels following stimulation. 
Furthermore, the function of candidate genes should be assessed during exposure to 
exogenous stressors that mimic those in ALS. For instance, one may knockdown a particular 
candidate gene in iPS-MNs and then compare motor neuron survival in knockdown and control 
cultures following exposure to Fas ligand, toxic astrocyte conditioned media from cells 
expressing mutant SOD1 (ACM), or excitotoxic stimuli such as kainate (Figure 6.1A). If 
candidate genes are playing causal roles, then cell death under these conditions may be altered 
following knockdown.  
However, such experiments must be interpreted carefully. Because some candidate genes 
are mediators of known cell death pathways (HIPPI, Casp3), manipulating them will likely affect 
cell viability in any cell type. Therefore, it will be important to assess their role specifically in 
ALS-relevant conditions.  
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If candidate genes are biomarker or compensatory changes, then manipulating the 
severity of disease causing factors may change their expression. This could be assessed using 
viral shRNA-mediated knockdown of SOD1 in ALS iPS-MNs, followed by FACS isolation of 
iPS-MNs, and quantification of changes in candidate gene expression (Figure 6.1B).The most 
interesting class of QT genes for this analysis would be those that are expressed higher in early 
sALS patients than in controls. This class contains 6 genes: HIST1H2BC, PLD1, SOAT1, 
NBEAL1, PGGT1B, and POLD3. These genes would be a first priority to measure in the context 
of SOD1 knockdown.  
Another method of asking whether or not a specific gene is expressed downstream in 
disease processes would be to measure expression in motor neurons before and after exposure to 
toxic astrocyte ACM. In cases where array data taken from motor neurons in these conditions 
already exists, the experiment could be performed in-silico by intersecting the list of onset-
dependent genes with the list of genes upregulated in motor neurons after exposure to toxic 
ACM. 
Finally, a generally applicable in-vivo approach would be to cross knockout mice for a 
particular candidate gene to SOD1 G93A mice and assess any changes in disease onset or 
survival. This approach is best reserved for genes with the clearest mechanistic links to ALS (See 
below).  
 




Figure 6.1: Future perspectives on onset-modifying candidate genes. 
(A, B) Outline of experiments to delineate two possible roles of onset-modifying candidate genes 
in ESMNs and iPSMns. (A) Causative model: If candidate genes play a role in ALS-relevant cell 
death pathways, their overexpression or knockdown in motor neurons during stimulation of these 
pathways may modify the motor neuron response. Potential ways of assessing this include 
survival and morphology of stressed motor neurons as well as frequency of spontaneous calcium 
activity and duration of recovery time following an excitotoxic stimulus. (B) Biomarker model: 
If candidate genes are downstream of ALS causing mutations or environmental factors, then 
knockdown of mutations or addition of environmental toxins may change the expression levels 
of candidate genes. If either of these possibilities turns out to be the case, then onset-modifying 
candidate genes may be viable therapeutic targets and/or provide further mechanistic insight into 
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Selected candidate genes from sALS correlation analysis: 
Several candidate genes from the QT analysis have mechanisms of action or known 
associations with disease that suggest specific experiments aside from the general approaches 
discussed above. These experiments either serve the role of validating previously described 
mechanisms in a new neural cell type (motor neurons), or of elucidating potential gene-specific 
effects that could play functional roles in ALS. They are described below for selected genes and 
are to be considered as supplemental to the experiments described above. 
Phospholipase D1 (PLD1): 
PLD1 is expressed at higher levels in early-onset ALS cases. PLD1 is an enzyme 
responsible for the hydrolysis of phosphatidylcholine into phosphatidic acid and choline. 
Although PLD1 is involved in many cellular processes, including a portion of acetylcholine 
biosynthesis, two particularly ALS-relevant functions involve the regulation of neurite outgrowth 
and starvation-induced autophagy (Yoon et al. 2005; Cai et al. 2006; Dall'Armi et al. 2010). 
Additionally, inhibition of PLDs with 5-fluoro-2-indolyl des-chlorohalopemide (FIPI) leads to 
increased insoluble tau aggregates in a mouse model of tauopathy (Dall'Armi et al. 2010).  
Thus, I propose modulating PLD activity in ALS and control iPS-MNs and then assessing 
cell viability, neurite outgrowth, and SOD1 protein aggregation as well as markers of autophagy 
(LC3 staining). Although adult human motor neurons express PLD1 (Rabin et al. 2010), my 
microarray and qPCR data on iPS-MNs shows that it is present at very low levels in these cells. 
Therefore, in order to proceed with in vitro experiments specifically on PLD1, iPS-MNs may 
need to be allowed a longer adherent maturation phase to express higher levels of the protein. 
Alternatively, primary rodent motor neurons may be used for these experiments.  
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If PLD1 activity is functioning to augment the removal of potentially deleterious SOD1 
aggregates in ALS by stimulating autophagy, inhibiting PLDs with FIPI or a PLD1 dominant-
negative construct may be a way of sensitizing iPS-MNs towards displaying ALS-specific SOD1 
aggregates. These aggregates, in turn, may lead to decreased viability in culture. If this were the 
case, it would suggest that autophagy plays a protective role in in-vitro models of ALS.  
Such a finding would be of considerable interest given the recent failure of another 
autophagy inducer, lithium, in ALS clinical trials and the still uncertain role of autophagy in 
animal models of ALS.  Furthermore, since not all forms of autophagy are induced by PLD1, 
studying the pathways specific to this protein might aid in clarifying previous conflicting results 
(see General Introduction).  
Since PLD1 knockouts are viable, crossing these animals to the SOD1 mouse model is 
another way to evaluate the role of PLD1 in ALS (Dall'Armi et al. 2010). However, since 
autophagy has not been genetically manipulated in the SOD1 ALS model system as of yet, 
interpretation of these results should focus on a broader range of potential mechanisms including 
changes in acetylcholine biosynthesis.  
Mitofusin 1 (MFN1): 
MFN1 and the related protein Mitofusin2 (MFN2) are GTPases critical for mitochondrial 
fusion (Koshiba et al. 2004; Zorzano et al. 2010). The balance of mitochondrial fusion and 
fission, in turn, determines mitochondrial size and is important for an array of mitochondrial 
functions including trafficking, biogenesis, and overall health (Chen and Chan 2005).  
MFN1 is an attractive candidate gene to study in ALS iPS-MNs due to the key role mitochondria 
are believed to play in ALS pathogenesis through their functions both as the primary calcium 
buffering source in motor neurons and as gateways to the apoptotic pathway (Schon and 
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Przedborski, 2011). Furthermore, MFN2 is the genetic cause of the CMT2A form of Charcot-
Marie-Tooth disease, a juvenile-onset motor and sensory neuropathy. Interestingly, a CMT2A 
patient who developed symptoms of ALS later in life has recently been discovered to have a 
novel MFN2 mutation (Marchesi et al. 2011). 
In vitro experiments with MFN1 should investigate its effects on mitochondrial size and 
dynamics as well as calcium buffering in motor neurons. Overexpression of MFN1 in chicken 
DRG neurons causes lengthening of mitochondria in axons and greatly reduces axonal 
mitochondrial motility (Amiri and Hollenbeck 2008).  The effects of these changes on 
compartment-specific calcium buffering are unknown. However, by perturbing axonal 
mitochondrial biogenesis and trafficking, increased levels of MFN1 may deleteriously alter 
localized calcium buffering or sensitize entry into cell death pathways. Reduced calcium 
buffering capacity could have pathogenic implications in ALS, especially in axons and nerve 
terminals, which are the first cellular locations to be effected in the disease. Alternatively, 
increased levels of MFN1 could be compensatory changes secondary to the increased 
mitochondrial fragmentation observed in ALS (Magrane et al. 2009; Kawamata and Manfredi 
2010). 
My preliminary studies demonstrate that MFN1 overexpression in iPS-MNs causes peri-
nuclear clumping of mitochondria, but have not yet addressed mitochondrial characteristics in 
axons or calcium buffering. In order to assess the effects of MFN1 overexpression in iPS-MNs, I 
used a lentivirus to drive MFN1-nlsGFP expression iPS-MNs and visualized mitochondria using 
Mitotracker Red (see Methods). I observed peri-nuclear clumping of mitochondria in Islet1/2+ 
cells labeled with viral nlsGFP, but not those without label (Figure 6.2). These results 
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demonstrate that overexpression of MFN1 in iPS-MNs changes mitochondrial size and 
distribution.  
However, more disease-relevant studies have yet to be conducted. It will be particularly 
informative to assess MFN1-mediated alterations in mitochondrial distribution and calcium 
buffering following kainate exposure in ALS vs. control and ealry vs. late onset iPS-MNs. 
Similar experiments should also be conducted on mouse primary motor neurons to determine if 
MFN1 overexpression corrects the mitochondrial size and mobility defects in these cells. 
Additionally, calcium-imaging experiments should pay specific attention to the differential time 
course of calcium transients in the soma and axon as MFN1-mediated redistribution of 
mitochondria may preferentially affect one cellular compartment over the other (See figure 
3.7.1). Finally, the peri-nuclear localization of mitochondria in MFN-1 overexpressing cells 
suggests that they may be undergoing autophagy. This hypothesis can be evaluated using LC3 
staining in an experiment similar to the one presented below in Figure 6.2. If aggregated 
mitochondria stain for LC3, it would suggest that MFN1 may play a role in regulating 
mitochondrial degradation in ALS. Whether this is protective or deleterious would need to be 
assessed by overexpressing MFN1 in a mouse model of the disease. 




Figure 6.2: Mitofusin 1 (MFN1) expression in iPSMNs. 
(A) Lentiviral expression of MFN1-nlsGFP causes peri-nuclear mitochondrial clumping 
consistent with mitophagy. (Green=LV-MFN1-ires-nlsGFP, Red=Mitotracker Red, 
Magenta=Islet1/2, Blue-DAPI). 1=MFN1 infected Islet1/2+ motor neuron. 2=non-infected 
Islet1/2+ motor neuron. 3=MFN1 infected non-motor neuron. 
 
 
Zinc finger RNA-binding motif serine/arginine rich 2 U2AF35-related protein (ZRS2R, URP): 
ZRSR2 (or URP) encodes a U2AF35 related protein that is required for both the major 
U2 and minor U12 splicing of pre-mRNA (Shen et al. 2010). This was the only gene in the QT 
analysis that showed an expression pattern positively correlated with age at onset. Although 
ZRSR2 is believed to be required in different steps of U2 and U12 splicing, both functions are 
dependent upon RNA binding at the 3’ splice site (Shen et al. 2010). Interestingly, there are two 
reports showing that U12 splicing is decreased in SMA, one in lymphoblasts from an SMA 
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link between motor neuron disease and reduced ZRSR2 function (Gabanella et al. 2007; 
Boulisfane et al. 2011). 
To assess whether or not ZRSR2 plays a potential role in the pathogenesis of ALS, it 
could be useful to evaluate the splicing of U12 dependent genes both in motor neurons from ALS 
patients as well as ALS iPS-MNs. A preliminary re-analysis of splicing defects in the Rabin et al 
(2010) dataset restricted to U12 substrates and comparing ALS vs. control as well as early vs. 
late ALS would seem the most rapid way to evaluate whether or not reduced ZRSR2 expression 
has functional consequences for mRNA splicing in motor neurons. 
Aminoacyl tRNA synthetase complex-interacting multifunctional protein 1 (AIMP1, P43): 
AIMP1 (p43) is a multi-functional protein that is required for neurofilament assembly 
and function (Zhu et al. 2009). Mice deficient in AIMP1 exhibit, hyperphosphorylation of NF-L, 
motor neuron axonal degeneration, defective neuromuscular junctions, and muscular atrophy 
(Zhu et al. 2009). Furthermore, mutations in AIMP1/p43 lead to a complex neurodegenerative 
disorder in humans in which spastic paresis (indicative of upper motor neuron degeneration) is 
present within a constellation of symptoms (Feinstein et al. 2010; Biancheri et al. 2011; 
Boespflug-Tanguy et al. 2011).  
Any role of AIMP1 in the pathogenesis of ALS presupposes that the protein acts 
similarly in mouse and human neurons. Modulating the expression of AIMP1 in human iPS-MNs 
and assessing the levels of phorphorlyated NF-L as well as axon length and motor neuron 
survival would be a useful way to assess whether or not AIMP1 functions in human motor 
neurons as it appears to in the mouse. If this is the case, then sensitivity to perturbation in AMIP1 
levels could be evaluated in both ALS and control iPS-MNs.  
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Neurobeachin like 1 (NBEAL1, ALS2CR16/17): 
NBEAL1 is a relatively obscure gene that was initially described within an ALS2 
candidate gene region on chromosome 2q33 (Hadano et al. 2001; Yang et al. 2001). Although 
NBEAL1 did not turn out to be the causative ALS gene in this region (Alsin), its proximity is 
worth noting (~500kb). NBEAL1 is expressed broadly in neural tissue and contains a vacuolar 
targeting motif as well as PH-BEACH and WD40 domains (Chen et al. 2004).  
Although very little is known about NBEAL1 function, its homology to two other 
proteins: Neurobeachin and ALFY, make it a promising candidate for future study. 
Neurobeachin (NBEA) is a protein involved in neuronal membrane trafficking and is required 
for the development of functional neuromuscular junctions as well as synapses and dendritic 
spines in the CNS (Wang et al. 2000; Su et al. 2004; Medrihan et al. 2009; Niesmann et al. 
2011). Additionally, the PH-BEACH and WD40 domains in NBEAL1 give it significant 
homology to WDFY3 (ALFY), a recently described regulator of autophagy involved in protein 
aggregate clearance in the nervous system (Chen et al. 2004; Filimonenko et al. 2010). The PH-
BEACH domain in ALFY interacts with p62 during regulation of autophagy, but it is currently 
unknown whether or not other PH-BEACH domain proteins do the same (Yamamoto and 
Simonsen 2011). Interestingly, ALFY knockout animals die shortly after birth and exhibit brain 
malformations, suggesting that ALFY may also be important for neural development 
(Unpublished, A. Yamamoto). It is also notable that mutations in p62 have recently been 
implicated in both familial and sporadic forms of ALS, suggesting another potential link between 
NBEAL1, ALFY, and ALS (Fecto et al. 2011). 
The exact relationships between NBEAL1, NBEA, and ALFY are currently a matter of 
speculation. However, given its potential involvement both in critical neural functions as well as 
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autophagy, NBEAL1 remains high on the list of candidate genes for directed study. It is possible 
that NBEAL1 is a previously undescribed regulator of neural development, autophagy, or both. 
Future work on this gene should include investigation both of its role in modulating autophagy in 
iPS-MNs as well as how it may influence the widespread synaptic connectivity in culture.  
Huntington interacting protein partner-1 (HIPPI, IFT57): 
During development, HIPPI plays a critical role in Sonic Hedgehog signaling and is 
required for proper formation of the neural tube (Houde et al. 2006). In the adult nervous system, 
however, HIPPI’s only known function is as an inducer of apoptotic cell death in Huntington’s 
disease (Gervais et al. 2002). 
HIPPI contains a pseudo death effector domain (pDED) through which it is known to act 
in Huntington’s disease. Under normal conditions, most HIPPI is inactive because it requires 
dimerization with Huntington interacting partner (HIP) to function, yet most HIP is bound and 
sequestered by the Huntington protein (HTT). However, in Huntington’s disease, HIP dissociates 
from mutant HTT and complexes with HIPPI in the cytoplasm. Once bound, HIP and HIPPI 
associate with pro-caspase8 and catalyze its auto-activation (Gervais et al. 2002). This begins an 
apoptotic cascade that culminates in caspase3-dependent cell death. Interestingly, the Fas 
receptor, which is thought to be involved in SOD1-dependnet cell death in ALS, also acts via 
pDED domains to activate caspase8 (Raoul et al. 2002; Raoul et al. 2006). The actions of HIPPI 
in motor neurons have not been described. 
In addition to its direct actions on pro-apoptotic pathways, HIPPI, when complexed with 
HIP, can translocate to the nucleus and alter gene expression. Once in the nucleus, the pDED 
domain of HIPPI influences gene transcription in a manner potentially deleterious to neurons. 
Nuclear HIPPI activity increases the expression of Casp1, Casp8, Casp10, and REST and inhibits 
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expression of the pro-survival proteins BCL-2 and Survivin (Majumder et al. 2006; Majumder et 
al. 2007; Majumder et al. 2007; Datta and Bhattacharyya 2011). Increased REST expression, in 
turn, downregulates the trophic factors BDNF and PENK, further reducing pro-survival cues 
(Datta and Bhattacharyya 2011). Thus, even in cells that are not undergoing HIPPI-dependent 
apoptosis, increased nuclear HIPPI could be tipping the scales towards cell death. 
In order to determine if HIPPI is functional in human motor neurons, I performed 
preliminary experiments with this protein. I virally transduced motor neurons from the ALS iPS 
lines 27b (n=3) and 39b (n=2), and from the control line 11c (n=3) with HIPPI-nlsGFP lentivirus 
and assessed survival 7 days thereafter (see Methods). I found that although HIPPI causes 
decreased survival in both control and ALS iPS-MN cultures, it does not differentially affect 
either. Furthermore, Islet 1/2+ motor neurons were not more sensitive to HIPPI than non-motor 
neurons in culture. 
This preliminary data suggests that HIPPI induces cell death in iPS-MNs. However, 
HIPPI does not seem to be functioning with grossly different effectiveness in ALS and control 
iPS-MNs. Future work should attempt to elucidate any subtle motor neuron or ALS-specific 
preferences in HIPPI-induced cell death. Furthermore, this work should define the mechanisms 
of HIPPI action in iPS-MNs. 
Several aspects of my preliminary data limit their interpretation and should be addressed. 
First, GFP-only lentiviral controls were not used in these experiments. Although I do not observe 
increased cell death following infection with other GFP-driving lentiviruses produced using 
identical protocols, it is still necessary to perform this control. Second, the number of iPS lines 
used was relatively small. To detect ALS vs. control differences, it may be helpful to expand the 
analysis to a larger panel of iPS lines. Third, a careful dose-response of HIPPI virus on iPS-MNs 
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would be a more effective way of determining motor neuron or genotype sensitivity to 
expression of the protein. 
The mechanisms of HIPPI action in iPS-MNs could be confirmed in multiple ways. 
Measurement of downstream gene expression changes and blocking cell death with caspase 
inhibitors are two such means. Additionally, HIPPI constructs with inactivating mutations in the 
pDED domain can be used to control experiments against off-target effects of HIPPI expression 
(Datta and Bhattacharyya 2011). 
Another approach that may produce more informative results would be to evaluate the 
role of HIPPI in existing models of ALS-specific motor neuron death. If HIPPI knockdown 
attenuates motor neuron death in either the toxic ACM model or Fas-induced cell death model, 
then it could possibly play an active pro-apoptotic role in ALS. (Of note: Fas experiments would 
likely need to be performed in primary rodent neurons and not iPS-MNs because no Fas-
dependent cell death pathways have yet been evaluated in iPS-MNs.) 
Finally, a HIPPI knockout strategy could be considered to evaluate the role of HIPPI in 
the G93A SOD1 mouse model. Because HIPPI is also required for sonic hedgehog signaling 
during development, this strategy would need to employ a conditional HIPPI allele. 
Expanding motor neuron transcriptional profiling to a broader ALS patient population 
using iMN technology: 
The iPS-MN profiling experiments performed in Chapter 4 identify some potentially 
exciting transcriptional changes in ALS iPS-MNs. The differences revealed are significant 
statistically but it would be beneficial to include further expression profiles from many more 
ALS and control samples. At a minimum, this could serve to confirm my results by providing 
samples for independent verification. Furthermore, one of the promises of iPS cells in general is 
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to model patient-specific phenotypes in cell types otherwise not accessible except in post-mortem 
tissues. However, larger numbers of iPS lines will be necessary in order to prospectively identify 
and investigate phenotypes of disease that go beyond disease vs. control status. As an example, 
consider the identification of onset-correlated genes in Chapter 5 that relied on expression data 
from 12 ALS patients and would ideally be confirmed in a data set of similar size. Currently, it 
would be quite challenging indeed to assemble iPS-MN expression profiles from 24 ALS iPS 
lines. Below, I will suggest how it may be possible to greatly expand our access to motor 
neurons from different ALS patients by direct conversion of transformed B-lymphocytes from 
the Coriell Cell Repositories into induced motor neurons (iMNs).   
Although panels of ALS and control iPS lines are now becoming available, significant 
hurdles still remain before they can be used in large-scale profiling studies. Aside from cost of 
reagents, the major reason I was only able to profile motor neurons from 4 ALS patients and 2 
controls was the time and labor necessary to prepare the samples. Leaving aside the potential 
derivation of motor neuron reporter lines, the bottlenecks in this process are expansion and 
culture of iPS lines, differentiation, and FACS isolation of labeled motor neurons. These 
procedures can become particularly challenging if the iPS lines being used show tendencies 
towards spontaneous differentiation in culture and require manual isolation of undifferentiated 
colonies for continued propagation. Although a well-organized and collaborative tissue culture 
effort can be used to overcome these obstacles, I believe it would be worth investigating methods 
of producing patient-specific motor neurons that are less likely to encounter them. 
Direct induction of motor neurons from patient-derived tissues is one such method that 
seems to be meeting with success.  In a process similar to the viral reprogramming techniques 
used to produce iPS cells, mouse and human fibroblasts can be directly converted into post-
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mitotic neurons (induced neurons, iNs.  (Vierbuchen et al. 2010; Pang et al. 2011). The 
reprogramming factors used to affect this conversion are master regulators of neural fate 
specification during development and include Ascl1 (Mash1), Brn2, and Mytl1, with the addition 
of NeuroD1 in human fibroblasts (Vierbuchen et al. 2010; Pang et al. 2011). In the case of 
human iN cells, postmitotic Tuj1-expressing, electrophysiologically active neurons were 
observed 8 days following viral transduction of fibroblasts (Pang et al. 2011). Importantly, 
doxycycline-inducible vectors have been employed during the above approaches, eliminating 
concerns about persistent reprogramming gene expression. Both dopaminergic neurons (iDA) 
and motor neurons (iMN) have also been produced using similar methods and fate-specification 
factors appropriate to the particular neural subclasses (Caiazzo et al. 2011; Hester et al. 2011; 
Pfisterer et al. 2011; Son et al. 2011).  
Electrophysiologically active iMNs have been induced from human fibroblasts, hESCs, 
and hiPSCs (Hester et al. 2011; Son et al. 2011). Reprogramming of hES/iPS cells requires only 
Isl2, Ngn2, and Lhx3 and occurs in as little as 11 days (Hester et al. 2011), whereas 
reprogramming of fibroblasts relied on 8-factors that also contained these three genes and was 
evaluated after 30 days (Son et al. 2011). In hiPSCs, reprogramming efficiency to HB9+ motor 
neurons was reported to be very high (~70%) (Hester et al. 2011).  
Although these results are promising, several factors would prevent the current version of 
iMN technology from being applied productively to large panels of ALS patient samples. To 
begin with, current approaches have not used doxycycline-inducible vectors, deciding instead to 
allow reprogramming-factor expression to persist in iMN cells. This could create a problem 
downstream if continued expression of reprogramming factors, particularly Lhx3, alters motor 
neuron maturation. Additionally, mixtures of viruses encoding for individual reprogramming 
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factors are currently used to produce iMN cells. This creates the potential for slightly variable 
stoichiometry of reprogramming factors that could influence reprogramming efficiency. Finally, 
although the iMN process can be quite efficient, a significant number of cells in culture are not 
motor neurons, complicating any profiling strategy that does not utilize a motor neuron-specific 
reporter.  
A slight re-working of the iMN reprogramming strategy should help to alleviate these 
problems. First, the use of a polycistronic doxycycline-inducible viral vector encoding Isl2-P2A-
Ngn2-P2A-Lhx3, would remove concerns about continued reprogramming factor expression as 
well as variable stoichiometry during reprogramming. Second, a strategy will need to be devised 
to purify or enrich iMNs from reprogrammed cultures. One potential solution to this problem 
would be to use the acquisition of a post-mitotic cell fate as a surrogate marker for motor neuron 
identity and to remove dividing cells from culture using anti-mitotic compounds. This approach 
would work best when reprogramming quickly dividing cells such as iPS cells and perhaps less 
so if using fibroblasts. Furthermore, it would depend upon the percentage of true motor neurons 
among the post-mitotic derivatives of reprogramming events: a quantity that is not yet known. In 
lieu of the antimitotic approach, iMN cultures could be transduced with a motor neuron reporter 
construct. Since it would be preferable to avoid FACS purification of motor neurons from large 
numbers of cultures, this should first be attempted with a drug resistance cassette. In this 
application of a motor neuron reporter, non-motor neurons could be removed from culture via 
drug selection. If the drug selection approach is unsuccessful, a surface tag or fluorescent marker 
would both remain viable secondary options. Thus, by containing iMN reprogramming elements 
to one doxycycline-inducible vector and applying selection strategies for post-mitotic motor 
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neurons, it seems possible to arrive at high purity iMN cultures in a reasonably high throughput 
manner.  
Finally, selection of the appropriate ALS patient and control samples for reprogramming 
should aid in the production of pure population of iMNs. Ideally, patient samples would be in the 
form of a rapidly dividing non-neural cell type that can be easily cultured. A quite extensive 
panel of such ALS-patient samples is available in the form of Epstein-Barr virus transformed B-
lymphocyte lines in the Coriell cell repository and may be useful in this respect.  Although iN or 
iMN cells have not yet been generated from EBV immortalized B-cell lines in the Coriell cell 
bank, a recent report has described the derivation of iPS cells from such lines, demonstrating that 
the approach may be technically feasible (Choi et al. 2011). Importantly, transformed B-cells lost 
the episomal EBV elements during the reprogramming process, presumably as they were 
removed from a culture environment in which the EBV genes conferred a selective advantage 
(Choi et al. 2011). Thus, attempts at moving iMN procedures to B-lymphocyte cell lines should 
be made to determine if they will be a useful source of ALS patient motor neurons for profiling.   




Throughout this thesis, I have discussed a range of topics with the common theme of developing 
a new model of ALS using human stem cells. This work began with the development and 
characterization of the first panel of human iPS lines designed to address this problem. Together 
with a group of collaborators, I helped to identify some of the basic contributors to 
differentiation potential and to argue against a prevailing notion that iPS cells may be a 
problematic substrate from which to derive neurons. Our work demonstrated that iPS cells can be 
used to efficiently derive ALS iPS-MNs which may be useful in disease modeling. I then went 
on to characterize some of the basic molecular and electrophysiological properties of stem cell-
derived motor neurons and to develop tools for their purification from culture. Using iPS cell 
lines derived as part of our collaborative efforts, I applied the iPS-MN purification techniques 
that I developed to produce the first expression profile of fALS in living human motor neurons. 
The expression data from ALS iPS-MNs indicate unexpectedly strong changes in patient-derived 
neurons in a set of genes that correlate remarkably well with our current hypotheses about ALS 
disease mechanisms. Finally, in an attempt to find patient-specific attributes of ALS to model 
using patient-derived stem cells, I identified a previously overlooked class of genes that exhibit 
expression levels correlated with ALS patient age at onset and also dovetail in intriguing ways 
with known aspects of ALS pathogenesis. Future work on these and other candidate genes 
identified in my thesis may help to elucidate some of the mechanisms of ALS and to point out 








MFN1 and HIPPI lentiviral constructs: MFN1 and HIPPI lentiviral constructs were obtained 
from the Precision LentiORF library (Thermo Scientific) (Collection maintained at CUMC by 
Jose Silva). Viral inserts contain the CMV promoter driving the ORF followed by an IRES 
sequence and nls-turboGFP-2A-BlastR. Viral constructs were produces as described in Chapter 
4.  
MFN1: iPS-MNs were differentiated using the 22 day protocol in Chapter 4, plated, and infected 
48-72 hours thereafter. Following 7 days of incubation with virus, mitochondria were labeled 
with Mitotracker Red (Thermo Scientific) and cells were stained for Islet1/2 and DAPI. 
Hippi: Hippi infection was performed on iPS-MN cultures from lines 11c (n=3), 27b (n=3), and 
39b (n=2). Total cell survival was reduced in all HIPPI infected cultures (uninfected ±STDEV = 
11c (53±17), 27b (65±9), and 39b (38±17). However, total survival was not different between 
ALS and control lines (p=0.9). Total survival was also not significantly different between the 
three lines tested, although the analysis was not powered to detect small differences (ANOVA 
p=0.212, F=2.148, d.f.=2). Percent cells infected and surviving at 7 days did not differ either in 
an ALS vs. control comparison (p=0.025) or in line-by-line comparisons (Kruskal-Wallis 
ANOVA on ranks, p(exact)=0.179, H=3.806, d.f.=2). Finally, HIPPI did not seem to 
preferentially kill motor neurons in either ALS or control samples. Percent Islet1/2+ motor 
neurons surviving compared to uninfected controls was not significantly different for the ALS 
vs. control comparison (p=0.71), or in line-by-line comparisons (ANOVA p=0.152, F=2.805, 
d.f.=2). This preliminary data suggests that HIPPI induces cell death in iPS-MNs. However, 
HIPPI does not seem to be functioning with grossly different effectiveness in ALS and control 
iPS-MNs.  
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Viral infection of iPS-MNs: day-22 SAG/PUR iPSMN differentiations were dissociated and 
plated as described above at 0.5M cells per well in a standard 12 well plate. 48-72 hours later 
MFN1-GFP or HIPPI-GFP lentivirus was added to the culture as described above form the 
sHB9::RFP lentivirus. Following 7 days of incubation, labeled iPS-MNs were fixed and stained 
for indicated markers. For HIPPI infection of iPS-MNs, virus was used at 40% of a titer which 
was observed to kill ~90% of cells in culture.  
Mitochondrial labeling: Mitotracker Red (Fisher Scientific) was used according to the 
manufacturer’s specifications.  
Survival assays: motor neurons were quantified using Metamorph software as described above. 
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Appendix 4.1: ALS iPS-MN vs. Control iPS-MN expression data. !E%41("$3"5&!56!32%!$(5P0%),!
Number of classes: 2  
Number of genes that passed filtering criteria: 54675  
Type of univariate test used: Two-sample T-test  
Class variable : ALS vs control  
WARNING: Distribution assumptions underlying the random variance model are not satisfied. Random variance model was not 
used.  
Permutation p-values for significant genes were computed based on 10000 random permutations  
Nominal significance level of each univariate test: 0.001  !=%&%4!C2"12!*(%!;"66%(%&3"*00D!%M$(%44%;!*)5&'!10*44%4,!
Number of genes significant at 0.001 level of the univariate test: 306  
Global test: probability of getting at least 306 genes significant by chance (at the 0.001 level) if there are no real differences 
between the classes: 0.026  
Table 1 - Sorted by p-value of the univariate test.  
Class 1: ALS; Class 2: Control. The first 306 genes are significant at the nominal 0.001 level of the univariate test with the 
fold change 1.5  
Parametr
ic p-value  
FDR  Permutati












ProbeSet  Symbol  Name  EntrezI
D  
1.14e-05 0.0217 1e-04 509.35 15.99 31.86 211986_at AHNAK AHNAK nucleoprotein 79026 
1.14e-05 0.0217 2e-04 183.33 5.9 31.09 235599_at LOC339535 hypothetical LOC339535 339535 
0.000451 0.124 0.0014 415.25 15.09 27.51 202071_at SDC4 syndecan 4 6385 
5.5e-06 0.0158 1e-04 365.19 14.27 25.59 239754_at NCRNA0018
8 
non-protein coding RNA 
188 
125144 
3.58e-05 0.0341 3e-04 2175.22 127.38 17.08 204984_at GPC4 glypican 4 2239 
0.000924
3 





0.153 0.0015 734.51 52.56 13.98 200904_at HLA-E major histocompatibility 
complex, class I, E 
3133 
7.8e-06 0.0194 3e-04 347.09 25.25 13.75 213110_s_a
t 
COL4A5 collagen, type IV, alpha 5 1287 
0.000545
5 





0.0734 2e-04 843.61 68.34 12.34 205904_at MICA MHC class I polypeptide-
related sequence A 
4276 
7.01e-05 0.0503 2e-04 2971.37 253.46 11.72 228335_at CLDN11 claudin 11 5010 
0.000484
6 
0.126 9e-04 386.32 38.16 10.12 204115_at GNG11 guanine nucleotide binding 





1e-04 552.67 55.44 9.97 242594_at BOD1L biorientation of 
chromosomes in cell 
division 1-like 
259282 
9.87e-05 0.0613 1e-04 931.32 97.81 9.52 212667_at SPARC secreted protein, acidic, 
cysteine-rich (osteonectin) 
6678 





0.162 0.0018 255.84 27.71 9.23 211756_at PTHLH parathyroid hormone-like 
hormone 
5744 
0.000316 0.108 3e-04 596.42 65.92 9.05 221729_at COL5A2 collagen, type V, alpha 2 1290 




ic p-value  
FDR  Permutati

















0.152 0.0011 286.65 33.53 8.55 202307_s_a
t 
TAP1 transporter 1, ATP-binding 





0.105 7e-04 117.82 13.84 8.51 201468_s_a
t 
NQO1 NAD(P)H dehydrogenase, 
quinone 1 
1728 






0.14 3e-04 173.71 21.23 8.18 1555847_a
_at 
LOC284454 hypothetical LOC284454 284454 
3.47e-05 0.0341 5e-04 1011.51 126.76 7.98 228487_s_a
t 
RREB1 ras responsive element 
binding protein 1 
6239 
5.42e-05 0.0456 3e-04 121.4 15.23 7.97 212459_x_
at 
SUCLG2 succinate-CoA ligase, 




0.133 6e-04 182.73 22.93 7.97 216264_s_a
t 
LAMB2 laminin, beta 2 (laminin S) 3913 
0.000453
3 








0.1 6e-04 199.47 26.45 7.54 227345_at TNFRSF10D tumor necrosis factor 
receptor superfamily, 
member 10d, decoy with 
truncated death domain 
8793 
5.9e-05 0.0471 2e-04 728.52 103.75 7.02 201792_at AEBP1 AE binding protein 1 165 
0.000434
7 
0.121 9e-04 65.57 9.43 6.95 235874_at PRSS35 protease, serine, 35 167681 





0.133 9e-04 1231.23 184.57 6.67 202894_at EPHB4 EPH receptor B4 2050 











0.0907 6e-04 725.67 129.83 5.59 203704_s_a
t 
RREB1 ras responsive element 




0.0673 3e-04 145.3 26.75 5.43 214835_s_a
t 
SUCLG2 succinate-CoA ligase, 




0.137 7e-04 84.88 15.81 5.37 1569923_s_
at 
LOC285708 hypothetical LOC285708 285708 
0.000277
2 
0.1 7e-04 9433.88 1768.45 5.33 1556499_s_
at 
COL1A1 collagen, type I, alpha 1 1277 
0.00023 0.0925 5e-04 91.73 17.34 5.29 215772_x_
at 
SUCLG2 succinate-CoA ligase, 




0.133 7e-04 1477.17 281.52 5.25 228062_at NAP1L5 nucleosome assembly 




0.132 3e-04 1285.7 260.26 4.94 37408_at MRC2 mannose receptor, C type 2 9902 
3e-07 0.0016
4 
1e-04 4960.09 1023.3 4.85 212377_s_a
t 
NOTCH2 notch 2 4853 





0.149 9e-04 253.87 53.2 4.77 229331_at SPATA18 spermatogenesis associated 




0.143 0.0015 89.46 18.94 4.72 1569183_a
_at 
CHM choroideremia (Rab escort 
protein 1) 
1121 
3.38e-05 0.0341 1e-04 40.63 8.67 4.69 1568619_s_
at 




1.4e-06 0.0058 1e-04 2454.17 523.96 4.68 209806_at HIST1H2BK histone cluster 1, H2bk 85236 




ic p-value  
FDR  Permutati

















0.163 0.0019 402.66 89.95 4.48 202711_at EFNB1 ephrin-B1 1947 
6.97e-05 0.0503 2e-04 883.42 199.38 4.43 41660_at CELSR1 cadherin, EGF LAG seven-






0.136 8e-04 621.53 140.89 4.41 208579_x_
at 
NA NA NA 
0.000347
7 
0.112 5e-04 91.26 21 4.35 230203_at FLJ46875 hypothetical LOC440918 440918 
2.74e-05 0.0307 2e-04 3077.24 708.58 4.34 202729_s_a
t 
LTBP1 latent transforming growth 











0.139 9e-04 1866.89 443.43 4.21 215071_s_a
t 
HIST1H2AC histone cluster 1, H2ac 8334 
4.2e-06 0.0135 2e-04 2954.46 703.81 4.2 202443_x_
at 
NOTCH2 notch 2 4853 





0.126 3e-04 1529.25 383.62 3.99 201830_s_a
t 





0.1 7e-04 2123.07 535.66 3.96 222392_x_
at 





1e-04 765.36 193.61 3.95 221553_at MAGT1 magnesium transporter 1 84061 
0.000132
4 
0.0739 3e-04 1404.6 357.13 3.93 37152_at PPARD peroxisome proliferator-




0.0822 7e-04 27.67 7.09 3.9 210756_s_a
t 
NOTCH2 notch 2 4853 
2.24e-05 0.0285 2e-04 649.68 167.97 3.87 211675_s_a
t 





0.159 0.001 324.82 88.49 3.67 226145_s_a
t 
FRAS1 Fraser syndrome 1 80144 
7.1e-06 0.0185 1e-04 5525.37 1524.72 3.62 228063_s_a
t 
NAP1L5 nucleosome assembly 




0.118 7e-04 235.26 65.23 3.61 213656_s_a
t 
KLC1 kinesin light chain 1 3831 
4e-07 0.0019
9 
1e-04 3291.13 922.54 3.57 211962_s_a
t 





0.0814 7e-04 892.07 250.69 3.56 224894_at YAP1 Yes-associated protein 1 10413 






0.157 0.0011 1236.3 358.39 3.45 228919_at NA NA NA 
0.000888
5 
0.158 0.0012 2219.58 654.81 3.39 212923_s_a
t 
C6orf145 chromosome 6 open 




0.1 5e-04 621.05 183.91 3.38 231511_at FRAS1 Fraser syndrome 1 80144 
0.000391
2 
0.117 3e-04 759.14 232.27 3.27 232720_at LINGO2 leucine rich repeat and Ig 




0.116 6e-04 525.83 161.55 3.25 201260_s_a
t 
SYPL1 synaptophysin-like 1 6856 
0.000345
1 





0.133 5e-04 274.48 88.88 3.09 209343_at EFHD1 EF-hand domain family, 
member D1 
80303 
6.05e-05 0.0473 4e-04 128.93 42.25 3.05 211965_at ZFP36L1 zinc finger protein 36, C3H 
type-like 1 
677 




ic p-value  
FDR  Permutati
















0.13 7e-04 1308.39 433.91 3.02 212845_at SAMD4A sterile alpha motif domain 
containing 4A 
23034 
0.00097 0.162 0.0012 737.69 246.97 2.99 218902_at NOTCH1 notch 1 4851 
0.000947
4 





0.126 9e-04 3730.79 1430.18 2.61 203362_s_a
t 
MAD2L1 MAD2 mitotic arrest 




0.135 3e-04 116.5 44.66 2.61 226478_at TM7SF3 transmembrane 7 




0.113 2e-04 1601 623.98 2.57 225239_at NA NA NA 
1.28e-05 0.0233 1e-04 1701.01 674.32 2.52 202026_at SDHD succinate dehydrogenase 
complex, subunit D, 




0.133 8e-04 2704.65 1078.33 2.51 204286_s_a
t 
PMAIP1 phorbol-12-myristate-13-
acetate-induced protein 1 
5366 
3.5e-06 0.012 1e-04 2638.3 1060.53 2.49 224899_s_a
t 
MAGT1 magnesium transporter 1 84061 
0.000649
9 
0.137 2e-04 906.79 363.69 2.49 204142_at ENOSF1 enolase superfamily 
member 1 
55556 
5.25e-05 0.0456 3e-04 4003.58 1671.03 2.4 218284_at SMAD3 SMAD family member 3 4088 
3.41e-05 0.0341 1e-04 4228.63 1789.19 2.36 201160_s_a
t 
CSDA cold shock domain protein 
A 
8531 












0.0907 3e-04 986 448.44 2.2 1557137_at TMEM17 transmembrane protein 17 200728 
0.000964
5 
0.162 0.0025 2971.92 1360.62 2.18 202704_at TOB1 transducer of ERBB2, 1 10140 
1.57e-05 0.0264 1e-04 1677.74 787.49 2.13 201366_at ANXA7 annexin A7 310 





0.137 2e-04 2097.1 1022.96 2.05 217975_at WBP5 WW domain binding 
protein 5 
51186 
0.000131 0.0738 2e-04 873.26 430.43 2.03 203395_s_a
t 





0.149 9e-04 514.94 255.6 2.01 218894_s_a
t 





0.133 0.0013 773.71 405.6 1.91 223397_s_a
t 





0.15 0.0019 2785.73 1479.26 1.88 225414_at RNF149 ring finger protein 149 284996 
5.36e-05 0.0456 2e-04 3254.77 1746.04 1.86 223073_at HIATL1 hippocampus abundant 
transcript-like 1 
84641 








0.135 3e-04 6531.15 3644.03 1.79 201579_at FAT1 FAT tumor suppressor 




0.133 6e-04 5161.38 3046.05 1.69 210093_s_a
t 






0.0768 2e-04 1440.46 912.31 1.58 232118_at NA NA NA 
0.000404
3 
0.118 4e-04 2820.17 1801.94 1.57 214934_at ATP9B ATPase, class II, type 9B 374868 
0.000279
7 
0.1 1e-04 3137.81 2050.49 1.53 223001_at OSTC oligosaccharyltransferase 
complex subunit 
58505 
3.06e-05 0.0325 2e-04 8341.18 5493.08 1.52 209377_s_a
t 






0.157 0.0028 5.54 8.43 0.66 235106_at MAML2 mastermind-like 2 
(Drosophila) 
84441 
0.000924 0.159 0.0019 3438.9 5181.33 0.66 1558097_at NA NA NA 




ic p-value  
FDR  Permutati

















0.1 1e-04 7.27 11.33 0.64 201964_at SETX senataxin 23064 
0.000266
6 









SEPT3 septin 3 55964 
0.000312
5 
0.108 5e-04 335.98 535.61 0.63 230350_at NA NA NA 
0.000732
6 
0.143 8e-04 14.68 23.44 0.63 206240_s_a
t 
ZNF136 zinc finger protein 136 7695 
0.000181
9 
0.085 1e-04 6.72 10.77 0.62 216933_x_
at 





0.124 0.0011 3252.43 5238.57 0.62 207871_s_a
t 
ST7 suppression of 
tumorigenicity 7 
7982 
0.000748 0.145 0.0014 166.53 270.1 0.62 202617_s_a
t 
MECP2 methyl CpG binding 




0.136 0.003 5.13 8.43 0.61 216480_x_
at 








0.0851 8e-04 5.49 9.14 0.6 231962_at AP4B1 adaptor-related protein 




0.0959 7e-04 566.73 951.89 0.6 243674_at NA NA NA 
0.000437
2 
0.121 8e-04 846.48 1418.6 0.6 234710_s_a
t 






0.132 0.001 485.82 806.81 0.6 212357_at FAM168A family with sequence 




0.142 0.0019 4.99 8.26 0.6 240242_at NA NA NA 
0.000908
3 
0.159 9e-04 2976.87 5001.02 0.6 220131_at FXYD7 FXYD domain containing 




0.133 0.0011 16.11 27.45 0.59 1555463_a
_at 
CHD6 chromodomain helicase 




0.0886 1e-04 2952.77 5108.21 0.58 204015_s_a
t 
















9.44e-05 0.0593 8e-04 5.31 9.33 0.57 206973_at PPFIA2 protein tyrosine 
phosphatase, receptor type, 
f polypeptide (PTPRF), 





0.121 0.0014 4.75 8.39 0.57 206142_at ZNF135 zinc finger protein 135 7694 
0.000406
7 
0.118 6e-04 391.88 702.96 0.56 226761_at IKZF4 IKAROS family zinc 




0.12 5e-04 7.41 13.24 0.56 243888_at NA NA NA 
0.000522
3 
0.13 6e-04 3200.45 5717.71 0.56 205522_at HOXD4 homeobox D4 3233 
0.000731
2 
0.143 0.0013 485.5 868.86 0.56 227768_at ZNF407 zinc finger protein 407 55628 
0.000794
8 
0.149 3e-04 4.71 8.38 0.56 222947_at ZNF224 zinc finger protein 224 7767 
0.000141
1 
0.0756 4e-04 5.14 9.3 0.55 231208_at NA NA NA 
0.000543 0.132 5e-04 1188.33 2169.06 0.55 213482_at DOCK3 dedicator of cytokinesis 3 1795 
0.000585 0.133 2e-04 4055.57 7387.26 0.55 238893_at LOC338758 hypothetical LOC338758 338758 
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0.137 9e-04 13.5 24.51 0.55 229786_at NA NA NA 
1.78e-05 0.0269 4e-04 10.26 18.92 0.54 1555848_at NA NA NA 
0.000159
3 
0.0792 1e-04 6.44 11.96 0.54 229550_at KIAA1409 KIAA1409 57578 
2.59e-05 0.0301 7e-04 33.32 62.8 0.53 1565894_at NA NA NA 
0.000198
9 





0.14 0.0014 1042.49 2000.07 0.52 226607_at C20orf194 chromosome 20 open 




0.143 3e-04 70.55 134.9 0.52 209991_x_
at 
GABBR2 gamma-aminobutyric acid 




0.145 0.0016 5.11 9.77 0.52 217697_at NA NA NA 
0.000784
3 





0.129 0.0056 4.6 9.09 0.51 226543_at MUTED muted homolog (mouse) 63915 
2.57e-05 0.0301 1e-04 824.64 1659.15 0.5 241803_s_a
t 
LOC401522 hypothetical LOC401522 401522 
0.000470
9 
0.124 4e-04 607.92 1221.25 0.5 226618_at UBE2QL1 ubiquitin-conjugating 




0.155 0.0026 5.51 11.31 0.49 244194_at NA NA NA 
0.000793
5 





0.162 0.0014 151.32 314.85 0.48 221812_at FBXO42 F-box protein 42 54455 










0.131 0.0017 1131.2 2402.89 0.47 232019_at ZKSCAN2 zinc finger with KRAB and 




0.133 6e-04 7.91 17 0.47 219027_s_a
t 
MYO9A myosin IXA 4649 
0.000403
7 
0.118 4e-04 529.21 1155.75 0.46 213223_at RPL28 ribosomal protein L28 6158 
0.000356
2 
0.113 5e-04 6.43 14.39 0.45 206466_at ACSBG1 acyl-CoA synthetase 
bubblegum family member 
1 
23205 
2.07e-05 0.0276 2e-04 311.49 710.25 0.44 1568625_at NA NA NA 
3.62e-05 0.0341 1e-04 337.21 772.4 0.44 227722_at RPS23 ribosomal protein S23 6228 
8.87e-05 0.0564 1e-04 1379.06 3148.28 0.44 230788_at GCNT2 glucosaminyl (N-acetyl) 
transferase 2, I-branching 
enzyme (I blood group) 
2651 
0.000585 0.133 0.0011 1215.92 2750.32 0.44 224076_s_a
t 
WHSC1L1 Wolf-Hirschhorn syndrome 









0.0874 1e-04 4.59 10.69 0.43 1562282_at ZNF568 zinc finger protein 568 374900 
0.000229
5 
0.0925 5e-04 5.4 12.44 0.43 243984_at NA NA NA 
0.000524
1 







0.16 0.0036 5.17 12.02 0.43 232709_at NA NA NA 
0.000360
2 
0.113 0.0019 5.33 12.61 0.42 220459_at MCM3APAS MCM3AP antisense RNA 
(non-protein coding) 
114044 
0.000566 0.133 5e-04 116.5 275.83 0.42 236537_at NA NA NA 
0.000703
8 
0.142 0.0011 764.57 1832.31 0.42 205277_at PRDM2 PR domain containing 2, 
with ZNF domain 
7799 
0.000997 0.164 8e-04 1273.67 3044.35 0.42 209794_at SRGAP3 SLIT-ROBO Rho GTPase 9901 
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ProbeSet  Symbol  Name  EntrezI
D  
6 activating protein 3 
5.94e-05 0.0471 1e-04 14.68 36.1 0.41 244307_s_a
t 
NA NA NA 
0.000114
4 
0.0673 3e-04 23.7 57.15 0.41 1552520_at TMEM74 transmembrane protein 74 157753 
0.000516
1 
0.13 4e-04 568.31 1378.06 0.41 209793_at GRIA1 glutamate receptor, 









0.133 0.001 9.2 22.18 0.41 203657_s_a
t 
CTSF cathepsin F 8722 
0.000903
1 
0.159 0.0027 6.63 16.34 0.41 243831_at NA NA NA 
2.6e-06 0.0102 1e-04 3105.8 7691.27 0.4 209198_s_a
t 
SYT11 synaptotagmin XI 23208 
3.05e-05 0.0325 1e-04 1086.19 2690.44 0.4 229580_at NA NA NA 
7.17e-05 0.0503 9e-04 5.01 12.63 0.4 1569792_a
_at 
C12orf72 chromosome 12 open 
reading frame 72 
254013 
7.52e-05 0.0517 1e-04 222.15 550.48 0.4 225066_at PPP2R2D protein phosphatase 2, 
regulatory subunit B, delta 
55844 
0.00034 0.111 3e-04 6.17 15.55 0.4 1557315_a
_at 
NA NA NA 
0.000358
3 










0.162 0.0017 10.22 25.23 0.4 232631_at CDH6 cadherin 6, type 2, K-









0.159 0.0017 122.73 311.02 0.39 235405_at GSTA4 glutathione S-transferase 
alpha 4 
2941 
7.16e-05 0.0503 5e-04 15.08 39.17 0.38 221299_at GPR173 G protein-coupled receptor 
173 
54328 
8.33e-05 0.0537 1e-04 2877.55 7642.31 0.38 209197_at SYT11 synaptotagmin XI 23208 
0.000173
2 
0.0822 1e-04 17.7 46.39 0.38 239109_at LOC728190 hypothetical LOC728190 728190 
0.000432
9 
0.121 3e-04 112.81 295.38 0.38 223522_at NCRNA0028
7 










0.124 3e-04 5.45 14.85 0.37 243444_at SRD5A3 steroid 5 alpha-reductase 3 79644 
0.000595 0.133 0.0019 10.95 29.45 0.37 235913_at ZNF880 zinc finger protein 880 400713 
2e-05 0.0273 1e-04 43.94 122.27 0.36 215153_at NOS1AP nitric oxide synthase 1 
(neuronal) adaptor protein 
9722 
4.2e-05 0.0379 1e-04 5.99 16.56 0.36 211973_at NA NA NA 
0.000303
8 
0.106 6e-04 119.54 333.34 0.36 238570_at NA NA NA 
0.000140
1 
0.0756 4e-04 5.17 14.76 0.35 228655_at NA NA NA 
0.000222 0.0907 2e-04 26.58 75.68 0.35 208230_s_a
t 
NRG1 neuregulin 1 3084 
0.000278
2 
0.1 8e-04 4.82 13.66 0.35 216643_at NA NA NA 
0.000907
2 
0.159 8e-04 10.32 29.84 0.35 232105_at NA NA NA 
0.000373
8 
0.114 5e-04 260.11 769.23 0.34 229130_at NA NA NA 
0.000943
3 
0.161 0.0013 404.82 1192.79 0.34 204364_s_a
t 





0.0734 2e-04 4.97 14.9 0.33 1555602_a
_at 
ELAVL3 ELAV (embryonic lethal, 
abnormal vision, 
Drosophila)-like 3 (Hu 
1995 




ic p-value  
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ProbeSet  Symbol  Name  EntrezI
D  
antigen C) 
0.000283 0.1 8e-04 2472.05 7567.66 0.33 223287_s_a
t 
FOXP1 forkhead box P1 27086 
0.000626
1 





0.142 0.0011 19.29 58.04 0.33 230613_at GMEB1 glucocorticoid modulatory 




0.0756 0.001 10.36 32.67 0.32 206582_s_a
t 





0.0886 1e-04 11.78 36.5 0.32 235322_at NA NA NA 
0.000858
3 
0.155 9e-04 65.52 205.09 0.32 216899_s_a
t 
SKAP2 src kinase associated 
phosphoprotein 2 
8935 
9.3e-06 0.0203 1e-04 20.1 67.67 0.3 220887_at C14orf162 chromosome 14 open 
reading frame 162 
56936 
2.3e-05 0.0286 4e-04 5.2 17.35 0.3 240642_at ZMYM2 zinc finger, MYM-type 2 7750 
0.000112
9 
0.0673 5e-04 6.11 20.28 0.3 215021_s_a
t 
NRXN3 neurexin 3 9369 
0.000337
3 
0.111 6e-04 8.77 29.23 0.3 222368_at NA NA NA 
0.000860
7 
0.155 0.0016 25.03 83.21 0.3 225584_at HCG18 HLA complex group 18 414777 
5.54e-05 0.0459 4e-04 15.61 53.14 0.29 219746_at DPF3 D4, zinc and double PHD 




0.0768 0.001 5.51 19.3 0.29 242736_at NA NA NA 
0.000150
3 










0.157 0.001 86.58 293.56 0.29 222020_s_a
t 
NTM neurotrimin 50863 
0.000169
4 
0.0814 3e-04 196.32 689.56 0.28 237131_at C1orf230 chromosome 1 open 




0.113 7e-04 22.17 78.46 0.28 238800_s_a
t 

















0.149 0.0017 22.17 78.65 0.28 236068_s_a
t 
NA NA NA 
1.08e-05 0.0217 2e-04 6.36 23.63 0.27 220184_at NANOG Nanog homeobox 79923 
1.15e-05 0.0217 1e-04 149.41 552.33 0.27 1559861_at NA NA NA 
6.25e-05 0.0481 3e-04 7.34 27.59 0.27 243310_at NA NA NA 
7.6e-05 0.0517 4e-04 5.12 18.71 0.27 1566772_at NA NA NA 
8.12e-05 0.0536 2e-04 89.51 335.14 0.27 237440_at NA NA NA 
0.000143
1 
0.076 1e-04 30.53 111.98 0.27 212392_s_a
t 





0.159 0.0015 23.13 84.67 0.27 213990_s_a
t 
PAK7 p21 protein (Cdc42/Rac)-




0.0851 4e-04 8.57 33.56 0.26 216197_at ATF7IP activating transcription 









0.0673 3e-04 6.66 27.73 0.24 1565602_at NA NA NA 
0.000270
3 
0.1 7e-04 10.43 42.78 0.24 234081_at NA NA NA 
0.000354
5 
0.113 7e-04 5.76 24.22 0.24 238254_at ZNF677 zinc finger protein 677 342926 
0.000103
1 
0.0633 4e-04 5.19 22.93 0.23 243694_at NA NA NA 
0.000204 0.0874 2e-04 36.01 154.15 0.23 231336_at CPNE4 copine IV 131034 
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0.136 0.0012 10.04 44.6 0.23 1554528_at C3orf15 chromosome 3 open 




0.136 0.0013 6.24 27.16 0.23 237194_at NA NA NA 
0.000687
4 
0.14 7e-04 1027.85 4378.7 0.23 229844_at NA NA NA 
0.000805
4 
0.15 0.0056 4.99 22.13 0.23 243791_at NA NA NA 
0.000917
4 
0.159 8e-04 57.59 250.04 0.23 221867_at N4BP1 NEDD4 binding protein 1 9683 
0.000169
8 
0.0814 3e-04 11.61 53.19 0.22 244696_at NA NA NA 
0.000237
4 
0.0947 2e-04 9.35 43.29 0.22 1553371_at EPHA10 EPH receptor A10 284656 
0.000273
6 






0.000567 0.133 0.0015 5.71 26.33 0.22 240063_at LOC441046 glucuronidase, beta 
pseudogene 
441046 
0.000321 0.108 0.0014 6.04 28.25 0.21 1566880_at NA NA NA 
0.000380
8 
0.116 0.0013 18.1 87.47 0.21 233888_s_a
t 
SRGAP1 SLIT-ROBO Rho GTPase 




0.124 2e-04 24.04 112.94 0.21 1552521_a
_at 
TMEM74 transmembrane protein 74 157753 
0.000915 0.159 0.0013 44.57 207.85 0.21 235930_at NA NA NA 
1.64e-05 0.0264 3e-04 7.43 37.95 0.2 239951_at NA NA NA 
7.13e-05 0.0503 1e-04 24.18 119.62 0.2 204633_s_a
t 
RPS6KA5 ribosomal protein S6 
kinase, 90kDa, polypeptide 
5 
9252 
8.14e-05 0.0536 5e-04 18.08 90.79 0.2 239359_at MARCH11 membrane-associated ring 









0.0959 0.001 13.87 70.14 0.2 224790_at ASAP1 ArfGAP with SH3 domain, 





0.113 0.0011 5.75 28.48 0.2 233401_at NA NA NA 
0.000598 0.133 7e-04 275.13 1353.38 0.2 215634_at NA NA NA 
0.000639
7 
0.136 6e-04 141.66 706.64 0.2 228998_at NA NA NA 
0.000713
6 
0.142 8e-04 8.72 43.88 0.2 204339_s_a
t 





0.163 0.0011 33.66 166.12 0.2 1559235_a
_at 
SOX30 SRY (sex determining 
region Y)-box 30 
11063 
6.91e-05 0.0503 5e-04 5.75 29.94 0.19 232637_at SEPT2 septin 2 4735 
0.000584
1 
0.133 0.0012 137.13 734.29 0.19 1553705_a
_at 
CHRM3 cholinergic receptor, 
muscarinic 3 
1131 
1.92e-05 0.0273 1e-04 4.64 26.46 0.18 231257_at TCERG1L transcription elongation 
regulator 1-like 
256536 
4.23e-05 0.0379 2e-04 49.69 270.86 0.18 232192_at NA NA NA 
0.000203
2 
0.0874 1e-04 29.41 160.79 0.18 1555904_at NA NA NA 
0.000503 0.129 0.0015 5.57 30.91 0.18 242959_at NA NA NA 
0.000535
5 





0.135 0.001 11.07 60.18 0.18 212289_at ANKRD12 ankyrin repeat domain 12 23253 
0.000674
6 





0.143 0.001 18.61 101.04 0.18 240165_at NA NA NA 
0.000730
8 
0.143 0.0021 7 38.69 0.18 215435_at NA NA NA 
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0.154 0.0018 15.31 86.59 0.18 213901_x_
at 
RBM9 RNA binding motif protein 
9 
23543 
1.72e-05 0.0269 3e-04 7.47 43.04 0.17 1558996_at FOXP1 forkhead box P1 27086 
2.59e-05 0.0301 3e-04 11.98 71.25 0.17 230809_at NA NA NA 
0.000199
8 
0.0874 0.0011 6.39 37.76 0.17 233273_at NA NA NA 
< 1e-07 < 1e-
07 
1e-04 44.48 277.03 0.16 213812_s_a
t 
CAMKK2 calcium/calmodulin-
dependent protein kinase 
kinase 2, beta 
10645 
7.66e-05 0.0517 3e-04 8.6 52.2 0.16 215020_at NRXN3 neurexin 3 9369 
0.000508
7 
0.129 5e-04 5.31 33.31 0.16 240433_x_
at 
CADM2 cell adhesion molecule 2 253559 
0.000807
1 
0.15 0.002 15.32 93.81 0.16 236468_at NA NA NA 
5.05e-05 0.0445 1e-04 9.32 61.71 0.15 223629_at PCDHB5 protocadherin beta 5 26167 
0.000294
4 
0.104 6e-04 61.34 413.55 0.15 219737_s_a
t 
PCDH9 protocadherin 9 5101 
0.000322
3 
0.108 0.0013 8.32 55.22 0.15 221942_s_a
t 
GUCY1A3 guanylate cyclase 1, 




0.118 0.0016 8.49 56.46 0.15 231455_at FLJ42418 FLJ42418 protein 400941 
0.000617
5 
0.135 5e-04 32.43 214.29 0.15 236181_at NA NA NA 
7.1e-06 0.0185 1e-04 4.74 33.08 0.14 243929_at NA NA NA 
0.000245
6 
0.0959 7e-04 5.95 44.04 0.14 244372_at NA NA NA 
0.000730
4 
0.143 0.001 11.76 85.33 0.14 214603_at NA NA NA 
1.64e-05 0.0264 2e-04 32.66 271.33 0.12 242677_at NA NA NA 
0.000190
3 





0.126 0.0013 8.64 69.81 0.12 239726_at ANK3 ankyrin 3, node of Ranvier 
(ankyrin G) 
288 
4.9e-06 0.0149 1e-04 5.36 49.6 0.11 239995_at NA NA NA 
0.000501
5 
0.129 7e-04 29.42 257.56 0.11 230041_at NA NA NA 
2e-07 0.0016
4 
1e-04 15.69 156.98 0.1 240445_at NA NA NA 
0.000154
9 
0.0777 2e-04 16.11 160.86 0.1 220679_s_a
t 
CDH7 cadherin 7, type 2 1005 
3.5e-05 0.0341 2e-04 20.97 214.24 0.098 233916_at KIAA1486 KIAA1486 57624 
0.000338 0.111 8e-04 21.13 226.02 0.093 205656_at PCDH17 protocadherin 17 27253 
< 1e-07 < 1e-
07 
1e-04 4.79 52.05 0.092 229019_at ZNF385B zinc finger protein 385B 151126 
0.000239
6 
0.0949 5e-04 24.75 280.6 0.088 207242_s_a
t 
GRIK1 glutamate receptor, 
ionotropic, kainate 1 
2897 
< 1e-07 < 1e-
07 
1e-04 19.91 252.94 0.079 221217_s_a
t 
A2BP1 ataxin 2-binding protein 1 54715 
3e-07 0.0016
4 
1e-04 5.07 65.5 0.077 1561425_a
_at 
ZNF568 zinc finger protein 568 374900 
0.000161 0.0793 7e-04 23.05 382.8 0.06 230876_at ZNF883 zinc finger protein 883 169834 
< 1e-07 < 1e-
07 
1e-04 4.59 91.85 0.05 237516_at NA NA NA 
< 1e-07 < 1e-
07 
1e-04 4.95 100.32 0.049 232677_at NA NA NA 
3e-07 0.0016
4 
1e-04 10.96 226.69 0.048 235070_at A2BP1 ataxin 2-binding protein 1 54715 
1.82e-05 0.0269 1e-04 14.35 668.38 0.021 1553422_s_
at 
A2BP1 ataxin 2-binding protein 1 54715 !
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E74-like factor 3 (ets domain transcription 
factor, epithelial-specific ) 1 5.60 5.30 8.71 6.59 5.70 5.73 0.12 0.08 0.16 0.20 0.52 0.07 0.12 80.47 8.33E-09 4.56E-04
222054_at LOC728448 similar to peptidylprolyl isomerase E 1 8.56 6.39 8.51 8.79 6.18 6.84 0.20 0.12 0.20 0.10 0.09 0.43 0.20 87.68 5.07E-09 2.77E-04
229842_at NA NA 1 5.99 5.99 10.64 8.05 6.17 5.95 0.29 0.07 0.14 0.32 0.75 0.37 0.29 71.70 1.62E-08 8.87E-04
227474_at LOC654433 Hypothetical LOC654433 2 5.36 8.04 5.33 9.24 8.47 8.68 0.26 0.14 0.14 0.12 0.39 0.67 0.26 74.69 1.28E-08 7.01E-04
227940_at LOC339803 Hypothetical protein LOC339803 2 7.49 7.66 8.29 8.16 7.34 3.82 0.22 0.32 0.34 0.32 0.25 0.23 0.22 103.25 1.96E-09 1.07E-04
228425_at LOC654433 hypothetical LOC654433 2 4.17 7.77 3.99 7.00 7.76 7.31 0.17 0.10 0.35 0.19 0.37 0.53 0.17 90.81 4.13E-09 2.26E-04
231213_at PDE1A phosphodiesterase 1A, calmodulin-dependent 2 4.28 7.01 4.32 4.12 4.00 4.26 0.26 0.32 0.25 0.18 0.09 0.14 0.26 81.71 7.62E-09 4.17E-04
233549_at PDE1A phosphodiesterase 1A, calmodulin-dependent 2 5.27 7.29 5.13 5.19 5.35 5.20 0.14 0.22 0.22 0.10 0.19 0.10 0.14 73.66 1.39E-08 7.59E-04
208396_s_at PDE1A phosphodiesterase 1A, calmodulin-dependent 2 5.71 9.02 5.17 5.73 5.62 5.60 0.29 0.19 0.30 0.22 0.10 0.14 0.29 127.78 5.62E-10 3.07E-05
234704_at NA NA 3 4.19 4.38 4.20 7.44 4.24 5.60 0.51 0.06 0.15 0.02 0.27 0.08 0.51 84.42 6.31E-09 3.45E-04
243432_at LOC642891 hypothetical LOC642891 3 4.23 8.74 7.20 7.81 4.57 9.99 0.76 0.06 0.26 0.50 0.27 0.51 0.76 76.36 1.13E-08 6.17E-04
1567183_s_at NA
NTera2D1 cell line mRNA containing L1 
retroposon, clone P1 3 5.57 5.47 5.71 8.89 5.04 6.73 0.19 0.22 0.29 0.22 0.40 0.08 0.19 93.08 3.58E-09 1.96E-04
204591_at CHL1
cell adhesion molecule with homology to 
L1CAM (close homolog of L1) 3 5.80 10.44 9.31 9.44 5.74 10.80 0.29 0.08 0.03 0.56 0.76 0.27 0.29 87.15 5.25E-09 2.87E-04
223122_s_at SFRP2 secreted frizzled-related protein 2 4 5.69 7.25 7.61 10.61 5.00 6.82 0.24 0.10 0.20 0.46 0.37 0.30 0.24 128.10 5.54E-10 3.03E-05
228640_at PCDH7 protocadherin 7 4 11.84 11.44 10.68 10.88 4.21 11.73 0.32 0.35 0.13 0.62 0.90 0.19 0.32 104.81 1.79E-09 9.80E-05
237516_at NA NA 4 7.43 6.31 4.55 4.48 4.51 4.40 0.03 0.25 0.16 0.36 0.15 0.01 0.03 124.62 6.51E-10 3.56E-05
1569110_x_at LOC728613 programmed cell death protein 6-like 5 9.94 9.75 10.30 9.73 5.61 9.71 0.11 0.37 0.20 0.25 0.30 0.53 0.11 88.33 4.85E-09 2.65E-04
220115_s_at CDH10 cadherin 10, type 2 (T2-cadherin) 5 10.82 10.85 9.61 11.01 5.25 10.94 0.11 0.50 0.25 0.50 0.63 0.45 0.11 79.41 9.00E-09 4.92E-04
224022_x_at WNT16
wingless-type MMTV integration site family, 
member 16 7 4.42 4.67 10.89 4.48 4.44 4.40 0.05 0.09 0.36 0.87 0.08 0.14 0.05 132.83 4.48E-10 2.45E-05
228546_at DPP6 dipeptidyl-peptidase 6 7 12.34 11.99 10.49 11.10 6.34 11.06 0.20 0.31 0.30 0.55 0.35 0.30 0.20 113.69 1.11E-09 6.09E-05
230117_at VSTM2A
V-set and transmembrane domain containing 
2A 7 10.17 10.18 9.56 9.21 4.33 9.55 0.18 0.39 0.28 0.36 0.37 0.07 0.18 168.28 1.11E-10 6.09E-06
236308_at VSTM2A
V-set and transmembrane domain containing 
2A 7 9.74 9.68 9.05 8.83 4.33 9.33 0.29 0.36 0.35 0.65 0.19 0.26 0.29 88.94 4.66E-09 2.55E-04
244082_at FIS1
Fission 1 (mitochondrial outer membrane) 
homolog (S. cerevisiae) 7 6.46 10.09 6.42 6.39 5.96 6.90 0.17 0.44 0.25 0.27 0.32 0.17 0.17 86.21 5.59E-09 3.06E-04
217720_at CHCHD2
coiled-coil-helix-coiled-coil-helix domain 
containing 2 7 6.02 12.72 12.62 12.67 12.40 12.12 0.16 0.19 0.23 0.33 0.20 0.44 0.16 276.66 5.87E-12 3.21E-07
220384_at TXNDC3 thioredoxin domain containing 3 (spermatozoa) 7 5.22 5.11 5.22 8.57 5.08 5.09 0.14 0.08 0.11 0.32 0.48 0.06 0.14 95.16 3.15E-09 1.72E-04
213122_at TSPYL5 TSPY-like 5 8 4.68 4.44 6.87 10.41 4.69 11.62 0.36 0.06 0.08 0.64 0.37 0.15 0.36 252.71 1.00E-11 5.49E-07
239983_at SLC30A8
solute carrier family 30 (zinc transporter), 
member 8 8 5.40 7.68 5.41 6.08 5.30 5.54 0.14 0.02 0.41 0.02 0.12 0.08 0.14 71.30 1.68E-08 9.16E-04
229309_at ADRB1 adrenergic, beta-1-, receptor 10 4.72 4.45 9.90 4.52 4.80 4.52 0.14 0.10 0.07 0.28 0.12 0.18 0.14 530.37 1.22E-13 6.66E-09
201432_at CAT catalase 11 4.09 8.12 4.06 4.04 4.01 7.83 0.28 0.06 0.21 0.08 0.06 0.07 0.28 544.56 1.04E-13 5.69E-09
240955_at PANX3 pannexin 3 11 4.65 6.06 4.73 4.63 4.59 4.68 0.05 0.07 0.17 0.13 0.06 0.09 0.05 95.11 3.16E-09 1.73E-04
214811_at RIMBP2 RIMS binding protein 2 12 9.56 9.95 8.95 7.95 9.00 4.95 0.37 0.38 0.20 0.20 0.20 0.44 0.37 99.49 2.43E-09 1.33E-04
225043_at SLC15A4 solute carrier family 15, member 4 12 8.32 9.25 8.19 8.53 9.24 5.48 0.46 0.32 0.33 0.20 0.13 0.13 0.46 70.84 1.74E-08 9.51E-04
232313_at TMEM132C transmembrane protein 132C 12 8.78 9.21 9.84 6.93 4.82 4.90 0.16 0.42 0.48 0.47 0.28 0.13 0.16 116.00 9.91E-10 5.42E-05
203108_at GPRC5A
G protein-coupled receptor, family C, group 5, 
member A 12 5.96 6.12 10.30 10.98 6.34 6.13 0.34 0.06 0.09 0.34 0.58 0.45 0.34 125.48 6.25E-10 3.42E-05
218454_at FLJ22662 hypothetical protein FLJ22662 12 6.26 6.52 10.07 7.84 6.32 6.02 0.03 0.31 0.39 0.43 0.37 0.16 0.03 73.20 1.44E-08 7.87E-04
229266_at LOC284033 hypothetical protein LOC284033 17 7.98 8.90 9.82 8.58 4.81 4.71 0.39 0.16 0.35 0.55 0.32 0.55 0.39 85.60 5.82E-09 3.18E-04
202790_at CLDN7 claudin 7 17 5.53 5.35 8.84 5.44 5.59 5.58 0.23 0.16 0.10 0.54 0.20 0.16 0.23 75.37 1.22E-08 6.65E-04
206032_at DSC3 desmocollin 3 18 4.14 4.22 6.54 4.19 4.22 4.21 0.06 0.06 0.10 0.16 0.02 0.05 0.06 367.20 1.09E-12 5.96E-08
221690_s_at NLRP2 NLR family, pyrin domain containing 2 19 5.50 4.84 8.52 9.37 4.81 8.26 0.01 0.53 0.13 0.10 0.39 0.10 0.01 161.98 1.39E-10 7.62E-06
227949_at PHACTR3 phosphatase and actin regulator 3 20 5.09 10.34 9.71 9.53 10.16 10.25 0.16 0.51 0.13 0.29 0.23 0.47 0.16 111.15 1.27E-09 6.95E-05
204239_s_at NNAT neuronatin 20 12.39 10.63 11.28 11.06 9.95 6.61 0.16 0.21 0.40 0.35 0.39 0.66 0.16 76.36 1.13E-08 6.17E-04
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214254_at MAGEA4 melanoma antigen family A, 4 X 9.98 4.95 5.06 4.78 4.76 4.64 0.05 0.42 0.34 0.56 0.01 0.12 0.05 126.80 5.88E-10 3.22E-05
224589_at XIST X (inactive)-specific transcript X 4.83 5.15 5.32 7.61 5.05 7.54 0.41 0.11 0.19 0.05 0.28 0.12 0.41 98.01 2.65E-09 1.45E-04
201909_at RPS4Y1 ribosomal protein S4, Y-linked 1 Y 13.83 6.14 6.66 6.66 6.66 6.75 0.27 0.08 0.14 0.04 0.15 0.55 0.27 374.05 9.77E-13 5.34E-08
206700_s_at JARID1D jumonji, AT rich interactive domain 1D Y 9.58 4.03 4.31 4.09 4.24 4.18 0.05 0.19 0.05 0.16 0.15 0.01 0.05 1031.52 2.33E-15 1.27E-10
207063_at CYorf14 chromosome Y open reading frame 14 Y 8.10 4.65 4.81 4.83 4.76 4.96 0.09 0.49 0.06 0.14 0.06 0.17 0.09 109.94 1.36E-09 7.42E-05
207703_at NLGN4Y neuroligin 4, Y-linked Y 8.06 4.28 4.29 4.32 4.26 4.27 0.11 0.49 0.06 0.03 0.04 0.02 0.11 165.47 1.23E-10 6.72E-06
235942_at LOC401629///LOC401630L 401629///LOC401630 Y 8.77 4.27 4.30 4.50 4.26 4.44 0.12 0.65 0.04 0.06 0.11 0.09 0.12 125.28 6.31E-10 3.45E-05
204409_s_at EIF1AY
eukaryotic translation initiation factor 1A, Y-
linked Y 10.30 4.28 4.42 4.68 4.37 4.36 0.02 0.40 0.09 0.08 0.26 0.14 0.02 403.27 6.24E-13 3.41E-08
205000_at DDX3Y
DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-
linked Y 10.13 4.48 4.66 4.59 4.65 4.57 0.02 0.39 0.08 0.07 0.06 0.07 0.02 518.72 1.39E-13 7.61E-09
214983_at TTTY15 testis-specific transcript, Y-linked 15 Y 10.27 4.52 4.53 4.55 4.56 4.55 0.06 0.34 0.09 0.11 0.18 0.07 0.06 567.35 8.15E-14 4.46E-09
228492_at USP9Y
ubiquitin specific peptidase 9, Y-linked (fat 
facets-like, Drosophila) Y 9.34 4.30 4.27 4.21 4.25 4.22 0.04 0.57 0.06 0.15 0.07 0.04 0.04 219.95 2.29E-11 1.25E-06



























List Import Model Comparison
2.8 !""#$%&'&() *+, granulin -./01234!""$ 530 6 78/910:3;-10) <.803 -10)
2.69 !=#"6=&'&() *+, granulin -./01234!""$ 530 6 78/910:3;-10) <.803 -10)
2.8 !""#$%&'&() *+, granulin
73441>!""?@A=!"@
*BCDE0,F*@ 530 6 CGC! +3HD>(9IJ3; <.803 *BCDE0,F*@
2.69 !=#"6=&'&() *+, granulin
73441>!""?@A=!"@
*BCDE0,F*@ 530 6 ?G#! +3HD>(9IJ3; <.803 *BCDE0,F*@
2.8 !""#$%&'&() *+, granulin
73441>!""?@AB"@
*BCDE0,F*@ 530 6 !G"% +3HD>(9IJ3; <.803 *BCDE0,F*@
2.69 !=#"6=&'&() *+, granulin
73441>!""?@AB"@
*BCDE0,F*@ 530 6 !G"6 +3HD>(9IJ3; <.803 *BCDE0,F*@
2.8 !""#$%&'&() *+, granulin K('3>(!""B 530 6 78/910:3;-10) <.803 *BCD@LL@E0@L+
2.69 !=#"6=&'&() *+, granulin K('3>(!""B 530 6 78/910:3;-10) <.803 *BCD@LL@E0@L+
2.2 !"=B66&() MNOP hexosaminidase B (beta polypeptide) -./01234!""$ 530 6 78/910:3;-10) <.803 -10)
2.2 !"=B66&() MNOP hexosaminidase B (beta polypeptide)
73441>!""?@A=!"@
*BCDE0,F*@ 530 6 CG"$ +3HD>(9IJ3; <.803 *BCDE0,F*@
2.2 !"=B66&() MNOP hexosaminidase B (beta polypeptide)
73441>!""?@A#"@
*BCDE0,F*@ 530 6 78/910:3;-10) <.803 *BCDE0,F*@
2.2 !"=B66&() MNOP hexosaminidase B (beta polypeptide) K('3>(!"=" 530 6 78/910:3;-10) <.803 *BCD@LL@E0@L+
20.74 !"66%B&0&() QR66 CD44 molecule (Indian blood group) -./01234!""$ 530 C 78/910:3;-10) <.803 -10)
14.81 !=!"#C&() QR66 CD44 molecule (Indian blood group) -./01234!""$ 530 C 78/910:3;-10) <.803 -10)
20.74 !"66%B&0&() QR66 CD44 molecule (Indian blood group)
73441>!""?@A=!"@
*BCDE0,F*@ 530 C ="GB +3HD>(9IJ3; <.803 *BCDE0,F*@
14.81 !=!"#C&() QR66 CD44 molecule (Indian blood group)
73441>!""?@A=!"@
*BCDE0,F*@ 530 C =%G%C +3HD>(9IJ3; <.803 *BCDE0,F*@
20.74 !"66%B&0&() QR66 CD44 molecule (Indian blood group) +(/1>!"=" 530 C !G"6 +3HD>(9IJ3; M8S(>@-Q< 0D-K@E0@Q.>)4.9
14.81 !=!"#C&() QR66 CD44 molecule (Indian blood group) +(/1>!"=" 530 C !G!! +3HD>(9IJ3; M8S(>@-Q< 0D-K@E0@Q.>)4.9
3.73 !"=##$&() *TD= gap junction protein, alpha 1, 43kDa -3>JU3>!"== 530 C !G"B +3HD>(9IJ3; K5?5 V)KWR=@E0@*BCD@K)(/930
3.73 !"=##$&() *TD= gap junction protein, alpha 1, 43kDa
73441>!""?@A#"@
*BCDE0,F*@ 530 C 78/910:3;-10) <.803 *BCDE0,F*@
3.73 !"=##$&() *TD= gap junction protein, alpha 1, 43kDa +(/1>!"=" 530 C !G"6 +3HD>(9IJ3; M8S(>@-Q< 0D-K@E0@Q.>)4.9
15.84 !"%B6B&0&() -*D-KC lectin, galactoside-binding, soluble, 3
L344(18.9.!""$@A=!"@
*BCDE0,F*@ 530 C ==G"6 +3HD>(9IJ3; <.803 *BCDE0,F*@
15.84 !"%B6B&0&() -*D-KC lectin, galactoside-binding, soluble, 3
73441>!""?@A=!"@
*BCDE0,F*@ 530 C !BGB! +3HD>(9IJ3; <.803 *BCDE0,F*@
15.84 !"%B6B&0&() -*D-KC lectin, galactoside-binding, soluble, 3 +(/1>!"=" 530 C =G#= +3HD>(9IJ3; M8S(>@-Q< 0D-K@E0@Q.>)4.9
2.87 !!C"6$&() Q<F<#
CKLF-like MARVEL transmembrane 
domain containing 6
L344(18.9.!""$@A#"@
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